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Summary 
 
Genetic differences within and between species predominantly lie in the 
noncoding sequence of the regulatory regions of the genome whose function and 
significance largely remain poorly understood. Despite significant progress in 
the field of genomics and the rapid progress in sequencing methods and the 
subsequent explosion of genomic data, our understanding of the role of the non-
coding genetic sequence in the regulation of tissue- and species-specific gene 
expression is still lagging behind, limiting our comprehension of the 
evolutionary mechanisms and pressures that shape those expression profiles, 
and their involvement in the health and disease. 
 
 The CTCF protein demarcates mammalian genomes into discrete 
transcriptionally active domains, providing the platform for complex spatial 
and temporal regulatory processing of genetic information that govern 
biological processes. In this thesis, I investigate the dynamics and functional 
implications of evolutionarily novel CTCF binding sites in two Mus genus 
mouse subspecies, Mus musculus domesticus and Mus musculus castaneus, 
separated by a short evolutionary time of only one million years. The project 
investigated the subspecies-specific binding of CTCF in terms of the repeat 
content, evolution, functional impact and involvement in chromatin 
conformation. The key findings of this investigation are: (1) the incorporation 
of young CTCF sites into the non-coding genome via action of transposable 
elements is followed rapidly with the exhibition of various characteristics of 
biological function; (2) Unlike other tissue-specific transcription factors, allele-
specific CTCF occupancy is affected by cis- and trans-acting regulatory 
mechanisms that exhibit similar functional characteristics; (3) CTCF 
evolutionary dynamics support both maintenance of pre-existing structures and 
functions and provide template for novel ones.  
 
 In summary, this thesis discusses the evolutionary dynamics of CTCF 
genomic occupancy and functional signatures in short evolutionary time, and 
 
 
illustrates how either novel species-specific CTCF sites, or common sites with 
newly-acquired genotypic variants integrate into existing genomic architecture 
and begin to exert their effects. 
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Chapter 1 
 
Introduction 
 
 
The transformation of a few pluripotent cells into fully-formed multicellular organisms 
stems from the differentiation of those cells into the various specialised types and cell-
lines. This is fundamentally governed by the complex array of regulatory networks 
that govern how the original set of identical DNA molecules in those progenitor cells 
are expressed in response to the innate developmental program and environmental 
cues. Understanding how the genome translates those biological and chemical signals 
into the spectrum of gene expression seen in the multitude of cell-types is a key 
question in the field of genomics. 
 
 The DNA-encoded information in eukaryotic genomes is first transcribed into 
a messenger RNA (mRNA) by RNA polymerases. RNA polymerase II (RNAP II) is 
responsible for the transcription of protein-coding genes. However, a large body of 
evidence points to the non-protein-coding regions of the genome as the location for the 
vast majority of genetic variants that influence the inter-individual and inter-species 
differences in phenotypic traits[1, 2]. Almost 90% of single nucleotide polymorphisms 
(SNPs) found to be associated with complex diseases are in the noncoding genome 
(40% in introns and 40% in intergenic regions) as revealed by the meta-analysis of 151 
genome-wide association studies (GWAS) [3-5]. Consortium efforts in the last decade 
have been successful in revealing millions of DNA noncoding elements with putative 
regulatory potential across >100 human cell lines that could potentially explain the 
myriad of biological phenomenon in health and disease[6-9]. Whereas approximately 
70% of protein coding sequences are evolutionary conserved, of the regulatory elements 
identified in the pilot ENCODE project only 10% were evolutionary constrained[6, 10]. 
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Figure 1.1: Regulation of gene transcription 
 
A summary view of the principle components of the transcriptional machinery. DNA 
is wrapped around histones in the chromatin, forming nucleosomes. Boundaries are 
demarcated by insulators. The transcription start site (TSS) comprises the proximal- 
and core-promotors, and binds RNA-polymerase II (blue circle) with its associated 
general transcription factors (little blue circles on top). Transcription factors (TFs, 
blue triangles/circles, pink sticks and green squares) bind to transcription factor 
binding sites (TFBSs) near the TSS (proximal elements) or far away (enhancers). 
TFBSs also form cis-regulatory modules (CRMs) when bound in clusters. Arrow 
indicate the various interactions acting on the gene promotor. Figure adapted from 
Lenhard et al.[11].  
 
Gene expression is critically regulated at gene level to ensure the homeostasis 
of the cell and fidelity of the developmental programme of the organism. The control 
of this regulation is shaped by the interactions of core transcriptional machinery, the 
communication with particular transcription factors and the three-dimensional (3D) 
conformation of the genome[12]. This is made possible by the presence of discrete cis-
regulatory DNA elements, known as enhancers, that control the spatiotemporal 
pattern of gene expression in tissue- and species-specific manners in the eukaryotic 
genomes[13]. This in turn is achieved through the action of multiple proteins/protein 
complexes that facilitate the interaction between these elements and the DNA at 
coding gene[14].  
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 Transcriptional enhancers are integral to the regulatory processes in the cell as 
they integrate both intrinsic inputs and extracellular signals to recruit transcriptional 
activators or repressors[15, 16]. The folding of chromosomes into favourable 3D 
structures allows for further complex patterns of transcriptional control by establishing 
physical links between genes, their regulatory elements, and the surrounding 
chromatin[17]. In the last few years, advances in the understanding of the nature of 
non-coding regulatory elements have allowed for the genome-wide mapping of 
transcription factor binding sites, long-range DNA interactions and chromatin 
signatures using assays based on chromatin accessibility and conformation capture [7, 
18-24].  
 
In this thesis, I have investigated how a master regulator of the genome, the 
CTCF protein, known to be involved in the various levels of transcriptional regulation 
has evolved to exert those functions in short evolutionary time scales. This 
investigation was based on a computational approach, focusing on the binding patterns 
of CTCF and the functional signatures of its genomic occupancy in tissue- and species-
specific manners. The evolutionary genomics governing the inheritance of CTCF were 
explored in an attempt to understand how evolutionarily variant CTCF sites are 
inherited and what patterns are observed by their binding in species-specific and 
hybrid biological contexts. This work was facilitated by the technical breakthroughs 
in next-generation sequencing (NGS) techniques, and the availability of high-quality 
genome sequences for the species involved in those investigations[25]. 
 
  Therefore, in this introductory chapter, I will give an overview of the field of 
transcriptional regulation and evolutionary genomics, as well as the methods relevant 
to the work conducted in this thesis. This chapter starts with a broad look at the levels 
of regulation of gene expression from promoter to sequence variants, with particular 
emphasis on the roles CTCF plays in this process. It then moves into an overview of 
the field of evolutionary genomics, with particular emphasis on the evolution of 
transcriptional regulation. This chapter concludes with a brief description of the 
methods and approaches employed in the investigations performed and reported in 
this thesis.  
 
 
1.1 Regulation of gene expression 
 
Regulation of gene expression is crucial to the development and maintenance of cellular 
processes of adult multicellular organisms. Transcription is the first and foremost step 
in this heavily regulated process and is where most of the rate-limiting steps are found. 
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Different cell types vary in their mRNA content and this variation correlates with the 
protein products of cell-type specific genes[26]. Failure to regulate transcription results 
in many disorders, particularly cancers[27, 28]. Regulation of transcription is achieved 
through the compound action of DNA cis-regulatory elements: core-promoters, 
promoter-proximal[11] and -distal elements such as enhancers[13, 29], repressors[30, 
31], insulators[32] and boundary elements[33](Figure 1.1). 
 
 Transcription initiates at the 5’ end of genes, within elements known as core 
promoters. Core promoters are short sequences of about 100 base pairs (bp) that 
surround the transcription start sites (TSSs) that recruit RNAP II, along with the rest 
of transcription factors required for the formation of the pre-initiation complex (PIC). 
This process determines the proper positioning and orientation for the initiation of 
transcription[34]. Core promoters, nonetheless, cannot maintain transcription, and on 
their own they yield basal transcriptional activity. Cell-type specific expression is 
further modulated by the integration of proximal and distal elements, enhancers[16, 
35]. Enhancers are DNA sequences, a few hundred bp in length, that function as 
platforms to recruit transcription factors to bind to specific DNA sequence motifs 
(reviewed in Spitz and Furlong[35]). Enhancers are capable of activating transcription 
regardless of their location, distance and direction to gene promoters. There are 
enhancers that were even observed to promote the transcription of olfactory receptor 
genes present on different chromosomes[36, 37]. It remains a challenge in biology to 
connect the regulatory elements to the genes they control since most of these are often 
separated by thousands of bps [38, 39]. 
 
 In addition to cis-regulatory elements, the unfolding of chromatin is a 
prerequisite to the activation of transcription. The decompaction of chromatin is 
facilitated by the action of enhancer-bound transcription factors that attract histone-
modifying enzymes, or through an ATP-dependent mechanism (more on this later in 
1.1.3)[40]. This process increases DNA accessibility for the various components of 
transcriptional machinery to assemble and initiate mRNA production.   
 
 The following sections go over the main layers of transcriptional regulation of 
gene expression: (1) regulation at the level of transcription initiation at the core 
promoter; (2) regulation of cis-regulatory elements via binding to transcription factors; 
(3) regulation at the level of chromatin through nucleosome modifications, looping and 
higher order structures and chromatin compartmentalisation; and (4) regulation via 
cis- and trans-acting variation.  
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1.1.1 Transcriptional regulation at the core promoter, 
initiation and PIC formation 
  
The classical definition of a gene promoter is that it is the DNA region required for 
the initiation of gene transcription[41]. Based on this definition, these regions overlap 
with the TSSs, the loci where the output of regulatory potential translates into gene 
expression via initiation of transcription. The fundamental function of the promoter is 
to provide a binding site for the assembly and positioning of the pre-initiation complex 
(PIC), which in turn recruits a DNA-dependent RNA polymerase (such as RNAP II). 
In eukaryotes, this region is termed the “core promoter”[11]. The core promoter 
consists of multiple interchangeable sequence elements, such as an initiator element 
and  a TA-rich sequence (TATA box), that bind the component of the PIC[42]. These 
elements are needed for the formation of the basal transcriptional machinery[43].   
 
 Whereas bacterial and archaeal gene transcription is carried out by only one 
RNA polymerase (RNAP), eukaryotic genomes are transcribed by three RNAPs that 
are highly conserved in evolution[44]. RNAP I is responsible for the synthesis of the 
ribosomal RNAs (rRNAs) RNA precursors of the translational machinery. RNAP II, 
as discussed above, transcribes all protein coding genes to mRNA. RNAP III is 
involved in the transcription of transfer RNAs (tRNAs) and small subunit of rRNA, 
in addition to small untranslated RNA such as general transcription factors (GTFs). 
Whilst the three RNAPs share a common catalytic core, essential polymerase-specific 
subunits and GTFs are needed for the proper regulation of each polymerase’s 
activity[45]. Importantly, the basal transcriptional activity of RNAP II is a concerted 
effort of the RNAP II complex with its associated GTFs: TFIIA, TFIIB, TFIIE, TFIIF, 
TFIIH and TATA-box binding protein (TBP). These components assemble together 
to form the PIC in a step-wise process[46, 47]. Additionally, during promoter melting, 
an ATP-dependent translocase activity of the GTF TFIIH is required by RNAP II in 
order for the transcriptional bubble to form[48-51]. 
 
 The process of DNA transcription contains at least eight (Figure 1.2) principal 
steps that can be regulated in a rate-limiting manner to ensure the precise control of 
gene expression. This is better understood as a cycle that starts with (1) RNAP II 
accessing the obstruction-free core promoter after being cleared from nucleosomes. (2) 
RNAP II and associated GTFs form the PIC on the core promoter. (3) Promoter 
opening follows, and transcription is initiated. (4) RNAP II escapes from the core 
promoter and begins early elongation of the nascent RNA chain, and moves into the 
promoter-proximal pause region. (5) Paused RNAP II is subsequently 
hyperphosphorylated, and clears the pause region, resulting in either the termination 
of transcription or continuing elongation of the mRNA chain. (6) If RNAP II undergoes 
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continuing elongation, it proceeds throughout the whole length of the genebody. (7) 
Transcription is terminated once RNAP II reaches the end of the gene, and (8) a new 
cycle of transcription is initiated if the conditions at (1) remain permitting[12](Figure 
1.2). The distribution of RNAP II across many genes have been studied in a number 
of species as a proxy to the rate-limiting steps in transcription[52]. A wealth of data 
on RNAP II density genome-wide is now available for multiple species such as 
yeast[53], fruit fly[54, 55] and humans[56]. 
 
 
Figure 1.2: The 8-step transcriptional cycle 
 
(1) DNA is packaged into nucleosomes (green), until an activator (orange oval) binds 
and nucleosome remodelling begins. (2) A 2nd activator (yellow diamond) promotes 
GTFs (blue rectangles) binding and attract coactivators (green hexagon). RNAPII 
enters the PIC. (3) DNA is unwound (oval inside RNAPII). (4) RNAPII begins 
transcribing 20-50 bp (purple line), then pauses, mediated by SPT4!SPT5 (pink 
pentagon) and negative elongation factor (purple circle). Ser 5 residues of RNAPII C-
terminal domain (CTD) are phosphorylated (red P). Step 5: P-TEFb (blue triangle) 
phosphorylates Ser 2 of RNAPII CTD, SPT5 and the NELF subunits (blue Ps). NELF 
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dissociates from the complex. RNAPII exits the pause. Step 6: Nucleosomes are 
disassembled and reassembled as RNAPII elongation complex proceeds along the gene. 
Step 7: After RNAPII complex transcribes the gene, it is removed from the DNA, and 
the mRNA is released. Step 8: The freed RNAPII reinitiate. Figure adapted from Fuda 
et al. [12] 
 
Regulation of transcription at the first step, for example, is established by 
limiting RNAP II access to core promoters that are covered by nucleosomes. 
Transcription of such genes requires the recruitment of nucleosome-remodellers and -
modifying enzymes. This is achieved by communication between the core promoter 
and proximal regions and more distal enhancer sequences, bound by activator or 
repressor transcription factors, indirectly via a Mediator complex of proteins[57]. 
Human and yeast activators have been shown to interact with the SWI/SNF 
remodelling complexes to allow nucleosome clearing and activation of transcription[58]. 
The recruitment of histone acetyltransferase Gcn5 to galactose-inducible genes by Gal4 
in yeast modifies the chromatin state at the promoter and allow for transcription 
initiation[59]. RNAP II recruitment provides another step for regulation of 
transcription. Following initiation, RNAP II proceeds rapidly towards elongation and 
becomes uniformly distributed across the gene body[60]. In response, PIC formation is 
accelerated by activators that interact with the GTFs TBP, TFIIA, TFIIB and 
TFIID[61]. The recruitment of the Mediator complex leads to further interaction with 
the GTFs, stabilization of the PIC, increased RNAP II recruitment and upregulated 
expression[62].  
 
 Another layer of regulation at the core promoter is based on DNA sequence 
content around the promoter-proximal regions in the genome. Stretches of ~ 1000 bp 
long with a base composition rich in GC-bases and high density of CpG dinucleotides 
are known as CpG islands (CGIs), and are prominent in mammalian genomes[63]. 
CGIs account for 1% of the genome, and incorporate the TSSs of most mammalian 
genes. They are significantly more enriched in GC-content that the bulk genomic DNA 
in humans (65% vs 40% G+C content)[64]. CGIs are found in the TSSs of about 60% 
of genes in human, and they can also be found within and between genes. Non-TSS 
CGIs additionally exhibit TSS-like characteristics, such as association with RNAP II, 
detection of present transcripts and colocalization with the trimethylation of lysine 4 
of histone H3 (H3K4me3) chromatin mark of transcriptionally active promoters, 
suggesting their regulatory potential as promoters[65-67]. 
 
 Based on their CGIs content, mammalian promoters can be classified into three 
major types: Type I (adult), Type II (ubiquitous) and Type III (developmentally 
regulated)[11]. Type I promoters are responsible for the tissue-specific gene expression 
1. Introduction 
 
 8 
in terminally differentiated adult cell lines. They are characterized by a narrow/sharp 
TSS and disordered nucleosome conformation, consistent with their spatiotemporal 
narrow range of expression. These promoters are also, crucially, the ones whose 
promoters are low in CGIs[68-71]. Type II promoters are expressed broadly throughout 
the organism, and are defined by a broad TSS and an ordered nucleosome structure. 
They are also the promoters highly enriched for CGIs[68-71]. Type III promoters are 
variably regulated during development and exhibit Polycomb-repression with a broad 
histone methylation marks (H3K27me3), and CGIs that extend into the 
genebodies[72].  
 
 CGIs have additionally been shown to be nucleosome-deficient in vivo, making 
CGI-rich promoters easily accessible for transcription factors, and they do not require 
the ATP-dependent SWI/SNF remodelling of chromatin discussed earlier[73]. 
Experiments in mouse brain cell lines indicate that promoter-associated, non-
methylated CGIs exert chromatin modifications by interaction with Cfp1 and other 
CGI-binding proteins[74]. Therefore, CGIs functional role in transcriptional regulation 
lies in its inherent ability to expose local chromatin of nucleosome, helping it adopt a 
transcriptional initiation-friendly configuration[64].  
 
 
1.1.2 Transcriptional regulation at distal enhancer 
elements via TF binding 
 
Enhancers are cis-regulatory elements located a considerable distance upstream or 
downstream from the core promoters that recruit transcription factors, RNAP II and 
chromatin remodellers to establish or maintain an active transcriptional state via PIC 
[75-80]. Enhancers interact with the core promoter via the Mediator complex and the 
GTF TFIID to help attract RNAP II to the PIC[81]. They modulate transcription of 
the genes they control, which may not be the closest ones based on their distance 
alone[82-88]. These interactions are not exclusively used for the initiation of 
transcription, but may also contribute to the release of RNAP II from the promoter-
proximal pausing region (step 4 discussed above)[89]. The first mammalian enhancer 
was identified downstream of the immunoglobulin (Ig) heavy-chain locus, which 
upregulates the expression of the Ig gene in the lymphocyte-derived cells during B-
lymphocyte differentiation[90, 91].  
 
Enhancers begin recruiting general and lineage-specific transcription factors at 
the ESC stage, whereas promoters are unlikely to be bound by developmentally 
important and tissue-specific factors[92-97]. Thus, enhancers play a central role in 
establishing the spatiotemporal pattern of gene expression in animals[13, 98-101]. 
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Highly-expressed genes that share common regulatory enhancers tend to cluster 
together at nuclear loci called transcription factories[102]. Enhancers are also capable 
of activating homologous and heterologous promoters independently of their position 
up/downstream of the genes or their orientation, and additionally display DNase I 
hypersensitivity, which is the main criterion used to identify enhancers in genome-wide 
scans of mammalian genomes[43].  
 
A new class of regulatory enhancers has been recently described as super-
enhancers[103-105]. These are enhancer-like cis-regulatory elements marked by the 
acetylation of histone H3 lysine 27 (H3K427ac) and occupied by master regulators, 
especially the Mediator complex. They form a cluster of regulatory elements up to 12.5 
kb in size, flanked by CTCF-binding sites, indicating that their influence may be 
regulated by boundary elements[106]. They have been identified in several cell lines, 
and were proposed to act as critical switches to determining cell fate[107-109]. 
However, a recent study using an erythroid cell line in a mouse model that targeted 
the constituents of the α-globin super-enhancer individually for deletion demonstrated 
that each element acts independently and in additive manner to exert their phenotype. 
No evidence of synergistic activity between the super-enhancer’s members or higher-
order effects were clearly observed[110]. 
 
In addition to recruitment of RNAP II to promoters, a number of studies in 
mammalian genomes have recently demonstrated that RNAP II is similarly recruited 
to active enhancer elements where is initiates widespread transcription of their DNA 
sequences[111-113]. Enhancer-transcribed RNAs (eRNAs) are 0.5-5 kb in length, 
similar to long-noncoding RNAs (lncRNAs)[114]. eRNAs had originally been 
considered as sequencing noise of nonspecific mRNA transcripts resulting from genomic 
regions accessible to transcriptional machinery[115], but there is a current agreement 
that these eRNAs may have a role to play in gene regulation, although the nature of 
this role remains controversial[43]. In vivo study in 2014 confirmed that many of these 
eRNAs are expressed in tissue-specific manner[116], followed a comprehensive 
transcriptomic profiling of eRNAs in humans[117]. A 2015 study demonstrated the role 
of the RNA exosome in regulating eRNA degradation[118], and another study showed 
some eRNAs are implicated in metabolic stress[119]. 
 
In order for enhancers to activate transcription, they require the binding of 
multiple TFs to ensure the integration of both cellular signals and extracellular cues 
from the environment[107, 120, 121]. The action of multiple TFs is critical to the 
function of enhancers as these elements have a high affinity to nucleosomes[122], hence 
the compound activity of all these factors provide a strong barrier to the repressive 
effect of chromatin on the underlying regulatory elements. Enhancer elements are thus 
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thought of as genomic ‘nexus’ sites where the input activities of myriad TFs are 
integrated into the overall array of transcriptional regulatory output. These TFs are 
assembled into a hierarchical logical organisation at the enhancer elements, as shown 
in a recent study using mouse liver cis-regulatory modules as a model for this 
interaction[123]. 
 
The interaction between the various TFs bound to enhancers in close proximity 
is thought to happen cooperatively and plays a central role in nucleosome eviction and 
subsequent enhancer activation[35]. Three main modes of cooperativity between TFs 
at enhancer elements have been proposed. The first mode, termed ‘direct 
cooperativity’, relies on the direct physical association between TFs prior to or 
concurrent with binding to their DNA motifs. The second mode, ‘indirect 
cooperativity’ or ‘collaborative competition’, occurs when a number of TFs compete 
over access to the enhancer element with the same histone octamer, as predicted in 
silico modelling[124], then experimentally demonstrated[125]. As a result, the more TF 
motifs found at an enhancer, the higher the rate of nucleosome eviction, DNA binding 
and gene expression; a view supported by multiple studies investigating endogenous 
enhancers and synthetic reporter assays[126, 127]. A third mode is observed at a 
number of developmental enhancers, where evidence of step-wise activation by lineage-
determining master regulators or ‘pioneer factors’ that bind directly to nucleosomal 
DNA and prime enhancers for action[128]. Pioneer factors are capable of recruiting 
chromatin remodellers, histone-modifying enzymes, easing the burden of direct 
competition between subsequent TFs and coactivators and nucleosomes on binding to 
the DNA[129]. 
   
Although pioneer factors are supposed to have universal remodelling and 
targeting capabilities, they have been demonstrated to display a level of cell-type 
specificity[129-131], influenced by various factors such cell-type-specific cofactors (e.g. 
FoxA1 and Sox2)[132-134], signalling (TNFα)[135] and chromatin state[136, 137]. A 
comprehensive investigation of the genomic occupancy of three such factors, FOXA2, 
GATA4 and OCT4, in multiple human cell lines have shown that all three TFs display 
tissue-specific occupancy, even when their expression is imposed ectopically. The 
expression of additional cofactors increased the enrichment at a subset of binding sites 
in alternative cell types, indicating the essential requirement of such cofactors for the 
correct function of pioneer factors[138].  
 
Coactivators are factors essential for the proper function of the DNA-binding 
TF, but not necessarily for the basal transcriptional machinery, and they do not 
exhibit site-specific binding on their own[81]. They exert their effects by modifying the 
chromatin context of enhancers using a host of histone-modifying enzymes: histone 
1. Introduction 
 
 11 
acetyltransferases (p300/ CBP, SAGA complex, MOF, TIP60), histone 
methyltransferases (MLL3/4, CARM1), chromatin remodellers (Brg1, CHD7), and the 
Mediator complex that facilitates the interaction with the PIC at the core promoter 
[81, 139, 140]. Therefore, coactivators are linked to most active enhancers 
independently of the cell-line they are found in, allowing their use for annotations of 
putative enhancers in a variety of tissues, using ChIP-seq to map their genomic 
occupancy [141-143]. 
 
Enhancers adopt different, but not mutually exclusive configurations to 
interact with their corresponding promoter based on the genomic distance between 
them. Three principal models have been proposed: a linking model, a tracking model, 
and a looping model[43]. In the linking model, a cohort of TFs are sequentially 
recruited after the binding of the first activator or pioneer TF which results in open 
chromatin conformation. A trail of TFs subsequently bind along the chromatin fibre 
extending from the enhancer element towards the core promoter, attracting the PIC 
for transcription initiation[134]. This model, however, is only applicable at short ranges 
as the formation of such a cascade is highly unlikely over vast genomic distances. In 
the tracking model, TFs occupying the enhancer element include active RNAP II and 
proceed towards the target promoter unidirectionally[144]. The most well-known 
example of this model is the 70-kb region containing the locus control region (LCR) of 
the human beta-globin gene[145].  
 
The most common model, however, involves the direct contact between 
promoters and enhancers by looping of the chromatin to bring close regions separated 
by long distances (Figure 1.3). The resultant loops are further stabilised by protein-
protein interactions between the TFs, coactivators, GTFs and RNAP II and the PIC. 
Specialised factors and protein complexes work to bridge the gap and allow physical 
contact between the cis-elements they occupy. These factors include the chromatin 
remodelling Mediator complex and the CCCTC-binding factor (CTCF)-cohesin 
protein complex[146] (Figure 1.3). In addition, eRNAs have being suggested to 
contribute to the process by stabilising enhancer-promoter looping via interaction with 
either the cohesin or Mediator complexes[147, 148].  
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Figure 1.3: Enhancer-promoter interactions 
 
Enhancer-promoter interactions allow the tethering of distal cis-regulatory elements 
to the core-promoter. Recruitment of TATA-binding protein-associated factor 3 
(TAF3) at endodermal enhancers by the CTCF-cohesin complex and chromatin 
looping activates the mitogen-activated protein kinase 3 (Mapk3) gene in mouse 
embryonic stem cells (mESCs). Figure adapted from Ong and Corces [80]. 
 
Functional enhancers harbour clusters of TF recognition motifs. These are DNA 
sequences that the DNA-binding domain on TFs can recognize and occupy in order to 
exert their effects. The discovery and annotation of these motifs has been the subject 
of large-scale experimental and in silico efforts leading to the establishment of two 
major databases of such information: JASPAR[149] and TRANSFAC[150]. The 
annotations included are based on experimentally determined cohorts of TF binding 
sites (TFBSs) that are subsequently aligned and the enrichment of bases at each 
position of the motif weighted to produce positional weight matrices (PWMs) for the 
plethora of TFBS in the eukaryotic genome[151]. 
 
The identification of genome-wide enhancer elements and TF motifs have 
opened the door for recent investigations attempting to link genetic variation in the 
noncoding genomes with particular phenotypes in health and disease. A study in 2013 
estimated that 7.5% of variation in TF-DNA binding events can at least be explained 
1. Introduction 
 
 13 
by alteration in TFBS motifs[152]. Using genomic data from the Genotype-Tissue 
Expression Project (GTEx)[9], a recent group showed that purifying selection in the 
general population has reduced haplotypes predicted to increase pathogenic coding 
variant penetrance, indicating that cis-regulatory variation could predispose to disease 
risk by modulating the penetrance of gene variants [153]. Another study used a 
CRISPR-Cas9 system to target DNase I hypersensitive sites of the beta-globin and 
HER2 loci in humans, affirming the role of known regulatory regions, and discovering 
previously unreported elements[154]. A similar method probing the function of 
enhancer clusters in mouse embryonic stem-cell lines (ECs) revealed the effect of 
deleting these enhancers varies greatly, with reduction in gene expression ranging from 
12% to 92%[155]. Partial deletions of one or more components of these clusters also 
demonstrated a degree of redundancy in gene regulation by these enhancers, a feature 
that may ensure the fine-tuning of transcriptional output and protect against arbitrary 
loss of some of these enhancers[155]. Views from cancer research support the 
importance of enhancer sequence fidelity for the proper functioning of these elements, 
with evidence from the analysis of 102 tumour cell genomes that somatic small 
insertion or deletions (INDELs) can nucleate oncogenic enhancer activity[156, 157]. 
An insertion in the enhancer of the LMO2 oncogene leads to its activation and the 
progression to leukaemia[157]. 
 
It is still a long road towards understanding how the interactions between the 
regulatory elements and our ability to predict the outcome of such interaction on the 
genomic-scale. The target genes for most enhancer elements are unknown, and whilst 
it is well-agreed that many genes are under the control of several regulatory 
elements[158, 159], our models of the multi-modular structure of gene regulation are 
still limited.  
 
 
1.1.3 Transcriptional regulation via modifications to the 
chromatin structure 
 
The 3D conformation of the genome performs a major role in the maintenance of 
genome stability, organization, and regulation of gene transcription in health and 
diseases. Chromatin is the most intricately regulated ensemble in the cell. It is made 
up of genomic nuclear DNA and its associated proteins and RNA molecules. DNA-
associated proteins include histones, TFs, the PIC, mRNA, coactivators and other 
complexes necessary for the replication and repair of the 3D genome. Although 
chromatin folding is governed by a set of general principles in all cells of the 
multicellular organism, the spatial configuration of the genome is highly variable 
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between cell lines to the extent that no two nuclei will exhibit the same range of 
chromosomal connections[160-162].  
 
A major determinant of DNA accessibility is the presence of nucleosomes. A 
nucleosome-wrapped DNA sequence is more resistant to the binding of TFs that the 
same sequence in a nucleosome-free state[163, 164]. A nucleosome is evicted from the 
DNA by action of remodelling factors that alter its location along the DNA 
molecule[40]. Nucleosome-depleted regions provide an amble opportunity for DNase I 
activity. There are over 870,000 DNase I hypersensitivity regions in humans, covering 
almost 9% of the genome[10]. These areas of open chromatin tend to cluster around 
the TSSs and coincide with CTCF binding sites when identified in multiple cell lines. 
However, cell-type-specific sites are found further away from the TSSs and harbour 
motifs recognized by the corresponding tissue-specific TFs[10]. 
 
Regulation of transcription at the level of chromatin also involves the post-
translation modification of the histones that make up the nucleosome complex[165].An 
extra layer of regulation of the chromatin is conferred by the Polycomb and Trithorax 
protein complexes[166-168]. Chromosomes are additionally partitioned into nuclear 
territories and compartments, made up in turn of topologically-associated domains 
(TADs), each involving a number of entangled DNA loops, formed by action of several 
proteins such as CTCF and the cohesin protein complex [169, 170]. Major development 
in chromosome conformation capture technologies in the last decade, coupled with 
advancements in mathematical modelling for interpreting the data, has revolutionised 
the analysis of chromatin and elucidated its involvement in various cellular 
process[171-176]. 
 
The following section will give an overview of the three main levels of regulation 
of gene expression via changes to the chromatin structure: (1) Nucleosomes and histone 
modifications at cis-regulatory elements; (2) DNA-looping and higher-order chromatin 
conformations; and (3) chromatin compartmentalisation and the establishment of 
TADs. 
 
1.1.3.1 Nucleosomes and histone modifications 
 
In eukaryotes, nuclear DNA exists in complex with a particular class of proteins known 
as histones. A DNA sequence of 147 bp wraps around the nucleosome core particle in 
1.7 supercoiled turns. The core nucleosome is comprised of two histones 3-histone 4 
(H3-H4) and two histone 2A-histone 2B (H2A-H2B) dimers. A 10-80 bp DNA linker 
associated with the linker histone 1 (H1) separates nucleosomes, by promoting 
compaction of neighbouring nucleosomes. H1 is common in heterochromatin where 
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greater compaction results in its condensed appearance. This complex of DNA and 
nucleosome folds into a 10 nm diameter fibre. In vitro studies have shown that in vivo 
this fibre forms a helical fibre containing 6-11 nucleosomes per turn. This in turn folds 
further to make higher order chromatin fibres in interphase, and a 200-300 nm 
structures during condensation of mitotic chromosomes (reviewed in Felsenfeld et. 
al[177]).  
 
 Histone modifications lead to changes in nucleosome occupancy and regulatory 
potential. These are post-translation modifications that have been reported to affect 
over 60 different amino acid residues on histones, instigated by protein-modifying 
enzymes, many of which also have non-histone substrates[178]. These include: 
acetylation, methylation, phosphorylation, ubiquitylation, propionylation, 
butyrylation, formylation among others[179, 180]. Enhancer-bound TFs have recently 
been shown to actively recruit histone-modifying enzymes through direct interactions 
with histone tails, and ATP-dependent remodellers of chromatin that disrupt 
nucleosome-DNA contacts and allow nucleosome displacement along the DNA, and its 
removal or exchange[40, 89, 181, 182]. Histone modifications are critical for regulation 
of transcription. For example, the acetylation of lysine residues on histone tails 
neutralises their positive charge and changes chromatin overall charge[183, 184]. 
Similarly, lysine methylation may lead to an increase in the binding affinity on the 
DNA-binding domains on a number of factors believed to act upon chromatin 
packaging[185]. Disruptions to the histone modification process have been associated 
with a number of disease phenotypes[186-188]. This is not unlikely given their function 
as transducers of intrinsic signals from the cell to the genome[189].  
 
The ‘histone code’ refers to the combinations of modifications required to 
instigate downstream events[165, 190] (Figure 1.4). It is now commonplace to refer to 
some of the modifications as ‘activator’ or ‘repressor’ marks depending on the outcome 
of the event they regulate[191]. There are currently over 150 described histone 
modifications, and a single nucleosome could carry multiple modifications at the same 
time, alas only a small number of these modification patterns have been discovered 
[67, 192]. Several groups have been working on profiling and mapping different histone 
marks genome-wide to identify the underlying code and how it associates with gene 
activation/repression, or other genomic features such as promoters, enhancers and 
insulators[21, 56, 193-195].  
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Figure 1.4: Histone modifications "code" for cis-regulatory elements 
 
Various histone modification combinations dictate the regulatory potential of 
promoters (a) and enhancers (b). Figure adapted from Zhou et al. [196]. 
 
As discussed earlier in 1.1.1, most promoters colocalise with regions of high GC 
content, CGIs, and are known as high GC promoters (HCPs), in contrast to their 
counterparts in low-CGI regions, the low GC promoters (LCPs). Studies have shown 
that the histone mark H3K4me3 coincided with HCPs, and were characterised with 
increased chromatin accessibility, histone acetylation, binding of histone H3.3 and 
marked DNase I hypersensitivity[197-199] (Figure 1.4a). Similar to the HCPs, these 
accessible H3K4me3-marked regions were also hypomethylated at the DNA level[200]. 
On the contrary, LCPs appeared inactive by default, and they lacked any measurable 
enrichment with either H3K4me3 or H3K4me2 in ESCs or adult cell lines. However, a 
minor subset of LCPs bore the H3K4me3 mark and were highly expressed compared 
to the unmarked LCPs[21, 200] (Figure 1.4a). 
 
Repressed promoters display a unique histone modification pattern that reflect 
their transcriptionally inactive state. They are usually marked by the tri-methylation 
of lysine 27 of its histone 3 (H3K27me3), which is also the prototypical mark of the 
Polycomb repressor complex. Polycomb repressor complexes, PRC1 and PRC2, inhibit 
transcription to maintain cell-type-specific gene expression patterns[201]. A large 
number of HCPs are targeted by Polycomb in mammalian genomes. For example, 
about 20% of HCPs in ESCs are bound by PRC2 and marked with its associated mark, 
H3K27me3[202-204]. Interestingly, these promoters also carry the H3K4me3 activator 
mark , thus are capable of ‘bivalent’ characteristics, being both activated and 
repressed[205]. ESC bivalent promoters show very low levels of gene expression[206], 
but later studies have identified some RNAP II enrichment[56, 207]. The tri-
methylation of lysine 9 of histone 3 (H3K9me3) is another repressed promoter mark 
that correlates with constitutive heterochromatin and DNA hypermethylation[196].  
 
Whereas mapping promoters is somewhat straightforward, histone 
modifications have been instrumental in helping identify enhancer elements in an 
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unbiased fashion[196]. Enhancers are characterised by the presence of particular 
histone marks in addition to the binding of TFs and other co-activators such as 
p300[75]. Analysis have shown enhancers to be enriched for marks such as H3K27ac, 
H3K4me2, H3K9me1, H3K27me1, H2BK5me1 and H3K36me1, indicating a degree of 
redundancy in the histone code[199] (Figure 1.4b). Nevertheless, an enhancer histone 
code could also be fine-tuned by acetylation of H2A.Z, resulting in corresponding 
differences in downstream gene activation[198]. Although enhancers are commonly 
marked with H3K4me1 and H3K27ac, they could also be marked with H3K4m3, the 
active promoter mark, if an enhancer is highly transcribed[195, 208, 209]. Therefore, 
putative active enhancers are identified by a cohort of criteria including measuring the 
ratio of H3K4me1 to H3K4me3, along with the presence of H3K27ac, the replacement 
of histones with the variant H2A.Z, the binding of coactivators p300/CBP and 
cooperative binding of master TFs[16, 210-215]. Poised enhancers, on the other hand, 
are characterised by the noted absence of the H3K27ac mark and the enrichment of 
H3K27me3 and/or H3K9me3, an epigenetic feature later found to be common a large 
number of enhancers with tissue specificity. This poised state could, however, be 
readily reversed when the histone mark H3K27me3 is modified and replaced with 
H3K27ac[209]. 
 
1.1.3.2 Long-range interactions and chromatin-loops  
 
Chromatin status provides a proxy to the level of cis-regulatory activity, and a measure 
of the widespread changes in enhancer position and activation state in relation to the 
gene promoters they interact with. In addition to trans-acting TFs, activation of 
enhancers is combined with the folding of chromatin into loops of long-range 
interactions between cis-regulatory regions and the core promoters of the genes they 
regulate[79, 216, 217].  
 
Chromatin long-range loops form when pairs of loci have stronger interactions 
than any of the other loci in-between[218]. ~30% of loops involve promoters and 
enhancers, resulting in changes in gene expression and transcriptional activity[219, 
220]. 66% of active promoters interact with their nearest enhancers, yet 30% bypass 
that enhancer, whereas 4% display preferential unidirectional interaction even if the 
enhancer in the other orientation is much closer[221]. In contrast to previous theories, 
90% of these promoters involve at least one more distant enhancer, leading to complex 
interaction patterns[221]. A recent major study in 17 human primary hematopoietic 
cell types found 17,500 interactions between promoters and promoter-interacting 
regions (median = 4 interactions/promoter), 50% of those interactions were with one 
promoter and 10% with =>4 promoters, further complicating the landscape of gene 
regulation through higher-order chromatin conformations[222]. This redundancy could 
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be explained from an evolutionary perspective as a safety mechanism to counter 
pathological effects of enhancer disruption by mutation[222].   
 
A 2012 study looking at the 1% of the human genome from the ENCODE pilot 
project showed that long-range interactions display asymmetrical preference for 
elements located 120 kb upstream of the TSS. These interactions were found to not be 
blocked by CTCF and cohesin occupancy, and that only 7% of the looping interactions 
are with the nearest promoter, emphasizing that proximity is not definite indicator of 
long-range interaction. Furthermore, promoter-enhancer looping interactions 
correlated significantly with gene expression and the presence of eRNAs[39].  
 
Using Promoter Capture Hi-C, a recent study generated a high-resolution atlas 
of chromosomal interactions in human pluripotent and lineage-committed cells for 
~22,000 promoters. They identified putative target genes for known and predicted 
enhancer elements, and revealed how gain and loss of promoter interactions changes 
the dynamics of cis-regulatory contacts upon lineage commitment[223]. The Mediator 
and cohesin protein complexes have been shown to be implicated in promoter-enhancer 
looping interactions[224]. Promoter-enhancer interactions also restrict divergent 
transcription of noncoding RNAs (ncRNAs) made by RNAP II from bidirectional 
promoters by adopting gene-loop configuration[225]. Interestingly, formation of 
promoter-enhancer loops is also associated with recruitment of the corepressors NCoR 
and HDACs, demonstrating that chromatin looping is coupled to activation of poised 
enhancers. MLL3/4-dependent H3K4me1 has been shown to orchestrate long-range 
promoter-enhancer interactions in mammalian cells. Yan et al. demonstrated that 
increased levels of chromatin interactions correlated with MLL3/4-dependent 
deposition of H3K4me1 at enhancers in differentiating mouse embryonic stem cells. 
H3K4me1 loss resulted in reduced levels of chromatin interactions and defective gene 
expression during differentiation[226]. H3K4me1 facilitates cohesin complex 
recruitment to chromatin in vitro/vivo, potentially allowing MLL3/4 to mediate 
chromatin interactions between enhancers and promoters. 
 
1.1.3.3 Topologically-associated domains (TADs) and chromatin 
compartmentalisation 
 
The 3D configuration chromatin assumes is central to its ability to carry out its 
biological function[227, 228]. Within the nucleus, heterochromatin is physically 
separated from euchromatin. This has been established firmly in several studies that 
have demonstrated that open, gene-rich genomic loci are found in distinct subnuclear 
regions to condensed, closed and gene-poor chromosomal domains[229-231] (Figure 
1.5). High-throughput chromosome conformation capture technique (Hi-C) has allowed 
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the identification of chromatin-chromatin interactions genome-wide[232], and revealed 
that higher eukaryotic genomes are organised into areas of active chromatin (A 
compartments) and inactive chromatin (B compartments)[232] (Figure 1.5). These 
compartments consist of a number of super-TADs, TADs and sub-TADs[78, 233-236].  
   
 
Figure 1.5: Levels of chromatin organisation in the mammalian nucleus 
 
(a) Chromosomes are organized into chromosome territories (CT). (b) CTs are 
compartmentalised into A & B (Red and Blue globules). (c) Topologically-associated 
domains (TADs) interact (i) within sub-TADs (frequent), (ii) between TADS of the 
same CT (rare), or (iii) between close CTs (very rare). (d) Chromatin as a 30 nm fibre, 
then (e) as a 10 nm series of nucleosomes (beads on a string conformation). Figure 
adapted from Hubner et al. [237]. 
 
TADs are largely invariable across different tissues and cell lines, and highly 
conserved in evolution[238], but recent evidence indicate TAD boundaries can display 
variable permissibility from ‘weak’ TAD boundaries that permit more inter-TAD 
interactions, to the more strict ‘strong’ boundaries that demarcate adjacent 
TADs[239]. Exposure to heat-shock in fruit flies resulted in changes in TAD boundaries 
and merging of neighbouring TADs[240]. Another example comes from the Hox cluster 
in mammals where TAD/sub-TAD boundaries are not rigid and their fluidity is 
associated with changes in gene expression during motor neuron differentiation[241]. 
TAD boundary strength is apparently positively linked to the binding of CTCF[241] 
(Figure 1.6a).    
 
TADs were first identified in a Hi-C analysis in mouse ES cells which identified 
2200 topological domains interacting locally, and occupying over 90% of the genome 
sequences[235]. These domains displayed enrichment for housekeeping genes, short-
interspersed repeat elements (SINEs), and punctuated by boundary elements with 
insulator characteristics such as the heterochromatic H3K9me3 histone modification 
and CTCF-binding (Figure 1.6c). The hierarchical architecture of chromatin domains 
was also found to be conserved between human and mouse, and invariable across 
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tissues. When compared with previously described A and B compartments described, 
replication time zones, lamina-associated domains (LADs) and large organized 
chromatin K9 modification (LOCK) domains, these domains appeared related to, but 
distinctly different from each of these domain-like structures[235]. Using ChIP-seq in 
a follow-up investigation, a significant concurrence with cis-regulatory enhancer-
promoter units was observed in this domain in 19 embryonic and adult mouse cell 
lines[242]. Genes within a single TAD are under transcriptional coregulation, and 
whilst TADs generally do not alter during development, intra-TAD interactions vary 
and rearrange during ESC differentiation, connecting chromatin and transcriptional 
regulation[78]. 
 
TADs partition the chromosomes in such a way that adjacent loci have low 
interaction frequency if they happen to be located on different TADs. This effect 
constrains the effect a regulatory element such as an enhancer could exert on the DNA. 
The exact number and size of TADs remains an open question, with number varying 
from 2200 originally identified TADs in mice to between 4000-9000 TADs in humans, 
and from 880 kb in size to between 40-3000 kb respectively[219, 238]. TADs consist of 
smaller sub-TADs (100s of kb long) and ‘contact domains’ (10-100 kb long)[219, 234]. 
CTCF clustering and transcriptional coregulation are correlated with TAD scales 
during differentiation[243]. Disruption of TADs have been linked to a number of 
clinical phenotypes such as limb malformations and cancer[244, 245]. Mitotic 
chromosome with deleted TADs display a more fluid genomic structure and various 
changes during cell cycle[244]. Higher TAD boundary insulation correlates with 
increased CTCF levels and varies across tissues. Super-enhancers are observed to be 
preferentially insulated by strong TAD boundaries, and are commonly co-duplicated 
in cancer patients[246]. 
 
Deletion of the cohesin-loading factor Nipbl in mouse liver leads to significant 
alteration of chromosomal folding. TADs vanish globally, even when transcriptional 
changes are not detected[247]. Structural variants can also reshape TADs, resulting in 
large-scale rewiring of regulatory interactions and gene mis-expression[248]. 
Interestingly, compartmentalisation is maintained and even reinforced. On the 
contrary, TAD removal reveals a finer compartment structure that accurately preserve 
the epigenetic landscape. The 3D organization of the genome is apparently the product 
of two separate mechanisms: cohesin-independent compartmentalisation of the 
genome, dictated by chromatin configuration; and cohesin-dependent TAD formation, 
linking distal enhancers to their target promoters by loop extrusion[247]. 
 
As mentioned previously, open and closed chromatin are located in distinct, 
spatially separated nuclear compartments, A and B compartments. These are further 
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divided on basis of the pattern of their chromatin-chromatin interactions into A1-2 
and B1-4 respectively[232]. Although both sub-compartments of A include highly 
transcribed genes and active chromatin histone marks (H3K427ac, H3K79me2 and 
H3K36me3, A1 contains shorter genes with higher GC-content and finishes its 
replication much earlier than sub-compartment A2[249]. Sub-compartments of the B 
compartment are found in the periphery of the nucleus near the nuclear lamina, or in 
the nucleoli, where each exhibits a different feature: facultative heterochromatin (B1), 
pericentromeric heterochromatin (B2), exclusive association with the nuclear lamina 
(B3), or only present on chromosome 19 (B4)[219, 232]. Inactive heterochromatic DNA 
in the B compartments associates with nuclear lamina either directly or indirectly 
though lamin-associated proteins[250]. Nucleolus-associated domains carry loci mainly 
transcribed by RNAP I and RNAP III, but they also have a number of RNAP II-
transcribed gene from the olfactory receptor family[251]. These genes were intriguingly 
silenced in the cell-lines where their presence in nucleolar chromatin was observed. 
This could be a mechanism for silencing RNAP II-dependent genes via chromatin 
compartmentalisation.  
 
 
1.1.4 Transcriptional regulation via cis- and trans-acting 
variation 
 
Although several layers of gene regulation were explored above, genetic causes of 
regulatory alterations to gene expression can be broadly categorised into two main 
types: cis- and trans-acting variation. Cis-acting variation is defined as changes that 
occur within of physically close to the gene they affect, and include various elements, 
some of which have already been discussed above such as promoters, enhancers, 
microRNA binding sites in 3'-UTRs, and splicing variants. On the other hand, trans-
acting variation instigate their effects on gene regulation via diffusible elements in the 
nuclear environment that affect physically distant/unlinked genes through the 
occupancy of their binding sites, such as transcription factors, Mediator protein 
complex, RNA binding proteins[252]. 
 
The binding affinity of a TF provides a useful measure to study the 
transcriptional activation and the specificity of the spatiotemporal pattern of its 
binding to gene regulatory regions[253-255]. TF binding specificity and intensity is, at 
least partially, by cis- and trans-acting variation, but our understanding of how it 
occurs is still lacking[256]. Unravelling the interplay between TF occupancy and the 
other components of the gene regulation machinery is key to understanding phenotypic 
diversity. There are mainly two approaches to dissect cis- and trans-acting influence: 
expression quantitative trait loci (eQTL) analysis and the use of F1 crosses from 
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genetically inbred organisms[257]. The first approach, eQTL, is based on the 
correlation of a measured molecular trait, in this case gene expression or TF binding 
affinity, with sequence variants. The second, F1 hybrid crosses, investigates regulatory 
mechanisms by analysing the allele-specific pattern of divergence occurring in F1 
hybrids compared to the parental strains. The placement of two alleles from different 
genetic backgrounds into a shared nuclear environment and comparing their relative 
allelic binding, the extent to which they are influenced by cis and trans-effects can be 
measured and evaluated[258]. More on these methods will follow in section 1.4.4.   
 
A 2015 study compared the splicing differences between cultured fibroblasts 
derived from the inbred mouse strains C57BL/6J (Mus musculus domestics) and 
SPRET/EiJ (Mus spretus) to investigate the extent of cis- and trans-regulatory 
contributions genome-wide[259]. They investigated the allele-specific splicing patterns 
in the F1 hybrid of the two mice species, and found that 417/5802 alternative splicing 
events (~7%) were differentially regulated between the two F0 parental species. 381 
(6.6%) of these events showed allele-specific patterns in the F1 hybrids. The parental 
splicing divergence was found to be the result of cis-acting regulatory variation (255 
significant cis-influenced divergence compared to 62 significant trans-influenced 
divergence). Further analysis of liver tissues in mice F1 hybrid strains showed the same 
pattern of gene regulation in gene expression and TF binding predominantly via cis-
acting variation[257, 260]. Observations in Drosophila melanogaster were; however, 
different. A study in 2014 reported that trans-acting variants played an equally 
important role in splice-site divergence[261].          
 
Using F1 hybrids to study cis and trans regulatory effect has proved invaluable 
to determining the relative importance of these changes in different gene regulatory 
layers. Combining this approach with QTL studies in humans, where data from all 
main levels of gene regulation and expression, could provide a fantastic opportunity to 
study the genetic basis of phenotypic variability in health and disease[252]. These 
approaches enable us to understand quantitatively the mechanism by which the 
different levels of regulatory variation contribute to tissue-specific transcriptional 
regulation[257]. 
 
 
1.2 The CCCTC-binding Factor, CTCF 
 
CTCF is an architectural protein that is generally considered a master regulator of 
genome state and function. Loop domains, TADs and chromosome compartments are 
all enriched for CTCF binding sites with a highly sequence-specific, information-rich 
motif[170, 262, 263]. The molecular structure of the protein consists of 11 zinc fingers, 
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in complex with zinc ions bound to cysteine and histidine residues, forming the central 
DNA-binding domain, surrounded by loose C- and N-terminal domains[264] (Figure 
1.7a). CTCF is suggested to act through recognition of diverse DNA sequences by 
combinatorial usage of its 11 zinc-fingers, a sort of “CTCF code”[265]. CTCF is an 
essential cellular protein, and its 11 zinc-finger DNA-binding domain is highly 
conserved in higher eukaryotes, with a 99% and 98.7% amino acid identity between 
humans versus chicken and Xenopus frogs respectively[266-268]. CTCF activity 
regulates gene expression in various way: transcriptional activation/repression, 
enhancer blocking and setting up boundary elements/insulators, tethering promoters 
and enhancer and promoting long-range interactions, as well as blocking the spread of 
active chromatin and demarcating active from silent genomic regions[170, 269, 270]. 
CTCF bridges the gap between spatial organization of the genome and its function 
and the underlying gene regulatory processes[271].  
 
The CTCF gene is also conserved in most bilaterian metazoan, widely expressed 
in both adult differentiated tissues and during embryonic development[266, 268, 272-
276]. CTCF is the only insulator protein to be identified in vertebrates, with an 
enhancer blocking activity in vivo[277-286]. In addition to loop domains, TADS and 
chromosome compartments, CTCF is found in interaction with nuclear lamina and 
chromatin boundaries, signifying the role CTCF plays in boundary formation. CTCF 
also interacts with RNA, and many CTCF sites are not engaged in chromatin folding 
or loop formation[287, 288]. CTCF genomic occupancy is sensitive to the methylation 
status of DNA, providing a measure of control on the regulation of epigenetically 
imprinted gene expression[289-293]. Mis-regulated DNA methylation in cancers with 
metabolic deregulation disrupts CTCF binding[294]. Chromatin conformation assays 
have demonstrated that the presence of CTCF binding sites correlates with long-range 
interaction[39, 235]. CTCF binding is additionally reported at the transitions between 
distinct chromatin states, marked by histone modifications[295]. This supports the 
hypothesis that at least a subset of CTCF sites are capable of forming boundaries, 
besides blocking the spreading of regulatory effects. There are; however, many more 
CTCF sites bound in vivo than chromatin boundaries[269], indicating the wide-range 
of functions CTCF is naturally involved with. 
 
The following section will focus on the role of CTCF in gene regulation and 
chromatin structure. It explores the basis of CTCF binding and its binding site, and 
the functional consequences on gene regulation, and how it associates with the cohesin 
protein complex to achieve its wide-ranging activities in genome organisation and 
function. 
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1.2.1 CTCF binding: features and consequences 
 
CTCF binds with a high-affinity to a nonpalindromic canonical motif in its binding 
site with a sequence consensus referred to as M1[269, 296-299] (Figure 1.7a). Studies 
have shown that the central zinc fingers, 4-7/8, are needed for this interaction[300]. 
This 20 bp core motif is common to nearly all known CTCF binding sites as identified 
by various immunoprecipitation methods, and the involvement of nonspecific zinc 
fingers, other than the ones mentioned previously, with the surrounding DNA sequence 
helps stabilize the binding[297]. A second 10-bp motif, termed M2, is found upstream 
of the canonical M1 separated by a DNA spacer[269, 297, 301], where it interacts with 
the 9-11 zinc fingers[302]. Findings suggest that the M2 motif is in conjunction with 
the M1 in 15%-25% of all CTCF binding sites, whereby CTCF binds with high affinity 
depending on the spacer between the motifs[303]. 
 
The presence of a CpG in the canonical motif’s consensus sequence lends 
support to the idea that methylation of cytosine residues at carbon 5 of the base to 
form 5-methylcytosine (5mC) in CGI-harbouring CTCF binding sites may underlie 
CTCF selectivity in different cellular contexts[304]. Studies support a model where 
DNA methylation is a common regulatory measure to control CTCF occupancy at 
many loci, such as CDKN2A, B-cell CLL/lymphoma 6 (BCL6) and brain-derived 
neurotrophic factor (BDNF)[305-307]. Comparison of DNA methylation patterns in 19 
human cell lines with mapped CTCF occupancy showed that 41% of tissue-specific 
CTCF binding sites are linked to differential DNA methylation[293]. On the other 
hand, 67% of those sites that were linked with variable DNA methylation, the presence 
of 5mC correlated with a corresponding downregulation of cell-type-specific CTCF 
binding. CTCF also forms a complex with poly(ADP-ribose) polymerase 1 (PARP1) 
and DNA (cytosine-5)-methyltransferase 1 (DNMT1), activating PARP1, which in 
turn inactivates DNMT1 by poly(ADP-ribosyl)ation, maintaining methyl-free CGIs in 
the genome[308, 309]. Furthermore, other studies in mammals have observed that 
CTCF can also cooperate with RNAs to stabilize its interactions with other protein 
complexes, such as the DEAD-box RNA helicase and p68 and their associated 
ncRNA[310]. These, along with more recent findings that demonstrate that CTCF 
binds to the Jpx RNA, indicate that ncRNA are involved in the stabilising of 
interactions mediated by CTCF and its protein partners[311]. Saldana-Meyer et al. 
reported at least 17,000 genomic RNAs that interact with CTCF[287]. 
 
One of the most interesting findings of recent years is that a pair of CTCF 
binding sites will only engage to fold chromatin, forming long-range loop interactions 
if they are in a convergent, linear orientations, producing asymmetrical insulator 
pattern[219, 312]. The  inversion of a single CTCF site is sufficient to rewire the 
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orientation of the looping and disrupt the packaging of the underlying chromosome 
segmentation pattern into an insulated TAD, proving that the proper arrangement of 
binding sites is crucial for the correct functioning of CTCF[244, 279, 282, 285]. In 
addition, the deletion of a TAD boundary in the vicinity of the Xist locus on 
chromosome X results in ectopic loop interactions general mis-regulation of gene 
expression[78]. Analysis of the Six homeodomain locus in zebrafish unveiled CTCF 
binding sites in oriented convergently with TADs at TAD boundaries, and attempted 
deletion of any of these boundaries results in erratic interdomain enhancer-promoter 
interactions[313]. 
 
Other regulatory factors may also contribute to augmenting or modulating 
CTCF function[314]. For example, Smad proteins interact with CTCF at the Igf2/H19 
imprinted control region[315]. Similarly, at the Igf2/H19 locus, p68 helps, along with 
the long noncoding RNA SRA, to stabilize cohesin binding and create an effective 
insulator. DNA-bound CTCF/cohesin complexes recruit the core promoter factor 
TFIII to helps stabilize CTCF binding at specific promoter-proximal regions at many 
loci in ESC[316, 317]. CTCF also associates with PARP1 to establish inter-
chromosomal contacts during the circadian cycle[318]. 
 
Homozygous knockout of CTCF is embryonic-lethal[319-321], and partial 
deletion of CTCF leads to an altered gene expression pattern, yet with more limited 
phenotypic impact, increasing radiation sensitivity, defective DNA-repair mechanism, 
and cell cycle arrest[80, 322]. Full removal of CTCF results in total loss of nearly all 
loop interactions in a highly dose-dependent manner[247, 323, 324]. Conditional Ctcf 
knockouts in a tissue-specific context, such as in oocytes, lymphocytes, neurons, and 
cardiomyocytes, lead to organ failures[276, 325-327]. Acute depletion of CTCF in vitro 
by both RNAi and transient auxin-mediated in mouse ESC yields full removal of 
CTCF from the nucleus, disruption of loop structures and TADs, yet high-order 
chromosome compartmentalization is maintained[269, 323, 328]. Although Ctcf 
hemizygous mice undergo normal development, they exhibit an increased 
predisposition to tumours[329]. Even though halving of CTCF protein concentration 
is physiologically tolerated, the process reduces the overall fitness of the organism. 
CTCF has also been shown to be a haploinsufficient tumour suppressor gene in human 
cancers[329-331]. A recent study observed that Ctcf hemizygous cells show modest but 
consistent changes in almost 1000 CTCF binding sites that are of lower affinity and 
weaker evolutionary conservation across the murine lineage. This coincided with 
dysregulation of several hundred genes' expression, which are ontologically enriched in 
cancer-related pathways. Chromatin configuration is, however, unaffected apart from 
disruption to some loop domains[332]. Mutations of CTCF motifs lead to oncogene 
dysregulation in some cancers[294], and defective limb development in humans and 
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mice[244]. Unlike germline variants, somatic missense and nonsense mutations of 
CTCF are abundant in human tumours [333, 334]. Hyper-methylation of the GC-rich 
CTCF binding motif was observed to decrease CTCF occupancy in glioma, and 
constitutive CTCF–CTCF binding site interactions are reportedly deleted in T-cell 
acute lymphoblastic leukaemia, resulting in oncogenic upregulation[245, 323]. 
 
 
Figure 1.6: CTCF regulates 3D chromatin architecture 
 
(a) An interaction heat map of a ~2.5-Mb chromosome segment. TADs, their 
boundaries and interiors are indicated. (b) multiple CTCF binding sites and TFIIIC 
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at TAD borders contribute to its formation. CTCF may act an as an enhancer blocker 
(left). On the other hand, CTCF bound inside TADs may act as an enhancer facilitator 
through looping the DNA with the help of cohesin. Blue boxes denote gene promoters, 
and black boxes denote genes. (c) The TAD borders in mammals are enriched for 
housekeeping and tRNA genes, SINEs and CTCF-binding sites. Figure adapted from 
Ong and Corces [80]. 
 
Intriguingly, Satou et al. recently found that CTCF binds to a motif in the 
Human T lymphotropic virus type 1 (HTLV-1; the human T-cell leukemia virus), when 
HTLV-1 is inserted into the host cell genome[335]. It is hypothesised that CTCF 
binding to the provirus can promote abnormal chromatin looping by dimerizing with 
CTCF in the surrounding host genome. The presence of a single CTCF-dependent 
chromatin loop in vitro T cell line has since been demonstrated[335, 336]. 
 
1.2.2 CTCF roles and functions 
 
CTCF is a versatile nuclear factor, involved in various roles such as transcriptional 
activations/repression, insulation, regulation of genetic imprinting, developmental 
programme modulation, structural domains organization and guarding genomic 
fidelity[337] (Figure 1.6). The mechanisms underlying the diverse functions of CTCF 
in genome biology derive from its function in mediating long-range interactions 
between two or more DNA sequences. 4C analyses of the mouse imprinted maternal 
H19–insulin-like growth factor 2 (Igf2) locus demonstrated that the H19 imprinting 
control region (ICR) is involved in extensive inter-chromosomal and intra-
chromosomal interactions across the genome that require the CTCF binding within 
the ICR[338]. CTCF binding at several DNase I hypersensitive sites is central to 
preserving the unique chromatin architecture at the murine haemoglobin subunit beta 
(Hbb) locus[339]. CTCF-mediated interactions modulate facets of genome function in 
a context-dependent manner. The functional consequences of these interactions rely 
on the sequences flanking CTCF- binding sites and the presence of other specific 
architectural  proteins[80]. 
 
Furthermore, CTCF promotes transcriptional activation of some genes, such 
as the case of CTCF binding to the amyloid precursor protein (APP) promoter[340] 
(Figure 1.6b). The structural domain of 107 amino acids in the N-terminal tail of 
CTCF regulates transcriptional activation and chromatin de-condensation, and 
upregulates its expression as it approaches the promoter location[341]. Conversely, 
CTCF may also play a role in transcriptional inhibition, by combining promoter and 
upstream silencer together. CTCF was originally identified as a transcriptional 
repressor of chicken c-Myc gene[266, 342]. CTCF binding along with thyroid hormone 
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receptor to the isogenous locus forms a repressor complex that lead to c-Myc reduced 
expression[343]. CTCF-mediated transcription repression could be achieved via 
recruitment of histone deacetylase and deacetylation of CTCF via binding of SIN3 
transcription regulator family member A[344]. Recent genome-wide studies indicate 
that CTCF can additionally act as an enhancer blocker at particular loci. 15,000 CTCF 
binding sites were identified in human genome-wide search for conserved regulatory 
motif. These sites appeared to demarcate adjacent genes which show notably conversed 
correlation in gene expression compared with genes that are in a similar architecture, 
but that are not separated by CTCF-binding sites[299]. CTCF also works as an 
insulator bounding factor inhibiting interactions between promoter, enhancer, and 
silencer, provided that the CTCF binding site resides in-between regulatory elements 
that fail to properly function[345]. A study identified a 42-bp insulator sequence that 
could block the promoter activity of β-globulin, and equally works as a binding site of 
CTCF in humans[346]. 
 
Despite being originally thought off as an insulator and blocker of gene 
activity(Figure 1.6b), recent studies have identified CTCF as an important factor in 
tethering distant enhancers to their promoters. 79% of long-range interactions between 
promoters and their regulatory sequences were shown not to be blocked by the presence 
of one or more intervening CTCF-bound sites[39]. Strikingly, a subset of these long-
range interactions are significantly enriched for CTCF and/ or histone modifications 
that are marked for active enhancers such as H3K27ac, H3K4me1 and H3K4me2. 
These results propose an alternative role for CTCF in genome biology may be to 
facilitate the communication between regulatory elements and promoters. Further 
support for this hypothesis came by finding a significant overlap between tissue-specific 
CTCF occupancy and enhancer elements, in addition to similar studies at several other 
loci[242]. For example, activation of major histocompatibility complex class II (MHC-
II) gene expression by treatment with interferon-γ (IFNγ) requires CTCF-mediated 
looping of the XL9 enhancer element and its core promoters, MHC class II 
transactivator (CIITA) and specific transcription factors[347]. Thus, CTCF-mediated 
topological organization precedes transcriptional activation[348].  
 
CTCF is also involved in regulating transcriptional pausing and modulating 
alternative mRNA splicing. For example, the first intron and upstream regulatory 
sequence in the mouse myeloblastosis oncogene (Myb) locus are bound by CTCF. 
CTCF-mediated looping between the first intron, promoter and upstream enhancer 
elements, along with its associated erythroid transcription and elongation factors is 
necessary for RNAP II to mediate transcriptional elongation and the upregulation of 
the Myb gene during erythroid differentiation[325]. The genome-wide distribution of 
CTCF binding sites at promoter-proximal regions and in 5’UTRs clearly correlates 
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with high pausing indexes suggesting that the effect of CTCF on Pol II elongation may 
be more common than previously thought[349]. Recent studies have shown that 
disruption of mRNA elongation by RNAP II by CTCF may cause the 
inclusion/exclusion of particular exons in the mature mRNA[350, 351]. CTCF binding 
to exon 5 of CD45 gene promotes its alternative splicing in the mRNA, whereas 
blocking CTCF binding results in removal of this exon from the final edited 
mRNA[351]. 
 
An additional role of CTCF is in chromosome X inactivation. During 
development in mammals, one copy of the X chromosome's pair in females undergoes 
a process of inactivation as a measure of gene-dosage control. The process relies on the 
expression of the inactive x-specific transcript (Xist) and is inhibits by the antisense 
gene Tsix[352]. The imprinting centre of the X chromosome harbours a battery of 
CTCF binding sites with methylation-sensitive enhancer blocking activity. CTCF in 
association with the inhibitory Tsix regulates the epigenetic switch of X chromosome 
inactivation by stimulating Tsix transcription or blocking Xist from interacting with 
its enhancer. Expression of Tsix prevents Xist mRNA accumulation[352]. 
 
1.2.3 CTCF and Cohesin 
 
CTCF and the ring-shaped cohesin complex have been repeatedly shown to colocalize 
in the genome[353] and bind at the anchors of chromatin loops[219, 339], and the TAD 
boundaries[78, 232, 235], demonstrably indicating their critical involvement in 
regulating genome folding. Targeted deletion of these sites disrupted loop formation 
and contact domain structures[279, 282, 285]. 
 
Cohesin is an architectural protein complex in the shape of a large ring 
molecule. Similar to the highly related condensin and Smc5/6 complexes, the cohesin 
complex core is made up of heterodimers of structural maintenance of chromosomes 
proteins (SMC), a highly conserved family of ATPases. The V-shaped SMC1-SMC3 
heterodimer is formed when they join their coiled-coil and hinge domains. This is then 
complemented by RAD21 (also known as SCC1), and the addition of SA1/SA2 (also 
known as STAG1 and STAG2) subunits to complete a 'ring' structure large enough 
to topologically 'embrace' two chromatin fibres (Figure 1.7b). Other proteins that 
associate with the complex include the SCC2/4 (also known as Nipbl/Mau-2 in 
mammals) adherin complex that help cohesin loading onto chromatin, and WapI, 
which is required for eventual cohesin removal[354, 355]. Cohesin is a major component 
of chromatin in cycling, non-cycling, and post-mitotic cells in higher eukaryotes. 
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Cohesin was originally identified as a complex that provides cohesion to the 
two sister chromosomes during DNA replication in S phase until cell division[87], 
allowing post-replicative DNA repair and faithful chromosome segregation and the 
fidelity of genomic information passed on from mother to daughter cells (or from a 
generation of multicellular organisms to the next) in both mitotic and meiotic cell 
division modes[224, 356]. In line with its role in post-replicative DNA repair and 
chromosome segregation, cohesin loading is increased at sites of DNA damage[357, 358] 
and at centromeres[354]. pointing to a role for cohesin outside of the division phase of 
the cell cycle. Accumulating evidence indicates that cohesin does play a role in 
mediating chromatin structural conformation and gene expression in interphase. 
Although cohesin partners with CTCF to play it its role in transcriptional regulation, 
it can also function independently from CTCF to achieve gene regulation in tissue-
specific context, for example via loading onto the promoter and enhancer elements in 
oestrogen-regulated gene expression[359, 360]. Whereas strong cohesin sites overlap 
with CTCF binding, 'weaker' cohesin sites map onto active promoters and enhancers, 
where it interacts with Nipbl, the Mediator complex, and cell-type-specific 
transcription factors to instigate its regulatory potential[224, 359, 361, 362]. In addition 
to CTCF and cohesin well-established roles in chromatin and transcriptional 
regulation, further investigations have associated them with various other roles such 
as transcription factor binding[361], transcriptional elongation[363], alternative 
splicing[350, 351] and interactions with noncoding RNAs[364].  
 
CTCF and cohesin binding is associated with ~90% of DNA loops, 92% of which 
involve CTCF anchor in convergent orientation that face the loop interior[219] (Figure 
1.7c). This recently identified feature of CTCF loop formation facilitates the prediction 
of loop formation in silico[285, 365]. When these CTCF anchor are inverted or deleted 
(e.g. by CRISPR/Cas9 genomic editing), the expression of nearby genes changes as 
predicted[327]. More recently extreme deep sequencing Hi-C studies in mESCs found 
~10,000 previously unidentified shorter loops with a median size of 185 kb in a complex 
nested structure[219]. These short, <200 kb CTCF-anchored loops (termed chromatin 
contact domains or super-enhancer domains) were enriched for CTCF and cohesin 
binding sites and tissue-specific genes and enhancers[327, 366]. They are; however, in 
the minority and do not explain the nuclear topological domains seen in high resolution 
Hi-C maps[219, 324, 367].  
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Figure 1.7: CTCF and cohesin are essential for the extrusion model of genome 
folding 
 
(a) CTCF and its motif. “GGG>” is the forward motif (blue), and “<CCC” is the 
reverse motif (red). The 11 zinc fingers of CTCF bind the CTCF canonical motif, and 
the C-terminal fingers project toward the 5’ end of the motif. (b) The cohesin complex: 
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the core subunits SMC1, SMC3, Rad21, and SA1 or -2. The ring-like structure 
accommodates 2 chromatin fibres. (c) Loops form primarily between convergent CTCF 
binding sites. (d) Extrusion forms chromatin loops and stops when two convergent 
CTCF-bound sites are encountered. (e) If a TAD border is lost, extrusion continues 
to form a larger TADs. The original TAD boundaries are marked with red and green 
fluorescence in situ hybridization (FISH) probes. (f) Simultaneous extrusions form two 
loops. (g) A single cohesin ring "embracing" a chromatin fibre slides smoothly along 
the genome without extruding a loop. (h) Two cohesin rings could embrace the 
chromatin fibres to extrude a loop by being linked either topologically (left) or by 
complex formation (centre), or a single cohesin ring sliding from the top of a preformed 
chromatin loop (right). Figure adapted from Merkenschlager and Nora & Hansen et 
al. [355, 368]. 
 
The extrusion model provides the mechanistic framework to explain how CTCF 
and cohesin could regulate chromatin topology and the underlying gene expression 
(Figure 1.7d). As the model proposes, when cohesin loads onto a genomic region in the 
vicinity of properly oriented CTCF anchor, an extrusion subunit is arrested, while its 
partners proceed along the chromatin. The CTCF-anchored element rapidly and 
transiently interacts with the entire genomic interval[369]. Recent work has shown 
that such a mechanism can facilitate V(D)J recombination at the immunoglobulin 
locus in developing lymphocytes[370]. In vitro studies illustrated how RNA 
polymerases can push cohesin rings along DNA[371]. The asymmetric nature of this 
model could explain the ability of promoters to interact with enhancers spread across 
100s kb. Hansen et al. demonstrated how CTCF and cohesin can form a rapidly 
exchanging ’dynamic complex’ rather than a typical stable one, suggesting that 
chromatin loops are dynamic and in continuous equilibrium between breaking and 
forming throughout the cell cycle[368] (Figure 1.7f-h).   
 
Although depletion of CTCF decreased cohesin occupancy at their binding 
sites, cohesin loading onto chromatin is unaffected. Conversely, the depletion of cohesin 
complex proteins does not significantly impact CTCF genomic occupancy patterns. 
Taken together, these observations suggest that CTCF alters cohesin genomic 
distribution, but not its association with chromatin in general, and acts upstream of 
cohesin to ensure its proper positioning in relation to its target sites[293, 372]. 
Experimental knockouts of the SA1 subunit of the cohesin complex, which normally 
interacts with the C-terminus of CTCF, cause the redistribution of the SMC1/3 
subunits and  reduce cohesin's association with CTCF binding sites[373, 374]. 
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1.3 The evolutionary genomics of transcriptional 
regulation 
 
Since Charles Darwin famously put forward his theory of evolution by means of natural 
selection[375], he forever changed the science of biology in all its branching complexity, 
and genomics is no exception. Comparative genomics attempt to explain the biological 
function using an evolutionary perspective, and how phenotypic differences observed 
in the natural world between species can be understood in the context of the genome. 
Part of heritable phenotypic variation is due to differences in transcriptional 
regulation, which determines the extent of gene expression in the different cells and 
tissues[376, 377].  
 
Gene expression levels are quantitative traits subject to evolutionary processes. 
Protein-coding genes have been subject to strong selective pressures as revealed by 
interspecies comparisons of mammalian genomes that confirmed the identity of almost 
all coding sequences[378].  The genetic basis for gene expression variation must then 
lie in the non-coding regulatory genome. Experimental evidence in molecular 
evolutionary studies have steadily enhanced our understanding of the underlying 
processes that may govern the evolution of gene regulation, especially in the domain 
of non-coding genome and role of epigenetics. Results from those studies have helped 
explain phenotypes from the pigmentation in fish and malaria resistance in wild 
primates[379, 380]. 
 
A major mechanism for the evolution of transcription regulation comes from 
the domain of transposable elements (TEs). It was the work of Barbara McClintock 
on maize[381] that demonstrated how TEs can control gene expression, and paved the 
way to recognising their evolutionary role in rewiring the gene regulatory networks[382, 
383]. Ever since, TEs have repeatedly been reported to harbour functional TF and 
DNase I hypersensitivity sites[384-387]. Data from the ENCODE project revealed that 
44% of open chromatin regions in the human genome are in TEs, as well as 63% of 
primate-specific gene regulatory elements, where a particular class of TEs, endogenous 
retrovirus-like elements (ERVs), have expanded into hundreds of thousands of novel 
regulatory elements, and reorganised the human gene regulatory landscape[388]. The 
incredible pace through which repetitive and other fast-evolving sequences evolve 
explains their ability to alter transcriptional regulatory circuits via the creation and 
disruption of sequence motifs[389]. This is the reason why mammalian genomes are set 
apart from other higher metazoans like birds and arthropod whose genomes are 
depleted from repetitive elements and show more signs of evolutionary constraint[390, 
391]. 
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For example, a study used a transchromosomic mouse strain, one that carries 
an almost complete single copy of human chromosome 21 via the female germline, to 
reveal that in a heterologous (mouse/human) regulatory context, transposon-derived 
human regulatory regions become transcriptionally active[392]. Hundreds of loci on the 
human chromosome 21 became associated with changes in DNA methylation at CpG 
dinucleotides and histone marks specific for transcriptional activation in germline and 
somatic tissues, resulting in apparent gene expression of the nearby loci. These sites 
on chromosome 21 were found to be enriched with primate and human lineage-specific 
transposable elements[392, 393]. A seminal work by the same group using ChIP-seq to 
profile the genome-wide occupancy pattern of 2 TFs, CCAAT/enhancer-binding 
protein alpha (CEBPA) and hepatocyte nuclear factor 4 alpha (HNF4A) in the liver 
of 5 vertebrates[394]. Although each TF was found to bind highly conserved DNA 
motifs, most binding events observed were lineage- and species-specific, and highly 
conserved binding events present in all five species were very uncommon. Genes whose 
expression levels are TF-dependent display evolutionary conservation and found bound 
by the TF in multiple species with no increased motif constraint. Motif sequences 
changes generally explained binding site divergence between species[394]. 
 
 In this section, I will give a broad view of the current state of research into 
the evolutionary genomic of cis-regulatory elements, with a particular focus on CTCF, 
and the role TEs play in the process of shaping the regulatory landscape of gene 
expression, particularly in mammals. 
 
1.3.1 Evolution of cis-regulatory elements and TF binding 
 
Whilst protein coding mutations have been well-catalogued and characterised, changes 
to cis-regulatory sequences have only recently come to the forefront of gene expression 
research. Despite this, only a fraction of those interactions in a limited number of 
organisms, in selected tissues and developmental stage, and under specific conditions, 
are known. Alterations to cis-regulatory elements can change the course and pattern 
of gene expression and pave the way for the evolution of species-specific traits[395, 
396]. 
 
Most components of the transcriptional machinery that regulate gene 
expression are highly conserved in evolution. As outlined earlier in 1.3, TFs and the 
sequence of their binding motifs are mostly conserved between human and fruit 
flies[397-399], and comparisons of the sequence of TFs motifs across different lineages 
yield a high degree of similarity[394]. It is the cis-regulatory elements, such as 
enhancers whose locations and activities in orthologous sequences that are less 
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conserved. An examination of the activation profiles in 41 pairs of conserved regulatory 
elements between human and zebrafish revealed that only a third of these regions 
displayed any form of conserved activity between the two species[400]. A major study 
by Villar et al. discovered that turnover of the regulatory activity is pervasive between 
even more closely related species (Figure 1.8). For example, only 1% of human liver 
enhancers exhibit consistent activity across the 20 mammals investigated[401]. Taken 
together, these studies suggest that orthologous regulatory regions display a varied 
level of activity across species, even though the TFs they bind and their motifs are 
very much conserved in structure. 
 
It has been suggested that the evolutionary conservation of genes and their 
regulation is a product of pleiotropic trade-off[399, 402-406]. Pleiotropy is the ability 
of a single gene/variant to influence several traits simultaneously. If a pleiotropic 
region is altered by mutations, newly-created variants may confer different effects on 
the multiple functions they contribute to. These variants may be advantageous in one 
facet, but gravely deleterious in others[406]. Intuitively, these regions should be under 
selective pressure to remain more evolutionarily constrained than other, non-
pleiotropic regions, and it follows that genes with pleiotropic functions are more likely 
to be found in orthologous regions in other species, and with a comparable expression 
level[403, 404]. Therefore, TF binding sites that are active tissue-wide and observed at 
several developmental stages are expected to be conserved between species[399]. 
Nevertheless, the sequences TFs bind to vary in terms of their information content 
which correlates strongly with how their occupancy evolves. Genetic drift causes low-
affinity, information-poor motifs to evolve rapidly[6, 394, 407-410], but sequence 
change alone is incapable of fully explaining the evolutionary trajectory of TF 
binding[407, 408, 411]. Larger, information-rich motifs, such as the CTCF motif, are 
selectively conserved[269]. 
 
Increasingly, investigations into the evolution of mammalian transcriptional 
regulatory elements are documenting the rapid turnover of enhancers and tissue-
specific TF binding sites[412-416]. Findings demonstrate that gene expression across 
similar tissues in different species is more correlated than different tissues within the 
same species, suggesting that tissue-specific expression pattern are evolutionarily 
stable[417, 418]. How this is achieved and maintained in the face of the ever-changing 
regulatory landscape is a central dilemma in evolutionary genomics. The evolutionary 
status of regulatory elements ranges from highly conserved to lineage-specific. Taken 
together, these various findings support the notion that the greater functional influence 
of a regulatory element, the more conserved across different species, tissues and 
developmental stages[401, 414, 419, 420]. Conversely, lineage-specific elements appear 
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to partially compensate for proximally lost events, and are often found in regions with 
pre-existing regulatory activity[394, 421].  
 
An integrated analysis of transcriptional circuit evolution across >25 animal 
species examined mRNA expression, transcription factor binding and cis-regulatory 
motifs. The results revealed that transcriptional regulatory networks evolve at a 
constant rate across the various lineages, even more so when only chromatin-accessible 
regions were considered[422]. Another more recent study compared conserved-activity 
enhancers to species-specific-activity enhancers using liver enhancers in ten diverse 
mammalian species. Conserved-activity enhancers exhibited greater regulatory 
potential and activity in humans than their species-specific counterparts. They 
appeared active across more cellular contexts and the genes they regulated were 
expressed in more tissues, providing further support to the pleiotropy argument 
mentioned earlier[423].  Bertholet et al. followed up their 2015 study by analysing 
promoter and enhancer activity with corresponding gene expression levels in liver 
samples from 15 species, and reached similar conclusions[424]. They also reported that 
the evolutionary resilience of transcription is dependent on the number of regulatory 
elements, with an emphasis on evolutionary conservation. Elements with conserved 
activity in more species have the most ability to drive stable gene expression. Recently-
evolved species-specific enhancers, on the other hand, have a weaker overall regulatory 
potential[424]. 
 
The mechanisms of gene regulation can be influenced by cis- and trans-acting 
variation with local and pleiotropic effects, respectively. These changes can instigate a 
much wider effect resulting in changes to gene regulation evolutionary dynamics[425]. 
A study used the analysis of RNA-seq to measure liver gene expression divergence 
between two mouse strains: C57BL/6J (Mus musculus domesticus) and CAST/EiJ 
(Mus musculus castaneus) to establish the extent of allele-specific expression in their 
F1 hybrid offspring. 535 genes were identified which displayed a parent-of-origin-
specific patterns of gene expression, but only few of those genes suffered complete 
allelic-silencing, indicating that genetic imprinting in somatic mouse tissues accounts 
for a relatively small number of genes[260]. 32% of non-imprinted genes demonstrated 
divergent expression between the parental F0 strains., of which only 2% were found 
out to be exclusively influenced by trans-acting variants. 43% of the set of non-
imprinted genes were attributed to variants acting only in cis. The remainder of genes 
(55%) showed gene expression divergence pattern consistent with a combinatory 
complex of cis- and trans-acting variation. The genes whose expression divergence is 
driven by trans-acting variation were additionally observed to have higher sequence 
constraint than genes whose divergence was caused by variants acting in cis. Gene 
expression changes instigated by variation in cis and trans were interestingly in 
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opposite directions, suggesting that compensatory regulation due to purifying selection 
may work to stabilize gene expression levels[260].  
 
 
Figure 1.8: Enhancer and promoter evolution in 20 mammalian species 
 
Comparative evolutionary genomic analysis in 20 mammals reveals rapid enhancer 
(orange triangles) and slow promoter (purple triangles) evolution across the 
evolutionary tree. Enhancers are only rarely constrained, and recently-evolved 
enhancers are predominant in their regulatory landscape, exhibiting lineage- specific 
positive selection. Grey arrows on the left indicate divergence time since last common 
ancestor in millions of years. Figure adapted from Villar et al. [401]. 
 
A more recent effort investigated tissue-specific TF (CEBPA, HNF4A, 
FOXA1) occupancy divergence in the livers of the same two strains and their F1 
hybrid to highlight the contributions of cis and trans variation on the dynamics of 
gene regulation[257]. They also identified that cis-directed mechanisms are 
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predominant in the birth of new TF binding sites in lineage-specific manner. 
Furthermore, they detected apparent coordination in the regulatory networks between 
TF occupancy, chromatin state, and gene expression in the F1 hybrids[257].  
 
 
1.3.2 Evolution of CTCF binding 
 
The multifaceted nature of CTCF roles have placed a strong purifying evolutionary 
pressure on its binding sites[298, 299, 384, 409, 426, 427]. Evidence from previous 
studies indicates that CTCF binding is evolving at a rapid pace despite the selective 
pressures it is under. Remarkably, the genome contains thousands of CTCF binding 
sites are found in rodent-specific SINE B2 repeat elements, meaning that they are not 
conserved with their human counterparts[384]. This provides an excellent example of 
a case where the early models of TEs as modulators of gene regulatory evolution via 
expansion of repeat elements driving divergence in eukaryotic genomes[409, 427-432]. 
 
The link between CTCF binding site evolution under the influence of SINE 
TEs first arose in a study of TFs occupancy patterns and their association with 
TEs[384]. A substantial portion of the B2 SINE TEs carrying the CTCF binding motifs 
in the mouse are bound by CTCF in vivo. This mechanism offers the means for rapidly 
expanding the long complex CTCT motif into a multitude of novel sites. This 
mechanism had previously been proposed for the repressor REST/NRSF, which also 
has a similarly large and complex binding motif[433]. A landmark study comparing 
CTCF motif occupancy in six mammals established that SINE repeats, which are 
incidentally still active in multiple mammalians lineages, carry the canonical CTCF 
motif[269].Hundreds to thousands of such sites were identified in dog, opossum, rat 
and mouse. The sequence surrounding the CTCF sites that are the oldest and most 
conserved are enriched for hundreds of fossilized SINE TEs in several mammalian 
species, separated by 180 million years of evolution. The various findings support an 
ancient mechanism of genome evolution, based repeat-driven expansion of CTCF 
binding sites from a set of ancient sites to their current genomic distribution. Primate 
genomes, remarkably, seem to have escaped this mode of regulatory rewiring as their 
CTCF binding sites do not show signatures of SINE-mediated repeat expansion[434]. 
Mouse showed the greatest extent of SINE repeat-expansion of all the species 
investigated, suggesting that the process may have undergone significant acceleration 
during the murine-lineage evolution, with almost 4 times more SINE B2 insertions 
with CTCF binding sites since their last common ancestor with rats[269]. 
 
Furthermore, the dependency on DNA sequence for CTCF recruitment and its 
functions in insulation and long-range chromosomal remodelling could mean that 
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CTCF has a role to play in linking genome sequence with the evolution of chromosome 
higher-order organisation. This is supported by the conservation of chromatin domain 
structures between human and mouse reported through both linear epigenomic analysis 
and high-throughput chromosome conformation capture (Hi-C) comparisons[235, 435]. 
Rudan et al. further confirmed CTCF role in modulating chromosomal organisation 
by showing that chromosome domain structures are robustly conserved in syntenic 
regions, and consistent with conservation of the pattern of genomic occupancy of 
CTCF[312]. Conserved CTCF sites, in complex with the cohesin protein complex, 
display enrichment at strong TAD boundaries, with binding motif in a favourable 
convergent orientation. On the other hand, evolutionary divergent CTCF sites coincide 
with corresponding evolutionary divergent internal TAD structures[312] (Figure 1.9). 
 
 
Figure 1.9: CTCF drives evolution of chromosomal domain architecture 
 
Large-scale chromosomal domain structure (the two large grey/orange/green loops) is 
highly conserved across species, along with the conservation of both the CTCF binding 
site (blue arrows) and the orientation of its motif (direction of arrowhead) demarcating 
these conserved domains. Internal domain structure (smaller grey/orange/green loops 
inside the larger ones) is more dynamic, correlating with the evolutionary dynamics of 
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CTCF sites (grey/orange/green arrows) and divergence of local insulation structure 
(direction of grey/orange/green arrowheads). Figure adapted from Vietri-Rudan et al. 
[238]. 
 
1.3.2 Transposable elements in the evolution of gene 
regulation 
 
One of the fundamental observations of the genomics era is that TEs comprise a 
significant proportion of vertebrate genomes[436]. 30-50% of mammalian genomes are 
made up of TES, mainly of the retro-transposon variety[436]. Transposable elements 
are repetitive sequences that have been integrated into the genomes of higher 
eukaryotes for millions of years[437]. Mammalian TEs can be classed into two main 
categories: retrotransposons, which use an RNA-mediated copy-paste mechanism to 
move around the genome, and DNA transposons which move directly in a cut-paste 
fashion instead[438] (Figure 1.10a). Retrotransposons are further classed into two main 
groups: long terminal repeats (LTRs), such as endogenous retrovirus (ERV)-like 
elements, and non-LTRs. Human LTRs are derived from ancient endogenous retroviral 
integration into the genome, accounting for 8% of the total length of the human 
genome[439] (Figure 1.10b,c). There are two subtypes of non-LTRs: autonomous short 
interspersed elements (SINEs) and non-autonomous long interspersed elements 
(LINEs). LINE-1 and Alu elements, which are also non-LTR retrotransposons, 
comprise about 25% of the human genome[440]. 
 
TEs contain their own promoters and regulatory elements that ensures their 
transcription and transposing activity in the host genome. TEs that lack this 
machinery such as SINEs are transposed by utilising another TEs mechanism[441-443]. 
The overrepresentation of TEs is an indication of their more efficient replicative 
capacity, which evidently surpasses that of the host genome[444, 445]. Some TEs are 
still active and transposing in humans, such as Long Interspersed Nuclear Elements 
(LINEs, mostly L1s), Long Terminal Repeat Retrotransposons (mostly ERV1-LTRs), 
, Short Interspersed Nuclear Elements (SINEs) of the Alu families, and SINE-VNTR-
Alus (SVAs)[446]. These TEs were recently shown to be the main source of novel DNA 
sequences in the primate lineage, driving the evolution of novel lineage-specific 
regulatory elements[447]. Ancient mammalian TEs were also proposed to mediate the 
formation of novel gene regulatory networks in the uterus[431, 448], and have a key 
involvement in pluripotency[449]. 
 
1. Introduction 
 
 41 
 
Figure 1.10: Mechanisms of TE mobilization 
 
(a) DNA transposons are flanked by terminal inverted repeats (TIRs; black arrows), 
carry a transposase (purple circles), and move by a 'cut and paste' mechanism 
(scissors). The transposase cut the transposon from its existing genomic location (light 
grey bar) and pastes it into a new location (dark grey bar). (b) LTR retrotransposons 
are flanked by two long terminal repeats (LTRs; black arrows) and carry Gag, 
protease, reverse transcriptase and integrase enzymes. The 5’ LTR includes a promoter 
recognized by the host RNAPII and transcribes the mRNA of the TE. Gag (small pink 
circles) assembles into virus-like particle that encodes the TE mRNA (light blue), 
reverse transcriptase (orange shape) and integrase. Reverse transcription copies the 
TE mRNA into double-stranded cDNA. Integrase (purple circles) next inserts the 
cDNA into the target site. (c) Non-LTR retrotransposons do not have LTRs and carry 
one or two open reading frames (ORFs). Transcription of non-LTRs produces a full-
length mRNA (wavy, light blue line). They move by target-site-primed reverse 
transcription (TPRT). In TPRT, an endonuclease causes a single-stranded 'nick' in 
the host DNA, releasing a 3’-OH which primes the reverse transcription of the RNA. 
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The new element (dark blue rectangle) is 5’ truncated and is retrotransposition-
defective. The integration of non-LTR retrotransposons causes TSDs or small deletions 
at the insertion site in the host DNA. Figure adapted from Levin and Moran [450]. 
 
The first TF binding site to be found on a TE in a genome-wide scan is the 
tumour-suppressor gene, p53. The binding sites of p53 (~30% in vitro) were found on 
a primate-specific ERV-LTR[432]. Many other studies followed finding TF binding 
sites on TEs, such as the previously-mentioned CTCF and pluripotency factors (OCT4, 
NANOG)[269, 384, 409]. Of note is an investigation which profiled the genomic 
occupancy of 26 TFs in two human and mouse cell lines, and produced a quantitative 
estimate of TEs contribution to TFs binding sites[399, 451]. They found an average of 
20% of TFs binding sites to be encoded on TEs in vitro[387]. 
 
TEs are demonstrably capable of rewriting existing regulatory networks in a 
manner consistent with the "gene-battery" model put forward by Britten and Davidson 
in 1969[452, 453]. The model provides a theoretical framework to elucidate how 
repetitive elements are an efficient mechanism for creating evolutionary divergent cis-
regulatory modules. The nature and aspects of TEs functions make them a good fit 
given their inherent ability to mobilise and readily and repeatedly integrate their 
sequences into the genome[454] (Figure 1.11). A 2017 study was the first to show how 
such a module of TF binding sites in mESCs could arise in mouse-specific TEs[454]. 
77% of TEs investigated showed measurable enhancer activity in mouse ESCs, and by 
mutating individual TF binding sites nested in the TEs, a module of TF motifs that 
cooperatively enhanced gene expression was discovered. The same motif module was 
obtained by in silico construction of the ancestral TE, similarly acting cooperatively 
to enhance gene expression. This result illustrates that TE expansion is indeed a viable 
mechanism to introduce novel cis-regulatory modules into mammalian genomes[454]. 
 
Significant association between LINEs and LTRs and lineage-specific gene 
family expansions was observed in both the human and mouse genomes[455]. LTRs 
were found enriched around the open chromatin neighbourhoods of gene families, 
whereas LINEs may have been involved in promoting gene duplication. The expansion 
of gene families, particularly in the mouse genome, seemed to have undergone two 
distinct phases: the first displayed an increased level of LTRs deposition, and their 
subsequent involvement in rewiring the gene regulatory circuits; whereas the second 
phase was marked by the build-up of LINEs, followed by rapid gene family duplication 
in a characteristically runaway process[455]. Whereas most TE classes are mainly 
accompanied with reduced gene expression levels, upregulation of gene expression has 
been reported with Alu elements in the human genome, and were the most likely of 
all TE classes to contribute to regulatory networks[438]. These results indicate that 
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young lineage- or species-specific TEs, such as SINEs, may have the biggest impact on 
the regulation of gene expression.   
 
 
 
Figure 1.11: Evolution of TF binding sites via TE action 
 
A gene (pink oval) is regulated by 3 TF binding sites (TFBS) (blue circle, green 
pentagon, and yellow square). 1) Novel sites could appear nearby by random mutation, 
causing turnover of previously present TFBS (green pentagon) or a new one arising 
(violet square). 2) Initial insertion of a TE in the vicinity, followed by random 
mutation leading to TFBS turnover and/or novel TFBS. Some pre-sites may just be 
one mutation from turning could eventually cause turnover of existent TFBS. Figure 
adapted from de Souza et al. [436]. 
 
The Roadmap[20] and GTEx[9] projects have shed more light on the extent of 
TEs contribution to gene regulation. An investigation into the association of TEs with 
chromatin in 24 tissues identified 112 human TE families enriched in active chromatin 
tissue-wide[446]. The most common TE classes were SINEs and DNA transposons, 
whereas LTRs were limited to particular tissues. However, genes whose expression is 
consistent across tissues display reduced association with TE insertions. On the other 
hand, different TE classes were enriched with different repressive marks: LTRs and 
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LINEs are enriched in regions marked by H3K9me3, while others overlapped with 
H3K27me3. TEs harbouring tissue-specific master regulator binding sites were 
enriched in tissue-specific active regulatory regions. Those included TEs in intronic 
enhancers and corresponded with tissue-specific variations in nearby gene 
expression[446]. 
 
 
1.4 Next-generation sequencing in regulatory 
genomics 
 
Understanding the relationship between TFs and the genes they regulate, and the 
definition of transcription regulatory networks has been facilitated by the great 
advancement in the experimental methods developed in the last few decades allowing 
the identification of TF-DNA interactions genome-wide. Such experiments were 
infeasible not so long ago. While the chemical composition of DNA was identified in 
the 19th century, 50 years elapsed before the molecular structure of DNA was 
determined[456], and we had to wait 25 more years before a method to decipher its 
sequence was eventually developed. The original Sanger sequencing method involved 
a process of sequencing by synthesis (SBS) of a radioactively labelled DNA strand 
using the dideoxy chain termination technique[457, 458]. Sanger sequencing, or "first-
generation sequencing", has later been refined and automated to use fluorescent-
labelled nucleotides instead of radioactive ones, and substituted fluorescent-labelled 
nucleotides instead of radioactivity for gel electrophoresis[459, 460]. Further 
improvements came in the shape of molecular biology techniques such as recombinant 
DNA technology and polymerase chain reaction (PCR), producing millions of copies 
of sequencing fragments[461, 462]. The use of Sanger sequencing dominated biology for 
over two decades, crowning its reign with the publications of the full genome sequences 
of D. melanogaster, the nematode C. elegans, mouse and eventually human 
genomes[440, 463-466]. 
 
Sanger sequencing; nevertheless, has some major limitations. For example, only 
one DNA sequence can be analysed per lane/tube, necessitating first breaking the DNA 
sequence into smaller fragments, then cloning them into vectors, artificial 
chromosomes, transforming into bacteria, and later extraction of individual fragments 
from the resulting colonies[467]. During the last decade, a steady shift from automated 
Sanger sequencing towards newer methods referred to as next-generation sequencing 
(NGS). There are currently several NGS strategies available from different vendors. 
They all share the same basic principles of template preparation, sequencing and 
imaging, and genome alignment and assembly[468]. NGS technologies have expanded 
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into every branch of genetic and genomic research. The field in which NGS has 
probably made the biggest impact in is the study of the regulation of gene 
transcription[469]. 
 
In the following section of this chapter, I will give an overview of the NGS 
technology, with a focus on Solexa/Illumina sequencing that has been employed in the 
work of this thesis. Then, I will broadly explore the particular method of chromatin 
immunoprecipitation followed by sequencing (ChIP-Seq) in terms of its experimental 
protocol, analysis pipeline and the computational methods used downstream to 
interrogate its output. I will also provide an overview of the approaches to study the 
effects of cis- and trans-acting variants on TF occupancy and gene expression 
regulation. I will finish with a section on the methods used to study chromatin 
conformation in 3D to understand the higher-order control of gene expression.  
 
1.4.1 High-throughput next generation sequencing (NGS) 
 
Next-generation sequencing (NGS) is based on massively parallel sequencing or high- 
throughput sequencing of DNA molecules, doing away with the need for physically 
separating the individual reactions into separate lanes/capillaries, as is the case with 
Sanger sequencing. To achieve this, the sequencing reaction takes place on a solid 
platform, the nature of which differs depending on the particular technology, with 
partial spatial separation between the individual reactions. This allows billions of 
reactions to simultaneously occur, reducing both labour and cost enormously, whilst 
vastly improving the throughput of the process[467].  
 
In this section I will focus on the Illumina/Solexa[470] NGS platform, which is 
incidentally the most widely-used technology for short read sequencing (Figure 1.12). 
Illumina uses a sequencing by synthesis technology, which had originally been 
developed by a company called Solexa, with improvements that increased read length 
and greatly improved accuracy and throughput[471, 472].  
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Figure 1.12: Overview of Illumina/Solexa sequencing technology. 
 
Illumina/Solexa solid-phase amplification technology starts with priming followed by 
extension of the single-stranded, single-molecule template. Bridge amplification of the 
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fixed template with adjacent primers forms clusters. The four-colour cyclic reversible 
termination (CRT) method is used next. Following imaging, cleavage removes the 
fluorescent dyes, and cycle restarts. Figure adapted from Metzker [468]. 
 
Like all NGS technologies, Illumina offers the ability to perform sequencing of 
many overlapping short (50-400 bases) DNA fragments by spreading, then fixing them 
onto a solid platform, then replicating them in parallel[473-475]. The solid-platform 
amplification phase of the process used high-density forward and reverse primers 
covalently-linked to the glass slide. Illumina solid-phase amplification yields around 
100–200 million spatially separated template clusters, with free terminal ends a 
universal primer can hybridise in order to initiate the sequencing reaction. Massively 
parallel sequencing then ensues via a DNA sequencing-by-synthesis manner, similar to 
Sanger sequencing, using dye terminator nucleotides[468]. This method utilises 
reversible nucleotide terminators in a cyclic manner that initiates with nucleotide 
inclusion, fluorescence imaging and cleavage. The DNA polymerase binds to the 
printed template and proceeds to incorporate nucleotides based on the template strand 
sequences until it encounters a dyed terminator nucleotide. Following the termination 
of synthesis on this template, the remainder of unincorporated nucleotides are 
removed. Imaging is then performed and the dye used for each of the four nucleotides 
is used to identify the incorporated nucleotide. The cleavage step removes the 
terminating nucleotide and the fluorescent dye, before the cycle restarts again[468]. 
This generates millions to billions of short stretches of DNA reads. The original 
template DNA molecule is thus synthesized multiple times, with each base covered by 
various degrees of depth. The depth of coverage could be defined as the minimum 
number of times each base is synthesized into an overlapping fragment. The resultant 
short reads are subsequently assembled, either with or without the aid of a reference 
genome, to recreate the original DNA template. 
 
The combination of NGS technologies with existing biochemical methods 
allowed the proliferation of novel methodologies to obtain genome-wide profiles of 
nucleosome positioning, DNA methylation, TF binding, transcription and 3D nuclear 
contacts. Examples of such technologies include Transposase-Accessible Chromatin 
with high- throughput sequencing (ATAC-seq)[24], bisulfite treatment coupled with 
next-generation shotgun sequencing (BS-seq)[476], NGS of RNA molecules (RNA-
seq)[477] and the various chromosome conformation assays[478]. ATAC-seq is a 
method for genome-wide profiling nucleosome occupancy and mapping chromatin 
accessibility, using hyperactive Tn5 transposase that inserts adapters into accessible 
regions of the genome. This allows for interrogating the accessibility of chromatin with 
sequencing reads, as well as identify TF binding sites and nucleosome positioning[479]. 
BS-seq is another powerful technique that utilises the parallel capability of NGS to 
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quantitatively detect the methylation status of every cytosine residue in the genome. 
This produces genome-wise methylation pattern of the DNA to the resolution of one 
bp[476]. RNA-seq facilitates the quantitative estimation of known and novel 
transcripts either from a cell (scRNA-seq) or a group of cells. RNA-seq provides 
information on gene expression level down to one bp resolution, and is useful in 
identifying variants in the transcriptome[477]. Capturing chromosome conformation 
(3C) and its scale-up variations (4C, 5C and Hi-C) are used to discern the pattern of 
3D chromatin interactions. 3C is used to identify kb-scale long-range chromatin loops 
between to loci. 4C is used to map all regulatory interactions of a particular "bait" 
locus. 5C detects multiple interactions with multiple loci. The Hi-C version uses 
proximity-ligation, restriction-enzyme digestion and NGS to map the entire set of 
chromatin contacts in the nucleus[478]. Furthermore, ChIA-PET, an adaption of 3C, 
is used to detects interactions between particular proteins or different loci in the 
genome[480]. 
 
In the next section, I will explore in more detail another NGS method that has 
been used in this thesis for mapping the genomic location of transcription-factor 
binding and histone modifications in vivo, chromatin immunoprecipitation followed by 
high-throughput DNA sequencing (ChIP-seq). 
 
1.4.2 Chromatin Immunoprecipitation followed by 
sequencing (ChIP-seq) 
 
ChIP-seq is currently the standard method to detect genomic regions associated with 
specific proteins and TFs within their native cellular context. Robertson et al. first 
developed ChIP-seq in 2007 to allow the mapping of DNA-protein interactions in vivo 
by capturing proteins in their physiological chromatin environment[22]. ChIP-seq's 
popularity, compared to its predecessors ChIP-chip, DNase I hypersensitivity and 
array-based methods, stems from its capacity to quickly and efficiently decode millions 
of DNA fragments simultaneously with high throughput and relatively modest 
cost[481]. Using ChIP-seq, DNA-occupancy and regions of histone modification can be 
identified and associated with functional annotations, specific binding motifs and gene 
expression. ChIP-seq output can additionally be combined with other NGS 
applications to produce a multi-level understanding of genomic functions[482]. 
 
Sample preparation for ChIP-seq starts with chemical treatment, usually with 
formaldehyde, of tissue samples to cross-link proteins covalently to DNA, followed by 
sanitation/enzymatic digestion of the cells to fragment the DNA to the optimal size of 
150-500bp. Immunoprecipitation of the target protein with its bound-DNA enriches 
the sample for those particular fragments relative to the starting material[483]. DNA 
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fragments are then sequenced as reads (typically 36–100 bp) (Figure 1.13). Most ChIP-
seq analyses are performed using single-end reads, but paired-end ones are sometimes 
used to enhance library complexity and increase mapping efficiency at long and/or 
repetitive elements[484]. ChIP-seq quality is dependent on the enrichment level 
attained during the affinity precipitation step, which is determined by specificity of 
the antibody[483]. Like all biological experiments, a proper set of control samples is 
essential for the interpretation of ChIP-seq findings. This is particularly critical for 
ChIP-seq as DNA shearing during the sonication step is not uniform, and open 
chromatin tends to be overrepresented in the purified sample[485]. Two methods are 
used to provide ChIP-seq control samples: (1) "Input DNA" isolated from cross-linked 
cells under the same set-up as the immunoprecipitated DNA; (2) "IgG control" with 
an antibody that does not bind to a nuclear antigen[483]. 
 
 
Figure 1.13: Experimental protocol for ChIP-seq 
 
Step 1: Cells are cross-linked with paraformaldehyde and sonicated. 
Immunoprecipitation isolates DNA-protein fragments. The DNA fragments are 
between 200-600 bp long. Step 2: NGS of DNA fragments collected by ChIP. Step 3: 
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The NGS machine produces 10-100 million raw short reads (red arrows). Short reads 
are 70–100 bp long. Step 4: Short reads are aligned to a reference genome. Step 5: 
Peaks (purple bell-shape) are called from aligned reads using statistical models to 
inspect their distribution (tan, sky-blue and red distributions). Bars indicate reads 
from 5' (forward read, tan) and 3' (reverse read, blue) on the chromosome 6. Figure 
adapted from Mimura et al. [486]. 
 
Sequenced short reads are often outputted as FASTQ sequence format, with 
each nucleotide assigned a quality score (Phred-like score). The Phred score defines 
the probability that the base call is correct. A quality control step is generally advised 
to check on the read length distribution, GC content, quality scores, overrepresented 
sequences and k-mer content[487]. FastQC[488] is a common toolkit for this purpose, 
and other tools are also available for further modifications to the data including 
adapter sequence removal and 3'-end sequence trimming. 
 
Sufficient sequencing depth is essential for effective analysis of ChIP-seq data, 
as the number of the DNA-protein regions identified positively correlates with the 
sequencing depth[489]. Sites with weaker binding achieve statistically significant 
enrichment over the background only with a greater number of reads, and without 
adequate sequencing depth, valuable information about their occupancy and 
functionality may be lost. The level of sequencing depth is based on the number and 
size of the protein/histone marks binding sites and the particular species genome size. 
Based on ENCODE guidelines, for mammalian TFs and histone modifications a 
coverage of 20 million reads is usually sufficient to capture the thousands of binding 
sites of those factors, which tend to occupy localised, narrow sites[483]. Factors with 
substantially more binding sites, such as the ubiquitous RNAP II, or broad histone 
modifications, need to be sequenced significantly deeper, up to 60 million reads, in 
order to properly capture a reasonable genome-wide occupancy pattern[484]. 
Furthermore, control samples must always be sequenced much deeper than factor-
bound samples in ChIP-seq in order to ensure proper coverage of the genome and non-
repetitive autosomal DNA[490]. 
 
Short read sequences are subsequently mapped onto the genome using 
alignment tools. ChIP-seq analyses do not usually require aligners to handle gapped 
alignments (INDELs) as the sequencing reads should normally not harbour any, except 
in the case of cross-species comparative studies, which sometimes map reads onto 
another species’ genomes. If the sample contains important information about single 
nucleotide polymorphisms (SNPs) and INDELs, such as the case of heterozygous 
variant analysis, an allele-specific mapper needs to be used[491-493]. Widely-used 
alignment algorithms are coded to handle ambiguities of repetitive sequence and 
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sequencing errors to a reasonable degree. The most common alignment algorithms are 
based on the Burrows-Wheeler Transform and designed for short read alignments. 
Long read alignment is usually carried out using hash table-based methods and the 
Smith-Waterman alignment[487]. Most-commonly applied aligners include Burrows-
Wheeler Aligner (BWA)[494], Bowtie[495], MAQ[496], SOAP2[497], GSNAP[498] 
(which is specifically coded to handle mismatches in heterozygous sites), and great 
many others. A recurrent issue of ChIP-seq alignment is whether to include reads 
mapping to multiple locations on the reference genome. Opting to include multiple 
mapped reads may substantially increase the number of reads available for downstream 
peak-calling and analysis, thus enhance detection statistics[492]. This; however, also 
increases the false discovery rate (FDR). Except in the case of in-repeat analysis, 
uniquely mapped reads of a particular TF should suffice[499]. 
 
Following the mapping step, the ChIP-seq experiment signal-to-noise ratio 
(SNR) needs to be determined using quality metrics such as strand cross-correlation 
or IP enrichment estimation[490]. These metrics are designed to identify the various 
ways a ChIP-seq experiment may fail, such as insufficient enrichment by the IP, 
inadequate fragment-size selection, or poor sequencing depth. The strand cross-
correlation metric is now already built-in some of the more common peak-callers such 
as MACS (version 2) and SPP. ChIP-seq short reads are now aligned, tagged with 
metadata and alignment scores, and ready to be used for peak-calling of DNA-protein 
regions and all further downstream analysis. 
 
1.4.3 Peak-calling and downstream computational 
approaches 
 
Peak-calling software are specialised packages designed to identify TF or histone mark 
genomic occupancy based on ChIP enrichment. The peak calls are outputted in the 
form of a ranked-list of regions based on either they read signal or p-value computed 
based on the significance of enrichment[483]. The most widely-used peak calling 
packages include MACS[500], PeakSeq[501], and SPP[502], but there many more[503]. 
Peak-calling programmes use the control sample to estimate the background 
distribution of the regions identified in the TF samples. Early peak-callers utilised the 
Poisson model that assumes a uniform genome-wide background distribution for the 
control reads. Due to the observed enormous variation in the read distribution that 
cannot be accommodated into the Poisson model, the model was extended into a 
negative binomial model adopting an overdispersion approximation to account for this 
variation. Later peak-callers extended it further to a zero-inflated negative binomial 
model because of the zero-inflated read distribution in zero- or low-mappable 
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regions[482]. The work presented in this thesis was analysed using MACS, a peak-
caller that adopts a local Poisson model[500]. 
 
Model-based Analysis of ChIP-seq (MACS) scales the total control read (or 
tag) count linearly to equal the total tag count[500]. Due to inherent biases in the 
sequencing method (5’ to 3’ sequencing direction), more tags accumulate in the forward 
part of the peak region than in the reverse one, resulting in a peak shift (Figure 1.14). 
MACS first estimates the distance of the peak shift from both DNA strands, and 
accordingly shifts the tag distribution to properly cover the true TF-binding site.  
 
 
Figure 1.14: Stranded bias in tag density of ChIP-seq experiments. 
 
The blue-shaded oval represents the TF bound to DNA (black lines). Wavy lines 
denote sense (blue) or antisense (red) short reads from ChIP-seq experiment. The 
thicker end of the line indicates the short-read tag. Following alignment to a reference 
genome and being given chromosomal coordinates (red and blue arrows), the distance 
between peaks (d) corresponds to the average sequenced fragment length. Figure 
adapted from Wilbanks and Facciotti [504]. 
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The genome-wide tag distribution is then modelled with a Poisson distribution, 
allowing the parameter λBG to capture the mean and the variance, and MACS 
calculates a p-value for each potential peak. MACS shifts every tag by distance(d)/2, 
utilising a 2d sliding window along the genome to identify significantly-enriched 
candidate peaks (Figure 1.14). MACS merges overlapping candidate peaks, extending 
each tag a d number of bases to the centre of the region. The summit, the location of 
TF binding, is the position where the highest fragment pileup is observed.  MACS 
dynamically estimates the local Poisson distribution for the surrounding region of the 
current window at a distance of 1, 5, and 10 kb from the centre of the window and 
computes the Poisson parameter for the window using the formula: 
λlocal = max(λBG,	λ1k,	λ5k,λ10k) 
This approach ensures small peaks in low-enrichment loci are detected and avoids local 
genome biases. Finally, using the same parameter MACS conducts a sample swap to 
find ChIP peaks over control and control peaks over ChIP. This step empirically 
computes the FDR as (No. Control Peaks/No. ChIP peaks)[500].  
 
The TF binding site is usually in the range from 8-20 bps[505]. Peak regions 
called from ChIP-seq data, on the other hand, are always much longer, in the range of 
several hundreds of bps long. Motif discovery is subsequently essential to pin down the 
position and identity of the actual binding sites within these peaks. The general 
principle behind Motif discovery is that the regions of the ChIP peaks should in all or 
most of the cases carry an oligonucleotide sequence that is sufficiently similar to be 
identified as the binding motif of that particular TF. This oligonucleotide sequence 
could be the same previously reported motif of its TF, or a newly discovered one. The 
same oligonucleotide should also not have any likeness to a random set of sequences 
built at random with a generator of “biologically feasible” DNA sequences, or appear 
at the same frequency[506]. This enriched oligonucleotide sequence is then used to 
identify the actual motif to which the TF binds based on PWMs created for each base 
in the sequence. Motif analysis can additionally be used to detect added motifs in the 
neighbourhood of these regions which could serve as binding sites for other TFs 
functioning as binding partners in cooperative manner, and thus involved in creating 
regulatory modules[507]. The MEME Suite of tools offers a wide variety of motif 
analysis options, ranging from discovery of de novo motifs to searching a reference 
motif database (such as JASPAR, UniPROBE, TRANSFAC, etc.)[508, 509]. JASPAR 
Vertebrates and UniPROBE Mouse is the one mostly used for vertebrates, and was 
the one utilised in this thesis whenever motif discovery or enrichment was 
required[510]. 
 
Following peak-calling, the ChIP-seq peaks obtained need to be functionally 
associated with genomic regions where they can undertake their roles, including 
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promoters, transcription start sites and intergenic regions. Packages such as 
BEDTools[511, 512] provide a universal toolbox for the systematic analysis of peak 
calls. BEDTools can be used to measure the distance from each peak to the nearest 
genomic feature of interest, or to up/downstream genes, and combine the findings with 
results from other NGS methods such as expression data from RNA-seq, methylation 
information from BS-seq, chromatin interactions from Hi-C. 
 
This is, however, easier said than done. associating distal TF binding sites to 
their true target genes is not always feasible. For example, NF-γ, which is strongly 
associated with promoter and TSSs, has most of its binding sites located a long way 
from those regions[513]. Restricting the analysis to TF bound near promoter sites only 
is not an option either, as this misses all distal targets for the TF, and severely limits 
understanding the extent of its regulatory potential. Furthermore, the number of TF 
binding sites identified in a ChIP-seq experiment is high enough that if each one was 
associated with its closest gene, a significant portion of the genome will be covered as 
targets[514]. Tools exist which attempts to tackle the problem such as GREAT and 
HOMER[515, 516]. However, basic criteria need to be applied first to reduce the 
number of TF considered for further downstream analysis, such as setting threshold 
on the distance from the TSS, and read enrichment signal. For instance, the Roadmap 
Epigenomics project an enhancer was only associated with a target gene if its TSS was 
located at less than 30 kb away[20]. 
 
1.4.4 Methods of studying sequence variation effects on 
gene regulation 
 
Adapting ChIP-seq and other NGS technologies to address the potential effects of 
genetic sequence changes on the presence or absence of regulatory event of interest 
such as TF occupancy has led to an increased understanding on how variants within 
and across populations/species shape the regulatory landscape. DNA sequence changes 
within regulatory elements have the capacity to influence TF binding stability and its 
ability to induce its effects on transcription or modifying chromatin state, ultimately 
affecting the regulatory potential of the region and its impact on transcriptional 
regulation.  
 
 To study the regulatory effects of sequence variants (see 1.1.4 for more details), 
two methods have been used extensively: expression quantitative trait loci (eQTL) 
mapping (using gene expression levels as a quantitative phenotypic trait), and allele-
specific expression divergence between parental strain and their F1 hybrid in 
genetically inbred organisms. eQTL are polymorphic DNA variants that are associated 
with changes in gene expression and phenotypes[517]. Modern eQTL studies use RNA-
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seq to provide allele-specific gene expression levels[518]. RNA-seq produces 10s-100s 
millions of sequence tags that provides a complete profile of gene expression and the 
isoform structure of each gene[519]. eQTL mapping have been utilised to identify 
regulatory regions driving variation in mRNA levels and differ between local regulators 
acting in short genomic range in allele-specific fashion (cis) and distant-acting 
regulators (trans)which influence the transcriptional processes by affecting the 
availability of other factors involved in gene expression, resulting in similar expression 
levels from both alleles[252, 518].  
 
 eQTL analysis comprises four main steps: DNA genotypes processing, RNA-
seq tags processing, counting of total sequence reads and eQTL mapping[520]. First, 
DNA reads are mapped back to their reference genome, the genotypes are called and 
their haplotypes are imputed using a phasing algorithm. Next, RNA-seq reads are 
aligned to the same reference and/or the two haploid genomes imputed based on the 
results of the phasing programme[521]. After that, total read counts per gene, per 
sample, as well as the allele-specific reads per allele of a gene, per sample are counted, 
removing reads with low mapability and quality scores. eQTL mapping follows 
whereby variation in allele-specific expression and total gene expression are associated 
with a cis/trans variants using a beta-binomial distribution to test for 
similarity/difference in gene expression between the two alleles of a gene[520]. A 
hierarchical Bayesian model has been suggested to test the disparity of gene expression 
across alleles, combining information across genome-wide loci[522]. 
 
 A variant on the method involves chromatin immunoprecipitation quantitative 
trait loci (ChIP-QTL)[523], which combines this approach with identifying TF-DNA 
contacts as discussed in the previous sections. eQTL has been implemented on a 
genome-wide scale successfully in a number of studies to investigate distant acting 
variation, epistatic interactions, and determining gene expression divergence 
phenotypes[524-527].  
 
 Resolving the regulatory effects between cis- and trans-acting variation in 
eQTL studies remains fairly challenging despite advances in both experimental 
techniques and computational approaches[528, 529]. First, eQTL analyses require a 
vast number of genetically diverse samples to reach sufficient statistical power for 
detection[530-533]. Furthermore, eQTL analyses cannot fully distinguish between cis- 
and trans-acting elements. Some of the trans-acting variants may be located in close 
proximity on the same DNA molecule of the target gene, and some cis-acting variants 
may be distantly located[534, 535].  In addition, trans-eQTL have much smaller effect 
sizes, are less robust, less common and require a high number of association tests to 
investigate than cis-eQTL[536], which in turn reduces the statistical power, hindering 
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their detection[537]. Additionally, trans-eQTL suffer from the same confounding 
factors that influence their cis counterparts, be they biological (e.g. haplotype effects, 
tagging cis-eQTL), technical (probe binding sites variation) and statistical (missing 
genotypes, population structures)[538].  
 
 The F1 hybrid method, in contrast, can avoid many of those caveats, and 
reliably resolve the regulatory changes brought about by cis- and trans-acting variation 
on gene expression and TF occupancy. In this approach, variation between the two 
parents allow allele- specific expression to be evaluated. In F1 hybrid of the two F0 
parental strains, cis-acting regulatory variants appear linked to their target gene 
reflected in allele-specific expression. Trans-acting regulatory variants affect both F0 
alleles equally due to the shared nuclear environment. These two fundamentally 
different effects allow comparison of differential expression between the F0 strains and 
the allele-specific expression in the F1 hybrids, resolving the regulatory divergence in 
cis and trans across the entire transcriptome. Genes differentially expressed due to one 
or more regulatory variants acting in cis result in a ratio of allele-specific expression 
in F1 hybrids equal to the ratio of expression between the parent strains. On the other 
hand, if both alleles are expressed equally in the F1 hybrids, the difference is due to 
one or more trans-acting regulatory variants[260]. Whereas eQTL studies require a 
large number of crosses/samples, it is a major additional advantage that the F1 hybrid 
method requires only two parental strains and their F1 hybrid for analysis[252]. This 
approach has been used to study allele-specific gene expression in F1 hybrids in 
yeast[539-541], fruit flies[542, 543], and mice[257, 260, 544, 545]. 
 
To apply this method to polymorphic sites that are linked to regulatory 
variation, ChIP-seq peaks can be investigated to search for sequences that align across 
a heterozygous base in F1 hybrids. An observed difference in the binding intensity 
signal of one allele versus the other suggest a possible allelic effect on TF binding. For 
a TF binding site with two alleles, the binding signal from both alleles in F0 and F1 
would be equal if no sequence effect is present, resulting in non-differential binding. 
On the other hand, if the binding signal differs between F0 strains or the F1 hybrids, 
this indicates sequence-specific effects on the regulation of TF occupancy. These could 
be due to cis- and/or trans-acting variation[493]. This type of analysis requires 
adapting the standard ChIP-seq analysis pipeline discussed above to accommodate 
sequence variants that may introduce bias at the alignment step as heterozygous sites 
where reads identical to reference genome are aligned at a higher rate due to 
‘mismatch’ penalty imposed on the non-reference allele. In the F1 hybrid analysis, two 
reference genomes may be created, each containing one allele for the variant site, 
making it possible to combine the separate alignments of reads to each of these 
genomes. Alternatively, one can map F1 reads to both reference genomes of the F0 
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strains, and subsequently combine aligned reads for further analysis[257]. Furthermore, 
there are allele-aware aligners that dynamically account for multiple alleles during 
alignments, such as the Genomic Short-read Nucleotide Alignment Program 
(GSNAP)[498]. In sum, this type of analysis requires particular care and consideration 
for alignment of sequence variants in order to allow the accurate detection of 
differential binding signals from TF binding sites. 
 
1.4.5 Methods of studying genome folding effects on gene 
regulation  
 
Resolving the dynamic conformation of the folded genome within the nucleus is 
paramount to our ability to decipher the role of genome topology in the regulation of 
gene expression. Two major approaches are currently taken to study the 3D structure 
of the genome: chromosome imaging (e.g. fluorescence in situ hybridization of DNA or 
DNA-FISH), and chromosome conformation capture (3C), of which Hi-C (high-
throughput chromosome conformation capture) is the most prominent method[546].  
 
 DNA-FISH contributed to the field of studying genome folding by allowing the 
visualisation of nuclear DNA topology in space[547]. This approach, on the other hand, 
is limited by low throughput that constraint the number of genomic interactions that 
can be investigated for each run. However, the concept of utilising matrices of contact 
frequencies to deduce chromatin folding[548] revolutionised the field, and resulted in 
the development of an array of high throughput 3C-based assays including 4C, which 
selects for interactions of one region with the genome (‘one versus all’)[338, 549], 5C, 
which enriches for contacts of a larger genomic stretch at high resolution (‘many versus 
many’)[550] and ChIA-PET, which combines ChIP, 3C proximity ligation and Paired-
End Tags sequencing to characterise genome-wide chromatin interactions[551].  
 
 Hi-C is a genome-wide 3C method that is used to map chromatin contacts 
genome-wide at a scale of few hundreds of kilobases to megabases (‘all versus all’)[232]. 
In this method, DNA restriction fragments are crosslinked with formaldehyde, labelled 
with biotin and subsequently ligated. The biotin labels are then removed from 
unligated fragments by the exonuclease activity of T4 DNA polymerase, leaving ligated 
fragments enriched with the biotin label in the sequencing library[232, 552]. Sequenced 
reads aligned to the reference genome are used to assemble the Hi-C dataset, and 
interacting DNA fragments are binned at a range of resolutions (from 5–100 kb bins), 
with bin sizes depending primarily on the depth of the sequencing library[553]. 
Sequencing depths of 200–400 million reads are required for conducting standard Hi-
C in mammalian genomes[546]. Binning reads produces a symmetric matrix of bins 
(genomic loci) for each row and column in the matrix. Matrices for the whole genome, 
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selected chromosomes, or genomic regions of interest are generally displayed as 
heatmaps that visualise DNA-DNA interactions by the number of reads each bin 
contains. There exists a host of computational pipelines for Hi-C data processing, such 
as HOMER[516], Juicer[554], HiCUP[555] and HiCPro[556]. 
 
 3C-based methods also do have their limitations. Low efficiency of ligation and 
the genomic topology of the two DNA interacting DNA fragments are known to affect 
the detection of such contacts[546]. Furthermore, chromatin interactions detection is 
dependent on the fragmentation step, and 3C-based methods in general tend to be 
biased towards the detection of low- vs. high-order chromatin contacts, resulting in 
the underestimation of the impact and functional implication of the more complex 
interactions in the regulation of gene expression during chromatin folding[546]. 
 
1.5 Thesis Outline 
 
In this introductory chapter, I presented the biological background, with 
particular emphasis on the evolution and functional roles of CTCF, underlying the 
work carried out in this thesis. Furthermore, I provided an overview of the methods 
relevant to the research projects conducted here, including the experimental 
approaches utilised to generate the data, and the subsequent computational analyses.  
 
Chapter 2 presents the findings of an investigation into the impact of novel 
subspecies-specific CTCF binding sites in two Mus genus mouse subspecies, Mus 
musculus domesticus and Mus musculus castaneus that diverged one million years ago. 
This chapter focuses on CTCF occupancy difference between sites conserved in binding 
in the two subspecies and the evolutionary young sites bound in one but not the other 
subspecies (Figure 1.15). The analysis revealed a recent expansion of SINE B2-B4 
transposable elements that resulted in the creation of novel subspecies-specific sites. A 
subset of evolutionarily young sites exhibited conservation of binding across multiple 
tissues in M. musculus domesticus (BL6). We additionally found a tandem duplication 
of a regulatory region comprised of a CTCF binding site and an interferon gene, 
forming a 15-gene BL6 specific immune locus. 
 
Chapter 3 uses an F1 hybrid system to look at the divergence of CTCF binding 
influenced by regulatory variation between the two closely related mice. This chapter 
investigates a set of CTCF sites whose binding site between the two species is 
characterised by the presence of single nucleotide variants that can be used to 
differentiate allelic-specific binding, and the regulatory variation in the binding site 
(Figure 1.15). Whilst cis-acting regulatory variation is the most common, we observed 
pervasive trans effects in allelic-specific binding.  We also investigated the tissue-wide 
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conservation of occupancy of these sites and described the pattern of evolution of 
lineage-specific sites, and the mode of inheritance CTCF binding sites demonstrate. 
 
Chapter 4 presents the analysis of the functional regulatory potential of CTCF 
binding in the context of both sets of CTCF sites derived from Chapter 2 and 3. 
Namely, this chapter compares the functional and regulatory characteristics of CTCF 
binding in binding sites either on the basis of their evolutionary and tissue-specificity 
(Chapter 2) and or the binding variation they display in the form of cis/trans 
regulatory variants (Chapter 3). We investigated the enrichment in repeat elements in 
cis/trans-acting variants and whether their SINE-derived sites stem from the recent, 
subspecies-specific expansion (Chapter 2) or is older. We also analysed the differences 
observed among the various types of CTCF binding sites in terms of their binding in 
active regulatory elements, TAD-boundary association and their interaction with 
cohesin-complex proteins. 
 
Chapter 5 provides general conclusions of our findings, and presents avenues 
for future research in which the results in this thesis could be taken.  
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Figure 1.15: Schematic diagram of the thesis structure and the analysis pipeline. 
 
 
 
 
 
 
 
 
Chapter 2 
 
Functional signatures of 
evolutionarily young CTCF 
binding sites 
 
 
2.1 Introduction 
 
The regulatory regions of the genome predominantly lie in the non-coding sequences 
of the genome, and differences in those regions are thought to drive the distinction in 
gene expression across tissues and cell-types[401, 413, 414, 557]. Whilst protein-coding 
genes have been subject to strong selective pressures, as revealed by interspecies 
comparisons of mammalian genomes[378],  tissue-specific transcription factor binding 
frequently diverges [6, 260, 269, 362, 392, 394, 408, 409, 558]. Changes in the regulatory 
non-coding genome seem to be the major force behind the variation in transcription 
factor binding between closely related species with both small-scale sequence 
variation[257, 393] and novel species-specific repeats playing important roles[559].  
 
Repeat elements have been shown to drive some of the changes in transcription 
factor binding, and the regulation of gene expression by altering the non-coding 
genome[387, 560-562]. In particular, CTCF binding has been shown to be the product 
of waves of species-specific expansion of repeats across several mammalian lineages 
that carried its canonical motif into novel genomic locations[269, 384]. This repeat-
driven, TF binding site birth mechanism has been observed in other cases of tissue-
specific transcription factors in stem cells[409] and in pregnancy associated tissues[431], 
suggesting that repeat expansions are a common mechanism used to remodel 
mammalian genomes[387]. 
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CTCF binding motifs have undergone expansion in Murine lineages via a rodent-
specific family of transposable elements[269, 384]: the B2 short interspersed elements 
(SINE-B2-B4)[563]. Although the evolution of CTCF binding in the Mus genus via 
this mechanism has been investigated recently[559], the potential functional roles of 
novel, species-specific CTCF binding sites and the pattern of their genomic occupancy 
is not yet known. 
 
Leveraging the high-quality genome sequences of different mouse strains and 
species within the Mus genus created by the Mouse Genomes Project[465, 564-566], 
we illustrate how highly active, expanding repeats have remodelled CTCF binding, 
and thus chromatin and transcription, in two Mus genus subspecies sharing a common 
ancestor one million years ago (MYA): Mus musculus domesticus (C57BL/6J or BL6) 
and Mus musculus castaneus (CAST) (Figure 2.1a). Subspecies-specific binding of 
CTCF reveals signatures of function, genomic occupancy patterns, and tissue-
independent characteristics that are largely similar to CTCF sites common between 
the subspecies. More importantly, a subset of these subspecies-specific sites are bound 
in multiple tissues, suggesting active participation in loop formation and the creation 
of novel regulatory modules. We also found a cluster of interferon genes with 
subspecies-specific CTCF binding sites on mouse chromosome 4 with a high degree of 
sequence similarity that apparently arose via a recent, BL6-only, tandem duplication 
event. Taken together, these results demonstrate the evolutionary pace at which CTCF 
binding sites expand in the genome and acquire functionality. 
 
This investigation is the result of a collaboration between Dr. Paul Flicek’s 
research group at the EMBL European Bioinformatics Institute and Dr. Duncan 
Odom’s laboratory at the Cancer Research UK Cambridge Institute. Dr. Christine 
Feig performed all of the wet lab experiments for this project. Dr. Jonathan M. Mudge 
did the manual genome annotation.  I carried out the computational analysis, except 
where otherwise specified. 
 
 
2.2 Methods 
 
2.2.1 Experimental methods 
 
2.2.1.1 Animal breeding and sample collection 
 
The experiments were conducted using mice from two strains: C57BL/6J (stock 
number: 000664, source: Charles River Labs) and CAST/EiJ (stock number: 000928, 
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source: The Jackson Laboratory). All biological replicates collected for the purposes of 
this investigation were sampled from adult male mice, 8-12 weeks of age, and harvested 
between 8 and 11 a.m. All animals were kept in similar husbandry conditions in the 
Biological Resources Unit of the Cancer Research UK–Cambridge Institute under a 
Home Office Licence.  
 
 Sampling of liver by perfusion was done on mice post-mortem, followed by 
tissue dissection. Harvested tissue samples were quickly chopped and transferred into 
a cross-linking solution with 1% formaldehyde in preparation for ChIP-seq protocol. 
Tissue samples were incubated for 20 minutes before quenching with 1/20th volume 
of 2.5 M glycine, then for a further 10 min. Samples were subsequently washed with 
PBS, flash-frozen and stored at !80 °C. 
 
2.2.1.2 Generation of CTCF ChIP-seq Data 
 
Chromatin immunoprecipitation followed by high-throughput sequencing 
(ChIP-seq) experiments for the CTCF protein[567] were performed using liver tissue 
sample isolates from two closely-related Mus subspecies: Mus musculus domesticus 
(C57BL/6J or BL6) and Mus musculus castaneus (CAST). The libraries were 
sequenced at 100 bp in paired-end fashion. In each case, three biological replicates 
from different 8-week old male mice, and a matched control liver sample from another 
animal. Technical details of the ChIP-seq procedures and antibodies used were 
previously reported[559]. 
 
2.2.2 Computational methods 
 
2.2.2.1 Sequence Alignment and Peak Calling 
 
All libraries were retrieved as raw ChIP-seq FASTQ reads were subject to 
quality control using standard parameters in FastQC version 0.11.5[488]. Good quality 
reads (min Phred score >= 30) were subsequently aligned to most recently available 
genome assembly in Ensembl (GRCm38 for BL6 and CAST_EiJ de novo assembly at 
ftp://ftp-mouse.sanger.ac.uk/, later in the Ensembl release 84 for CAST). We aligned 
the sequence reads to the reference genomes using BWA version 0.7.12[494] using both 
paired ends reads for each biological replicate and control. Aligned reads were 
afterwards filtered for duplicate and non-unique reads, sorted and indexed using 
SAMtools version 1.2[568]. CTCF binding sites were identified by peak calling from 
aligned sequence reads using MACS version 2.1.0[500] with a p-value threshold of 0.001 
to call peaks representing CTCF binding regions. Peaks found in at least two biological 
replicates out of the three were used for downstream analysis. Motif analysis focused 
on the summit point (±50 bp) of each identified CTCF binding sites using the MEME 
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suite version 4.10.2[508, 509]. Most common motif found in each dataset is reported in 
Figure 2.1b.  
 
2.2.2.2 Interspecies comparisons 
 
We quantified the conservation of CTCF occupancy in one of the two mice 
subspecies using the orthologous alignments of the CTCF binding sites in the other 
subspecies. Interspecies comparison between BL6 and CAST was performed first using 
a multiple alignment of 15 de novo assemblies of laboratory and wild-derived strains 
genomes within Mus musculus[566, 569]. Orthologous regions with a CTCF binding 
site present in both subspecies was considered a “musculus-common” site, whilst sites 
found in only one of the subspecies, but absent from the other, was considered 
“subspecies-specific”.   
 
 
2.2.2.3 Repeat Masking of CTCF binding sites 
 
CTCF binding regions from musculus-common and subspecies-specific sets of the data 
of both subspecies were screened for repeat elements using RepeatMasker 4.0.5[570] 
(http://repeatmasker.org) using the rodent repeat libraries from RepBase (v20140131) 
for the two murine subspecies, with the cross_match search engine, running in slow 
speed/sensitivity, masking for interspersed and simple repeats and RepeatMasker 
matrix choice for GC level. Fragmented hits found to be part of the same repeat were 
merged as one. 
 
To calculate the background representation of the 4 superfamilies of transposable 
elements (TEs) (SINEs, LINEs, LTRs, DNA transposons) in the mouse genome for 
comparison with musculus-common and BL6 subspecies-specific sites enrichment, the 
sum total of the sequences occupied by each TE superfamily divided by the total length 
of the genome. We retrieved the full set of TEs for the C57BL/6J mouse genome from 
those published in Thybert et al[559]. To derive the random set of genomic sequences, 
we used the BEDTools version 2.2.5.0[511, 512] shuffle tool to generate sequences equal 
in number and length to the total number of CTCF peaks obtained from our ChIP-
seq libraries. Random sequences were matched for the chromosomes, but non-
overlapping with any of the sequences in the CTCF peaks set. 
 
We used the intersection between CTCF peaks and the full set of the four TE 
superfamilies to derive the proportion of sequence occupied in each CTCF binding site 
and the relative age of the repeat element present. To determine the fraction of 
sequence occupied, we used BEDTools intersect 2.2.5.0 with the option -wo to return 
the overlap between the peak sequence and the repeat, then divided the overlap by 
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the total length of the peak to obtain the percentage of sequence occupied by TE for 
every single peak/random sequence. We defined the relative age of a repeat element 
as the percentage of sequence substitutions in each repeat from the consensus. The 
higher the percentage of substitutions in TEs compared to the consensus, the older the 
sequence is.  
 
2.2.2.4 Repeat Content Analysis of liver-specific transcription factors 
(TF) binding sites 
 
Raw ChIP-seq libraries from Stefflova et al.[558] were used for repeat content 
comparison to other two liver-specific transcription factors, CEBPA and FOXA1 for 
both mice subspecies. In each case, three biological replicates from different 8-week old 
male mice, and a matched control liver sample from another animal. Peaks found in 
at least two biological replicates out of the three were used for all downstream analysis. 
The raw FASTQ sequence were run through the same pipeline outlined earlier for peak 
calling. Interspecies comparison and repeat masking as described above for CTCF. 
 
For studying the correlation between repeat content and the signal intensity of 
the TF binding site, all datasets for each transcription factor/CTCF in both subspecies 
were subsequently divided into ten 10% bins based on descending intensity of the 
ChIP-seq signal for each of the three evolutionary classifications: musculus-common, 
BL6-specific and CAST-specific. The repeat content for each bin of TF binding sites 
was then determined using the methodology detailed previously in 2.2.2.3.  
 
2.2.2.5 Cross-Tissue Analysis of subspecies-Specific CTCF Binding 
 
CTCF ChIP-seq data for BL6 adult (8 weeks) male mice were retrieved from 
the ENCODE Project data repository[451] for 12 tissues: lung, bone marrow, bone 
marrow macrophages, cortical plate, cerebellum, heart, kidney, thymus, spleen, 
olfactory bulb, small intestine and testis. We additionally used ENCODE libraries for 
the liver as a technical replicate to identify CTCF binding sites common in multiple 
tissues. In each case, two biological replicates from different 8-week old male mice, and 
a matched control tissue sample from another animal. Peaks found in both two 
biological replicates were used for downstream analysis. The raw FASTQ sequence 
data were used and run through the same pipeline outlined earlier for peak calling.  
 
We used the overlap between our liver-derived CTCF peaks and the peaks from 
every ENCODE tissue to determine the tissue-sharedness of musculus-common/BL6-
specific binding sites, using BEDTools intersect 2.2.5.0 with the options -wa -wb. 
UpSet plots were generated using the ComplexHeatmap package in R[571]. 
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To calculate ENCODE tissues CTCF diversity index, we used the log10 of the 
p-value at peak summit computed by MACS version 2.1.0 during the peak calling step. 
For each liver-derived CTCF peak, if that peak was bound in an ENCODE tissue, the 
p-value for the binding of CTCF was retrieved. These values were subsequently used 
to calculate the Shannon Diversity Index for each tissue using Vegan package in 
R[572]. CTCF occupancy conservation across tissues was calculated as the fraction of 
CTCF peaks whose occupancy is conserved within each bin of Shannon diversity index. 
 
Based on the results of the ENCODE tissue analysis, BL6-specific sites were 
then defined as tissue-shared or tissue-specific. Tissue-shared sites were CTCF binding 
sites found to be the intersection of all BL6-specific binding sites from the top four 
ranking tissue, plus the ENCODE liver technical replicate. All other BL6-specific sites 
were deemed tissue-specific. 
 
2.2.2.6 Chromosome 4 Interferon-zeta gene-cluster Analysis 
 
CTCF binding sites coordinates in bed format along with ChIP-seq coverage 
reads in those regions were uploaded for display on the Ensembl genome browser 
release 89[25]. These included reads from liver and the other four tissues, plus ChIP 
coverage reads from two histone marks for liver, H3K4ac27 and H3K4me3, from 
ENCODE data repository. Ensembl genome browser was used to display gene 
annotations, pairwise alignments with CAST and Rat, repeat elements enrichments 
for transposons and LTRs and genomic annotations. Sequence similarity for the 15-
gene cluster, upstream CTCF binding regions, and the complete 15 constructs of 
CTCF binding sites plus the gene sequence plus ±500 bp were determined using 
Clustal Omega[573], using default parameters.  
 
We utilised the Comparative Genomics tool of the Ensembl Genome Browser 
to look at the BLASTz/LASTz whole genome alignment between the Chromosome 4 
Interferon-zeta gene-cluster and all available pairwise alignments with other 
organisms[574]. An orthologous gene was found in the pig genome whose target 
sequence matched 14/15 from the mouse cluster with Query %id of > 50%. We used 
BLAST/BLAT to scan the pig genome for paralogues to the gene based on sequence 
similarity. As with the mouse cluster, the Ensembl genome browser was used to display 
gene annotations, repeat elements enrichments for transposons and LTRs and GERP 
scores. Next, we scanned the 1 kb sequences upstream of each gene's TSS for the 
enrichment of motifs using MEME (4.12.0), setting 5 as a maximum number of motifs, 
and a motif width between 6-50 bp. The top 5 motifs from all upstream sequences 
were subsequently submitted to TOMTOM (2.14.0) to search available databases for 
annotated motifs to match[508, 509]. 
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The manual annotation review of the locus on chromosome 4 determined that 
the annotation of the region was essentially correct with only a couple of minor issues 
identified and corrected. Specifically, Gm16686 was identified as a spurious protein-
coding gene that will be removed in the next GENCODE release and has already been 
removed from RefSeq. RP23-400P11.4 was added as novel interferon pseudogene 
located at BL6 chr4:88754471-88754678 due to the clear pseudogenic characteristic of 
a significantly truncated 3' end. Finally, we reviewed Gm13286, which is annotated as 
a pseudogene in GENCODE, but considered protein-coding by RefSeq. It has a 
premature STOP compared to other family members, though it only loses the last 3aa 
of the typical protein. Based on the GENCODE annotation guidelines, Gm13286 is 
correctly annotated as a pseudogene although the coding status should be further 
investigated to make a definitive determination. 
 
 
2.3 Results 
 
2.3.1 CTCF binding is highly conserved, yet a considerable 
degree of occupancy is subspecies-specific 
 
We performed chromatin immunoprecipitation followed by high-throughput 
sequencing (ChIP-seq) of CTCF in liver samples from BL6 and CAST (Methods). 
Comparable numbers of binding sites were obtained from all replicates in both 
subspecies. We limited our analyses to CTCF bound locations that yielded higher 
enrichment of signal when compared to control in at least two out of three of the 
biological replicates. Overlap analysis of binding sites based on the pairwise alignment 
of both subspecies revealed that most CTCF binding between CAST to BL6 was found 
at orthologous locations, with over 80% (>32,000) of the CTCF binding sites in 
common (musculus-common). This is consistent with previous reports across 
mammalian and rodent lineages[238, 575]. Nevertheless, we were able to determine 
that  ~ 20% of binding in either subspecies was found to be subspecies-specific, with 
approximately 7,000 of these subspecies-specific sites in BL6 compared to over 4,000 
sites in CAST (Figure 2.1b). The disparity in the number of subspecies-specific sites 
between BL6 and CAST could be an artefact of the difference in CTCF peaks between 
them (Figure 2.1a).  
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Figure 2.1: Identification of specific-specific CTCF binding in the genomes of 
BL6 and CAST mice. 
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a A schematic example of the contribution of transposable elements novel 
subspecies-specific CTCF binding. Approximate divergence times in millions of 
years are displayed on the left-hand side of the panel[576]. The peaks represent 
CTCF binding as determined from ChIP-seq experiments, while the boxes denote 
transposable elements. The table shows the peak counts (binding sites) retrieved 
from the three biological replicates for each subspecies. All downstream analysis 
utilised peaks common to a minimum of two replicates. b Overlap analysis of 
ChIP-seq peaks sub divides CTCF binding into five categories: Total BL6, BL6-
specific, Total CAST, CAST-specific and musculus-common. The numbers inset 
are the binding sites in two subspecies-specific and the musculus- common sets. 
The most common motifs are indistinguishable among each set. c Bar plot 
showing the fraction of sequence annotated as repeats in each category described 
in b. The asterisks indicate the significance of enrichment of SINE B2-B4 
elements between subspecies-specific sets and the entire set of binding sites for 
either subspecies and the musculus-common set (binomial tests with Bonferroni's 
correction, ***p-value < 0.0001). 
 
Motif analysis was performed on the CTCF sites retrieved by peak-calling from 
each subspecies. In both subspecies, the canonical CTCF binding motif was obtained 
regardless of whether we considered all binding sites, or the subspecies-specific subset 
of sites, or those that were common to both subspecies (Figure 2.1b).  
 
2.3.2 SINE repeat expansion is major driver of subspecies-
specific binding 
 
CTCF binding site evolution is known to be driven by repeat element expansion, 
particularly of the Short-Interspersed Elements (SINEs) superfamily of transposable 
elements (TEs)[269, 384]. We, therefore, investigated transposable element enrichment 
in the CTCF binding sites. The repeat content in all CTCF binding sites for either 
subspecies was comparable between the two subspecies, with an average of 21% of all 
sequences bound by CTCF embedded in repetitive elements (Figure 2.1c). Two-thirds 
of these sequences occurred within SINE TEs. With most of the binding sites shared 
between the two subspecies, it was unsurprising that the musculus-common binding 
sites have the same repeat composition (Overall: 18%, of which SINE: 12.4%) (Figure 
2.1c). 
 
However, the subsets differed substantially when the analysis was limited to the 
20% of CTCF sites bound in a subspecies-specific manner. Compared to the musculus-
common binding sites, the subspecies-specific sites were enriched in transposable and 
repetitive elements. Indeed 34% of BL6-specific CTCF sequences occurred within a 
SINE element, a more than a two-fold increase (BL6-specific vs. All BL6 binomial test 
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p-value=3.12766E-07, BL6-specific vs. musculus-common binomial test p-
value=8.96592E-10). Comparable results were seen with the CAST-specific binding 
sites (CAST-specific vs. All CAST binomial test p-value=7.41176E-06, CAST-specific 
vs. musculus-common binomial test p-value=1.85083E-07) (Figure 2.1c). The 
enrichment of repeat content in subspecies-specific CTCF binding sites may be an 
underestimation of the true contribution as the approximately 15% of sites that were 
identified in only one replicate—and were thus left out of further analysis—also exhibit 
increased enrichment in repeat content. 
 
When the musculus-common and BL6-specific sets of CTCF binding sites were 
compared to the four most common TE superfamilies in the mouse genome, CTCF 
was found to be highly enriched with SINE TEs at 71% for musculus-common sites, 
rising up to 76% for subspecies-specific sites for all sequences embedded in repetitive 
elements (χ2 test, p-value < 2.2e-16). This constituted a three-fold increase over both 
randomised genomic regions matched for number and size, and the overall genomic 
background occupied by TEs in the BL6 mouse (Figure 2.2a). Conversely, longer 
repeat elements, from the LINE and LTR superfamilies, were clearly depleted for 
CTCF binding sites (χ2 test, p-value < 2.2e-16), with subspecies-specific sites showing 
a slightly lower level of sequences occupied by LINE elements (7% vs. 9%). Whilst 
CTCF sites that are musculus-common showed a slight enrichment for DNA-
transposons compared to randomised regions and the background (4% vs 2.8-3%), they 
were almost absent in subspecies-specific sites (~1%) (Figure 2.2a).  
 
In addition to the observations in Figure 2.1c, CTCF binding site sequences were 
not only bound in SINE repeats more often than their musculus-common counterparts, 
but for each subspecies-specific binding site embedded in a SINE TE, most of the 
sequence is SINE-derived (Figure 2.2e). The majority of these BL6-specific sites were 
nearly all masked by SINE repeats (median = 77% of sequence), compared to either 
musculus-common site (39%) and randomised regions (31%). These differences in 
repeat element contributions to the sequence of CTCF binding sites were found to be 
highly statistically significant (Man Whitney U test, both p-value < 2.2e-16).  
 
We next quantified the age of all TE-derived sequences, estimated by the 
sequence substitutions of the repeat elements within binding sites, in musculus-
common, subspecies-specific and randomised genomic regions. We used the percentage 
of mismatch in TE sequence from the consensus as a measure of the relative age of the 
TE element. Using sequence mismatches to estimate the relative age of repeat 
elements, evolutionary young sites inserted into new genomic positions via repeat 
expansion of TE elements have only had a relatively short evolutionary time to 
accumulate mutations. Conversely, binding sites in TE elements characterised by 
increased level of mismatches in the sequence originate from much older repetitive 
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sequence. Using this rationale, and in agreement with the results reported above, 
CTCF BL6-specific sites have a significantly lower levels of sequence mismatches in 
their TE-derived sequences (median = 17%) than either musculus-common sites (22%) 
or randomised genomic regions (21%) (Man Whitney U test, both p-values < 2.2e-16) 
(Figure 2.2b). This indicates the recent evolutionary origin of these sites in comparison 
with either conserved or randomised regions. Most of these evolutionarily young 
sequences originate from expansion of SINE repeat elements as evidenced by the 
restricting the analysis on the subset of CTCF binding sites within SINE TEs. These 
sites show a significantly younger age, illustrated by the low levels of sequence 
mismatch in their sequences (median = 16% for BL6-specific versus 22% and 24% for 
musculus-common and randomised genomic regions respectively) (Figure 2.2c). This 
recent cluster of SINE-derived CTCF sites is evidence of post-divergence expansion of 
the binding site that continued in each mouse lineage separately, and may yet still be 
ongoing. As with general TEs, these differences in SINE elements ages were 
statistically significant (Man Whitney U test, both p-value < 2.2e-16).  
 
 
 
Figure 2.2: SINE transposable elements drive CTCF subspecies-specific binding 
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a Horizontal bar chart shows the proportion of major TE superfamilies in CTCF 
binding sites that are masked by repeat elements. The top bar represents the 
percentage each TE superfamily occupies in all repeat masked sequences in the 
BL6 mouse genome as a background. The bottom bar shows the fractions of 
these superfamilies in a matched set of randomised regions of the same length. b 
Box plot of the percentage of sequence mismatches/substitution from the TE 
consensus sequence of the all TE superfamilies in the different evolutionary 
categories of CTCF sites, compared to a matched random set. c Violin plot of 
the proportion of sequence mismatches/substitution from consensus in SINE TEs 
for the same categories from b. d 100% stacked bar plot of the proportions of 
the most common families of SINE TEs in all sequences masked by SINE 
elements in the different types of CTCF binding sites (The Alu family in the 
panel refers to the Alu/B1 rodent-specific family). e Violin plot of the proportion 
of sequence masked by SINE repeat elements in conserved/subspecies-specific 
CTCF sites, compared to the matched random set. The boxplots within each 
violin plot show the variation in extent of sequence masking for each category. 
The dashed grey line denotes the average genomic sequence occupied by SINE 
TEs in all TE-masked sequences of the mouse genome. 
 
Most SINE-derived CTCF sequences in mouse belong to the B2-B4 rodent-
specific family[269, 384, 409]. Analysis of SINE families make up in CTCF binding 
sites and randomised region showed that this is indeed the case, particularly with BL6-
specific sites in which a further enrichment of the B2-B4 elements was evident (95% 
compared to 86% in musculus-common) (Figure 2.2d). However, our results provide 
evidence that the timing this CTCF binding expansion, previously known to be mouse- 
or rodent-specific, is in fact subspecies-specific and continued after the divergence 
between BL6 and the closely-related CAST subspecies. Even though SINE-derived 
musculus-common CTCF binding sites were made up of mostly B2-B4 elements, they 
appear to have been primarily involved in the evolution of subspecies-specific CTCF 
binding sites (χ2 test, p-value < 2.2e-16). 
 
2.3.3 CTCF binding sites have distinctive repeat profiles 
 
For comparison, the evolutionary and repeat content analyses of musculus-
common versus subspecies-specific binding sites was analogously performed for the 
liver-specific transcription factors CEBPA and FOXA1. First, ChIP-seq analyses of 
publicly available libraries for these two factors [558] were done to identify musculus-
common and subspecies-specific binding in BL6 and CAST as described above for 
CTCF (see Methods). In both subspecies and for both transcription factors, repeat-
based elements contributed more to specific-specific than to common binding, but to 
a lesser extent than that for CTCF. (Figure 2.3a left). However, unlike CTCF, few 
2. Pervasive effects of trans-acting variation on CTCF occupancy  
 73 
SINE B2-B4 elements were bound by the tissue-specific transcription factors. Instead 
the repeat content in all sets of binding sites for both transcription factors originated 
from the various superfamilies of repeat elements with no obvious major contributor 
(Figure 2.3a right and 2.3b).  
 
Taken together, comparison with the other two transcription factors showed that 
the expansion of subspecies-specific CTCF binding sites by SINE B2-B4 elements is 
not a general trend seen in liver-specific transcription factors.  
 
We next asked whether there was a correlation between the repeat content of a 
CTCF binding site and its signal intensity as measured by the number of ChIP reads. 
From the subspecies-specific and musculus-common sets, binding sites were sorted by 
their signal intensity and then collected into 10 equal-sized bins. In the musculus-
common set of CTCF binding sites, the repeat content increases as the intensity of the 
binding site decreases, In contrast, in the two subspecies-specific sets both the overall 
repeat content and the number and percentage of SINE B2-B4 elements remain 
roughly constant, regardless of the ChIP-seq signal intensity (Figure 2.3b left). Thus, 
the repeat content in both subspecies-specific sets is independent of the signal strength 
of the binding site.  
 
Repeating this analysis for the two tissue-specific transcription factors revealed 
that the overall repeat content does not change with the ChIP-seq signal intensity, 
but remains roughly constant (Figure 2.3b middle and right). The contribution of SINE 
B2-B4 subfamily to this is negligible (~2-3%) (See Appendix 1).  
 
The relationship between ChIP signal intensity and repeat content supports the 
expectation that CTCF subspecies-specific binding sites have recently arisen from 
SINE B2-B4 elements and thus have a different evolutionary origin than binding sites 
of typical tissue-specific transcription factors. However, the sites with low signal 
intensity and observed in multiple replicates are not mere sequencing noise, because 
the CTCF motif was retrieved from these sites, and their genomic distribution is 
indistinguishable from those CTCF binding sites with higher intensity (Figure 2.1b). 
Furthermore, though not SINE-driven, we showed that liver-specific TF binding sites 
are also actively evolving in those two subspecies since the time of their divergence. In 
sum, these results illustrate the power with which transposable elements rapidly 
modulate transcription factor binding, shaping nearly 50% of the subspecies-specific 
CTCF occupancy profile in just one million years of divergence time between BL6 and 
CAST. 
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Figure 2.3: CTCF binding sites have distinctive repeat profiles as compared to 
tissue specific transcription factors 
 
a For CTCF, CEBPA and FOXA1, subspecies-specific binding sites are enriched 
in repeat elements (left) (binomial test, all p-values <  2.2e-16), but only CTCF 
is associated with the SINE B2-B4 sub-family (right). b The characterisation of 
the different categories of repeat elements in the binding sites of CTCF and the 
two TFs from (a) shows that the CTCF has a distinctive TE profile. INEs stands 
for Interspersed Elements. Whilst the types of TE in the binding sites of CEBPA 
and FOXA1 widely vary between them, and within their binding sites depending 
on their evolutionary status, SINE B2-B4 elements almost exclusively make up 
all TE-derived occupancy in CTCF regardless of subspecies-specificity. The sizes 
in each plot are proportional to the sequence occupied by each type of repeat 
element, and their overall proportion of the total binding site sequence masked 
by TEs according to their evolutionary status. c Subspecies-specific CTCF sites 
contain a consistent level of repeat annotated sequence regardless of ChIP-seq 
signal intensity. More intense musculus-common binding sites have a lower 
fraction of repeat annotated sequence. The same pattern is observed for the 
subset of CTCF sites within SINE B2-B4 elements. The x-axis is arranged in 
10% bins based on binding site signal. 
 
2.3.4 A subset of BL6-specific CTCF binding is tissue-
shared. 
 
Although CTCF is known to be bound across multiple-tissues, the numbers and 
locations of its binding sites can vary among tissues[577]. We, therefore, investigated 
the association between subspecies-specificity and tissue-specificity by profiling the 
pattern of CTCF binding in tissues other than the liver using publicly available data. 
We used ENCODE CTCF ChIP-seq data for BL6 adult (8 weeks) male mice from 13 
tissues: liver, lung, bone marrow, bone marrow macrophages, cortical plate, cerebellum, 
heart, kidney, thymus, spleen, olfactory bulb, small intestine and testis[451]. Since 
ENCODE did not perform ChIP-seq analysis on CAST samples, all tissue analyses 
were limited to BL6 only. 
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Figure 2.4: Almost a 1000 BL6 subspecies-specific CTCF binding sites are 
shared among five tissues. 
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a, b and c UpSet plot of the liver-derived CTCF binding sites found across the 
12 mouse ENCODE tissues for all sites (a), conserved (b) and BL6-specific (c). 
The number of sites bound at each combination of tissues is indicated on the y-
axis on the top bar chart. The original plot was reduced to these 26 combinations 
representing only highly tissue-shared and tissue-specific. The rightmost bar on 
each UpSet plot (boxed) indicates the number of CTCF binding sites that were 
not found to be bound in any other ENCODE tissue library. d Density plots of 
the association between CTCF binding strength in musculus-common/BL6-
specific sites and occupancy conservation across 12 tissues. The plots display the 
frequency of CTCF shared binding across tissues. Diversity values are indicated 
on the x axis as calculated using Shannon Diversity Index from the p-value 
estimates of peak calls of each category (see Methods). The red line is for the 
proportion of conserved CTCF occupancy within each bin of Shannon index, 
calculated based on the number of CTCF sites bound for each category across 
tissues separately. e Bar plot of the proportion of CTCF binding sites bound in 
ascending number of tissues in conserved versus BL6-specific sites. The y axis 
represents the cumulative percentage of binding sites found at the minimum 
number of tissues on the x axis. The dashed grey line denotes the minimum 
number of tissues at which 50% sites are shared. f Overlap of CTCF binding 
from 13 ENCODE Project derived data sets with our liver-specific BL6 data.  
The four tissues with the highest overlap are enclosed and used for further 
analysis. The number of peaks shared with each tissue are inset. g Number of 
BL6-specific CTCF binding sites shared among subsets of the four selected 
tissues, plus the ENCODE liver as an added technical replicate. 
 
Analysis of ENCODE tissue libraries of CTCF showed that at least 10.5% of all 
binding sites, are bound in all ENCODE tissues (almost 4000 sites), and over 1800 
more have their occupancy conserved in a minimum of 11 tissues (Figure 2.4a). On 
the other hand, 17% of all CTCF sites appear to be liver-specific, with no shared 
occupancy in any other ENCODE tissues. Of all ENCODE tissues analysed, kidney 
appears to have the highest degree of tissue-shared binding with the liver, with more 
than 78%, of which over 2000 sites are bound exclusively between the two tissues 
(Figure 2.4a). When we stratified these sites based on their evolutionary origin, the 
patterns above were mirrored in the musculus-common set of CTCF binding sites; 98% 
(> 3900) of all CTCF sites bound in all 12 tissues were musculus-common (Figure 
2.4b). The results from the BL6-specific set of CTCF sites were, on the other hand, to 
the contrary. Slightly over 1% of all BL6-specific CTCF sites were bound in all 12 
tissues, and 41% of these sites (>2800) were found only in the liver (Figure 2.4c). The 
kidney, again, appeared to be the tissue with which most occupancy  is shared, albeit 
greatly reduced now from 85% in musculus-common to just about 50% in BL6-specific 
sites (Figure 2.4c). 
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In addition to looking at shared CTCF occupancy in other tissues, we evaluated 
the strength of CTCF binding sites in all of the 12 mouse ENCODE tissues, using the 
Shannon Index[578] as a measure of their diversity of evolutionarily variable CTCF 
binding on the basis of their abundance and conservation. The expectation is that sites 
that are tissue-shared are more likely  involved in regulatory functions, hence they are 
under increased selective pressure that keeps their levels of shared binding high tissue-
wide[399].  
 
Results confirmed the findings above, showing high Shannon index values across 
tissues, correlated with a great degree in CTCF occupancy conservation (Figure 2.4d 
rightmost panel). These results were more strongly observed in musculus-common sites, 
with higher density at higher values of the diversity index (Figure 2.4d leftmost panel). 
The Shannon index high values distribute smoothly in a bi-modal trend, with the 
bottom five tissues from Figure 2.4a and b clustering together towards the lower range 
of the diversity index, and the top 5 tissues occupying the cluster at the higher end of 
the curve. The diversity curve for the BL6-specific CTCF sites was, however, markedly 
different. The calculated tissue index values were much lower and extended in a wider 
scale, flattening the distribution, a further sign that subspecies-specific CTCF binding 
is predominantly tissue-specific, its occupancy in other tissues is far more restricted. 
 
In light of the analyses performed above, we explored the possibility of finding a 
subset of BL6-specific CTCF binding sites with elevated levels of tissue-sharedness. 
We theorised that increased tissue-permeation to CTCF subspecies-specific binding 
could be a precursor to their adopting functional roles. We first looked at how many 
of these sequences are found in progressively more tissues (Figure 2.4e). Analysis of 
ENCODE tissue data showed that whilst a minimum of 50% of all musculus-common 
CTCF sites are found in at least 6 tissues, the same proportion of sites can be found 
in only one other tissue for BL6-specific sites. The analysis; however, suggested that 
16% of subspecies-specific sites can be tissue-shared in a minimum of 5 tissues (Figure 
2.4e).  
 
We identified the top five ENCODE tissues by the number of CTCF binding 
sites that co-occur with our liver BL6 ChIP-seq datasets for further analysis. As 
expected, ENCODE liver and kidney have the most overlap with our liver datasets 
(Figure 2.4f). For the BL6 binding sites we identified as musculus-common, 67-85% 
are shared in these five tissues and 26-49% of the BL6-specific sites we identified in 
liver are also bound in these five ENCODE tissues. The analysis only used CTCF 
binding sites that were retrieved from at least two ENCODE biological replicates, 
making the number of estimated binding sites, especially those that are BL6-specific, 
likely conservative (Methods).  
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Focusing only on the five ENCODE tissues most similar to liver in CTCF binding 
profile (Figure 2.4f enclosed), we were able to identify a subset of CTCF subspecies-
specific sites that are bound in all five tissues. There were 912 CTCF sites found in 
our data and shared with ENCODE liver, kidney, heart, lung and cortical plate (Figure 
2.4g), spread over all mouse chromosomes. These sites constitute 13% of all of our 
BL6-specific CTCF sites, but we hypothesise that shared binding in these different 
tissues may indicate an increased involvement in genomic functions compared to their 
tissue-variable counterparts. 
 
2.3.5 Tandem duplication event of BL6-specific CTCF 
binding sites linked to the expansion of an interferon gene 
cluster. 
 
While investigating the subset of BL6-specific and tissue-shared CTCF sites 
genomic distribution, we uncovered a single TAD on chromosome 4, band C4, that 
contains a cluster of 15 BL6-specific, tissue-shared CTCF binding sites within a 58 kb 
window. A CTCF binding site precedes the TSS of each of 15 copies in a cluster of 
type 1 interferon zeta (Ifnz) genes. No musculus-common CTCF binding sites were 
found inside this cluster of genes, whether in genic or intergenic regions, and all nearest 
musculus-common sites are scattered in no particular pattern or clustering (Figure 2.5 
Top). All 15 CTCF binding sites collocated with cohesin, were of similar lengths and 
exhibited comparable read coverage signal in every tissue. This genomic cluster is 
contained on a single clone within the reference BL6 mouse genome assembly 
(https://www.ebi.ac.uk/ena/data/view/AL928605) and is thus unlikely to be the 
result of a genome assembly artefact. 
 
The 15 genes in this uncharacterised cluster are all from the type 1 interferon 
family of genes, for which many other members are present in and around the same 
locus. Although many of the upstream and downstream interferon genes have been 
previously described[579, 580], this 15-gene cluster, though previously reported[581],  
is yet to be functionally characterised. All but one have putative gene names, and two 
are annotated as pseudogenes. We have manually reviewed the annotation for all of 
the genes in the cluster and found it to be sound (see Methods). Specifically, the 
majority of the genes are novel or predicted protein coding genes in the GENCODE 
annotation[582], and all have evidence on the transcript level[583, 584]. The Gene 
Ontology[585, 586] terms most associated with these genes are for cytokine activity 
and type 1 interferon receptor binding molecular functions, with involvement in 
adaptive immune response in the defence mechanisms against viral infection. 
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Figure 2.5: Evidence of a tandem duplication event of BL6-specific CTCF 
binding sites on Chromosome 4 in multiple tissues linked to the expansion of a 
family of interferon genes. 
  
Top: A zoomed out summary view of 200 kb of Chromosome 4 band C4. The 
tops two tracks show the CTCF-Cohesin regions in musculus-common and BL6 
tissue-shared sites. The next track in blue indicates read coverage signal from 
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CTCF BL6 tissue-shared binding sites. Below that, a summary of all genes in 
the 200 kb window. The arrowheads next to the gene names indicate the direction 
of transcription. The next two tracks in yellow and purple are pairwise alignment 
of the region between BL6 and CAST and Rat respectively, showing the 
noticeable lack of any orthologous regions in either subspecies. The bottom three 
tracks in grey shading illustrate the repeat content of the whole genomic region 
with the noticeable lack of any large scale repeat elements in the highlighted 
region.  
Middle: A zoom-in view of the 57.6 kb region 4:88752534-88810107 in which 
CTCF-Cohesin BL6-specific, tissue-shared binding was observed. The top two 
tracks in orange and brown indicate read coverage signal from H3K4me3 and 
H3K27ac respectively. The next five tracks in blue indicate CTCF ChIP-seq read 
coverage in each of the five tissues discussed in Figure 2.4. The corresponding 15 
genes are shown below the tracks.  
Bottom: A heatmap of sequence similarity in the multiple sequence alignment 
of the 15 CTCF-Cohesin binding sites on the C4 band of BL6 chromosome 4. 
The numbers denote the start and end positions of each binding site. The 
heatmap also shows sequence similarity in the multiple sequence alignment of 
the 15 genes on the C4 band of BL6 chromosome 4 that are all preceded by a 
CTCF-Cohesin binding site. The numbers denote the transcription start site and 
the name of each gene. The dendrograms on the left of each heatmap are 
clustering trees showing the relationship between the sequences based on their 
sequence similarity. 
 
Although we identified this region by the presence of BL6-specific CTCF binding, 
the entire region containing the gene cluster does not, in fact, have an orthologous 
region in the CAST genome (Figure 2.5 Pairwise Alignment). Moreover, there is 
neither an orthologous region in Rat nor any of the other 13 mouse strains/species 
available in the pairwise alignment of mouse strains available in Ensembl release 
91[25].  
 
Strikingly, this cluster was characterised by the absence of transposon-driven 
repeat elements, with a complete lack of type 1 SINE or LINE transposons, despite 
them occurring both up- and down-stream of this region. Indeed, the only repeat 
elements within the 58 kb window were LTRs, all from the LTR-ERVK subfamily, 
and all either 450 or 550 bp in length (Figure 2.5 Grey Tracks). The LTR elements 
within the cluster generally occurred in intergenic regions with none in the CTCF 
bound regions or 500 bp up or downstream from the gene bodies, with the exception 
of one cluster of repeats in the intron of a pseudogene (Gm13284). Upstream CTCF 
binding sites were completely devoid of repeat elements with only six, short simple 
repeats in those 15 genes (ave. simple repeat length 50 bp). 
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Figure 2.6: Convergent evolution of an orthologous interferon gene cluster in 
pig. 
 
a Genome browser display of BL6-Pig LASTz pairwise alignment of the 15-gene 
cluster. Pink tracks show the BL6 genome regions aligning to sequences in the 
pig genome. b A zoom-in view of the orthologous gene cluster of interferon 
precursors in the pig genome. The orthologous gene in (a) is shown as the 
leftmost gene in the window in brown italics. The 12 paralogues to this gene are 
highlighted in brown italics with the other interferon genes in light grey. The 
arrowheads indicate the direction of transcription. The dark grey tracks at the 
bottom indicate the LTR repeat content of the region. c A schematic diagram 
showing the position of the CTCF motif enriched at around 1 kb from the TSS 
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of 12/13 genes in the cluster, with the motif composition below the orange track 
indicating the position. The motif underneath is the CTCF canonical motif with 
the p-value of the probability that the match occurred by random chance. 
 
Both the upstream CTCF regions and the genes in this cluster exhibit high 
sequence similarity, with near identical sequences for large portions of their lengths 
(Figure 2.5 Heatmaps). The sequence similarity also extends beyond the genic regions 
into the LTR repeat elements punctuating the intergenic distances between them. 
These characteristics suggest a tandem duplication event that repeatedly carried the 
ancestral gene, and copied its sequence along with upstream regulatory regions to 
produce the regulatory landscape of this cluster. We do not, however, find any evidence 
of SINE or LINE transposon activity in the duplication event. As these genes have a 
high degree of similarity with each other, and other interferon genes outside the cluster 
on chromosome 4, we could not discern the evolutionary history of this BL6-specific 
gene cluster. To assess whether these regions are regulatorily active, we used  
previously published histone modification data for H3K27ac and H3K4me3[451]. We 
observed that the CTCF binding sites co-located with both modifications (Figure 2.5 
Middle), which taken together generally signify an active promoter signal[209].  
 
Nevertheless, genomic region comparison with other eutherian mammals revealed 
that 14 of the 15 genes in the cluster align to a single gene in the pig (Sus scrofa)[587]. 
LASTz pairwise whole genome alignments show that all but one of the BL6 genes align 
with between 50-100% coverage to the ENSSSCG00000039987 gene, a novel predicted 
protein-coding gene on pig chromosome 1 (Figure 2.6a). There are 13 annotated 
paralogues to this gene in the pig genome that all lie within a 500 kb cluster, albeit 
separated by 24 intervening genes between them. All of these genes belong to the same 
Ensembl protein family in pig, PTHR11691 (Interferon Precursor), and all of the 
members of this family, except one, are within this cluster. Unlike the cluster found in 
BL6, however, the pig genes are evenly divided between reverse and forward 
orientation (Figure 2.6b). The pig cluster is also enriched for LTRs and these also 
punctuate the intergenic distance between the genes. The cluster has very low GERP 
conservation scores compared with no constrained elements, unlike the regions up- and 
downstream of the cluster. We used the 1kb flank of all 14 pig genes orthologous to 
BL6 genes for motif discovery and found the CTCF motif in 13 of the 14 genes (Figure 
2.6c). Taken together, the observation of two clusters comprising related immune genes 
that are closely associated with subspecies-specific CTCF sites suggests a role for 
CTCF in immune response reflected here potentially via a convergent evolutionary 
process. 
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2.4 Discussion 
 
While TE-derived expansion of CTCF binding sites is a well-documented model 
of the evolution of TF occupancy in several mammalian lineages[269, 384, 559, 588], 
our results newly reveal how rapidly expanded repeats can acquire distinct functional 
signatures, even between two closely related mammalian species.  
 
In this chapter, we used two closely-related mouse subspecies, BL6 and CAST, 
separated by one million years of evolution to study the evolution of CTCF binding 
and the functional signature of evolutionary young sites. Our results demonstrate that 
many subspecies-specific CTCF binding sites are bound across multiple tissues that 
originate from different germ layers. This similarity of genomic behaviour hints at a 
potential functional role that they may play, either independently or as potentially 
redundant binding in case of the loss of a nearby musculus-common CTCF binding 
site due to mutation. Whether evolutionary young binding sites are capable of taking 
over the functions of ancestral sites or may be more associated with lineage specific 
function will require further investigation. The latter model finds support in a recent 
computational approach that showed 15% of lineage-specific transcription factor 
binding sites are enriched for genes involved in cell-type specific pathways, such as the 
fast-evolving olfactory pathway, and have distinct biological implications when 
compared to ancestral ones[589].  
 
Our data provide insight into how frequently functional CTCF binding sites are 
conserved between subspecies and/or shared among tissues. Previous observations 
have shown that tissue-shared CTCF binding sites are more conserved than cell type-
specific CTCF-binding sites[590] and, reciprocally, that cell-type specific CTCF 
binding sites are more likely to be lineage- or subspecies-specific than tissue-shared 
sites[589]. To illustrate the functional differences between evolutionary young CTCF 
sites, we determined the level of CTCF occupancy conservation across tissues. Our 
findings demonstrated that whilst the majority of these young sites exhibit significant 
tissue-restriction in terms of their occupancy when compared to the musculus-common 
set, a subset of sites do show consistent binding across several tissues belonging to all 
three germ-layers. Other studies have reported that TE-derived subspecies-specific 
binding in primates, tissue-specific in particular[446, 591], demonstrates the potential 
for regulation of gene expression. Taken together, our results define a hierarchy for 
CTCF sites: those that are both evolutionarily conserved and tissue shared are most 
likely to be functional, followed by those that are either conserved or shared, and then 
those that are subspecies and tissue specific. 
 
We discovered that a cluster of 15 type 1 interferon zeta family genes, associated 
with retrotransposable expansion of LTR elements, where BL6-specific, tissue-shared 
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CTCF binding was observed just upstream of every gene in the cluster. The CTCF 
binding, co-localised with histone modifications indicative of active promoters, is an 
example of a region where subspecies-specific binding may have led to the introduction 
of novel transcriptional regulation. The LTR elements punctuating the intergenic 
distance between the genes of this cluster may have facilitated the observed tandem 
duplication via non-allelic homologous recombination, or helped derive novel binding 
site locations for transcription factors and regulatory elements[592]. 
 
Even though this gene cluster has previously been shown to derive from a lineage-
specific expansion of IFNα-like gene in rodents only[581, 593], this gene cluster has not 
been well-described in the literature, and no functional annotation work has been done 
on any of its members. Flanking genes in the interferon locus have been characterised, 
however, including the identification of orthologues in the interferon locus on human 
chromosome 9[580]. Another study showed that some of the flanking genes had 
constitutive transcriptional activity at low levels in the absence of viral infection[579]. 
This latter study reported the tandem array of 16 consecutive genes we have 
characterised here, which they incorrectly thought to be an assembly artefact[579]. 
Another study looking at the evolution of IFNα reported a similar expansion of genes 
from the family between the BL6 and 129/5v mouse strains[579]. A potentially similar 
BL6-specific expansion has been observed in the Abp gene cluster although not 
involving CTCF and progressively correlated with LINE and LTR enrichment[455, 
559].  
 
The phenomenon may yet transpire to be more common than observed in mice. 
The IFNδ gene cluster found in the pig genome carried several similarities to the 
cluster in BL6. Although we do not have CTCF binding data in pig, the presence of 
the CTCF canonical motif less than 1000 bp of the TSS in almost all of the genes is 
indicative of possible involvement. Xu et al. [581, 593] reported that ancestral IFNα-
like genes duplicated during mammalian evolution and segregated into subtype. Of 
these IFNα-derived interferon subtypes, IFNδ and IFNζ underwent convergent 
evolution, forming an outgroup as a result of similar selection pressures in different 
subspecies, namely rodents and pigs. Whilst IFNδ propagated in the porcine genome, 
while it failed to gain a reproductive response in the mouse, and vice versa for 
IFNζ[581, 593].  
Our results demonstrate a set of evolutionarily young CTCF sites that have been 
captured into operational regions of the genome and apparently adopted similar 
functions to musculus-common CTCF sites. Previous work has shown that mouse and 
rat subspecies-specific CTCF sites are comparable to mammalian conserved CTCF site 
in their ability to demarcate chromatin domains and modulate transcription[269], but 
our results go further by focusing on a cohort of several thousand of the evolutionarily 
youngest CTCF binding sites that have arisen in just the last 0.5 MY. Indeed, the 
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subset of these sites shared across multiple BL6 tissues show the strongest and most 
convincing functional signatures. 
 
Further investigation will be required to establish the phenotypic consequences 
of evolutionarily young and subspecies-specific CTCF binding sites. The exact 
biological functions of many of these subspecies-specific CTCF sites will have to be 
established through targeted deletions of particular sites in vivo or using conditional 
knockdown of CTCF in suitable cell-line as CTCF knockout is embryonic lethal. 
However, it is clear that even the youngest CTCF sites carry multiple functional 
signatures that are indicative of contribution to transcriptional regulation in one or 
many tissues. Other transcription factors may have evolved subspecies-specific 
regulatory functions in a lineage-specific manner either through duplication events or 
in consequence to transposable element activity. The expansion of subspecies-specific 
regulatory elements concurrent with lineage-specific gene clusters, as we show in this 
study, is likely to be a common feature in mammalian genome evolution.  
 
 
 
 
 
 
 
 
Chapter 3 
 
Pervasive effects of trans-acting 
variation on CTCF occupancy 
 
 
3.1 Introduction 
 
Regulatory variants that change gene expression levels can be broadly classified 
into two main categories based on their physical genomic location relative to the genes 
they regulate: (1) cis-acting regulatory variants which mediate differential expression 
in a direct manner by influencing the local genomic sequence such as variants in 
promoters, enhancers and cis-regulatory modules; (2) trans-acting regulatory variants 
which mediate differential expression through diffusible elements such as proteins 
(TFs) or ribonucleic acids (ncRNAs, eRNAs, etc.). These variants result in the 
divergence of gene expression levels between species (in cis) or within individuals of 
the same species (in trans)[260]. These two classes reflect the differences in the gene 
expression levels that their inheritance mechanisms result in, and the type of selective 
pressure they are subject to[395, 542, 594]. Cis- and trans-regulatory factors undergo 
distinct evolutionary trajectories, displaying  various extents of pleiotropic effects, as 
has been experimentally reported for loci affecting gene expression[595].    
 
The contribution of cis and trans regulatory variants on the divergence in gene 
expression has been investigated in two main methods at the genome-wide level. The 
first method uses expression quantitative trait loci (eQTL) to identify regulatory 
mutations. In this method, the total gene expression level is measured across a 
population, and genetic variants (single nucleotide variants, or SNVs) are genotyped 
for the same individuals, then correlated with the expression levels[517]. The other 
method to detect cis and trans variants is to compare expression differences between 
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species with expression differences between alleles in inter-species F1 hybrid 
progeny[544, 596]. This method has been recently used to characterise cis and trans 
regulatory potential in flies[542, 543, 596-599], yeast[539-541] and mice[257, 260, 600]. 
These studies have improved our understanding of regulatory divergence within and 
between species. 
 
Direct mutations affecting the TF binding site are a rare occurrence[558, 601, 
602]. Recent studies propose this to be explained by long-range TF correspondence or 
cis-acting variants near, yet outside, the core motif[603, 604]. Many cis variants are 
not the primary targets of natural selection as suggested by the observation that 
expression levels of genes are fine-tuned by cis variants, following regulatory changes 
in trans [260]. Wong et al. demonstrated that cis-acting variants are the main driver 
of TF occupancy divergence using a similar approach in three tissue-specific TFs: 
CEBPA, HNF4A and FOXA1[257]. 
 
CTCF binding is, on the other hand, strikingly conserved across hundreds of 
millions of years of evolution, suggesting that CTCF binding sites are under similar 
selective pressures as the coding sequences of genes, a feature unique among TFs[267]. 
However, genetic heterogeneity and cell type specificity drive inter- and intra-
individual variation in the expression of CTCF in a variety of tissues[605, 606]. A 
study using human lymphoblastoid cells found that 7% of DHS sites and 11% of CTCF 
binding sites exhibit allele-specific effects, and another showed allelic bias in CTCF 
binding sites in analysis of footprints with predicted binding factors[607, 608]. A 
previous study using eQTLs to measure binding of CTCF in 51 HapMap cell lines 
identified 1000s of QTLs where genotype differences were associated with differences 
in CTCF binding intensity. Hundreds of these were subsequently confirmed by 
observable allele-specific binding bias. However, the majority of these loci were at least 
1 kb from the CTCF binding motif[609].  
 
To our knowledge, an investigation into allelic-specific CTCF binding in 
response to cis- and trans-acting variants using an F1 hybrid system has not yet been 
conducted. Here we leverage the methodology developed in Goncalves et al.[260] and 
Wong et al.[257] to dissect CTCF occupancy divergence in mammals using F1 hybrid 
mice from two closely related subspecies, separated by half a million years of evolution. 
We highlight that CTCF binding, unlike tissue-specific TFs, is influenced by cis and 
trans factors that mediate its binding in allele specific contexts. CTCF binding does 
not display measurable coordination of regulatory mechanisms with proximal or distal 
CTCF sites. CTCF lineage-specific cis/trans-influenced binding is not common. 
Furthermore, cis- and trans-acting effects on CTCF occupancy, though mainly 
additive, display detectable dominant effects. Taken together, these results elucidate 
the complex pattern of effects a tissue-wide TF like CTCF displays in response to 
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genetic differences in its binding site that is considerably different from tissue-specific 
counterparts.   
 
This investigation is the result of a collaboration between Dr. Paul Flicek’s 
research group at EMBL's European Bioinformatics Institute and Dr. Duncan Odom’s 
laboratory at the Cancer Research UK Cambridge Institute. Dr. Bianca M. Schmitt 
performed most of the wet lab experiments for this project, Dr. Emily S. Wong ran 
the initial alignments and provided the (cistrans_cat_assignment.R) code, and I 
carried out the remainder of the computational analysis, except where otherwise 
specified. 
 
 
3.2 Methods 
 
3.2.1 Experimental methods 
 
3.2.1.1 Animal breeding and sample collection 
 
The experiments were conducted using mice from two subspecies: C57BL/6J 
(stock number: 000664, source: Charles River Labs) and CAST/EiJ (stock number: 
000928, source: The Jackson Laboratory). These two mouse subspecies were used as 
parental F0, and were mated to breed for the reciprocal crosses of the F1 mice. All 
biological replicates collected for the purposes of this investigation were sampled from 
adult male mice, 8-12 weeks of age, and harvested between 8 and 11 a.m. All animals 
were kept in similar husbandry conditions in the Biological Resources Unit of the 
Cancer Research UK–Cambridge Institute under a Home Office Licence.  
 
 Sampling of liver by perfusion was done on mice post-mortem, followed by 
tissue dissection. Harvested tissue samples were quickly chopped and transferred into 
a cross-linking solution with 1% formaldehyde in preparation for ChIP-seq protocol. 
Tissue samples were incubated for 20 minutes before quenching with 1/20th volume 
of 2.5 M glycine, then for a further 10 min. Samples were subsequently washed with 
PBS, flash-frozen and stored at !80 °C. 
 
3.2.1.2 ChIP-seq experimental protocol 
 
ChIP-seq experiments were carried out using the protocol described by Schmidt 
et al.[567]. Liver tissue samples previously harvested and cross-linked, were lysed and 
sonicated. DNA was immunoprecipitated for CTCF-DNA binding, and its ends 
repaired at 20 °C for 30 min, then we added Adenine overhang at 37 °C for 30 min, 
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followed by Illumina sequencing adapters ligation at room temperature for 15 min 
before 16 cycles of PCR amplification. PCR cycles conditions were as follows: (1) 
98 °C - 30 s; (2) 98 °C - 30 s, 65 °C - 30 s, 72 °C -30 s, 16 cycles; (3) 72 °C – 5 min. 
Using a 2% agarose gel, DNA fragments (200 - 300 bp) were selected for 50-bp single-
end read sequencing on Illumina HiSeq 2000, following the manufacturer’s instructions. 
In order to minimise the impact of possible batch effects, biological replicates for both 
F0 and F1 generations were prepared and sequenced in independent flowcells. 
 
3.2.2 Computational methods 
  
3.2.2.1 Read mapping and measuring allele-specific binding signal 
  
We used the Mus musculus castaneus genome assembly previously constructed 
by mapping back SNV calls from CAST on the latest version of the Mus musculus 
reference assembly (GRCm38/mm10)[257, 558]. Nucleotides at each CAST SNV 
position on the GRCm38 assembly were altered to represent the single variants in the 
other subspecies. The process mapped all SNV calls for autosomes and the X 
chromosome. Furthermore, a combined genome of both GRCm38.p2 (BL6) and CAST 
was used to map all alleles from the F1 mice. 
 
 First, we filtered and trimmed raw ChIP-seq reads using Trimmomatic (Version 
0.3)[610]. Using a sliding window of 20 bp, a phred minimum score of 30 was applied 
and reads were retained only if they met these conditions, while having an overall 
length of 40 bp minimum. Next, we aligned ChIP-seq reads from the F1 mice to an 
alignment index of the combined genome assemblies using BWA (Version 0.7.3a)[494]. 
Filtered reads were aligned allowing for a maximum of two mismatches per read (-n 
2), and filtering by the “XT:A:U” alignment tag, reads that aligned to multiple 
locations were discarded. Equivalent proportions of F1 reads mapped to the combined 
BL6 and CAST genomes, and to the individual genomes as well (Figure 3.1c). The 
ratio of BL6 to CAST CTCF binding sites in the F0 parental mice was also similar 
(Figure 3.1b).  
 
Additionally, we mapped reads from F0 and F1 replicates to the GRCm38 
reference genome using GSNAP[498]. Relaxed mismatch threshold criteria (allowing 
for a maximum of three mismatches per read) were used in order to make it possible 
for F1 reads of CAST origin to align back to the BL6 genome. This allowed us to 
assess the quality of each ChIP-seq library. Results from this analysis showed very 
good correspondence on the percentage of aligned reads from CAST libraries onto a 
BL6 background (e.g. 45% of F0 CAST libraries aligned to BL6 vs. 55% aligned to 
CAST genome assembly). 
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To determine the read coverage for each base of the joint genome assembly, we 
used the SAMtools mpileup program[568]. These counts were then filtered by SNV 
positions that allow for resolution of subspecies of origin for the DNA sequence only. 
A minimum of 10 reads per SNV across replicates was required for the retention of the 
site for further analysis. At this stage, this process was carried out at each ChIP-seq 
site regardless of the presence of one or more SNVs at each ChIP-seq peak. CTCF 
peak calling was performed using the callpeaks command from MACS2 with the 
parameter -g 'mm' indicating a mouse-specific effective genome size and default p-
value cutoff to call peaks against input controls for both mice subspecies, BL6 and 
CAST, and appropriate control from their hybrid reciprocal crosses[500]. 
  
 Reads were subsequently normalized for varying sequencing depth due to 
differences in library sizes across biological replicates in F0 and F1 mice. Normalisation 
for read coverage differences was done using R Bioconductor package “DESeq”[611]. 
This package estimates a constant scaling factor for each library/biological replicate 
using the median of the ratio of counts over every SNV over its geometric mean across 
replicates tested. The underlying assumption is that differences in read coverage at 
each SNV due to biological effects should only be present in a minority of sites. We 
then applied the resultant normalisation constant to all replicates, and these 
normalised read counts were used for fitting statistical models and downstream 
analyses. 
  
 We detected over 7,000 CTCF binding regions where more than one SNV lie 
in close proximity to each other, comprising about 50% of the total set of CTCF sites 
where an SNV with a minimum read coverage was identified and passed the various 
filters set earlier. However, all further downstream analysis was done using one SNV 
per 250 bp region in order to avoid multiple counting of the same CTCF binding sites. 
The overall number of reads aligned and peaks called was equivalent across replicates 
and generations (Figure 3.1b). 
 
3.2.2.2 Statistical models for regulatory category assignment 
 
CTCF binding sites were assigned different regulatory categories using ChIP-
seq read counts as a proxy for the binding signal intensities of CTCF to the DNA[253] 
utilizing the method reported by Goncalves et al.[260] and Wong et al.[257]. 
“Conserved” sites were defined as those whose occupancy, despite the presence of SNVs 
in the binding region, between BL6 and CAST in both F0 and F1 libraries is similar. 
Cis-acting variants were defined as CTCF sites where the binding ratios between the 
parental BL6 and CAST F0 libraries is the same as the one obtained between the 
alleles in the F1 libraries, being locally determined by SNVs in the genetic sequences 
of these regions. CTCF binding sites influenced by trans-acting variants were defined 
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by the similarity of the signal from both alleles in the F1 despite occupancy differences 
between the F0 parents. Cis–trans-acting variation was defined as for the remainder 
of CTCF sites where the pattern observed comprised of both cis and trans-effects. 
 
 We modelled the counts from both BL6 and CAST parental F0 libraries as a 
negative binomial marginal distribution, and modelled F1 counts on a beta-binomial 
distribution. The parameters of the beta distribution were used to model the 
proportional contribution from each allele. We had 2 replicates (i) for each F0 parental 
subspecies and 2 replicates (j) for F1 offspring. Therefore, we assumed that F0 counts 
for both subspecies (xi and yi) to follow negative binomial distributions, whereas F1 
counts (nj) were modelled on an allele-specific basis (zj) using a beta-binomial 
distribution: 
 
!! ∼ Po(#!), $! ∼ Po(%!), &" ∼ Bi('",(") 
 
#! ∼ Ga)*	, !!"#!!-, .! ∼ Ga/*	,
!"
"#!"
0, (" ∼ Be(1,2) 
 where: 
 
 xi = the binding intensity of the variant in the ith BL6 F0 mouse 
 yi = the binding intensity of the variant in the ith CAST F0 mouse 
 nj = the number of reads mapping across both allelic variants in the jth F1 
hybrid 
 zj = the number of reads mapping to the BL6 allele in the jth F1 hybrid. 
 
 The dispersion parameter r for F0 libraries was estimated using the function 
“estimateDispersions” from the “DESeq” Bioconductor package with local regression 
fit. r was defined as the reciprocal of the fitted dispersion value as computed using 
“estimateDispersions”. Parameter estimation for the two distributions was constrained 
based on the four different regulatory scenarios outlined above, and we derived 
maximum likelihood values for all four scenarios on a “site-by-site” basis, as follows: 
 
Conserved: (#=($ and 1=2 
Cis: (#≠($ and $$%& = 
#!
$%#!
#!
$%#!%
#"
$%#"
 
Trans: (#≠($ and 1=2 
Cis-trans: (#≠($ and 1≠2. 
 
 The most likely model at each site was determined using the Bayesian 
Information Criteria (BIC) estimation for each of the hypothetical cases. stated earlier, 
only variants separated by a minimum distance of 250 bp were used for this and all 
other analysis. 
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 To allow for meaningful comparison, the statistical model described above was 
also used to assign the four regulatory categories in two biological replicates, selected 
randomly from the set of 6 biological replicates reported in Wong et al.[257] for the 
three liver-specific transcription factors (TFs): CEBPA, FOXA1 and HNF4A. Raw 
reads from these two replicates were normalized for differences in library sizes across 
replicates in F0 and F1 mice, and their dispersion parameter r was estimated similar 
to the method discussed above prior to be fitted with the same statistical models. An 
example of the R code used for statistical modelling and category assignment is 
available in the appendix. 
 
3.2.2.3 Subsampling strategy to investigate the effect of library 
availability on regulatory category assignment 
 
 Due to the availability of only two biological replicates for the analysis of 
cis/trans variation effect on CTCF occupancy in hybrid F1 mice, a subsampling 
strategy was undertaken to evaluate the effect of extra libraries inclusion on the results 
of regulatory category assignment. The approach consisted of randomly selecting 2 
biological replicates from a possible 6 replicates for each of the F0 parental subspecies 
and their reciprocal F1 hybrid progeny (ensuring that the for each F1 replicate the 
reads for both alleles corresponding to the same animal are included) for each of the 
liver-specific TFs mentioned above in section 3.2.2.2. The raw reads overlapping the 
full set of SNVs were retrieved, normalised across all replicates in F0 and F1 for library 
size differences, and had their dispersion parameter calculated as previously detailed. 
Normalised reads in those replicates were then fitted with the statistical models to 
assign regulatory category based on the binding site signal intensities peculiar to those 
replicates. An example of the R code used for statistical modelling and category 
assignment is available in the appendix. 
 
This was repeated for 1000 random combinations of any two replicates for any 
of the 6 for each F0 and F1 line, for each TF separately. The subsampling strategy 
was then repeated for an increasing number of replicates, running it for 1000 runs of 
random combination of 3, 4 and 5 replicates for each TF. The estimations of regulatory 
category from each run, for each number of replicates and each TF were outputted 
and used to estimate the effect of incorporating extra biological replicates on the 
accuracy of category assignment.  
 
We compared this effect to the category assignment proportions derived from 
the full set of 6 biological replicates available for each TF. The CTCF estimate was 
calculated from 2 replicates only by multiplying the fraction of each category by the 
total number of SNVs in each TF to generate TF-specific estimates for each category. 
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3.2.2.4 CTCF inter-peak coordination of binding intensity 
 
Correlation coefficients for the binding signal intensities between pairs of CTCF 
sites at incremental genomic intervals were calculated in order to test whether these 
genomic regions are under the influence of CTCF cis-acting regulatory variants. 
Spearman’s correlation coefficient of allelic proportions (BL6/(BL6+CAST)) was 
computed between CTCF sites at successive bins anchored by cis-acting variants to 
capture the coordination between CTCF sites at anchor points and those in the 
consecutive bins. Spearman’s ρ for each mutually exclusive bin with the corresponding 
anchor CTCF site was determined, increasing the interval to the next bin by one extra 
kb (1 kb) from the cis-acting variant.  
 
To test the decay in signal by increasing distance, Spearman’s ρ estimates for 
the entire set of CTCF cis sites at each distance were used as the outcome variable in 
a linear regression model using log-transformed distances as the predictor variable. A 
null distribution for the correlation of binding signal was created by comparing binding 
levels of anchor CTCF sites with the other CTCF locations randomly sampled across 
the genome. We subsampled an equal number of CTCF sites randomly from the total 
pool without replacement as null anchor points, then simulated a set of binned peaks 
for each null anchor, keeping them constant. The total number of these null anchor 
peaks and their simulated binned peaks pair was equal to the total number of 
anchored–binned peak pairings originally observed. Spearman’s ρ estimates for this 
null set was then calculated similarly, and the values were fitted with a linear 
regression model. 
 
3.2.2.5 Statistical models for lineage-specific CTCF occupancy 
 
We used a similar statistical model to tease apart the influences of cis and cis–
trans acting variants on lineage-specific CTCF binding sites. Normalized read counts 
between F0 and F1 libraries were used to define lineage-specific CTCF sites based on 
the ratios of F0 and F1 (ratioF0 = B6F0/(B6F0/CASTF0) and ratioF1 = 
B6F1/(B6F1/CASTF1)), where ratios were calculated between mean levels of binding 
signal across biological replicates. Lineage-specific sites were defined using the 
following criteria: (ratioF0 < 0.05 and ratioF1 < 0.05) or (ratioF0 > 0.95 and ratioF1 > 
0.95).  
 
A lineage-specific site solely influenced by cis-acting variation would have F1 
read counts that are half of that in F0. Variants acting in trans would cause a 
significant stray from this 2:1 ratio. To test the likelihood of these two scenarios, a 
statistical model was modelled using the negative binomial distribution, and applied 
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to each lineage-specific site, followed by maximum likelihood estimation and BIC to 
select the best fitted model. 
  
!! ∼ Po((!), 2$! ∼ Po(4!) 
 
(! ∼ Ga)*	, '&'()"#'&'()-, 4! ∼ Ga/*	,
'*
"#'*
0, 
 where: 
 
 xi = the normalized read count binding intensity of the variant in the ith F0 
mouse from the subspecies of lineage-specific binding 
yi = the binding intensity of the variant in the ith F1 mouse summed across 
both alleles. 
The dispersion parameter, r, was estimated using “DESeq”. The two following 
scenarios were tested: 
 
Cis: 5pmax=5o 
Cis-trans: 5pmax≠5o. 
 
 Results from the lineage-specific statistical modelling outlined above were 
compared to estimates derived from fitting 2 randomly-selected replicates for the three 
liver-specific TFs mentioned above with the same models to facilitate comparison. An 
example of the R code used for statistical modelling and category assignment is 
available in the appendix. 
 
3.2.2.6 Statistical models for CTCF inheritance mode assignment 
 
Normalized read counts across all F0 and F1 libraries were used to investigate 
the mode of inheritance of CTCF binding intensities at genomic locations characterised 
by cis- and trans-acting variation. The counts from every SNV were then fitted to 
statistical models assessing either additive or dominant/recessive inheritance modes. 
The statistical models were constructed based on the assumption that if F1 binding 
intensities were inherited in an additive manner, the total binding intensity from both 
alleles should, in theory, equal the total binding intensity of F0 summed across both 
parental alleles. If these were, however, showing a dominant/recessive mode of 
inheritance, the total binding intensity from both alleles should equal the total binding 
intensity of one of the F0 parents and not the other. The inheritance modes were 
modelled on negative binomial distributions defined as follows: 
 
!max,! ∼ Po((max,!), !min,! ∼ Po((min,!), $! ∼ Po(4!), 
 where: 
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 !max,! = the normalized read count of the variant in the ith F0 mouse showing 
the higher median binding intensity among replicates 
 !min,! = the normalized read count of the variant in the ith F0 mouse with 
the lower median binding intensity among replicates. 
 $! = the binding intensity of the variant in the ith F1 mouse summed across 
both alleles. 
 
(max,! ∼ Ga)*	, '&'()"#'&'()-, (min,! ∼ Ga)*	,
'&'+,
"#'&'+,
-, 4! ∼ Ga/*	, '*"#'*0. 
 
As done previously, the dispersion parameter, r, was estimated using “DESeq”. 
Maximum likelihood estimation was used to fit the counts, followed by BIC to assess 
which of the following two models best fit the binding intensity from each CTCF site 
affected by variation in cis or trans. 
 
Dominant: 5pmax=5o or 5pmin=5o 
Additive: 5pmax≠5o and 5pmin≠5o. 
 
Sites where the parameter estimated for the offspring, So, could not be resolved from 
the parameters estimated for both parents (i.e., if So = Spmax and So = Spmin) were 
excluded from the results. These sites were identified by testing both modes of 
inheritance separately for pmax,i and pmin,i , and discarding sites that fit the dominant 
model in both cases. An example of the R code used for statistical modelling and 
category assignment is available in the appendix. 
 
 Only sites assigned to each mode with a BIC > 1 were used in the analysis to 
further improve the accuracy of the model. The stringent criteria rendered the use of 
this model to assign modes of inheritance in 2 randomly-selected replicates in the liver-
specific TFs impractical, as very few trans-acting variants were found to have a BIC 
>1. We, therefore used the full set of 6 biological replicates to assign the mode of 
inheritance using the model described above and used the estimates derived for 
comparison with CTCF. 
 
3.2.2.7 Cross-Tissue Analysis of cis/trans-acting variation in CTCF 
binding 
 
The same CTCF ChIP-seq libraries for adult BL6 male mice used for the 
equivalent analysis in section 2.2.2.5, were retrieved from the ENCODE Project data 
repository[451]. The analysis compared cis/trans-influenced CTCF occupancy in 12 
tissues: lung, bone marrow, bone marrow macrophages, cortical plate, cerebellum, 
heart, kidney, thymus, spleen, olfactory bulb, small intestine and testis. using 
BEDTools intersect 2.2.5.0 with the options -wa -wb, the overlap between cis/trans 
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liver CTCF peaks and the peaks from every ENCODE tissue was used to investigate 
the tissue-sharedness of these binding sites. UpSet plots were generated using the 
ComplexHeatmap package in R[571]. 
 
Similar to analysis explained in section 2.2.2.5, we calculated the tissue 
diversity index for these cis/trans CTCF sites using the log10 of the p-value at peak 
summit computed by MACS during peak calling. P-values for each cis/trans CTCF 
binding site were used to calculate the Shannon Diversity Index for each tissue using 
Vegan package in R[572]. CTCF binding conservation across tissues was measured by  
the proportion of CTCF binding sites bound within each bin of Shannon diversity 
index.  
 
The tissue conservation analysis was repeated for sites defined as lineage-
specific in 3.2.2.4. Subsequently, the extent of tissue-wide occupancy conservation was 
investigated across the categories of cis/trans variants in CTCF binding sites for both 
the total set and lineage-specific set. 
 
3.2.2.8 Analysis of the effect of incorporating extra biological 
replicates on cis/trans variation 
 
Increasing number of replicates were randomly selected from the full set of 6 
for each of the three TFs, CEBPA, FOXA1 and HNF4A and used to analyse the effect 
of increasing number of replicates on the various aspects of cis/trans regulatory effects 
on TF occupancy detailed above. After running the normalisation followed by 
statistical modelling for regulatory category assignment in section 3.2.2.2, the 
difference between the smallest and second smallest BIC values (dif_BIC) was used 
as an estimate of the reliability of cis/trans variant calling. The higher the value of 
BIC, the more reliable the call was. We used a minimum BIC value of >=1 to analyse 
the effects of increasing replicate number on the type and number of high-confidence 
category assignment. 
 
We additionally used the random set of 2-5 replicates for each TF to estimate 
the effect of cis/trans variation on their occupancy. Pearson’s correlation coefficient 
(r) was measured between ratios of BL6 in F1 vs F0. Correlation coefficient of 0 
indicated equal effect of cis- and trans-acting variations, whereas a correlation 
coefficient of 1 suggested the lack of any trans influences. The results were compared 
to the cis/trans-acting variation effect on occupancy for the full set of 6 replicates.  
 
Furthermore, the random set of 2-5 replicates were analysed for the effect of 
replicate number on the type of lineage-specific binding in each TF. Of particular 
interest was the how the addition of more replicates enhances the ability to define 
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lineage-specific binding, and tease apart the effect of cistrans variants on F1 allelic 
binding intensity (diversifying vs. compensatory).  Modes of inheritance for increasing 
number of replicates were also determined using the statistical models described in 
3.2.2.6 in cis and trans variants of each TF. Analysis of inheritance mode was restricted 
to sites where the absolute difference in the average binding intensities across the F0 
parental subspecies was greater than or equal to twice the standard deviation of the 
average binding signal across biological replicates (>=19 normalised read). To further 
minimise the noise from the data, only sites whose cis/trans variation was assigned 
with a minimum of BIC >=1 were used to improve the reliability of the results. 
 
 
3.3 Results 
 
3.3.1 Equal cis and cistrans effects on CTCF occupancy 
 
CTCF-bound genomic regions were retrieved from liver samples of adult mice of 
the same two inbred mice subspecies of the Mus musculus genus used for the analysis 
in Chapter 2: Mus musculus domesticus (C57BL/6J or BL6 for short) and Mus 
musculus castaneus (CAST), and their F1 hybrid offspring of two reciprocal crosses 
(BL6xCAST and CASTxBL6). Binding sites were derived from chromatin 
immunoprecipitation followed by high-throughput sequencing (ChIP-seq) libraries of 
CTCF in two biological replicates for each of the four lines, for a total of 8 biological 
replicates (2 for each F0 parental subspecies and 2 for each of the two F1 hybrid 
crosses) (Figure 3.1a). Differences in binding affinities, by proxy of varying read 
enrichments, between the F0 parental mice and their F1 hybrid offspring were used to 
discern the evolutionary, genomic and functional dynamics of cis and trans variation 
and their impact on the pattern of CTCF binding. 
 
By using normalised ChIP-seq read counts, different regulatory categories were 
assigned to each binding sites, based on the presence of single nucleotide variants 
(SNVs) overlapping ChIP-seq peaks and the differences in their read enrichments. 
Using the approach detailed in the Methodology, we were able to distinguish between 
four possible regulatory categories that describe the binding of CTCF between the two 
subspecies into 4 categories: conserved, cis, trans, cistrans (Figure 3.1a). Under the 
conserved category, SNVs do not exhibit any measurable differences in their binding 
signal intensities between either F0 parental alleles or their F1 progeny. Cis-acting 
variant read enrichment is associated with that of the specific parental allele [257, 260, 
612]. Despite distinctly different read signals from both F0 parental alleles, trans-
acting variation affect both alleles in F1 equally, due to diffusible elements in the 
shared nuclear environment. Lastly, the cistrans classification encompasses the 
remainder of cases where allelic binding intensities were different between both 
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parental subspecies, but their binding among their progeny was also observed to be 
different. This could indicates either a combination of cis- and trans- acting variation 
influencing CTCF binding in F1 due to both a common environment and allele-specific 
effects, or insufficient signal to allow for confident category assignment that may 
improve with adding more biological replicates. 
 
 
 
Figure 3.1: Overview of the experimental design and preliminary results. 
 
a CTCF occupancy was profiled using ChIP-seq of liver samples of male mice 
from C57BL/6J (BL6), CAST/EiJ (CAST), and their reciprocal F1 crosses: 
BL6xCAST and CASTxBL6 in 2 biological replicates for each genetic 
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background. Normalized ChIP-seq read counts between BL6 and CAST at SNVs 
were used to assign regulatory classes for variation in CTCF binding. Based on 
the schematic diagram, by comparing BL6 and CAST ratios between F0 and F1 
mice, CTCF binding sites can be classified into four regulatory categories: 
conserved, cis, trans, and cistrans. b Summary table for the results of library 
alignment and peak calling sorted by genetic background. Lower mapability of 
aligned reads is caused by the stringent criteria of maximum mismatch of two 
bases per read (See Methods). c Bar plots of the results of ChIP-seq read 
alignment of F1 libraries to both F0 genomes. Top plot shows the F1 reads 
aligning to BL6 and CAST genomes, whereas the bottom plot shows F1 CTCF 
peaks called from reads aligned to BL6/CAST genomes (in 1000s). Similar 
number of peaks were called in F1s with BL6 or CAST genomes the majority of 
them overlap over 90% reciprocally. 
 
A sufficient read depth was obtained following ChIP enrichment, and >20 million 
reads (over 50% of all reads) from each replicate aligned to their corresponding genome 
despite stringent mapping criteria (See Methods) (Figure 3.1b). A comparable number 
of CTCF peaks was obtained from all replicates in both F0 and F1, with a mean of > 
44,000 peaks per replicate, consistent with the overall number of CTCF binding sites 
previously reported[269, 559]. Notably, an equal proportion of F1 ChIP reads mapped 
back to both parental, BL6 and CAST, genomes, and produced a comparable number 
of binding sites when each set of aligned reads were peak called (Figure 3.1c), 
confirming the ability to map back alleles from each F1 hybrid to their parent of origin, 
and the feasibility of drawing comparisons between the two subspecies.  
 
A total of over 58,000 CTCF binding sites were identified across replicates/crosses. 
The majority of these sites (75% of all binding sites) were not characterised by the 
presence of SNVs, thus it was not possible to investigate their allelic differences in 
binding between the two subspecies as they could not be told apart. There were, 
however, about 25% of binding sites that had one or more SNV within the peak region 
with sufficient read enrichment signal to quantitively resolve the difference in allelic 
binding in both the F0 and F1 mice (Figure 3.2a). Half of these sites have a single 
SNV in the peak region, with the remainder carrying two or more SNVs in their 
sequence. The numbers obtained in this analysis roughly compare to those obtained in 
a study looking at the other liver-specific transcription factors (Figure 3.2a)[257]. In 
order to avoid conflating the results by repeatedly counting binding sites with more 
than one SNV, all downstream analysis used SNVs that are at least 250 bp from the 
next SNV, restricting them to a single SNV per binding site (see Method). 
 
CTCF binding sites with SNVs informative for allelic differentiation were assigned 
one of the four classes outlined above using statistical modelling (see Methods).  
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Figure 3.2: Regulatory categories assignment demonstrates that CTCF 
occupancy levels are equally cis- and cistrans-driven for 2/3 of sites. 
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a Pie charts for the number of CTCF binding sites obtained after peak-calling 
and SNV mapping with associated number of SNVs. The percentages for the 
nested pie charts reflect their proportions out of the total number of binding 
sites. b Scatterplots of BL6 vs CAST log2 ratios of CTCF binding intensity 
signals in F0 and F1 mice. Every point represents an SNV. Regulatory categories-
assignments are colour-highlighted in individual scatterplots. Direction of 
distribution of SNVs is indicated above each plot. Grey-coloured points are the 
remainder of SNVs that are not assigned to the highlighted category. c Pie charts 
displaying the regulatory class make-up of SNVs overlapping CTCF compared 
to those derived from 2 randomly selected replicates for each of the three other 
TFs. The numbers in brackets indicate the total number of TF binding sites with 
a minimum of one SNV in their sequence for each TF. 
 
In order to verify this class assignment, the differences in the binding ratio between 
the F0 and F1 alleles were visualised as the ratios of the F1 BL6 allele to its CAST 
counterpart against the corresponding ratio of F0 alleles. As seen in Figure 3.2b, Cis-
acting variants cluster along the diagonal line as their F1 ratios correspond to those 
of the parental lines, whereas trans-acting variants form a straight line parallel to the 
F0 ratios, a result of their departure from their parental alleles signals. Cistrans-
variants significantly deviate from the diagonal line, filling the area between cis- and 
trans- variants (Figure 3.2b).  
 
In total, there were 14,364 CTCF binding sites characterized by the presence of 
SNVs with sufficient read coverage to allow the resolution of allelic difference, and 
that we were also able to assign regulatory categories to, equivalent to the number of 
sites used for other TFs (13,000 – 17,000) (Figure 3.2c). Although CTCF binding sites, 
similar to liver-specific transcription factors, were most frequently influenced by cis-
acting SNVs (35%), these were followed very closely by cistrans (28%), then conserved 
(20%) and trans variants (17%) (Figure 3.2c). The enrichment of cis variants on CTCF 
was noticeably lower than observed in the liver-specific TFs with an equal number of 
biological replicates. CTCF, on the other hand, showed a marked increase in the 
fraction of trans regulatory variation in occupancy compared to all other three TFs 
(17% vs 10%). Estimates for the contribution of conserved (cons) variation in CTCF 
and other TFs binding were equivalent (Figure 3.2c). Assignment of binding regulatory 
variation in CTCF was found to be statistically significantly different from all 3 liver-
specific TFs (c2 test for pairwise comparison between CTCF and other TFs with 
Bonferroni correction, all p-values < 2.2e-16). 
 
Although cis-acting variation was the most prominent mode of variation present in 
the liver-specific TF binding sites in the original analysis that used 6 biological 
replicates, conserved binding, even when associated with sequence changes in the form 
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of SNVs, is always the second most common type of regulatory variation in TF 
occupancy, with trans and cistrans variation contributing less than third[257]. The 
increase in the cistrans effect size when the analysis was run in two biological replicates 
instead seems to have come at the expense of both the conserved and cis variants 
(Figure 3.2c).  
 
A subsampling approach was undertaken in order to assess the validity of the 
assignment of cis/trans categories to CTCF binding sites based on only two biological 
replicates and ensure comparability with the three other liver-specific TFs. The aim 
was to elucidate the effect of biological replicate number on the ability to resolve the 
difference in read coverage into distinct regulatory categories. By randomly combining 
a specific number of biological replicates (from 2 to 5) for each of the three TFs, then 
running the cis/trans category assignment algorithm for one thousand times, we were 
able to obtain the range of category estimates for each of the four subsampling 
strategies (Figure 3.3). The results of the subsampling strategy of biological replicates 
in other TFs show an overall improvement in the estimates of the four regulatory 
categories with the addition of every extra replicate towards the values obtained when 
the experiments where run with 6 biological replicates (Figure 3.3 density plots). This 
is additionally evidenced by the narrower distribution of values, reflecting less 
dispersion of values, with increasing replicate number (Figure 3.3 dot plots).  
 
These improvements, however, are not uniformly distributed among the cis/trans 
categories. The most conspicuous change is invariably observed with the resolution of 
cistrans sites into other categories, as their proportions strongly decrease with the 
addition of extra replicates (starting from 3 replicates). The range of value obtained 
in all cistrans 2-replicate runs for all TFs never matches the original 6-replicate 
estimate. Conserved sites (cons) show exactly the opposite pattern, increasing 
considerably with the addition of extra replicates. The range of cons values for 2 
replicates is not that of 6-replicate. The estimates of cis-influenced do slightly increase 
with increasing the number of replicates, but the overall distribution of values for 2-
replicate runs mostly overlaps with that of higher replicate number, and occasionally 
(especially in the case of CEBPA) considerably overlaps with the 6-replicate estimate. 
The pattern for trans sites is even subtler, with tighter ranges of values, and estimates 
that do not generally deviate from the 6-replicate estimate. For example, CEBPA 2-
replicate mean values are nearly at the 6-replicate estimate (Figure 3.3). 
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Figure 3.3: Ascending subsampling of biological replicates in other TFs support 
the cis and trans proportions observed in CTCF. 
 
Density plots of all 1000 randomised combinations of biological replicates in 
ascending number of replicates (from 2-5) for the 3 liver-specific transcription 
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factors (CEBPA, FOXA1 and HNF4A), faceted by the 4 regulatory categories: 
cis, cistrans, conserved (cons) and trans. The area under each curve correspond 
to the entire range of values (number of binding sites classified as such after one 
run of the algorithm, repeated for a 1000 randomised runs) for each category, 
number of replicates and TF. The horizontal dot plots under each facet illustrate 
the distribution of the values obtained for each category per number of replicates 
in that TF, and correspond to the width of the curve above. The black dashed 
line indicates the original estimate for the number of sites for the particular 
category in that TF as derived from the original analysis in Wong et al.[257]. 
The grey dashed line indicates the number of CTCF sites calculated for 2 
biological replicates, estimated for every TF based on the proportion of each 
particular category in CTCF, and multiplied by the overall number of sites in 
each TF.   
 
These results validates the proportions of the cis and trans observed in CTCF. 
Although the cistrans estimate for CTCF almost always overlaps the mean/median 
for 2-replicate runs in other TFs, and may similarly resolve into other categories with 
the addition of extra biological replicates for CTCF, the estimates for the three other 
categories appear different than those of the other TFs (Figure 3.3). The estimate for 
cons sites were generally higher than the equivalent 2-replicate mean values (almost 
equal to mean/median of 3-replicate runs in CEBPA and HNF4A). CTCF cis variants 
estimates are always lower than any of their 2-replicate counterparts in other TFs. 
Although this estimate may similarly go up with the addition of extra replicates (via 
the resolution of cistrans sites), on this evidence CTCF cis variants would remain less 
abundant than in other TFs. Conversely, the CTCF trans estimate is always much 
higher, and as trans-assigned sites only slightly decrease with added replicates, the 
CTCF trans component looks to be distinctly higher. 
 
Even though cis-acting variation was the most common in CTCF binding, the effect 
size on its occupancy was also different. This is clearly reflected in the Pearson’s 
correlation coefficient of CTCF occupancy between the two parental subspecies and 
their offspring (Figure 3.4a). When cis- and trans-acting variations have an equal effect 
on occupancy differences between the F0 and F1, absence correlation (correlation 
coefficient = 0) would be observed, whereas a perfect correlation (correlation coefficient 
= 1) signals the lack of any trans influences. Although all four TFs (CTCF, CEBPA, 
FOXA1 and HNF4A) showed correlation coefficients that are considerably large (r >= 
0.7, all p-values  < 2.2e!16), the distribution of read enrichments from CTCF binding 
sites exhibit a higher degree of dispersion and deviation from the strongly-cis pattern 
seen in other TFs (Figure 3.4a). This is further evidenced by a lower correlation 
coefficient (r = 0.70), that is statistically significantly different compared to that for 
CEBPA, FOXA1 and HNF4A (z-test, all p-values < 0.0001).  
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Figure 3.4: Cis-acting variants do not display inter-peak correspondence in 
CTCF. 
 
a Scatterplots for the mean F0 vs. F1 binding intensity ratios (BL6 vs. CAST) 
for CTCF (left) and the 3 liver-specific TFs (right). Data from 2 randomly 
selected replicates for the other TFs were used for plotting to allow for 
meaningful comparison. The correlation coefficient (r) indicate the level of cis-
directed regulatory effect. b Schematic diagram (left) for the method of 
measuring the span of cis-regulatory effects. Consecutive 1 kb bins were taken 
3. Pervasive effects of trans-acting variation on CTCF occupancy  
 107 
from each CTCF site affected by cis-acting variation in both directions for a 
distance of 400 kb. Spearman’s ρ was computed for each bin through the 
BL6:CAST allelic ratio between SNVs in bins vs anchored SNVs. Spearman’s ρ 
values for each bin (right) were plotted (black dots). Red line is the linear 
regression line. Grey dots represent the null distribution of random subsampling 
from the total set of cis/trans CTCF sites. The grey line is the linear regression 
line for the Spearman’s ρ values from the null distribution. c A blow-up of the 
Spearman’s ρ values for each bin in the 50 kb range from the anchorage points 
for CTCF. The red line is the linear regression line and the red dashed lines mark 
the 90% confidence intervals of the slope of the line. Grey dots represent the null 
distribution. The grey line is the linear regression line for the Spearman’s ρ values 
from the null distribution.   
 
3.3.2 Effect of distance on cis-acting inter-peak 
correspondence 
 
Whereas cis variation effect size decreases at a logarithmic rate with increasing 
genomic distance in other TFs with tissue-specific activity, CTCF cis acting variants 
do not seem to exert any effect on either proximal or distal CTCF binding sites. The 
correspondence of ratios between cis and other SNVs at variable genomic distance 
cannot be distinguished from the null distribution of the genomic background, and the 
linear regression line is flat. The effect is absent in both proximal (<50 kb) and distal 
(400 kb) distances (Figure 3.4b, c). This indicates that the genomic scope of cis-acting 
variants, proposed to be of short-range[257, 613], does not necessarily hold true for 
CTCF. CTCF binding intensity between proximal sites is not dependent on the 
presence of other nearby CTCF sites (cis or otherwise), hence they do not show the 
pattern of decay of signal correlation with increasing distance between their genomic 
positions.  
 
3.3.3 Lineage-specific CTCF binding is driven by cis 
variation 
 
We next applied statistical models to study cis/trans dynamics in CTCF and tissue-
specific TFs occupancy, to test cis and cistrans effects in lineage-specific CTCF binding 
(see Methods). We tested whether such variation caused by SNVs on CTCF binding 
could be responsible for the rise of novel binding sites in a lineage-specific fashion. 
Lineage-specific binding was defined as occupancy events detected in one parental F0 
subspecies, with a single allele-specific corresponding signal in F1 (Figure 3.5a). If the 
divergence is the product of cis acting variation only, the binding signal intensity in 
the corresponding F1 allele will be half that of the parental subspecies, whereas if 
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CTCF binding is additionally influenced by cistrans variation, the binding intensity 
of the signal in the F1 allele would be either stronger or weaker than half of that 
observed in the F0 subspecies of origin (Figure 3.5a).   
 
 
 
Figure 3.5: Lineage-specific CTCF occupancy is driven by cis-acting variation 
 
a A model for lineage-specific class assignment. Lineage-specific binding sites 
were those where binding occurs exclusively in either BL6 or CAST in F0 parents 
and in an allele-specific manner in F1 individuals based on a cut-off (F0B6/(B6+CAST) 
> 0.95, F1B6/(B6+CAST) > 0.95, F0B6/(B6+CAST) < 0.05, F1B6/(B6+CAST) < 0.05), sorted 
into three categories. b. A scatter plot of average CTCF log2 F0 total read 
counts against average log2 F1 read count (BL6 + CAST allele) multiplied by 2, 
using averages across biological replicates. CTCF binding sites affected by cis-
acting variants are expected to distribute along the diagonal. CTCF binding sites 
affected by cistrans-acting variants will deviate from the diagonal. The direction 
of this deviation is an indication of the type of lineage-specific variation described 
in a. c Pie charts showing the relative proportions of the three categories set in 
a for CTCF and 2 replicates for the 3 liver-specific TFs estimated using a 
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statistical model to fit binding sites affected by cis or cistrans variation (see 
Methods). d Bar plots showing compensatory vs diversifying cistrans modes of 
regulation. These are compared here to cistrans sites from non-lineage-specific 
CTCF binding sites.  
 
Cistrans acting variants influencing binding of CTCF in lineage-specific sites exert 
these effects in two modes reflecting different selective forces. Those binding sites that 
exhibit either greater or lower signal intensity in the F1 allele compared to the signal 
from the corresponding F0 can be classified into cis-acting variants that are either 
compensated or diversified by trans-acting variation (i.e. cistrans). If the binding 
intensities in the F1 are lower than in the F0, these changes were classified as 
compensatory, whilst they were deemed diversifying if those binding intensities are 
greater in the F1 than in the F0 (Figure 3.5b). Under the null hypothesis, the effects 
from trans-influenced variation on lineage-specific binding should not substantially be 
preferential towards either selective force. There is almost equal contribution from 
compensatory cistrans-acting variation on the lineage-specific binding of CTCF 
(36/250) to diversifying cistrans variation (44/250) (Figure 3.5b). The effect seen here 
in CTCF is equivalent to previously observed in liver-specific TFs (Figure 3.5c). 
 
Based on the statistical model classification of lineage-specific binding events, over 
two thirds (68%, 170/250) of these CTCF sites were assessed to be under the influence 
of cis variants exclusively. The remainder of sites (32%, 80/250) were influenced by 
variation acting in cistrans (Figure 3.5c). There is; however, a major difference in 
terms of the number of lineage-specific sites obtained from those TFs (500-1000 sites) 
compared to CTCF (250 in total), although this may be explained by the greater 
degree of conservation in CTCF occupancy in general[269, 559], and between these 
two mouse subspecies in particular (see Chapter 2). This is in stark contrast to the 
results obtained in liver-specific transcription TFs using 6 replicates, where the effect 
was predominantly the result of cis-acting variation in the vast majority of cases (84-
87%), whilst the effect from cistrans-acting variants was fairly marginal (More on that 
in section 3.3.6). The number of lineage-specific CTCF binding sites were equivalent 
between the two parental subspecies (120 and 130 for BL6 and CAST, respectively). 
 
When non-lineage-specific cistrans CTCF binding variants where effects of cis and 
cistrans variants are found on both F0 and F1 alleles (3958) were classified to 
compensatory and diversifying modes of selections, these sites were distributed equally 
between the two categories (52% vs 48% respectively) (Figure 3.5d). Nonetheless, the 
differences between observed lineage- and non-lineage-specific CTCF binding sites in 
terms of their compensatory/diversifying modes of selections were not statistically 
significant. This suggests that CTCF sites influenced by cistrans effects on both alleles, 
and shared among both subspecies of mice, are neutral and do not particularly favour 
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either mode of selection, at least at the level we could detect with our available data. 
Taken together, these results indicate that novel CTCF binding sites are formed, either 
directly or indirectly, mostly via the contributions of variation in cis.  
 
3.3.4 Dominant inheritance affect cis-directed CTCF 
occupancy 
 
 Previous work has shown inherited TF binding sites to be expressed in an additive 
or non-additive (dominant) fashion[257, 542, 594]. Additive inheritance was observed 
when the combined binding intensity of the two F1 alleles is equivalent to the sum of 
the two parental F0 alleles, whereas dominant (non-additive) inheritance when the 
total allelic binding signal from the F1 alleles is equal to that of either F0 parent. 
Dominant inheritance; therefore, could also be sub-categorized as “high” if the signal 
from the F1 alleles equals that of the parent with the higher binding intensity, or “low” 
if that signal is similar to the one from the parent with the lower binding intensity 
signal (Figure 3.6a). Inheritance in this context is defined by the total allelic signal 
from each replicate, whereas regulatory categories discussed above were assigned based 
on the ratio of signal between the F1 alleles and the ratios of their F0 parent of origin. 
 
As with regulatory and lineage-specific category assignment, we fitted statistical 
models to test the three inheritance patterns outlined above, using Bayesian 
Information Criteria (BIC) to assess the outcomes in manner equivalent the one 
reported by Wong et al.[257] (see Methods). Of the CTCF binding sites under cis-
influenced variants, 1021 passed the BIC difference minimum of 1 for inheritance 
pattern assignment, and 178 of the trans-acting variants were assigned an inheritance 
pattern with BIC > 1. In both cases of cis- and trans-acting variation, the predominant 
form was additive inheritance in which the total allelic signal from the F1 was equal 
to the sum of both parental allelic signals (55% and 43% respectively) (Figure 3.6b). 
The contributions of dominant inheritance of the inheritance observed in cis- and 
trans-influenced CTCF sites; however, were not equal. Most dominantly inherited cis-
acting CTCF sites belonged to the dominant high variety of non-additive inheritance, 
in which the total allelic signal from the F1 was equal to that of the parent with the 
higher binding signal (34% vs 11% for dominant low). The same was observed, albeit 
to a much smaller scale, in trans-influenced CTCF sites (36% high vs 21% for low). 
When stratified by the F0 parent in with the higher median binding intensity (F0MAX), 
the general distribution of inheritance modes did not differ between BL6 and CAST, 
and all trends in total, cis and trans were consistent in both mouse subspecies, and 
reflected the overall pattern (Figure 3.6b). A slight enrichment of sites inherited in 
dominant low form in BL6 in trans was observed, but owing to the small numbers 
involved, this might be a small number effect. 
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Figure 3.6: CTCF occupancy affected by cis-acting variation is show higher 
dominant effects 
 
a A schematic model for assigning modes of inheritance for the cis- and trans-
influenced TF binding sites. F0MAX and F0MIN refer to the F0 parental subspecies 
with the higher and lower median binding intensity, respectively. Binding 
intensities were summed across replicates in F0, and across alleles for F1.  b The 
bar plots (top) show the proportion of cis- and trans-acting variants in CTCF 
binding sites based on their assigned mode of inheritance. The circle plot (bottom) 
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breaks down each mode of inheritance by the F0 father of origin with the higher 
median binding intensity (F0MAX), with the number of sites per subspecies 
denoted inside the circles. The radius of each circle indicates the proportion of 
that mode of inheritance for the particular F0MAX parent for the same category 
of cis/trans variation. c Pie charts showing the relative proportions of the three 
modes of inheritance for CTCF and 3 liver-specific TFs as determined using a 
statistical model to fit binding sites affected by cis or trans variation (see 
Methods). d A heatmap showing CTCF (left) binding events affected by cis- and 
trans-acting variation. Different modes of inheritance were defined in a (see 
Methods for the statistical model). The data from CEBPA assigned modes of 
inheritance (right) for both cis- and trans-acting variation was used for 
comparison (see Methods). Total F1 counts were individually scaled to 1 
(yellow). 
 
This observation, in the case of cis-acting variation, is significantly different from 
the pattern observed in other TFs, where although the most prevalent mode of 
inheritance was additive (Figure 3.6c), the contribution of dominant inheritance was 
much reduced (c2 test for pairwise comparison between CTCF and other TFs with 
Bonferroni's correction, all p-values < 2.2e-16). Although non-additive inheritance was 
the predominant form for trans-acting variation in CTCF and other TFs, the 
contributions of additive and both forms of non-additive inheritance varied in TF-
specific fashion. For example, the enrichment of the dominant high mode of inheritance 
in trans-acting variation observed in CTCF was not seen in HNF4A, in which the 
dominant low mode was more common (Figure 3.6c). 
 
A close inspection of the ratios of the signal in CTCF cis and trans in comparison 
with CEBPA reveals that the overall effect of regulatory variations in additive 
inheritance tends to centre the ratios of F0MIN to F1 towards 1, with few sites showing 
enrichments towards the lower ends (Figure 3.6d). Only dominant inheritance of the 
low variety shows a clear difference of the pattern in those ratios between F0MAX and 
F0MIN in cis-influenced inheritance (Figure 3.6d). This indicates that in CTCF even 
binding sites classified as influenced by cis-acting variation are under a clear dominant 
low influence that skews the inheritance pattern from the expected additive mode, 
which in turn could explain the increased effect of non-additive inheritance observed 
in the ratios of CTCF total binding signals compared to other TFs. 
 
3.3.5 Cis/trans CTCF binding is associated with higher 
occupancy conservation across tissues 
 
Tissue-shared binding of CTCF is usually an indicator of both evolutionary 
conservation, and potential functional implication in regulatory activities. We thus 
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looked at the pattern of occupancy conservation of cis/trans-influenced variation on 
CTCF sites in previously described mouse ENCODE tissue CTCF libraries (see 
Chapter 2). 15.21% of all liver derived CTCF binding sites under cis/trans variation 
had their occupancy conserved in all 12 ENCODE tissues (over 2000 sites) (Figure 
3.7a). A thousand more sites have shared occupancy in at least 11 tissues (7%). 5.44% 
of all cis/trans sites are bound in another tissue only, mostly in the kidney, whilst 8% 
have no observed binding in any other tissue but the liver. Out of a total of over 14000 
cis/trans CTCF binding sites, 7 tissues exhibit shared occupancy of at least 5000 of 
these binding sites (Figure 3.7a). Similar results were obtained when the whole peak 
sequence of the SNV-containing binding sites were considered.   
 
TF binding sites that are involved in tissue-wide regulatory functions are known to 
be under increased selective pressure, which manifest in the form of elevated levels of 
shared occupancy of their binding sites across tissues[399]. We evaluated the strength 
of each cis/trans CTCF binding sites in all of the 12 mouse ENCODE tissues, and 
used the Shannon Diversity Index[578],  to characterise the diversity of cis/trans 
CTCF binding in terms of their abundance and conservation. Cis/trans CTCF binding 
conservation estimates derived from the analysis outlined above were additionally used 
to illustrate how changes in occupancy conservation across tissues track with the 
diversity of binding instance in varying numbers of cell types.  
 
The high Shannon index value observed across tissue attest to the great degree in 
CTCF occupancy conservation, and is strongly correlated with cis/trans binding in 
the 12 ENCODE tissues included. The values, albeit generally high, form a bi-modal 
distribution, with the 5 tissues with fewer than 5000 cis/trans shared CTCF sites (seen 
in Figure 3.7a) forming a cluster towards the lower range of the Shannon index, and 
the top 7 tissues with greater tissue-sharedness in  occupancy forming the cluster at 
the higher end of the distribution. These differences are mirrored in the degree of 
binding conservation of CTCF sites from 25% at one end to ~ 80% at the other end 
(Figure 3.7b). 
 
The pattern of increased CTCF occupancy across tissues, however, does not hold 
true for the subset of cis/trans-influenced sites classified as lineage-specific (see section 
3.3.3). Whereas a minority of the general pool of cis/trans CTCF sites (~8%) were 
only bound in the liver, 36% of lineage-specific sites were found to be liver-specific 
(Figure 3.7c). This is further reflected in overall lower number of shared sites across 
tissues. For example, of all cis/trans CTCF sites, 50% had shared binding in a 
minimum of 7 tissues. A similar fraction of sites was found to be bound in only three 
other tissues in the lineage-specific subset of cis/trans CTCF sites(Figure 3.7c). 
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Figure 3.7: Cis/trans CTCF site exhibit higher binding conservation across all 
tissues 
 
a UpSet plot illustrating the number of tissue-shared/specific cis/trans CTCF 
binding sites across the 12 mouse ENCODE tissues. The number of binding sites 
bound at each combination of tissues is indicated on the y-axis on the top bar 
chart. The original plot was reduced to only these 26 combinations to highlight 
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only highly tissue-shared and tissue-specific sites (original number of 
combinations with a minimum of 1 site was 613). The last bar (right, boxed) 
shows the number of CTCF sites that were tissue-specific to the liver. b Plot 
representing the association between cis/trans CTCF binding and occupancy 
conservation across 12 tissues. The density plot shows the frequency of CTCF 
shared binding in different tissues, whose diversity values are indicated on the x 
axis, calculated using the p-value estimates of cis/trans peak calls (see Methods). 
The higher the value on the x axis, the higher the number of CTCF sites bound. 
The red line represents the proportion of conserved CTCF binding within each 
bin of Shannon index. c Bar plot elucidating the fraction of cis/trans CTCF 
binding sites shared in increasing number of tissues for all SNV-influenced sites 
and lineage-specific ones. The x axis indicates the decreasing cumulative 
proportion of binding sites found at the minimum number of tissues on the y 
axis. The dashed grey line denotes the minimum number of tissues at which 50% 
sites are shared. d Heatmaps showing the proportion of tissue-sharedness in the 
different regulatory categories of CTCF binding (All on the left, lineage-specific 
on the right).  
 
The patterns of tissue-wide conservation (in the case of general cis/trans sites) and 
tissue-specificity (in lineage-specific cis/trans sites) are mirrored across the underlying 
regulatory categories of which they are composed. All four cis/trans sites show the 
same level of occupancy conservation in the same tissues, with a slightly higher 
enrichment for the cons sites across the top ranking 7 tissues (Figure 3.7d left). No 
statistically significant difference between these categories were observed (χ2 test, p-
value = 0.9091). Although lineage-specific sites show a general lack of occupancy 
conservation in other tissues, 41-59% of those exhibit shared occupancy in at least the 
top 4 tissues, kidney, heart, cortical plate and lung (Figure 3.7d right). The effect is 
strongest in lineage-specific cis CTCF sites, where tissue-shared occupancy ranges 
between 44-64% in the top 4 tissues (Figure 3.7d right). These differences, however, 
reflected the differing proportion of these two categories, and no statistically significant 
difference between them were observed (χ2 test, p-value = 0.8768).    
 
3.3.6 The inclusion of biological replicates improves 
outcomes of analysis on cis/trans variation in TFs 
 
As the results from the subsampling strategies, explored in section 3.3.1 earlier, had 
indicated, adding extra biological replicates to the analysis prove useful in enhancing 
our ability to call the cis/trans regulatory region in TF binding sites more confidently 
and significantly improve our estimation of the true proportion of these categories. 
This was particularly apparent in the case of TF binding sites under influence from 
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cistrans variants, whereby the availability of more ChIP-seq libraries helped resolve 
them into their true cis/trans/cons categories (Figure 3.3). 
 
As a concluding section for the work done in this chapter, an investigation was 
carried out into the different facets the addition of more replicates improves in our 
analysis. By randomly selecting 2, 3, 4 and 5 replicates out of the originally available 
6 for all three TFs, CEBPA, FOXA1 and HNF4A, we looked at how these changes 
reflect on the various aspects originally studied. As seen previously, the progressive 
addition of replicates does change the proportion of the cis/trans regulatory classes of 
TF ChIP-seq signals (Figure 3.8a). The cistrans category is generally reduced in 
proportion with increasing number of replicates, although this change is not completely 
uniform. At 2 replicate, they make up the second most common type of regulatory 
variants, but starting from 3 replicates onwards, they are progressively reduced in 
numbers and the conserved (cons) variants take their place as the second most 
common type of variant in FOXA1 and HNF4A. This; however, was not the case for 
CEBPA, where they remained the 2nd most common type at 3 and 5 replicates. This, 
nonetheless, maybe a stochastic effect arising from the random selection of libraries for 
this analysis, and different set of libraries at 3 and 5 replicates may reflect the general 
pattern seen in the other two TFs. The reduction in the number of cistrans sites 
invariably lead to the enrichment of the three other categories, particularly the cons 
and trans sites. The changes in numbers estimated from adding replicates in all four 
cis/trans categories was consistently statistically significant (χ2 test, all p-values < 
2.2e-16).  
 
These changes were not limited to the overall number of sites within each category 
alone, but also extended to other features of our ability to confidently assign variants 
to their appropriate category. As explained in the Methods section of this chapter, 
category assignment was carried out using Bayesian Information Criteria (BIC), by 
looking at the difference in value from the category with the lowest BIC value to the 
second lowest. This differential BIC value can be used as a measure of the confident 
of variant category assignment; the higher the value of BIC, the more reliable the call.  
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Figure 3.8: The addition of extra biological replicates enhances category 
assignment and BIC estimation 
 
a Pie charts displaying the regulatory variant make-up of 3 TF binding sites 
under cis/trans influence derived from randomly selecting an increasing number 
of biological replicates. b 100% stacked bar chart of the fraction of each cis/trans 
category that are called with a minimum BIC of >=1 in 3 TFs in increasing 
number of replicates. c Boxplots of the differential BIC values (see Methods 
section 3.2.2.8) for all CEBPA binding sites under cis/trans regulatory variation 
in ascending number of libraries. d Line plots of the number of cis/trans TF 
binding sites called at BIC >=1. The "All" category represents the total number 
of sites from all four cis/trans categories present at each number of replicates. 
The plot shows the data for CEBPA. e Hexagonal heatmaps for the mean values 
of F0 versus. F1 binding intensity ratios (BL6 vs. CAST) for every cis/trans 
CEBPA site in 2 to 6 biological replicates.  
 
As the results from re-running the analysis with ascending number of replicates 
have shown, the availability of extra libraries does increase the overall number of TF 
sites whose assigned BIC value is >=1, and provides a more balanced representation 
of the four categories at variants called with higher confidence (Figure 3.8b).  At 2 
replicates only, only a subset of almost exclusively cis and cistrans variants have BIC 
values >=1, with cistrans being the most abundant sites with higher confidence calls. 
The situation immediately improves at 3 replicates, with cons and trans sites now 
being present, albeit at frequencies that do not reflect their overall proportion of the 
total set of TF binding sites. This increase from 3 replicates onwards, however, 
invariably happens at the expense of the cistrans variants, whose fraction at BIC >=1 
is progressively diminished (Figure 3.8b). The increase in the overall number of TF 
binding sites called with higher confidence is not limited to sites with a BIC value >= 
1. The overall BIC value estimation of the all sites improves markedly with ascending 
number of biological replicates (Figure 3.8c). The changes in the BIC estimations of 
all TF binding sites were found to be strongly statistically significant (Kruskal-Wallis 
test, p-value < 2.2e-16). The same results were observed for the other two liver-specific 
TFs (see Appendix 2, Figure S2.1). 
 
The changes seen in differing proportion of cis/trans category at higher BIC values 
with increasing replicate number could be the result of either more variants being 
called with higher reliability whilst the number of high-BIC cistrans sites remains 
roughly the same, or due to the resolution of some these sites into other categories. To 
address this question, we looked at the frequency of all sites with a BIC >= 1 at each 
number of replicates (Figure 3.8d). As the results indicate, it does look like the former 
explanation is the one the data supports. As more libraries are added, more sites have 
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their variants assigned at higher BIC value in general and particularly in cis, cons and 
trans (χ2 test, p-value < 2.2e-16). The number of cistrans variants with BIC >=1 
remains effectively the same (Figure 3.8d). This indicates that even though the overall 
results of cis/trans assignment generally improve with the addition of more input data, 
cistrans calls made with higher confidence are not affected, and do not resolve to 
variant calls to other categories.  
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Figure 3.9: Availability of more libraries markedly improves estimates for 
lineage- specificity and inheritance patterns of in cis/trans TF sites 
 
a Bar chart showing the number of TF binding sites classed as lineage-specific 
for both cis and cistrans variants in 2 to 6 biological replicates. The "Total" bar 
is equal to the sum of the two regulatory categories. The plot shows the data for 
CEBPA. b Scatter plots of average CEBPA log2 F0 total read counts against 
average log2 F1 read count (BL6 plus CAST allele) multiplied by 2, using 
averages in 2 to 6 biological replicates. TF binding sites affected by cis-acting 
variants are expected to correlate between the F0 and F1 along the diagonal 
(grey line). TF binding sites affected by cistrans-acting variants disperse further 
away than the expected straight line, reflecting their direction of lineage-specific 
variation. c Bar plot (top) of the number of CEBPA binding sites based on their 
assigned mode of inheritance in ascending number of biological replicates. Note 
the different y-axis for each between the "Additive" and "Dominant" inheritance 
modes. The circles (bottom) illustrate the make-up of each mode of inheritance 
by the type of cis/trans variation acting on the binding site for each number of 
replicates, with the number of sites per category denoted inside the circles. The 
radius of the circles encodes the relative number of sites compared to the numbers 
observed across different number of replicates for the same category of cis/trans 
variation. No trans sites passed criteria for inclusion in this analysis (See method) 
for 2 biological replicates. 
 
As with the differences in category assignment and higher confidence calls, the 
availability of extra biological replicate improves other aspects of the analysis explored 
in this chapter. This is, for example, evidenced in the distribution of cis/trans TF 
binding sites differences between the two subspecies (Figure 3.8e).  Although the 
overall pattern observed between the ratios of F0 and F1 read enrichments is strongly 
correlated, these ratios exhibit a higher degree of dispersion and deviation from the 
linearity at 2 replicates for CEBPA, but it clearly improves with the addition of more 
libraries. This improvement is reflected in higher R values for Pearson correlation 
coefficients from 2 to 6 replicates (R = 0.85, 0.9, 0.91, 0.92, 0.93 respectively, all p-
values < 2.2e-16).  It is worth noting that even at 2 replicates only, the R correlation 
coefficient for CEBPA was still statistically significantly different from that of CTCF 
(R = 0.7, t-test, p-value < 2.2e-16). Results from the other two TFs produced the 
same pattern (see Appendix 2, Figure S2.2). 
 
The inclusion of more biological libraries additionally has a defining effect on the 
ability to distinguish the regulatory variation driving the evolution of lineage-specific 
TF binding sites. As defined in 3.3.3, lineage-specific binding sites are a subset of sites 
that are bound exclusively in subspecies-specific manner in one F0 parent, and whose 
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allelic read enrichment in F1 hybrids is specific to the parent of origin allele. By virtue 
of this definition, only cis and cistrans variants can be classed as lineage-specific (see 
section 3.3.1). When this definition was applied to the binding sites of CEBPA in a 
series of analyses using 2 to 6 replicates, we obtained two key findings. Firstly, the 
total number of sites classed as lineage-specific does not apparently change much with 
the addition of extra data (Figure 3.9a). There was only 8% increase in the number of 
lineage-specific sites from 2 replicates (1113) to 6 replicates (1217). However, the 
biggest difference appears to be the regulatory variation acting on these sites. The 
number of lineage-specific cis sites gradually increase with every additional library 
until it reaches 87% of all lineage-specific sites. This rise coincide with the reduction 
in cistrans lineage-specific sites from 40% (in 2 replicates) to only 13% (16 replicates) 
(Figure 3.9a). This change is statistically significant (χ2 test, p-value < 2.2e-16). These 
changes did not show any preference towards a particular F0 subspecies and 
distributed roughly equally between the two parental subspecies across all replicate 
numbers. 
 
The second notable outcome of looking at lineage-specific binding in increasing 
number of replicates is that even though the total number of sites did not seem to 
change, they still display a different pattern when their parental read enrichments 
were visualised against their hybrid offspring (Figure 3.9b). At 2 replicates, there is 
no clear distinction between cis and cistrans CEBPA binding sites and the read 
enrichment values between parents and offspring is skewed further away from the 
linear fashion seen in 6 replicates. This quickly improves with the addition of an extra 
replicate, and from there on, the distribution takes a more uniform shape. The 
distinction between cis and cistrans values, however, remains generally 
indistinguishable and only begin to resolve at a much higher number of replicates (5) 
(Figure 3.9b). The same pattern was observed in the other two TFs, although the 
number of lineage-specific sites varied in a TF-specific manner (see Appendix 2, Figure 
S2.3).  
 
The effect of incorporating additional biological replicates can also be seen in teasing 
apart the inheritance pattern of cis/trans-influenced TF binding sites. Similarly to 
CTCF, the distribution of inheritance patterns of CEBPA binding sites between F1 
and F0 in 2 replicates shows signs of increased dominance (high) in its occupancy 
pattern that corresponds to stronger F1 occupancy levels compared to parental 
measurements (Figure 3.9c). Even though additive inheritance starts to become the 
predominant mode from 3 biological replicates onward for cis variants, contributions 
from the dominant (low) only reach their relative proportion in higher number of 
replicates (>4). Notably, roughly the same number of cis TF sites are inherited in the 
dominant high mode regardless of the replicate number (Figure 3.9c). The pattern of 
trans sites inheritance in ascending number of replicates appeared to vary considerably. 
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This might be due to their generally smaller number combined with the stochastic 
effect of the random subsampling of replicates. A clear pattern of increased number of 
trans sites that met the threshold to for inheritance mode assignment is apparent with 
the addition of extra biological replicate. The same results were observed for the other 
two liver-specific TFs (see Appendix 2, Figure S2.4). This suggests that to tease apart 
the true contribution of the different modes on inheritance in trans-acting variation, a 
higher number of biological replicates is required. 
 
 
3.4 Discussion 
 
Regulation of gene transcription is the outcome of complex interplay between 
TFs and the genes they regulate. This regulation is at least partially dependent, and 
explained, by variation in genome sequence affecting TF occupancy and gene 
expression. Regulation of transcription can be mediated via cis-acting elements (e.g. 
promoters, enhancers, TF binding sites, etc.) or trans-acting elements (TF, diffusible 
elements, ncRNAs, nuclear environment, etc.)[614]. The cross-talk between cis- and 
trans-acting variation generates transcriptional regulatory circuits that process this 
complex array of information, and produce robust gene expression[615]. Whereas most 
TFs show a high degree of variability in their occupancy among genetically identical 
individuals[616], and an accelerated evolutionary divergence of their bindings[394], 
CTCF is notable for exhibiting a high level of binding conservation[269], particularly 
around genomic features of direct transcriptional involvement[399]. Previous work has 
focused on how genetic sequence variants correspond to TF binding differences 
between alleles in mouse and human cell lines[257, 260, 601, 615, 617]. However, to 
out knowledge, CTCF occupancy difference in response to genetic sequence variation 
in cis/trans has not been reported.  
  
 In this study, we have interrogated the mechanisms underlying sequence 
variation effect on CTCF occupancy using a hybrid mouse model. This model had 
previously been used to examine cis- and trans-acting variation influence on TF 
binding and gene expression, where differences in TF occupancy were mainly the 
product of variation acting in cis[257].  
 
Due to the disparity in biological replicate availability between our study and 
the one in Wong et al.[257], we re-ran comparative analyses between CTCF and three 
liver-specific TFs (CEBPA, FOXA1 and HNF4A) on two randomly selected biological 
replicates from the 6 replicates report previously for these TFs to allow for meaningful 
comparisons. Our results demonstrably indicate that quantitative differences in CTCF 
binding sites are driven by a significant contribution by trans-acting elements.  
 
3. Pervasive effects of trans-acting variation on CTCF occupancy  
 123 
Whereas the effect of genetic differences acting in cis and cons contributed to 
63-64% of differences in occupancy of liver-specific TFs, the effect of these variants is 
only 55% in CTCF. The remainder of effect comes from either trans- or cistrans 
variation acting on CTCF binding sites. However, the results obtained from 2 
replicates in liver-specific TFs show an increase in cistrans assignment of regulatory 
variants when compared to the original study. Our subsampling approach indicated 
that this had come at the expense of both the conserved and cis variants. However, 
the results of subsampling support our observations of fewer cis and more trans 
regulatory variants in CTCF as consistently different from the proportions observed 
in liver-specific TFs in ascending number of replicates.  
 
Although CTCF binding has been shown to exhibit higher degree of 
conservation than most TFs[269, 559, 618], and particularly between these two mouse 
subspecies (See Chapter 2), this conservation of binding does not necessarily translate 
to either conservation of sequence (number of binding sites with SNVs), or signal (a 
reduction in the sites classified as conserved/cis compared to liver-specific TFs). The 
contribution of trans-acting variants has a substantial effect on individual allelic signal 
in F1. Notably, CTCF occupancy transmission from parent to offspring in mouse was 
equivalent to the rate observed in human lymphoblastoid cell line (LCL) (r = 0.66, p-
value = 6.3e-10) [152].  
 
 Comparison of various facets of cis- and trans-acting variation on CTCF 
occupancy, as compared to other TFs, has produced a number of fascinating insights. 
Allelic differences in CTCF occupancy at cis-affected sites do not correlate with the 
binding signal of neighbouring sites either on the long or short range. This in contrast 
to previous studies looking at TF binding coordination of binding in response to 
cis/trans variation in mouse, and analysis of local and distant correlation of gene 
expression and human eQTLs[257, 603, 613, 619]. The way the analysis was conducted, 
on the other hand, may have missed the long-range interactions driven by CTCF 
enrichment at chromatin contacts as these were not specifically selected for during this 
analysis.  
 
 Analysis of cis and cistrans variation on lineage-specific binding of CTCF 
exhibited a similar pattern to that seen in liver-specific TFs. CTCF occupancy; 
however, showed a substantial difference in terms of the number of lineage-specific 
sites (250 in total) compared to those obtained from those TFs (500-1000 sites). This 
is likely a consequence of the greater degree of conservation in CTCF occupancy in 
general[269, 559], and between these two mouse subspecies in particular (see Chapter 
2). Previous work demonstrated that new binding sites rise and become fixed on 
microevolutionary timescales under assumption of neutral evolution, and both 
compensatory and diversifying trans effects should be equally favoured[541, 620]. This 
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was further confirmed with previous work on liver TFs whose subspecies-specific 
binding was influenced equally by both compensatory and diversifying modes of trans-
acting influence[257]. 
 
The effect of increased trans-acting variation on CTCF is further seen when 
the pattern of allelic signal inheritance was investigated. The predominant form was 
additive in both cases of cis- and trans-acting variation. Nevertheless, most dominantly 
inherited cis/trans-acting CTCF sites came in the form of dominant high, in which the 
CTCF occupancy in hybrid offspring corresponded to that of the parent with the 
higher binding intensity. This was, particularly in the case of cis-acting variation, 
notably different from the mode of inheritance observed in liver-specific TFs, in which 
even though the additive mode of inheritance was most prevalent, the contribution of 
dominant inheritance was significantly reduced. We additionally observed that even 
CTCF binding sites influenced by cis-acting variation are under a clear dominant high 
influence that skews the inheritance pattern from the expected additive mode, 
suggesting that it could be driving the increased effect of non-additive inheritance 
observed in CTCF compared to liver-specific TFs. This can be explained by the 
pervasiveness of trans-acting variants at the higher and lower ends of the distribution 
of binding signal values driving the ratios between the total signal of F1 alleles to 
either parent towards the middle, diluting the effect from cis-acting variants. The 
differences in inheritance pattern also extend to trans-influenced CTCF binding sites, 
where even though these sites are dominantly inherited, their dominant inheritance 
comes in the “high” variety. Indeed, a study by Stergachis et al. proposed that selection 
on gene regulation during mammalian evolution is specifically targeted at the trans-
regulatory network level, enabling potential cis-regulatory plasticity[618]. 
 
As we discussed in Chapter 2, conserved CTCF binding exhibits higher tissue-
sharedness in its occupancy than evolutionary young, subspecies-specific sites. We 
investigated the extent of occupancy conservation across cell-types in CTCF sites 
subject to cis/trans regulatory variation. Similar to musculus-common sites, cis/trans 
CTCF sites, regardless of their regulatory category, exhibit a substantial degree of 
binding conservation across tissues. The type and number of tissues in which these 
sites bind is similar to the pattern observed in conserved CTCF sites. Even though 
lineage-specific cis and cistrans are restricted in their tissue distribution, some are still 
bound across multiple tissues. These findings support the findings from Chapter 2, and 
further illustrate that conserved sites, even when influenced by sequence variants in 
the binding site, remain strongly associated with tissue-wide binding. 
Lineage/subspecies-specific sites, on the other hand, are more restricted in their 
binding across tissues, and only a subset with higher regulatory potential manage to 
exhibit tissue-wide occupancy. 
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The findings of this investigation; nonetheless, do have their limitations. First, 
only two biological replicates were obtained for each of the reciprocal crosses to 
produce hybrid F1 mice. More replicates have the potential to either enhance or reduce 
the effect sizes we measured in this analysis. We performed an exploratory analysis 
into the effect of inclusion of extra biological replicates on the outcomes of some of the 
analyses carried out in this chapter. By randomly selecting 2, 3, 4 and 5 replicates out 
of the originally available 6 for all three TFs, CEBPA, FOXA1 and HNF4A, we 
observed changes in the proportion of the cis/trans regulatory classes of TF. The 
proportion of TF sites assigned to the cistrans category decreased gradually with 
increasing number of replicates. This reduction was most likely due to the resolution 
of low-confidence cistrans sites into the three other categories. 
 
The re-assignment of low-confidence cistrans sites was further evidenced by 
analysis of the number and proportions of TF cis/trans sites whose category-
assignment calls were made with higher-confidence. We showed that the incorporation 
of more biological replicates not only enhanced our ability to assign categories more 
reliably (particularly conserved and trans sites), the category assignment confidence 
scores significantly improved with increasing replicate number. Whereas the total 
number of high-confidence conserved, cis and trans TF sites increased with increasing 
replicate number, high confidence cistrans sites remained roughly the same. This 
indicates that the general reduction in cistrans sites in higher number of replicates 
does not affect those sites, but it is the lower quality category-assignment that resolve 
into the other categories when more data is made available for the analysis.  
 
Furthermore, we observed an improvement in cis effect sizes in the ratios of 
TF binding signal in hybrid offspring compared to the parental subspecies when extra 
replicates are integrated into the analysis. Again, this is most likely the result of the 
increase in sites assigned as conserved and/or cis due to the resolution of cistrans sites. 
Similarly, although the number of lineage-specific cis/trans TF binding sites do not 
change with increasing replicate number, the ratios of cis to cistrans do, again due to 
the re-assignment of sites previously categorised as cistrans. Additionally, the inclusion 
of more biological libraries has a marked effect on our ability to discern the regulatory 
variation underlying the evolution of lineage-specific TF binding sites.  
 
We also observed a clear effect on teasing apart the inheritance pattern of 
cis/trans-influenced TF binding sites when incorporating additional biological 
replicates. Similar to CTCF, even though additive inheritance remains the 
predominant mode of inheritance for cis variants in 2-6 replicates, liver-specific TFs 
shows signs of a dominant effect (high) in their occupancy pattern. However, 
contributions from the dominant (low) form of non-additive inheritance only manifest 
the proportion reported in Wong et al.[257] in higher number of replicates. This 
3. Pervasive effects of trans-acting variation on CTCF occupancy  
 126 
indicates that establishing the correct modes on inheritance in cis- and trans-acting 
variation, a higher number of biological replicates is generally required. 
 
It is worth mentioning that most of the CTCF sites, similar to other TFs, had 
no informative SNVs that can be used to discern differential allelic signal in the F1, 
so the full extent of this effect is not fully resolved. The prevalence of CTCF binding 
sites affected by variation acting in a cis/trans fashion complicates the pattern of 
impact on differential allelic signal in the F1. Adding more replicates or deeper 
sequencing may allow for the partial resolution of this band of regulatory elements, or 
alternatively emphasize their effect on the binding of CTCF. Lastly, all definitions of 
regulatory classes of sequence variations effects on CTCF and other TF bindings were 
based on statistical models. These sites in their nuclear environment are naturally 
biologically heterogeneous, and the spectrum of effects on their occupancy is 
potentially wider.  
  
Nevertheless, this study provides further support to the use of this model to 
investigate the differential binding of TFs in hybrid nuclear environments to discern 
the various effects that influences their occupancy and the selective forces at work. 
This work, along with previous studies[152, 257, 260], shows the value of this approach 
in studying the roles genetic variation plays in TF binding regulation of gene 
expression. 
 
 
 
 
 
 
 
 
Chapter 4 
 
Regulatory potential of CTCF 
binding in closely-related mice 
 
 
4.1 Introduction 
 
Repetitive elements have played a major role in the in shaping the regulatory 
sequence of the non-coding genome throughout the evolution of mammalian lineages 
through the creation of novel loci for the binding of transcription factors[387, 560-562]. 
CTCF is a prime example of this mechanism, where waves of short nuclear interspersed 
elements (SINEs) expansions spread the CTCF binding site within the mouse 
lineage[559, 621]. 
 
CTCF binding, coupled with interaction with the cohesin complex of proteins, 
is a major component of the process that establishes and maintains the integrity of the 
3D genome structure[622, 623]. CTCF binding colocalization with the formation of the 
cohesin complex is part of the process of chromatin loop formation through a loop 
extrusion mechanism, whereby the loop anchors are marked with two bound CTCF 
molecules that help stabilise the loop, resulting in the establishment of topologically 
associating domains (TADs)[227, 235, 285, 577, 624, 625]. TADs have reportedly been 
highly conserved during mammalian evolution, appearing invariably at consistent 
genomic loci across species and cell-types[235, 312, 626]. 
 
The presence of TE-derived CTCF binding sites in evolutionary young sites, 
along with CTCF association with TADs in chromatin loop anchors provide the basis 
for possible evolutionary mechanism to forming novel higher order chromatin 
structures. The insertion of subspecies-specific binding sites by action of SINEs in the 
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vicinity og more conserved CTCF binding sites gives opportunity for novel loop 
contacts to form. This model is supported by findings reporting TE-derived CTCF 
occupancy observed in association with chromatin loop anchors in mouse[219, 238]. 
 
CTCF-mediated chromatin looping is reported to allow distal enhancers, lying 
further away up/downstream of their target genes, to interact in physical space with 
target promoters to activate gene expression[355, 627, 628]. Cohesin-loading near 
promoters interacts with CTCF bound near distal enhancers to mediate promoter-
enhancer contact. A study in ES cells demonstrated the potential of CTCF when 
interacting with cohesin complex near active regulatory elements to readily recruit the 
core promoter factor TAF3,  and via the establishment of TAF3- dependent loop, 
CTCF facilitates promoter-enhancer contact[317].  
 
In Chapter 2, we observed the expansion of these SINE-derived CTCF binding 
sites in two main clusters: an older expansion shared among sites in the musculus-
common set of sites, and a recent one that took place after the divergence of both 
subspecies, and is found primarily evolutionary young sites. The results from Chapter 
3 illustrated the contribution of cis- and trans-acting variation on the binding of CTCF 
in a set of sites shared between the two closely-related subspecies and characterised 
by informative SNVs. In this chapter, we present our analysis of at the regulatory and 
functional potential of CTCF occupancy, comparing and contrasting between CTCF 
sites differing in their evolutionary/tissue-specificity (from Chapter 2) and sites that 
exhibit binding variation in the form of cis/trans regulatory variants (from Chapter 
3). Our findings provide evidence of dynamic evolutionary conservation in TAD-
boundary association where conservation of binding coincides with substantial 
contribution of both sites under cis/trans regulatory variation and subspecies-specific 
CTCF sites. We also observed strong association between CTCF and cohesin-complex 
proteins in cis/trans-influenced sites and evolutionary young, tissue-shared sites 
equivalent to the level seen in more conserved sites. The regulatory and functional 
aspects of CTCF binding in all sets of binding sites considered in this thesis appeared 
to maintain the stability of pre-existing higher-order chromatin structures, whilst also 
providing a template for subspecies- and tissue-specific genomic innovation. 
 
This investigation is the result of a collaboration between Dr. Paul Flicek’s 
research group at the EMBL European Bioinformatics Institute and Dr. Duncan 
Odom’s laboratory at the Cancer Research UK Cambridge Institute. I carried out the 
computational analysis, except where otherwise specified.  
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4.2 Methods 
 
4.2.1 Repeat content in cis/trans-influenced CTCF sites 
 
The full set of transposable elements (TEs) for the C57BL/6J mouse genome 
was retrieved from Thybert et al[559] and used to analyse repeat content in cis/trans-
influenced CTCF and three liver-specific TFs (CEBPA, FOXA1 and HNF4A) binding 
sites. The contribution of repeat elements to the binding sites was estimated using the 
intersection between the TF (CTCF, CEBPA, FOXA1 and HNF4A) binding sites and 
the full set of the four TE superfamilies to calculate the fraction of sequence occupied 
in each binding site. We additionally used the full set of mouse TEs to calculate the 
background representation of the 4 most common superfamilies of TEs (SINEs, LINEs, 
LTRs, DNA transposons) in the mouse genome to compare to all four TFs.  
 
A non-cis/trans TF binding sites set was derived for CTCF and the other 3 
TFs to use for comparison of repeat content. A union peak file was generated for all 
ChIP-seq identified binding sites for each TF. BEDTools version 2.2.5.0[511, 512]with 
the option -v was used to filter out all binding sites shared with the SNV-containing, 
cis/trans-influenced set of binding sites. 
 
BEDTools intersect 2.2.5.0 with the option -wo to return the length of sequence 
overlap between the peak sequence and the repeat, followed by division by the total 
length of the binding site to return the percentage of sequence occupied by repeat 
elements. To estimate the relative age of the repeat element in which a TF binding 
site is embedded, we used the percentage of sequence substitutions in each repeat from 
the consensus in the same way described in Chapter 2 Methods section 2.2.2.3. A 
random set of non-overlapping, chromosome-matched genomic sequences to cis/trans 
CTCF sites was generated for comparative analysis using BEDTools version 2.2.5.0 
shuffle tool to generate sequences equal in number and length to the total number of 
CTCF (cis/trans and non-cis/trans) sites. 
 
4.2.2 Gene feature analysis of CTCF sites 
 
We utilised basic gene features derived from the most recent mouse genome 
assembly (GENECODE Release M23 (GRCm38.p6)[629])  to investigate the genomic 
distribution of CTCF binding sites classes, both on the basis evolutionary/tissue-
specificity (Chapter 2) and cis/trans-acting variation (Chapter 3), in addition to the 
3 liver-specific TFs mentioned above. We defined five main classes of features: 
Intergenic, Promoters, TSSs (transcription start site), Exons and Introns. We 
performed the genomic characterisation of TF binding sites using the annotatePeaks.pl 
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tool from HOMER (Hypergeometric Optimization of Motif EnRichment) suite 
(v4.11)[630].  
 
CTCF binding sites regions were analysed with GREAT version 3.0[515] using 
default parameters to determine the distance from each CTCF site of each category 
to the nearest transcription start site (TSS). All CTCF sites more than ±100 kb from 
the nearest TSS were pooled together. CTCF proximity to downstream gene bodies 
was measured using PeakAnalyzer version 1.4[631], with annotation from the most 
recent mouse genome assembly (GRCm38). 
 
4.2.3 CTCF occupancy at proximal active regulatory 
elements 
 
Liver ChIP-seq libraries for H3K4me3 (a histone modification predictive of 
active promoter regions) and H3K27ac (a histone modification predictive of active 
promoters and enhancers[209]) were obtained for C57BL/6J (BL6) from Wong et al 
2017[257], each with three biological replicates. Reads were aligned, filtered and peaks 
were called using the methodology explained in detail in Chapter 3 Methods section 
3.2.2.1. Only peaks common in a minimum of two replicates were used to define active 
regulatory elements. A promoter region was defined by the localisation of either 
H3K4me3 only, or with overlapping H3K27ac signal, whereas enhancers were defined 
by the presence of the histone modification H3K27ac alone within the peak region. 
 
Co-localisation of TF binding sites in regulatory elements was defined using an 
intersection of at least 1 bp between the TF binding site and the regulatory element. 
TF. BEDTools intersect 2.2.5.0 with the option -wa -wb to retrieve all overlaps 
between binding sites and active regulatory regions. The analysis was performed 
similarly for both TFs under cis/trans regulatory variation, and CTCF in different 
evolutionary/tissue-specificity classes.  
 
CTCF proximity to active regulatory regions was measured using BEDTools 
closest 2.2.5.0, with the options -D ref and -mdb all against all active regulatory region 
to return only the closest enhancer/promoter but not both at the same time. We 
excluded any sites whose distance to the CTCF binding site is 0 (i.e. overlaps the 
binding site) as these sites have already been considered for the co-localisation analysis 
outlined earlier.  
 
4.2.4 CTCF occupancy at TAD-boundary analysis 
  
To calculate the distance from each TF binding sites to the nearest 
up/downstream topologically-associated domain (TAD) boundary, mouse liver TAD 
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boundary data from Vietri Rudan et al. 2015[238] were used. We defined the TAD 
boundary as the start or end nucleotides for every TAD in that dataset. The distance 
from each TF binding site and its nearest TAD boundary was measured using the 
BEDTools closest 2.2.5.0 tool. This was done for binding sites under cis/trans 
regulatory variation (CTCF and other TFs) and evolutionary common/young 
(CTCF).   
 
Enrichment of TF binding sites within single TADs was measured by counting 
the number of each TF within TADs using BEDTools intersect 2.2.5.0 with the option 
-c. These resultant counts were compared against expected counts. As TADs vary 
widely in size, a unique expected frequency needed to be calculated separately for each 
TF. This TF-specific expected frequency was derived by dividing the total sequence 
length occupied by all TADs by the number of SNVs of each TF, producing the 
frequency in which a SNV is found in the genome. By dividing the length of each TAD 
by the particular frequency for each TF, an estimate of the number of SNVs/binding 
sites expected for each TAD individually.   
 
4.2.5 CTCF recruitment of cohesin-complex proteins 
 
ChIP-seq data for three cohesin-complex subunits (Rad21, STAG1 and 
STAG2) in liver, two biological replicates for each subunit, from adult male mice and 
matched controls were retrieved for BL6 from Faure et al. 2012[362]. Sequence reads 
were aligned to the GRCm38 reference genomes using BWA version 0.7.12[494] for 
each biological replicate and control. Cohesin-complex subunits regions were identified 
by peak calling from aligned sequence reads using MACS version 2.1.0[632] callpeak 
function with a p-value threshold of 0.001 and default parameters to call peaks 
representing cohesin-bound regions in the genome. 
 
Genomic regions where at least two cohesin subunits peaks overlap were merged 
using BEDOPS version 2.4.3[633], and cohesin merged regions overlapping with 
musculus-common/BL6-specific/BL6-tissue-shared from our CTCF liver binding sites 
were identified. The intersection analysis was done for CTCF co-occupancy with two 
and three subunits, owing to the significantly fewer number of ChIP-seq peaks 
retrieved from the STAG1 data. The set of regions where a minimum of 2 cohesin 
subunits were bound was used for all further analysis involving CTCF (both cis/trans-
influenced and evolutionary common/specific) and the liver-specific TFs.  
 
When comparing cohesin-complex recruitment between CTCF and the liver-
specific TFs, we considered two types of cohesin-bound regions. Cohesin-and CTCF 
(CAC) sites are defined as sequences where a CTCF site (cis/trans or otherwise) co-
localises with a minimum of two overlapping two cohesin subunits. Cohesin-non-CTCF 
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(CNC) sites are sequences where the recruitment of two overlapping cohesin subunits 
was not associated with the binding of any CTCF.  
 
To investigate the correlation between the evolutionary/tissue-specificity type 
and cohesin-recruitment by CTCF, we divided each set of CTCF binding sites into 
ten 10% bins based on descending ChIP-seq signal. ChIP signal in this context referred 
to the reads pileup per peak from the replicate where the peak signal was at its highest, 
for each of the three evolutionary/tissue-specific classifications: musculus-
common/BL6-specific/BL6-tissue-shared. Signal intensity was then compared to the 
level of cohesin recruitment, defined as the fraction of CTCF sites belonging to each 
evolutionary/tissue-specific type that falls within a 2-subunit cohesin-bound region.  
 
4.2.6 Cohesin-and-CTCF motif analysis. 
 
Motif identification in CTCF binding sites (both cis/trans-influenced and 
evolutionary common/specific) was done using the MEME suite v.5.05[508, 509]. 
FASTA sequences from the CTCF binding sites were obtained using BEDTools 
getfasta 2.2.5.0. These sequences were then scanned for CTCF canonical binding motif 
(M1) JASPAR database (JASPAR motif MA0139.1) using the MEME suite motif 
scanning function Find Individual Motif Occurrences (FIMO) with default parameters. 
We used FIMO-assigned CTCF motif orientation and motif scores for further 
downstream analysis.  
 
In the case of CTCF binding sites with more than one instance of the M1 motif 
in their sequences, the motif that is closest to the summit of the replicate where the 
peak signal was at its highest, as defined by the output of peak-calling step using 
MACS, was selected in the case of evolutionary common/specific sites. The motif with 
the highest motif score was selected in the case of cis/trans-influenced CTCF sites 
because of the variation in SNVs distances to the summit within the binding site. 
CTCF sites with 0 motif instance in the BL6-specific set of CTCF sites were subject 
to further motif scanning using alternative CTCF motifs, retrieved from CTCFBSDB 
2.0[634, 635] (http://insulatordb.uthsc.edu/download/CTCFBSDB_PWM.mat). 
Visualisation of both the canonical motif and the alternative motifs was performed 
using the position weight matrices for each motif as obtained from their respective 
sources, and carried out using the PWMScan from PWMTools[636].   
 
A motif with a (+) strand orientation indicated that the motif is present on 
the Watson strand (the + genomic strand), and a motif orientation with (-) orientation 
is on the Crick strand. We next determined the distance from each cohesin-and-CTCF 
site with an M1 motif to its nearest cohesin-and-CTCF site. All sites were sorted by 
chromosome and then by start position, before calculating their distance to the nearest 
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downstream sites using BEDTools closest 2.2.5.0, with the options -D ref and -t first. 
The motif combinations between pairs of nearest CTCF sites were defined as "Tandem" 
if their orientations were in agreement (++/--). If the pair of sites were in opposite 
orientation, a "Convergent" combination resulted when the upstream motif was in (+) 
orientation, or "Divergent" combination when the upstream motif was in (-) 
orientation. The expected proportions of cohesin-and-CTCF pairs of nearest sites based 
on their evolutionary/tissue-specificity type were calculated from their overall 
proportion of the total set of sites. For example, the expected frequency of musculus-
common sites, which constitute 89% of all cohesin-and-CTCF sites, to be nearest to 
similar musculus-common sites if randomly distributed equals 0.89x0.89 = 0.797 
(79.7%). The Circos plot from Figure 4.6g was generated using the table visualisation 
webpage: http://mkweb.bcgsc.ca/tableviewer/[637] 
 
 
4.3 Results 
 
4.3.1 Depletion of repeat content in cis/trans-influenced 
CTCF sites indicates older evolutionary origin  
 
Having established that the evolution of CTCF occupancy in subspecies-specific 
manner occurs via the expansion of SINE B2 elements in the short evolutionary time 
since the divergence of BL6 and CAST (see section 2.3.2), we investigated the 
contribution of repeat elements activity in driving CTCF occupancy in sites under 
cis/trans binding variation. Analysis of the extent of repeat content enrichment in 
DNA sequences occupied by TF binding sites influenced by cis/trans variation revealed 
a number of interesting observations of the differences between CTCF and other liver-
specific transcription factors.  
 
Compared to the four most represented transposable elements (TE) 
superfamilies in the mouse genome, CTCF is strongly enriched with SINE TEs; 60%, 
three times as many as the background genomic sequences masked by TEs (χ2 test 
without Yates correction, p-value < 2.2e-16). On the other hand, CTCF is depleted 
for longer repeat elements, namely LINE and LTR TEs, even though LTRs are second 
most common TE in cis/trans CTCF binding sites, 21% compared to 29% in 
background (χ2 test without Yates correction, p-value < 2.2e-16). There is a slight 
enrichment for DNA-transposons compared to the background, but it only accounted 
for 5% of the all sequences masked by TEs (Figure 4.1a). The three other TFs 
(CEBPA, FOXA1 and HNF4A) have higher than expected SINE elements content 
(1.5-2 times as much as background), with similar depletion in LINE TEs. They do 
exhibit an elevated enrichment of LTR TEs, as much as SINE TEs contribution to 
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their sequence (35%-39% for the 3 TFs compared to 29% background). This is 
consistent with the observed relative enrichment (compared to musculus-common) of 
LTRs in the evolutionarily-young, subspecies-specific binding sites for two of these 
TFs (CEBPA and FOXA1) in both BL6 and CAST (see section 2.3.2). Similar 
enrichment for DNA transposons to that of CTCF were also observed for the other 
TFs, albeit contributing only 6-8% of the all sequences masked by TEs. All differences 
were statistically significant with χ2 test and p-values < 2.2e-16. 
 
A breakdown of CTCF sites by their cis/trans regulatory categories reveals the 
same pattern of contribution of the four superfamilies of TEs in all categories, with 
SINE TEs being the most represented, making up 60% of all repeat content in binding 
site sequences (Figure 4.1a). No statistically significant differences between either the 
four categories or the overall pattern for cis/trans CTCF sites were found (χ2 test, p-
value > 0.7). Cis/trans patterns for the other TFs were also found to reflect the general 
pattern of the total binding sites for each TF (see Appendix 3, Figure S3.1). 
 
Comparison of the overall repeat content in all binding site sequences between 
cis/trans and non-cis/trans sites show that CTCF is the only TF whose cis/trans sites 
are significantly depleted for repeat elements (30% reduction from 29% to 19%), along 
with a corresponding depletion in SINEs 11% versus 19% in their non-cis/trans 
counterparts (χ2 test, p-value < 0.05) (Figure 4.1b). Surprisingly, they have slightly 
higher enrichment with LINE and LTR TEs compared to non-cis/trans. Conversely, 
cis/trans in CEBPA and HNF4A have twice the repeat content as their non-cis/trans 
sites (χ2 test, p-value < 0.01). There was no statistically significant difference between 
the two with FOXA1 (χ2 test, p-value > 0.6). The repeat content of the total sequence 
of the mouse genomic background was found to be higher than both cis/trans and 
non-cis/trans TFs binding sites (χ2 test with Bonferroni correction, p-value < 0.001 
for both cis/trans and non-cis/trans sites across TFs) (Figure 4.1b).  
 
Cis/trans sites depletion in repeat elements is further supported by looking at 
the proportion of sequence occupied by TEs in the four regulatory categories compared 
to non-cis/trans and randomised genomic regions of the same size. The same overall 
depletion in repeat elements is seen across the four major TE superfamilies (Figure 
4.1c). Significantly lower fraction of the sequences is occupied by SINE elements in 
cis/trans sites than their non-cis/trans counterparts (Mann-Whitney U test, p-value 
< 2.2e-16), and their contribution to sequence is similar to randomised regions level 
(Mann-Whitney U test, p-value = 0.111). Both cis/trans and non-cis/trans CTCF 
sites are depleted for LINEs when compared to random regions (Mann-Whitney U 
test, p-value < 2.2e-16). This is consistent with recent reports of selection against long 
sequence deletions at the CTCF sites[638]. All regions studied were enriched for DNA-
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transposon over the genomic background, even though their overall contribution to 
the total sequence occupied by TEs remained marginal (~5%).  
 
 
 
Figure 4.1: Cis/trans-influenced CTCF sites are depleted for repeat content 
 
a Horizontal bar chart shows the fractions of different TE superfamilies in 
cis/trans TFs binding sites masked by repetitive sequences. The top bar refers 
to the percentage each TE superfamily comprises in all repeat masked sequences 
in the BL6 mouse genome as a background. The vertical bar chart (below) 
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visualises a breakdown of CTCF sites per their cis/trans category constituents. 
b Stacked bar chart illustrating the extent of sequence masking as a fraction of 
the total length of sequence occupied by TF binding sites in both cis/trans and 
non-cis/trans assigned peaks. The last bar on the right represents the proportion 
of repeat content in the total genomic sequence of the BL6 mouse by the type of 
TE superfamily these repeats originate from. c Boxplots displaying the 
percentage of sequence length of cis/trans CTCF binding sites that is occupied 
by TE superfamilies, compared with their non-cis/trans counterparts and 
randomised genomic regions matched for length. d Violin plot of the fraction of 
sequence mismatches/substitution from the TE consensus sequence of the SINE 
TEs in the same categories from c. The boxplots within each violin plot show 
the variation in sequence mismatch level from the consensus in all categories. 
 
 The percentage of mismatch in TE sequence from the consensus can be 
construed as a measure of the relative age of the TE element. As the TE element gets 
older, the TE consensus sequence acquires more mutations/substitutions in sequence. 
Evolutionary young sites brought upon via repeat expansion of TE elements have only 
had a relatively short evolutionary time to accumulate mutations, and hence their 
mutational load is light. Therefore, binding sites in TE elements characterised by 
increased level of mismatches in the sequence are considerably older than their 
mismatch-free counterparts. We used this observation to investigate the relative age 
of CTCF cis/trans sites, in comparison with non-cis/trans sites and matched 
randomised regions in the most represented TE superfamily, SINEs (Figure 4.1d). The 
results obtained revealed that CTCF cis/trans sequences occupied by SINE TEs 
exhibit a higher degree of mismatches from TE consensus sequences invariably across 
all four cis/trans categories. This indicates the significantly longer evolutionary age of 
these sites in comparison with either non-cis/trans or randomised regions (Mann-
Whitney U test, p-value < 7.517e-15). Since cis/trans sites represent, by definition, 
genomic loci where binding CTCF binding is observed between the two subspecies 
(lineage-specific binding is rare. See Chapter 3), it is likely that these sites are 
evolutionarily older, and may even further be more deeply conserved through the 
murine lineage. 
 
4.3.2 Evidence of regulatory potential of cis/trans CTCF 
sites at proximal active regulatory elements 
 
In order to establish the potential regulatory effect of cis/trans-influenced 
CTCF binding, we evaluated the genome-wide distribution of these sites with relation 
to the genomic features they occupy. A higher fraction of cis/trans CTCF sites are 
found in intergenic regions than any other TF, whereas their binding in intronic regions 
is distinctly smaller than in liver-specific TFs (Figure 4.2a left). A comparatively higher 
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number of cis/trans sites are also bound at or around TSSs than the other three TFs. 
All differences were found to be statistically significantly different between CTCF and 
other liver-specific TFs (χ2 test, p-value < 2.2e-16). 
 
CTCF cis/trans sites overlap exons from 170 genes. Gene Ontology analysis 
of these genes returned no statistically significant hits for either biological process, 
molecular function or cellular component, suggesting that this binding is just a 
reflection of CTCF genomic distribution and is not associated with a particular 
function. Further investigations of the distribution of the four cis/trans categories in 
genomic features revealed the same pattern of distribution to the one observed in all 
cis/trans sites, with the vast majority of CTCF sites binding in intergenic/intronic 
sequences (Figure 4.2a right). χ2 test for differences between cis/trans categories in 
their genomic features did not return any statistically significant differences (p-value 
= 0.25). Cis/trans patterns for the other TFs were also found to reflect the general 
pattern of the total binding sites for each TF, although an apparent enrichment in 
promoter sequences is observed across all liver-specific TFs (see Appendix 3, Figure 
S3.2).  
 
We next investigated the binding of cis/trans CTCF and other TFs in/around 
active regulatory elements. We mapped the genome-wide co-localisation of TF binding 
sites with genomic location characterised by the presence of the H3K4me3 histone 
modification, a known promoter marker, and the H3K27ac histone modification, a 
marker of regulatory enhancer activity, in addition to marking active promoters when 
coupled with H3K4me3. Results show that, unlike liver-specific TFs, cis/trans CTCF 
sites co-binding with markers of gene expression is not common and is generally 
unfavoured (Figure 4.2b). The effect is most apparent in enhancers, where only 5% of 
cis/trans CTCF sites bind to enhancer sequences, compared to 28-38% in other TFs. 
Similar pattern is observed with promoter sequences, albeit smaller in scale (10% 
versus 17-22%) (Figure 4.2b). These differences in regulatory element enrichment 
across promoters and enhancers were found to be strongly statistically significant (χ2 
test with Bonferroni correction, all p-values < 2.2e-16). These difference reflect the 
biology of these different factors. CEBPA, FOXA1 and HNF4A are tissue-specific TFs 
that bind to active regulatory element to activate tissue-specific gene expression[362].  
 
A closer inspection of TF regulatory element occupancy affected by cis/trans 
variation across the liver-specific TFs considered in this study reveal that these 
differences also vary in effect depending on the type of variant present in each binding 
site. For liver-specific TFs, both cis- and cistrans-acting variation in the three TFs 
were underrepresented at promoter regions compared to their proportion of all 
cis/trans sites, except for FOXA1 (Binomial test with Bonferroni correction, all p-
values < 0.001)(Figure 4.2c). The same was observed in cis/trans TF binding sites at 
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enhancer regions, but to a slightly lesser significance. Cons-variation acting on TF 
binding sites was, on the other hand, universally overrepresented for both promoters 
and enhancers (Binomial-test with Bonferroni correction, p-values < 0.0001) (Figure 
4.2c), confirming the results we obtained from looking at the pattern of genomic 
distribution (see Appendix 3, Figure S3.2). This provides evidence that these cons-
acting liver-specific TFs do not only bind at regions designated as promoters in 
annotation, but also marked for regulatory activity with histone modifications in the 
tissue of interest, exhibiting likely transcriptional potential. Cis/trans-influenced 
CTCF occupancy of promoters/enhancers, on the other hand, does not vary from one 
type of regulatory category to the other.  
 
When the distance from each of the cis/trans CTCF sites to their nearest 
regulatory element (promoter/enhancer) was measured, we found that the majority of 
these sites occupy sequences located significantly closer to active regulatory elements. 
The median distance from cis/trans sites to their nearest promoter was 23 kb (16 kb 
when sites overlapping promoter sequences were included). The distances from CTCF 
cis/trans sites to their nearest enhancer was even closer, at a median distance of 17.5 
kb (12 kb when sites overlapping enhancer sequences were included). Cis/trans-acting 
variants in CTCF binding sites are significantly closer to enhancer elements than 
promoters (Mann-Whitney U test, p-value < 2.2e-16) (Figure 4.2d). 50% of all non-
enhancer overlapping cis/trans CTCF sites are within 12 kb of an enhancer, whereas 
50% of all non-promoter overlapping sites are within 17 kb of a promoter. 95% of all 
cis/trans CTCF sites are within 75 kb of an active regulatory element (Figure 4.2d). 
Even though cis/trans CTCF binding sites do not appear to be bound at active 
markers of regulatory activity, they still bind very closely by. This indicates the 
potential for these CTCF sites to take part in modulating gene expression in 
cooperation with these active regulatory elements.  
 
 CTCF binding sites at proximal active regulatory regions do not exhibit 
variation in their occupancy pattern based on their cis/trans variation status (Figure 
4.2e). All four categories of cis/trans variation in CTCF occupancy are found at the 
same distance from active enhancer and promoter sites (Kruskal-Wallis test, p-value 
= 0.9914). Similar to the patterns observed above, there are significantly more CTCF 
sites in the proximity of enhancer elements than promoters, as evidenced by the 
increased density of all four type of cis/trans variation around enhancer elements 
(Figure 4.2e). There are, however, no statistically significant difference between any 
of these categories in terms of their enrichment around either promoters (Kruskal-
Wallis test, p-value = 0.6356) or enhancers (Kruskal-Wallis test, p-value = 0.1631) as 
their signal signature is identical, strongly peaking in and around the proximity of 
active regulatory elements.  
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Figure 4.2: Enrichment of cis/trans CTCF sites at proximal active regulatory 
elements suggest potential regulatory activity   
 
a Top: a schematic diagram of the different genomic features in which CTCF 
and other TFs occupancy was measured. The horizontal bar chart highlights the 
fraction at which different TFs are found in the respective genomic features 
derived from the most recent mouse genome assembly (GENECODE Release 
M23 (GRCm38.p6)[629]) . The vertical bar chart shows a breakdown of CTCF 
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sites genomic features by the type of cis/trans variant present at the binding 
site. b Bar chart displaying the fraction of TF sites bound to active regulatory 
elements, based on co-localisation with histone modifications (see Methods). c 
Proportional bar charts illustrating the fraction of TF locations at promoters (P) 
and enhancers (E), broken down by their type of regulatory variant present at 
the binding sites. The widths of bars are based on the overall proportion of 
binding sites in each category (A). The fractions of cis/trans categories 
localisation in promoters (P) and enhancers (E) for the liver-specific TFs were 
derived from a random selection of two replicates for each TF. d A graph of the 
empirical cumulative density function for the distance between a cis/trans CTCF 
site and its nearest, non-overlapping regulatory element. The two horizontal 
dashed grey lines indicate the fraction at which 50% and 95% of all cis/trans 
CTCF sites are at in relation to their distance to the nearest regulatory element 
defined by the histone modifications present. e Density plots of the distribution 
of CTCF site according to their distance to the nearest non-overlapping 
regulatory element, by their cis/trans category. The boxplots under each curve 
show the variation in distance toward their respective regulatory element. 
 
4.3.3 Evolutionary young CTCF binding exhibit the same 
genomic profile of conserved sites 
 
We next looked at whether evolutionary young CTCF sites show hallmarks of 
possible functionality though binding in the vicinity of active regulatory elements 
similar to the set of CTCF sites in BL6 and CAST characterised by subspecies-specific 
SNVs with cis/trans binding variation. To establish the potential for functional impact 
of subspecies-specific CTCF binding sites, we examined the genome-wide distribution 
of these sites with relation to the genomic characteristics of their occupancy. 
Consistent with previous estimations[639], 41 to 44% of CTCF binding within both 
musculus-common and BL6-specific sites, respectively, is intergenic, and the remainder 
takes place within promoters and genebodies (where it occurs mostly in intronic 
sequences) (Figure 4.3a). Only marginal differences were found between the two 
categories of evolutionary conservation, with the BL6-specific sites 50% depleted in 
exonic sequences (with corresponding gains in intergenic and intronic sequences), 
compared to their musculus-common counterparts (Figure 4.3a).  
 
To probe further into the potential for functional roles of these evolutionarily 
distinct CTCF binding classes, we examined the proximity of these musculus-common 
CTCF sites and subspecies-specific sites, either tissue-restricted or tissue-shared, to 
transcription start sites (TSSs), calculating the distance from each CTCF binding site 
to the transcriptions start site (TSS) of the nearest downstream gene. We observed a 
large proportion of sites near the TSS (median = -11 kb), regardless of the type 
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evolutionary status or tissue-sharedness of the binding site (Figure 4.3b). The majority 
of the remaining sites lie further away from the TSS, more than 100 kb upstream. 
CTCF binding also appears to be depleted directly downstream of the TSS within the 
gene body. Further analysis looked at CTCF binding site positions relative to the 
nearest downstream gene. Results revealed an almost identical genomic location 
distribution, regardless of evolutionary conservation, with the largest portion of CTCF 
binding more than 10 kb from the nearest downstream genes (Figure 4.3c). 
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Figure 4.3: BL6-specific binding shares the same characteristics of musculus-
common CTCF binding. 
 
a Pie chart of the fraction at which musculus-common (shared with CAST) and 
BL6 subspecies-specific CTCF sites are found within the most common gene 
features (intergenic, promoters, TSSs, exons and intronic). b Density plot of the 
position of CTCF binding sites  in terms of their evolutionary/tissue-specificity 
based on their distance to the transcription start site (TSS) of the nearest 
downstream gene. The black square inset display the median point of the data. 
c Bar plots of the fraction of CTCF sites in (a) in incremental distances to their 
nearest downstream genes. d Bar chart displaying the proportion of CTCF sites 
in terms of their evolutionary/tissue-specificity at active promoters (H3K4me3 
or H3K4me3+H3K27ac) and enhancers (H3K27ac only) against a matched set 
of random, non-overlapping genomic regions. e Density plot of the distance from 
musculus-common and BL6-specific CTCF sites to their nearest, non-overlapping 
active regulatory region in a ±100 kb window from active regulatory elements, 
separated by the type of regulatory element compared to the distribution of 
random genomic regions around the same elements. The bar chart inset shows 
the type of regulatory element that is closest (but non-overlapping) to musculus-
common and BL6-specific CTCF sites. f Empirical cumulative density function 
plot for the distance between CTCF binding sites and their nearest, non-
overlapping regulatory element, separated based on their evolution/cell-type 
specificity. The horizontal dashed grey line indicates the fraction at which 75% 
of all CTCF sites are at in relation to their distance to the nearest regulatory 
element, with the vertical marking that distance to 50kb. The purple line 
indicates the distance from the random set of regions (e) to their nearest non-
overlapping regulatory element. 
 
The proximity of CTCF sites to regions upstream of TSS indicate that these 
sites may elicit their functional impact by acting on/collaborating with active histone 
modifications near these regions of regulatory activity. We mapped the genome-wide 
co-localisation of all CTCF binding sites with genomic locations characterised by the 
presence of the H3K4me3 and H3K27ac histone modifications. As observed previously 
with cis/trans-influenced CTCF sites, results revealed that, regardless of evolutionary 
class or tissue-specificity, CTCF occupancy does not often coincide with markers of 
gene expression (Figure 4.3d). Only 12-13% of all CTCF binding sites bind within 
promoter sequences (H3K4me3), and a further 3-6% co-bind in regions characterised 
by the presence of the H3K27ac histone modification alone, marking active enhancers. 
BL6 tissue-shared sites appear to be slightly depleted in enhancers, but these 
differences were not found to be significant (χ2 test, p-value > 0.05). Despite marginal 
CTCF occupancy within these regulatory elements, it is still significantly higher than 
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would be expected for a chromosome-matched, non-overlapping set of genomic regions 
of the same length and number (Binomial test with Bonferroni correction, all p-values 
< 0.001). 
 
Although CTCF sites do not show substantial co-occupancy within active 
enhancers/promoters, they could still bind sufficiently close to these elements to allow 
them to play a role in gene regulation. We determined the distance from each of these 
CTCF sites to their nearest, non-overlapping active regulatory element using the two 
markers above. We found that the majority of these sites occupy sequences located 
significantly closer to active regulatory elements, with median distances of 22.7 kb and 
17.7 kb to their nearest promoter and enhancer, compared to 105.6 kb and 75 kb, 
respectively, for a matched set of randomised genomic sequences (Figure 4.3e). This 
statistically significant difference in proximity between promoters and enhancers (Man 
Whitney U test, p-value = 0.02) could be explained by the enhancers greater genome-
wide number, making it more likely for a CTCF site to be nearer to an enhancer than 
a promoter. On the other hand, promoters are the nearest regulatory element to 52% 
of CTCF binding sites, both musculus-common and BL6-specific (59% in BL6 tissue-
shared sites). Enhancers are the closest to CTCF in 29-30% of sites, with slightly fewer 
(25%) BL6 tissue-shared sites near enhancers (4.3E bar chart).  
 
Stratifying the distance to the nearest regulatory element by the evolutionary 
class and tissue-specificity of CTCF binding revealed that BL6 tissue-shared sites lie 
the furthest away from active regulatory regions (median distance = 30.2 kb) 
compared with either musculus-common or all BL6-specific sites (20.9 and 19.8 kb 
respectively). Differences between these categories; however, were not large enough to 
be deemed significant in either promoter (Kruskal-Wallis test, p-value = 0.6552) or 
enhancer (Kruskal-Wallis test, p-value = 0.9451). 75% of all CTCF sites were found 
within a 50 kb distance of regulatory element (Figure 4.3f). Taken together with the 
results from 4.3.2, the results indicate the potential for even evolutionarily young, 
tissue-shared or otherwise, CTCF sites to be involved in regulating gene expression in 
cooperation with exiting active cis-regulatory elements. They also provide evidence 
that subspecies-specific CTCF binding perform similar functions to the more conserved 
musculus-common sites. 
 
4.3.4 Cis/trans CTCF occupancy is strongly TAD-
boundary associated 
 
CTCF binding has repeatedly been reported to contribute to the formation 
and maintenance of topologically-associated domains (TADs), by colocalising with the 
cohesin protein complex[623, 640]. We next set out to investigate whether regulatory 
variation in CTCF occupancy brought by cis/trans-acting variants in the binding sites 
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influences the binding of CTCF near TAD boundaries. CTCF binding sites under 
influence of regulatory variation acting in cis/trans tend to cluster around TAD 
boundaries, reaching their highest density just up/down stream from the boundary 
(Figure 4.4a). The proportion of TAD boundary-associated CTCF sites, defined as 
CTCF sites bound within a 50kb window of the nearest TAD boundary[575], is higher 
than that of any of the three other liver-specific TFs (40% compared to 20% only in 
CEBPA, FOXA1 and HNF4A, binomial test with Bonferroni correction, p-value < 
2.2e-16), or their non-cis/trans counterparts (26%) (binomial test, p-value < 2.2e-
16)(Figure 4.4a). The median distance from any cis/trans-influenced CTCF site to its 
nearest TAD boundary is 79.6kb, over 30% shorter than the median distance of any 
liver-specific cis/trans TF sites (112-116kb). These differences were observed to be 
statistically significant (Kruskal-Wallis test, p-value < 2.2e-16).  
 
A breakdown of cis/trans CTCF sites distribution with regards to their 
proximity to TAD boundaries revealed that there is no observed difference between 
any of the four regulatory categories of CTCF binding and their clustering around the 
TADs. About 39-40% of all cis/trans CTCF sites were found to be TAD-boundary 
associated, regardless of their regulatory category, and their overall frequencies 
reflected their general contribution to the total number of CTCF sites, with cis and 
cistrans sites being the most abundant (Figure 4.4b top). There was no statistically 
significant difference in the distribution of these sites near TAD boundaries (χ2 test 
without Yates correction, p-value > 0.05). A closer inspection of the immediate 
neighbourhood (10kb up/downstream) of the TAD boundary for the regulatory 
composition of CTCF binding sites confirmed the previous observation. All four 
categories are proportionally bound in numbers reflecting their contribution to the 
total pool of cis/trans-acting variants on CTCF binding (Figure 4.4b bottom). No 
statistically significant differences were observed between categories bound in 1kb 
incremental bins around the TAD boundary (χ2 test without Yates correction, p-value 
= 0.78) 
 
We next evaluated the abundance of TF binding sites under cis/trans acting 
variation in TADs to understand the pattern of their genomic distribution and the 
possibility of clustering in regulatory modules. Out of a total of 3643 mouse liver 
derived TADs, 368 (10%) were free from any CTCF binding, fewer than any of the 
three other liver-specific TFs (17%-25%) (Figure 4.4c). However, this parity is 
significantly reduced in TADs harbouring a single TF binding site. TADs containing 
more than 1 TF binding sites are strongly enriched for the binding of CTCF in 
comparison with other TFs, although this effect decreases as more TF sites are bound 
in TADs until this difference is diminished (at about 7-9 TF binding sites per TAD). 
This trend is reversed for all TADs with 10 or more TF binding sites, wherein liver-
specific TF occupancy becomes the most abundant (Figure 4.4c). All these differences, 
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except in the case of TADs with 7-to-9 sites, were found to be statistically significant 
(χ2 test with Bonferroni correction, p-value < 0.0001).  
 
 
 
Figure 4.4: Cis/trans CTCF occupancy is strongly TAD-boundary associated 
 
a Density plots illustrating the relative enrichment of cis/trans TF binding sites 
within a ±100 kb window up/downstream from the TAD boundaries. The non-
cis/trans CTCF sites also shown to illustrate the difference in TAD-boundary 
association between CTCF sites with SNVs and those without. b Frequency 
polygons (Top) showing the density of four different categories of cis/trans 
variation in CTCF binding sites around TAD boundary. The higher spikes in 
density at ±100 kb from the TAD boundaries are the results of pooling together 
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all sites at a distance of more than 100 kb up/downstream from the nearest TAD 
boundary. The stacked bar chart (Bottom) represents the absolute frequencies 
of the different cis/trans categories of CTCF sites at 1 kb intervals of the TAD 
boundary.  c Bar chart of the number of cis/trans TF binding sites found in 
individual TADs. The counts for all TADs with 10 or more TF binding sites 
were pooled together. The strip (below) denotes the level of statistical significance 
for the comparison between all TFs (all χ2 test with Bonferroni correction, p-
values > 0.004 considered not significant (NS)). d Bar chart of the number of 
observed cis/trans TF binding sites (c) compared to the number of sites expected 
under the assumption of random distribution in single TADs. The counts for all 
TADs with 10 or more TF binding sites were pooled together. The strip (below) 
denotes the level of statistical significance for the comparison between observed 
and expected counts (all binomial test, with Bonferroni correction, p-values > 
0.001 considered not significant (NS)). 
 
These differences in TF binding in TADs were additionally found to be either 
more (or less) than expected based on the assumption of random distribution in 
genomic sequences and TAD sizes (Figure 4.4d). There were universally more TADs 
with no TF binding for any of the four factors than would be expected, and 
significantly fewer than expected in 1-3 per TAD. As mentioned earlier, CTCF was 
more abundant in smaller numbers per TAD (4-6) than either expected or compared 
to the other TFs. In TADs with 10 or more TF binding sites, liver-specific TFs are 
found in higher abundance than expected, whilst CTCF frequencies are within the 
range of their background genomic distribution.  
 
This indicates that CTCF, a tissue-wide factor with highly conserved binding 
across cell-types, tend to bind across the genomic landscape of TADs, which in turn 
dilutes the number of sites found per TAD. Tissue-specific TF occupancy, on the other 
hand, favour clustering within TADs that harbour the regulatory modules they bind 
to activate gene expression. 
 
4.3.5 Evolutionary young, tissue-shared binding actively 
associates with cohesin. 
 
The strong association observed between cis/trans CTCF sites with TAD 
boundaries suggests these sites contribute to the regulation of chromatin folding and 
overall genomic architecture. To investigate whether evolutionary young sites exhibit 
the same preference to TAD-boundary association as their subspecies-orthologous 
counterparts, we next evaluated the possible contribution of different evolutionary 
classes of CTCF to large-scale 3D genome structure. We leveraged available HiC 
experiments that determined the position of topologically-associated domain (TAD) 
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boundaries in liver[238] to determine the distribution of each type of CTCF binding 
site to the nearest TAD boundary. Apart from known CTCF enrichment around the 
TAD boundaries, the majority of CTCF binding sites are located well inside the TADs 
and further away (> 100 kb) from the boundaries themselves (Figure 4.5a).  
 
At all distances from the TAD boundary, both the frequency and the 
approximate ratio of musculus-common, BL-specific and tissue-shared CTCF binding 
sites are the same (Figure 4.5a bar plot). This ratio holds also true in 1 kb increments 
from the TAD boundaries. The musculus-common sites are expectedly[312] enriched 
around the TAD boundaries compared to their subspecies-specific counterparts 
whether or not they are tissue-shared (Figure 4.5a). Thus, tissue-dependence of BL6-
specific sites does not affect their distribution around the TAD boundaries. These 
results suggest that although TADs do not vary across tissues[235], some TAD 
boundaries may, at least partially, be maintained by tissue-specific CTCF binding. 
 
Increased occupancy of CTCF sites around TAD boundaries is reportedly 
accompanied by co-localising with cohesion-protein complex to form chromatin 
loops[80, 641]. CTCF-associated cohesin ring formation is known to be instrumental 
in chromatin loop formation and maintenance[219]. Upon binding to the two ends of 
a transcription regulatory unit, CTCF recruits cohesin to aid in the formation of a 
chromatin loop (Figure 4.5b diagram). To elucidate potential functional involvement 
of these CTCF elements, we determined the level of co-location of CTCF with cohesin 
complex proteins in BL6 mice. This was done using ChIP-seq data from adult mouse 
liver in two biological replicates for three proteins from the cohesin complex: RAD21, 
STAG1 and STAG2[362].  
 
Co-location of CTCF and cohesin was determined using a minimum stringent 
condition of at least two cohesin subunits whose binding overlaps the same genomic 
segment binding CTCF. All classes of CTCF binding sites show cohesin co-location 
with the highest level (approximately 80%) observed for musculus-common CTCF 
sites. BL6-specific CTCF sites co-localised with a significantly reduced level of cohesin 
such that only half of these sites showed signal from at least two cohesin subunits (p-
value = 2.8x10-9). However, of those BL6-specific sites, the tissue-shared subset (i.e. 
the ones bound in all five tissues in Figure 2.4g) exhibited cohesin co-localisation at 
essentially the same level as the set of all CTCF binding sites, and only slightly less 
than that of the musculus-common sites (Figure 4.5b).  
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Figure 4.5: Recent BL6 tissue-shared CTCF binding efficiently recruits cohesin 
and is associated with higher ChIP-signal 
 
a Plot of the distance from each of the CTCF binding sites to the nearest 
up/downstream topologically-associated domain (TAD) boundary. The outline 
box indicates the region between -10 kb and +10 kb from the nearest TAD 
boundary. The bar chart below shows the proportion of CTCF sites in this region 
in 1 kb intervals based on their evolutionary/tissue-specificity type. b Bar chart 
of the recruitment of cohesin-complex subunits by CTCF. The x-axis shows the 
percentage of CTCF binding sites in which a cohesin-complex signal was found. 
The schematic diagram next to the bars is an overview of the structure of the 
Cohesin-complex. The asterisks indicate the significance of Chi-square goodness-
of-fit test (p-value = 2.8x10-9). c Line plot of CTCF-cohesin co-occupancy at 
matched tiers of signal intensity (reads/site) for CTCF binding sites. All 
categories of CTCF where within a distinct range of signal for each bin, even 
though their numbers were variable. Co-occupancy was calculated as the number 
of CTCF sites that co-localise with a 2-subunit cohesin-bound region. d Bar plot 
of the percentage of BL6-specific sites (subspecies-specific and the tissue-shared 
subset) present within each signal tier from (c), from the total set of CTCF sites 
of that type. e Box plot of the variation in signal intensity across the different 
types of CTCF binding sites. f Violin plots of the kernel density of CTCF binding 
sites according to the length of the binding site (left) and the depth of sequencing 
(read/bp) of the different evolutionary categories of CTCF. g Plot of the number 
of BL6-specific tissue-shared CTCF binding sites in single TADs. 
 
This increased level of cohesin recruitment coinciding with BL6 tissue-shared 
binding sites in comparison to their tissue-variable counterparts hints at increased 
involvement in the formation of chromatin loops, and perhaps important functions. 
The same pattern was also observed for all types of CTCF binding sites with three 
cohesin subunits instead of two, albeit with reduced ratios (Figure 4.5b yellow bars). 
This could be attributed to the uniformly lower ChIP enrichment from the cohesin 
subunit STAG1 which limited our sensitivity to detect three cohesin subunits.  
 
We next asked whether the differences in cohesin recruitment in BL6 tissue-
specific sites can be explained by lower overall CTCF ChIP signal enrichment of these 
sites. We determined CTCF cohesin recruitment at matched tier of ChIP signal 
intensities for all evolutionary/tissue classes of CTCF binding sites. At the top 10% of 
the signal, almost all CTCF sites are associated with cohesin recruitment to the DNA, 
regardless of the evolutionary or tissue-specificity of the binding site (Figure 4.5c). 
However, as signal decreases, CTCF-cohesin co-occupancy markedly decreases, 
particularly in BL6 tissue-specific sites which start to show accelerated reduced 
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recruitment at 30-40% of the signal.  At the bottom 10% tier of the signal, only 56% 
of musculus-common CTCF sites are associated with cohesin, and even fewer at BL6 
tissue-specific sites (38%). Curiously, cohesin recruitment for BL6 tissue-shared sites 
is generally intermediary between the former two, yet rises considerably at the last 
two tiers above both the total and musculus-common level of recruitment (Figure 
4.5c). This indicates that although reduced cohesin with lower ChIP signal is indeed 
stronger in BL6 tissue-specific, the effect does not quite register for the tissue-shared 
subset of subspecies-specific sites, remaining generally high even at low signal values. 
This observation, however, could be the result of the small number of CTCF sites in 
this particular category, especially at lower tiers of signal intensity.  
 
We further determined the proportions of these BL6-specific sites within each 
tier of signal intensity. The results revealed that only 2% of these sites (136) were 
found within the top 10% range of signal (Figure 4.5d), 82 of which (60%) transpired 
to be tissue-shared. The proportion of BL6-specific sites in subsequent tiers rose 
gradually, but over half of all subspecies-specific sites occupied the lower 20% range of 
the signal. On the hand, proportion of BL6-specific tissue-shared sites in the different 
tier of signal remained roughly the same, and even though they rose slightly towards 
the lower end of signal, that coincided with higher cohesin recruitment than all other 
classes of CTCF binding (Figure 4.5c). Furthermore, whilst BL6-specific tissue-shared 
sites make up over half the subspecies-specific CTCF sites in the top 40% range of the 
signal, their proportions quickly dwindle at the lower 50% range of the signal, and as 
the tissue-specific sites become more predominant, levels of cohesin recruitment lower.  
 
This is further evidenced by comparing signal values of CTCF binding across all 
three classes (Figure 4.5e). BL6 subspecies-specific sites have a significantly lower 
signal (median = 158 bp/read) than either musculus-common (451) and BL6 tissues-
shared sites (246.5) (Man Whitney U test, p-values < 2.2e-16 in comparison with 
both). These results were not affected by the size of the binding site, as both musculus-
common and tissue-shared sites have longer peak sequences (Man Whitney U test, p-
values < 2.2e-16) in spite of which they still exhibited higher depth of sequencing than 
their tissue-specific equivalents (Figure 4.5f). In sum, these results suggest that BL6 
tissue-shared are mostly responsible for heightened cohesin recruitment for subspecies-
specific CTCF sites. As the number of their tissue-specific counterparts start to 
increase at lower levels of ChIP signal, their association with cohesin-complex subunits 
is reduced.   
 
We investigated whether these BL6 tissue-shared CTCF-cohesin regions may 
participate in novel looping interactions and found no clear evidence. We speculated 
that BL6 tissue-shared CTCF-cohesin regions could act as novel loop anchors within 
established TADs and so limited our analysis to TADs with a minimum of two of these 
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regions. There were fewer than 100 such regions in the whole genome and more than 
half of the potential novel loop anchors are found in single sites per TAD (Figure 4.5g). 
We suggest that these sites are either stabilising existing TAD structures or maybe 
involved in intra-TAD domain loop formation. 
 
4.3.6 CTCF sites under cis/trans-acting variation highly 
co-localise with cohesin-complex proteins 
 
We followed up the analysis in 4.3.4 with an investigation of TF binding sites 
co-occupancy with 3 cohesin subunits, Rad21, STAG1 and STAG2, in sites 
characterised by variation in cis/trans in CTCF and the three liver-specific 
transcriptions factors (see section 4.3.5). The results confirm that CTCF sites under 
the influence of cis/trans regulatory variation strongly co-localised with cohesion-
protein complex subunits, with 90% of all sites (>13000) binding in a region where a 
minimum of two cohesin subunits bind (Figure 4.6a). Slightly fewer sites bind in 
regions characterised by the binding of 3 cohesin-subunits (slightly over 80%). The 
enrichment of cohesin-bound regions is distinctly weaker in liver-specific TFs, even 
though HNF4A does appear to show co-binding with a minimum of 2-subunit cohesin-
regions in 50% of its peaks (Figure 4.6a left). Liver-specific TF binding in cohesin-
complex regions was found to be associated mostly with cohesin-non-CTCF (CNC) 
sites invariably for all three TFs (Figure 4.6a right). This is consistent with previous 
reports of CNC enrichment at tissue-specific promoters and enhancers that function 
to maintain TF complexes at regulatory elements [224, 362]. 
 
Cis/trans CTCF site bound in cohesin-complex regions exhibit the same 
pattern of enrichment in the vicinity of TAD boundaries as seen in 4.3.4 (Figure 4.6b). 
The median distance from these sites to the nearest TAD boundary was found to be 
77.8 kb, only marginally shorter than the distance reported above. That is not 
unexpected as almost all cis/trans CTCF sites co-bind with cohesin subunits, thus the 
pattern of their binding should be comparable. This difference in distance to TAD 
boundary was found to be statistically insignificant (t-test, p-value = 0.1573). This 
pattern of enrichment near TAD boundaries invariably matched across the different 
categories of cis/trans CTCF sites, with no category showing any statistically 
significant difference (Kruskal-Wallis test, p-value = 0.2514) (Figure 4.6b). 
 
The results further indicate that the majority of all cis/trans CTCF sites that 
co-localise with cohesin-complex subunits are TAD-boundary associated (Figure 4.6c). 
Nearly 75% of sites in ±100 kb window from the TAD boundary are within a distance 
of 50kb up/downstream from the nearest TAD boundary, regardless of the type of 
cis/trans variation acting on the CTCF binding site. These results strongly suggest a 
role of these sites in the regulation and maintenance of TAD boundaries.  
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These CTCF-cohesin occupied regions are found near the base of the loop, 
whereby a convergent orientation of their motifs is generally preferred during looping. 
Looping of chromatin whereby the CTCF motifs at the base are in tandem orientation 
is also observed, albeit in reduced capacity [303]. We first investigated the enrichment 
of the canonical motif (M1) in cis/trans-influenced CTCF binding sites. Nearly 97% 
of these sites harbour one or more instances of the canonical CTCF motif within the 
peak sequence (Figure 4.6d). Two thirds of sites have only a single motif within the 
sequence. For peaks with more than one motif instance, the motif with the highest 
score/p-value was selected. 
 
In order to establish the orientation of CTCF motifs are the base of possible 
chromatin loops, we investigated the motif combinations between pairs of CTCF sites 
that co-localise with cohesion-subunits. We set a minimum distance of 5kb 
up/downstream from the nearest potential CTCF binding site. We were able to 
identify 7456 pairs of CTCF sites that met these criteria. The pie chart in Figure 4.6e 
shows a breakdown of the three possible combinations in these pairs of cis/trans 
CTCF-cohesin sites. Almost half (48%) the motif combinations of pair of cis/trans 
CTCF sites were in tandem orientation (++/--). A third of all pairs had a divergent 
motif combination pattern of (-+), i.e. the upstream CTCF motif was on the reverse 
strand, whereas its downstream counterpart was on the forward strand. Convergent 
motif combinations in neighbouring CTCF sites were found to be slightly in the 
minority (22%). The differences in motif combinations between the three different 
types were found to be statistically significant (χ2 test, p-value 0.011). 
 
Next, we looked at the distance between these CTCF binding sites to their 
nearest neighbour and the motif combinations they form. Tandem-oriented pair of 
CTCF motifs and those in divergent orientation were found to have shorter distances 
to their nearest potential pair than their convergent counterparts, which were found 
to have the furthest distance from their pairs (Figure 4.6f). These differences were 
found to be statistically significant between convergent pairs and both tandem and 
divergent pairs (Man Whitney U tests, p-values < 0.00001), but not between the latter 
two (p-value = 0.24) (Figure 4.6f). 
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Figure 4.6: TAD-boundary associated cis/trans CTCF occupancy is 
accompanied with cohesin-complex co-localisation  
 
a Bar chart (left) representing the proportion of cis/trans TF binding sites co-
localising with cohesin-complex regions characterised by the presence of 2-3 
subunits. The second bar plot (right) shows a breakdown of the type of cohesin-
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complex regions liver-specific TF sites (boxed) were found to co-localise with 
(CAC= cohesin-and-CTCF, CNC= cohesin-non-CTCF). b Density plot (left) 
showing the distribution of cis/trans CTCF-cohesin associated sites in terms of 
their distance to the nearest TAD boundary. The smaller density plot (right) 
offers a closer look at the ±100 kb window around the TAD boundary of the 
same distribution, separated by the type of cis/trans variant present in the 
CTCF binding site. c Empirical cumulative density function plot for the distance 
between a cohesin-associated cis/trans CTCF site and its nearest TAD 
boundary. The horizontal dashed grey line indicates the fraction at which 75% 
of CTCF sites in ±100 kb window from the TAD-boundary are within a ±50 kb 
distance, the vertical dashed grey line, for the 4 cis/trans categories of variation 
in CTCF sites co-localised with cohesin-complex subunits. d Bar chart of the 
number of instances the CTCF M1 canonical motif (in the panel above the graph 
area) was identified in the peak sequence of cis/trans CTCF sites. e Pie chart of 
the relative proportions of motif combinations between pairs of neighbouring 
cohesin-associated, cis/trans-influenced CTCF sites that are within a minimum 
distance of 5 kb from each other. f Boxplots of the distances of the CTCF sites 
from e their nearest CTCF site in kb by the motif combination they form. g 
Plot of the cis/trans categories of each pair of neighbouring (min. distance = 
5kb) CTCF binding sites. Ribbon size encodes the fraction of each category's 
association with the other categories in pairs. The outermost circle shows the 
relative proportions of each combination for the total number of sites in each 
category separately.   
 
These differences, however, did not translate to differences in the proportion 
in the various categories of CTCF binding sites under cis/trans variation in terms of 
their combinations (Figure 4.6g) or their distances to the nearest CTCF sites. The 
proportions of combinations of CTCF sites reflected their overall proportions, with cis- 
and cistrans-variation in CTCF binding being the most common either in 
combinations within the same category, between them, or with the other two categories 
forming the majority of pairs of neighbouring sites. Contributions from the other two 
categories were also equivalent to their overall proportions. 
 
4.3.7 Tissue-shared binding clusters closer to regions of 
CTCF binding and favours tandem motif orientation. 
 
As explained above, a pair of CTCF bound to their sites in the favourable 
convergent orientation of their motifs recruit cohesin subunits to the base of the loop, 
although chromatin loop of tandemly oriented CTCF motifs is also reportedly 
observed. To determine the potential for the evolutionarily young sites to take part in 
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such formations, we analysed motif content and orientation of these cohesin-associated 
CTCF sites.  
 
We scanned musculus-common and BL6-specific (tissue-shared and tissue-
specific) CTCF sites for presence of the M1 canonical binding motif (Figure 2.1b). 
Whereas only 5% of all musculus-common sites have 0 instances of the motif within 
their sequence, (9%) did not carry the motif in BL6 tissue-shared sites, and almost 
15% of BL6 tissue-specific sites lack the canonical motif in their peak sequence (Figure 
4.7a left). These differences were statistically significant compared to the musculus-
common set (Binomial test, p-values 7.131e-07 and < 2.2e-16 for tissue-shared and 
tissue-specific respectively). We next investigated these 0-motif sites for the presence 
of 5 alternative CTCF motifs (Figure 4.7a right) obtained from the CTCFBSDB 2.0 
database[642]. 40% of BL6-spcific tissue-shared sites harboured one or more of 
alternative motifs in their sequences, yet tissue-specific sites again showed a depletion 
in motif content with only a third of sites having any alternative motifs at all within 
their CTCF binding sequences (Figure 4.7a middle). For all subsequent analysis, the 
closest canonical motifs to the peak's summit were only selected. 
 
Whereas motif orientation is expectedly invariable among the different categories 
of CTCF binding (musculus-common, BL6-specific tissue-shared and tissue-specific), 
the distance from the closest motif to the summit significantly differs in BL6 tissue-
specific sites, whereby ~54% of sites have their motif further away from the summit 
(χ2 test, p-values 1.94926E-78 and 1.14951E-11 compared to musculus-common and 
BL6 tissue-shared respectively) (Figure 4.7b). The increased distance between the 
summit and the motif from musculus-common to BL6 tissue-specific sites coincided 
with a corresponding drop in motif score (Figure 4.7c). These differences were all found 
to be statistically significant in both overall and one-to-one comparisons (Kruskal 
Wallis p-values all < 2.2e-16 for motif score and distance. Man Whitney U tests, p-
values range from 5.257e-08 to < 2.2e-16).  
 
We investigated the motif combinations between pairs of cohesin-associated 
musculus-common and BL6-specific (tissue-shared and tissue-specific) CTCF sites to 
determine the orientation of CTCF motifs are the base of possible chromatin loops, 
using a minimum distance of 5kb from the nearest CTCF binding site. Based on these 
criteria, musculus-common sites were found to form pairs with their nearest CTCF 
sites in the same frequency as expected based on their overall proportion of all CTCF 
binding sites (Figure 4.7d). 
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Figure 4.7: Motif characteristics of CTCF binding in sites with 
evolutionary/tissue-specificity variation  
 
a Bar plot (left) of the proportions of musculus-common and BL6-specific (tissue-
shared and tissue-specific) CTCF binding sites lacking the canonical M1 motif 
in their peak sequence. The asterisks indicate the significance of Chi-square test 
(p-value < 0.0001) for BL6 Tissue-shared sites versus the other two categories. 
The smaller bar plot (middle) shows the proportion of those 0-motif BL6-specific 
CTCF sites (boxed) in which one of the other CTCF motifs from CTCFBSDB 
2.0 (rightmost) were alternatively identified. b 100% bar plots of the fraction of 
musculus-common and BL6-specific (tissue-shared and tissue-specific) CTCF 
sites according to the distance of their motifs to the peak summit (top) and the 
motif orientation (bottom).  c Box plots of the distribution of non-overlapping 
motifs (>0) distance to the peak summit in bp (left) and the motif scores as 
calculated from the information content (PWM) of the canonical 
motif[508](right) according to their evolutionary/cell-type status. d Donut charts 
of the evolutionary/tissue-specificity type of CTCF sites that cohesin-associated 
CTCF sites are nearest to (min. distance 5 kb). The outer circle indicates the 
observed proportions for the identities of the other cohesin-associated CTCF sites 
in the pairs, compared to the expected proportions (inner circle). e Bar plot 
(top) of the relative proportions of motif combinations between pairs of 
neighbouring cohesin-and-CTCF sites that are within a minimum distance of 5 
kb from each other. The circles (bottom) display a breakdown of each motif 
combination observed based on the evolutionary status of the neighbouring 
CTCF sites, with the number of sites per category denoted inside the circles. The 
size of the circles indicates the proportion of neighbouring CTCF sites motifs in 
tandem, divergent and convergent orientations, respectively. f Empirical 
cumulative density function plots (left) for the distance from cohesin-associated 
CTCF site and their nearest cohesin-associated CTCF counterparts, separated 
by the motif combination (e). The vertical dashed grey line indicates the 5kb 
minimum distance threshold used for this analysis. The box plots (right) show 
the distribution of these distances for each motif combination (e). 
 
The majority of pairs were between two musculus-common sites (80%). BL6-
specific; however, differed from those expected frequencies, appearing to be nearer to 
other BL6-specific sites, regardless of their tissue-specificity, significantly more often 
than expected. This was markedly so in BL6 tissue-shared sites in which 6 times as 
many neighbouring sites were also BL6 tissue-shared (6.47% vs 1.04% expected) based 
on their fraction of the total number of CTCF sites (Figure 4.7d). These proportions 
did not change when the threshold of 5kb minimum distance was relaxed, remaining 
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almost identical between these two classes. The proportions of motif combinations 
between neighbouring CTCF binding sites, regardless of evolutionary/tissue-specificity 
or cis/trans regulatory variation in the binding sequence, appear to be global features 
of CTCF binding, and could indicate a deeper evolutionary mechanism driving this 
pattern of motif orientation they take in short- or long-range. 
 
Like CTCF sites characterized by cis/trans variation, motif combinations 
between neighbouring sites were in tandem orientation in 51% of all pairs of CTCF 
sites regardless of their evolutionary origin or tissue-binding pattern (Figure 4.7e top). 
Pairs of motifs in the convergent orientation were found to be the least common (22%). 
These differences were found to be statistically significant (χ2 test, p-value < 0.0001).  
This disparity in motif orientation, on the other hand, varied among pairs based on 
the evolutionary origin of their sites (Figure 4.7e bottom). Whilst the overall pattern 
held true for pairs of musculus-common sites, pair containing one or two BL6-specific 
CTCF binding sites were found to either equally be in convergent and divergent 
orientation (in mixed pairs) or even have more motif combinations in the favourable 
convergent orientation (in BL6-specific only pairs). Notably, the proportion of tandem 
motif pairs in those BL6-specific only motif pairs is much higher (55%). Further 
analysis of the motif combinations of these pairs of cohesin-CTCF regions revealed 
that, similar to the pattern observed in cis/trans CTCF sites, tandem/divergent motif 
orientations are associated with closer pairs of CTCF sites (Figure 4.7f). Motifs in 
convergent orientations, on the contrary, were further apart (Man Whitney U tests, 
all p-values < 0.00001).  
 
Taken together, the combination of convergent neighbouring CTCF pairs of sites 
being further away from each other and occurring only in 22% of all possible motif 
combinations suggest that chromatin loop formation tend to form between non-
neighbouring sites at farther distances. These observations were consistent for all types 
of CTCF sites, regardless of their evolutionary age, tissue-specificity or the regulatory 
variation influencing its binding. 
 
 
4.4 Discussion 
 
4.4.1 Repeat content in cis/trans-influenced CTCF sites 
 
The CTCF canonical binding motif is known to be carried over by transposable 
elements in many mammalian lineages[384, 409]. Comparative genomics approaches 
have shown that lineage-specific CTCF occupancy in mammals is linked to species-
specific tRNA-derived SINE expansion. SINE B2 elements have expanded the CTCF 
binding sites into hundred (in canines) to thousands (in rodents) of new loci in many 
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mammalian lineages[238, 269, 643]. However, all previous work has been done at large 
evolutionary distance between the species involved. For example, Schmidt et al.'s work 
reported waves of SINE-driven expansion of the CTCF  binding sites between species 
separated by 80 million years of divergence time (from canines to rodents and 
primates)[269].  
 
In this thesis, we investigated this phenomenon in two subspecies that diverged 
1 million years ago. This provided us with a unique opportunity to study CTCF 
evolution by SINE-driven expansion in short evolutionary time. Our analysis of 
subspecies-specific binding of CTCF in two closely related mice subspecies have 
confirmed previous findings, but more importantly, have further provided evidence of 
evolutionary-recent SINE B2-B4 expansion activity in the murine lineage that may 
well still be ongoing. Results from Chapter 2 have shown that subspecies-specific TE-
derived CTCF binding is almost exclusively associated with SINE B2-B4 elements. 
This is strikingly different from tissue-specific TE-derived TF (CEBPA, FOXA1 and 
HNF4A) binding in which various superfamilies have played part in contributing to 
either conserved or divergent TF binding. Though it has been reported that particular 
TE superfamilies/families drive for the binding of distinct TFs[387], we show here that 
this process has at least been recently active even for tissue-specific TFs in these two 
subspecies. TE-derived tissue-specific TF occupancy was observed in a wide range of 
TE superfamilies, both in subspecies-specific sites and those characterised by 
informative SNVs that exhibit binding variation between the two subspecies.  
 
Nevertheless, the strong enrichment of SINE B2-B4 elements in CTCF 
subspecies-specific binding sites show equal contributions of TE superfamilies 
(particularly SINEs) to that of musculus-common binding sites despite significant 
differences in fraction of binding sites within TEs in general. This supports the idea 
that the SINE B2-B4 enrichment we observed in evolutionary-young CTCF sites is 
not the result of an acceleration of the process of TE expansion since the divergence 
of BL6 and CAST, but rather a continuation of that rodent-specific process that 
predates the split in their lineage. It is worth noting that any ancient expansion might 
be undetectable by the methods available to us. Furthermore, some of the musculus-
common sites are not only conserved between the two subspecies, but given the body 
of knowledge on CTCF evolution, could also include sites conserved even deeper 
throughout mammalian lineages. Therefore, the SINE repeat content of these 
musculus-common sites may have been underestimated as any SINE-derived elements 
in the binding sequence may have diverged too much to be detected by repeat masking 
algorithms. 
 
Further evidence to recent expansion is provided by analysis of relative age of 
SINE repeats in both musculus-common and BL6-specific binding sites. SINE B2-B4 
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repeats in BL6-specific sites are much more recent than both musculus-common sites 
and random genomic background, whereas SINEs in musculus-common sites belong to 
an expansion event that had taken place much earlier based on their higher sequence 
divergence. Furthermore, most of these SINE-derived BL6-specific sites sequences are 
almost completely covered by SINE repeat elements. Complete masking by SINE 
repeats could also be a by-product of the small size of BL-specific binding sites, 
particularly those that are tissue-specific (Figure 4.5f).  
 
On the other hand, CTCF sites characterised by the presence of cis/trans 
regulatory variants in BL6, despite harbouring distinctive SNVs to their CAST 
counterparts, show a repeat enrichment pattern that most closely resembles that of 
musculus-common CTCF sites. Whilst the overall proportion of various TE 
superfamilies in their sequences is similar to the one discussed above, the fraction of 
binding sites that are enriched for repeat elements is lower than in non-cis/trans CTCF 
sites. SINE B2-B4 elements are again the most predominant type of repeats, but their 
contribution to the sequence of binding site is 10% lower than in non-cis/trans sites. 
The reduction in repeat content of cis/trans CTCF sites, compared to SNV-free sites, 
was observed in all superfamilies of TEs, and for all regulatory categories of cis/trans 
variants equally. 
 
This was significantly different to liver-specific TFs. First, the most represented 
TE superfamily in their binding sites were also SINEs (except for CEBPA), exhibiting 
a marked two-fold enrichment to the genomic background (Figure 4.1a).  They were 
closely followed by LTRs. This is not unexpected, as explained earlier, as TE-derived 
TF occupancy is driven by different TEs in TF-specific manner. Unlike CTCF, 
however, cis/trans-influenced binding of liver-specific TFs was generally associated 
with higher enrichment in repeat elements than their non-cis/trans counterparts 
(except for FOXA1). Nonetheless, the proportions of the different TE superfamilies 
remained roughly the same between cis/trans and non-cis/trans sites across all TFs.  
 
The reduction in repeat content enrichment in cis/trans CTCF sites in 
comparison to SNV-free sites could be the result of BL6-specific sites in the latter set, 
contributing their previously-established (Chapter 2) higher repeat content. Their 
higher enrichment for TEs in comparison to their non-cis/trans counterparts shows 
the opposite pattern, and could indicate an underlying mechanism by which TEs have 
driven the particular occupancy of these TFs between BL6 and CAST. The binding of 
these TFs is far less conserved between these subspecies than CTCF[394, 621]. 
However, cis/trans sites for these TFs are, by definition, conserved in both orthology 
(alignability of the sequence between the two subspecies) and occupancy (conserved 
binding) (only 3-6% of sites show lineage-specificity, see Chapter 3). A possible 
explanation could be that these TE-derived cis/trans sites were the results of older TE 
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activity that had created these sites, which subsequently underwent sequence 
divergence and acquired SNVs.  It is worth mentioning that regardless of the 
differences described above for CTCF and the liver-specific TFs, the repeat content 
across all cis/trans regulatory categories was similar and corresponded to their overall 
proportions of cis/trans sites. 
 
Like musculus-common CTCF binding sites, cis/trans-influenced TE-derived 
CTCF binding was observed to appear in SINE elements belonging to an older cluster 
of TE expansions. One possibility is that newer SINEs are less likely to have 
distinguishing SNVs due to the shorter evolutionary time available for them to 
accumulate over the sequence of SINE elements. Another explanation could be that 
non-SINE CTCF sites are more likely to have SNVs as their SINE-containing 
counterparts are resistant to mutation due to their ongoing transposon activity. A 
recent report proposed that TEs could take advantage of CTCF loop-forming activity 
to propagate using the host’s transcriptional machinery and integrate into 
genome[644]. Another suggested mechanism involves the  association of CTCF and 
double strand breaks repair to allow TEs to insert themselves in the genome[645]. 
Perhaps introducing sequence variants represses SINEs ability to transpose effectively, 
leading to the absence of cis/trans variants in recent active SINEs. 
 
Prominent TE enrichment in CTCF sites, particularly in subspecies-specific 
sites, along with the well-established role of CTCF in chromatin loop anchoring is a 
potential major mechanism for introducing novel higher order chromatin structures. 
The introduction of CTCF binding sites to new loci via the action of TEs have the 
potential to divert CTCF from more conserved binding sites, leading to the formation 
of novel loop contacts. There is evidence that CTCF binding divergence strongly 
contributes to such a mechanism and SINE-derived CTCF sites have been observed 
to concentrate at chromatin loops anchors in mouse[219, 238].  
 
In sum, CTCF occupancy evolution in short evolutionary time appear to be 
considerably attributed to SINE-derived TE insertions that transfer the CTCF binding 
motif into novel loci. This wave of CTCF binding expansion evidently occurred after 
the divergence of the two subspecies and may yet still be ongoing. Shared CTCF 
binding, though enriched for SINE repeat elements compared to liver-specific TFs or 
genomic background, appear to be the result of a more ancient expansion. This held 
true for both sets of shared CTCF binding sites whether in musculus-common sites, or 
the subset of shared sites with SNV-derived cis/trans variation in binding. 
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4.4.2 CTCF occupancy at active regulatory elements 
 
Transcriptionally active regions in the genome are nucleosome-free, hence are 
highly accessible when the cells are in interphase[646]. There is accumulating evidence 
that these regions are enriched for intra-TAD CTCF binding, particularly in enhancer 
regions [328, 647]. Activating transcription alone has been shown not to be sufficient 
to result in chromatin insulation, and promoter-enhancer interactions and specific TFs 
binding, or preceding chromatin conformation changes were suggested to likely 
contribute to enabling gene expression at specific loci and creating insulation[220]. 
Recent results proposed the coupling of cohesin loading to lineage-appropriate 
enhancers and specific genomic locations of CTCF binding  to contribute to cell-type-
specific control of genome topology[648].   
 
Our analysis showed that CTCF exhibits a preference to bind in intergenic and 
intronic regions rather than protein-coding sequences or their upstream regulatory 
elements. This binding pattern is similar across all aspects of CTCF binding 
investigated in this chapter. Evolutionary young BL6-specific sites had a similar 
pattern of genome-wide localisation within gene features as musculus-common sites. 
Additionally, cis/trans regulatory variation in CTCF occupancy did not produce any 
discernible differences across any of their categories in this regard.  
 
All BL6 CTCF binding sites, regardless of their evolutionary class, were found 
to be bound near the same distance to TSSs and downstream genes, mostly just 
upstream. This is supported by a recent study demonstrating that CTCF sites cluster 
are significantly closer to TSSs[575]. Distant (in relation to TSS) CTCF binding tends 
to be more common far upstream than downstream of gene bodies. This could be 
reconciled with the finding that an RNA strand can bind to and gather multiple CTCF 
protein molecules near cognate binding sites (the observed clusters of CTCF near 
TSSs), improves the search for targeted binding sites and enhances the chances of 
CTCF binding to its sites[649, 650].  
 
These similarities in binding patterns in gene features extend to their co-
localisation with histone modifications predictive of active regulatory activity in the 
liver. CTCF does not appear to co-bind active regulatory regions as much as liver-
specific TFs. This makes sense in light of the known biology of CTCF and these liver-
specific TFs. CTCF is a genome-wide master regulator that is involved in a wide array 
of genomic functions, whereas CEBPA, FOXA1 and HNF4A are representative TFs 
whose evolution and roles are similar to other tissue-specific regulators in mammals 
that tend to exert their functions by binding to divergent regulatory regions[394, 558]. 
There is, however, marginal enrichment of CTCF binding in promoter sequences that 
is significantly higher than would be expected by random. This is consistent with the 
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observation of CTCF binding just upstream of TSSs. Again, BL6 CTCF binding sites, 
regardless of their evolutionary class or cis/trans-acting variants, were bound in 
enhancer/promoter sequences in equivalent proportions reflecting their contribution to 
the total number of CTCF in each set. Taken together, these results illustrate that 
the process of formation of subspecies-specific CTCF binding sites resulted in the 
maintenance of the same genomic profile and functional signatures as those more 
conserved (musculus-common) or under binding regulatory variation (cis/trans).  
 
Promoters were found to be the closest active regulatory regions to CTCF sites, 
both varying in their evolutionary/tissue-specificity type or under cis/trans regulatory 
variation, more often than enhancers. However, when an enhancer was found near a 
CTCF binding site, regardless of classification, the distance between them was always 
significantly shorter. There were more active regulatory regions that were designated 
as enhancers than promoters. This could be explained by their tendency to occur closer 
to TSSs, and their associated promoter sequences. Even though promoters are 
generally lower in number compared to enhancers, the latter lie further away, possibly 
resulting in fewer of them associating with CTCF. A previous study showed that the 
CTCF occupancy at/close to promoters coupled with their nearby cohesin-bound 
enhancers is associated with upregulation of gene expression[362]. The distance from 
CTCF sites to their nearest regulatory elements, however, was similar, and there were 
no significant differences between sites based on their evolutionary/tissue-specificity 
class, or the category of cis/trans regulatory variation. 
 
A recent study reported a positive correlation between the enhancer activity as 
indicated by H3K27ac and CTCF binding, suggesting that CTCF binding influences 
enhancer activity[627]. They additionally observed that active promoters show higher 
interaction with CTCF occupancy nearby, and the enhancers interacting with these 
CTCF sites in turn show higher interaction with active promoters.  
 
Taken together, our findings point to a potential role of evolutionary dynamic 
CTCF binding, both BL6-specific and cis/trans-influenced, in facilitating regulatory 
interaction between distal enhancers and the promoters they regulate. This could 
potentially explain the reported findings of subtle effects on gene expression observed 
following targeted CTCF and/or cohesin degradation[651]. 
 
4.4.3 CTCF occupancy at TAD-boundary analysis 
  
TADs are chromatin domains that insulate regulatory modules from 
undesirable interactions, and have been reported to be retained across cell-types and 
deeply conserved across mammalian lineages[235, 262, 312]. TAD boundary 
conservation implies that species-specific TE-driven re-wiring is not common. It has 
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been recently reported that their evolutionary conservation could be the result of 
clusters of SINE-derived CTCF binding sites at TAD boundaries that help maintain 
genomic organisation[652]. Mutations affecting TAD loop anchors result in gene 
expression dysregulation and have been linked to cancer [624, 653]. CTCF is enriched 
around the anchor loops at TAD boundaries and play a crucial role in the formation 
and maintenance of TADs.  
 
Our analysis of CTCF occupancy within TADs in sites differing in their 
evolutionary/tissue-specificity and those affected by cis/trans regulatory variation has 
shed light on how short evolutionary time has shaped these sites tendency to associate 
with TAD boundaries. Cis/trans-influenced CTCF sites exhibited a strong association 
with TAD-boundaries. TAD-boundary association for this set of CTCF sites was 
significantly stronger than general SNV-free CTCF sites. The higher conservation of 
their binding around TAD boundaries is possibly a product of their sharedness across 
the two subspecies. Even though they harbour informative SNVs, these sites are, by 
virtue of their definition, orthologous to their CAST counterparts. Non-cis/trans 
CTCF sites, on the other hand, are likely to include sites that are subspecies-specific, 
TE-derived and otherwise, which in turn may affect their association with TAD 
boundaries. All categories of cis/trans-acting variation in CTCF binding sites were 
found to be equally TAD-boundary associated, showing that TAD-boundary 
association is independent of allele-specific effects. 
 
This is supported by the observations from CTCF binding around TAD 
boundaries in musculus-common and BL6-specific sites. Whilst the musculus-common 
sites exhibit the characteristic enrichment in the immediate vicinity of TAD 
boundaries, BL6-specific sites are less TAD-boundary associated, regardless of tissue-
specificity. Nonetheless, subspecies-specific still exhibit consistent binding around TAD 
boundaries, even if their contribution to TAD-boundary associated CTCF sites is 
proportionally lower than expected based on their overall numbers. These results 
suggest that even though TAD-boundaries seem to favour more conserved CTCF 
binding, CTCF sites with dynamic regulatory variation brought on by the introduction 
of SNVs, or evolutionary young subspecies-specific are not excluded. In fact, sites with 
cis/trans-acting variants appear to be more highly associated with TAD-boundaries 
than general CTCF sites. Recent findings showed that CTCF binding at TAD 
boundaries are under stronger constraints on their sequence and functional compared 
to other CTCF sites, independent of their evolutionary conservation between murine 
lineages. This dynamic evolutionary process was found to be the result of insertions of 
new species-specific CTCF binding sites in proximity to older ones[575]. Our results 
provide evidence that these new sites are the result of evolutionary young TE insertions 
that associate with TAD boundaries in subspecies-specific fashion and, particularly in 
4. Regulatory potential of CTCF binding in closely-related mice  
 165 
the tissue-shared subset of BL6-specific sites, actively associate with cohesin-complex 
subunits.  
 
It is worth mentioning that despite observed enrichment of CTCF binding near 
TAD boundaries, the vast majority of CTCF binding sites are widespread in the 
genome and are located further within TADs structure. The precise nature of the 
difference between TAD/intra-TAD loop-anchoring sites and the greater number of 
non-anchoring CTCF sites is still an open question, and role they play in nuclear 
organisation is still unclear[170, 328, 654]. Given CTCF role to interact with other 
TFs, bind RNA, and regulate splicing mechanics, these present potential other 
functions that are not TAD-boundary associated[311, 351, 655]. 
 
Our results also indicate that tissue-specific TF binding appears to cluster 
within certain TADs, whereas ubiquitously bound CTCF genomic distribution within 
TADs in more uniform. We found out that cis/trans-influenced liver-specific TF 
binding sites (CEBPA, FOXA1 and HNF4A) tend to be found in higher number within 
TADs than would be expected if randomly distributed. This was apparent in bigger 
TADs where their numbers considerably increase, in contrast to smaller TADs where 
the number of observed binding events lower than expected. On the contrary, cis/trans 
CTCF sites were found in higher frequency in smaller TADs, but as the size of TADs 
increased, their numbers became indistinguishable from the expected frequencies.  
 
This may be explained by their differing mode of genomic action. Tissue-specific 
TFs bind to regulatory element in genomic regions where they can carry out their 
function in activating expression of their target genes. These regions are not found 
genome-wide, instead these are found in defined TADs. These TADs contain genes 
that tend to be co-regulated as well as genes whose expression is tissue-restricted that 
are likely to reside within the same TAD. Thus, their binding tends to cluster where 
their binding is functionally important, resulting in higher occupancy than expected 
based on random genomic distributions in those TADs. CTCF binding sites, on the 
other hand, are universally found within almost all TADs where they form the anchors 
required for TAD and intra-TAD loop formation and maintenance. Their higher 
number in smaller TADs could be a by-product of the clustering near TAD boundaries 
discussed above. In large TADs, TAD-boundaries are sufficiently enriched with CTCF 
binding sites, and the remainder of sites distribute randomly within TADs, where they 
could be involved in the formation of intra-TAD loops, regulating gene expression, 
binding RNA or take up other functional roles.   
 
Together with results of repeat content enrichment in CTCF sites, our results 
support the model for dynamic evolutionary conservation around TAD boundaries, 
whereby CTCF binding sites associated with TAD-boundaries are more conserved, but 
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with a substantial contribution of both sites under regulatory variation characterised 
by the presence of cis/trans variants and evolutionary young CTCF sites. The several 
facet of CTCF occupancy evolution appear to work in tandem to provide stability to 
functional higher-order chromatin structures. In addition, the observation that, despite 
significant TAD-boundary association, the majority of CTCF sites reside well within 
the TADs yet still strongly associate with cohesin-complex subunits suggest potential 
involvement in the formation of intra-TAD loop anchors. This, coupled with proximity 
to regulatory active regions, makes them candidate for the formation of novel loops 
that mediate promoter-enhancer contacts and gene expression. Indeed, a recent report 
indicates that TE-derived loop anchors are associated with variable chromatin looping 
across species and cells[644]. 
 
4.4.4 CTCF recruitment of cohesin-complex proteins 
 
To carry out its function in establishing loop contacts and setting up insulated 
regulatory domains, CTCF interacts with cohesin-complex proteins found near the 
TAD boundaries[235, 328, 625, 656].  
 
Our analysis revealed that CTCF sites that are under cis/trans-acting variation 
strongly co-localise with cohesin-complex subunits. Liver-specific cis/trans TFs, on the 
other hand, show a variable degree of co-localisation with cohesin. Their pattern of 
cohesin co-localisation, however, showed that they mostly associate with cohesin-non-
CTCF sites (CNC). CNC sites are often at tissue-specific promoters and 
enhancers[224]. These same liver-specific TFs have previously been found to associate 
with CNC sites to help stabilize large TF complexes by facilitating the binding of 
master regulators and enhancer-markers, resulting in the upregulation liver-specific 
gene expression[362]. CNC sites bound by TF binding sites facilitate distinct gene 
expression states by promoting cohesin-driven interactions within an existing 
chromatin structures[657]. These results, combined with previous observation of 
regulatory elements enrichment (particularly in enhancer regions) and their tendency 
to cluster within certain bigger TADs, suggest that liver-specific binding of these TFs 
reflects significant hallmarks of functional activity even when under cis/trans 
regulatory variation. These sites have also been shown (see Figure 4.1b) to have a 
higher enrichment in repeat content in their binding sites compared to their SNV-free 
counterparts, potentially implicating TE-derived TF occupancy in promoting these 
functional signatures in cell-type specific context.    
 
Our analysis has also shown that cis/trans CTCF co-binding with cohesin is 
predominantly TAD-boundary associated, regardless of the type of cis/trans 
regulatory variation characterising the binding site. In terms of their 
evolutionary/tissue-specificity class, however, we observed significant difference in co-
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localisation with CTCF. Whereas musculus-common sites were found to be strongly 
associated with cohesin-complex subunits, BL6-specific sites differed based on their 
tissue-specificity. BL6 tissue-specific sites exhibited striking reduction in co-localisation 
with cohesin-subunits, whereas BL6 tissue-shared sites showed a much stronger 
association with higher recruitment of cohesin.  
 
Furthermore, stronger CTCF sites were found to co-localise with cohesin more 
often than weaker ones regardless of evolutionary/tissue-specificity class. However, due 
to the majority of BL6 tissue-specific sites exhibiting generally lower ChIP signal, fewer 
of them are associated with cohesin in total, explaining the apparent reduction in 
cohesin co-localisation in this subset of CTCF binding sites. BL6 tissue-shared site, on 
the other hand, exhibit a uniform distribution in ChIP-signal with roughly equal 
proportion at each tier of binding signal, hence they have stronger signal and cohesin 
recruitment.  
 
Taken together, our findings from the analysis of CTCF co-localisation with 
cohesin in evolutionary/tissue-specificity and cis/trans variation contexts provide 
some clues as to what factors are involved in this process. First, the more conserved a 
CTCF site is, the higher the co-localisation with cohesin subunit. Orthologous CTCF 
binding sites under cis/trans regulatory variation were found to show a similar pattern 
of association with cohesin as musculus-common sites, despite the presence of sequence 
variants by virtue of their subspecies-sharedness (only 1.7% of sites showed lineag-
specific binding. See Chapter 3). Even though BL6-specific sites showed reduced 
association with cohesin, as a subset of these acquired tissue-wide occupancy, their co-
localisation with cohesin rose significantly to almost equal that of a more conserved 
status. A second factor influencing CTCF co-localisation with cohesin was ChIP signal. 
When sufficiently high, all CTCF sites were found to equivalently co-localise with 
cohesin regardless of their conservation state. However, as their signal dwindled, the 
level of their association with cohesin dropped, and depending on the fraction of sites 
for each class of CTCF within the tiers of ChIP signal, the overall level of association 
with cohesin was affected.  
 
A couple of computational approaches have attempted to predict intra-TAD 
loop formation based on CTCF and cohesin peak strength as the primary 
predictor[658, 659], lending support to the idea of CTCF signal as a proxy to its 
association with cohesin and its involvement in chromatin remodelling.  
 
A study estimated that ~90% of DNA loops are associated with CTCF and 
cohesin binding, in which 92% comprised of CTCF anchors whose motifs were in 
convergent orientation[219]. Convergent orientation has been a consistent feature for 
identifying chromatin loops using computational methods[285, 365]. However, loops 
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exhibiting other orientations have been observed to represent as few as 8% (in loop 
domains), and as many as 20% (in insulated Neighbourhoods)[219, 624]. 
 
Our investigation into the motif combinations of neighbouring CTCF sites 
showed equivalent results. In CTCF-and-cohesin (CAC) binding sites under influence 
of cis/trans-acting variants, half of cis/trans CAC sites are in tandem orientation, 
which is expected based on the frequencies of the +/- motif proportions. However, 
almost a third are in divergent orientation, and fewer than expected are in the 
preferable convergent orientation most common in chromatin loops. Pairs of 
neighbouring CTCF sites in convergent orientation are additionally found further away 
in their distance than the other two orientations. These findings did not differ across 
the different regulatory categories of cis/trans variants.  
 
The results of the same approach in CAC sites differing in their 
evolutionary/tissue-specificity classification were generally similar, particularly in the 
ratios of motif combinations in pairs of neighbouring CTCF sites and their distance to 
each other. There were, however, some notable differences. BL6-specific CAC sites 
were more likely to be nearer BL6-specific sites (particularly tissue-shared ones) than 
expected. Furthermore, even though more pairs of motifs were in divergent than 
convergent orientation, this was only limited to all musculus-common pairs. Mixed or 
BL6-specific pairs either exhibited similar proportion of the two (tissue-specific) or 
appeared more convergent orientation (tissue-shared).  
 
These results indicate that CTCF sites, in association with cohesin, do not 
generally exhibit favourable motif orientation in short distances between pair of 
neighbouring sites. Given that median size of shorter loops in complex nested intra-
TADs is 185 kb[219], it is most likely that these loops take place between CTCF-
cohesin anchors separated by several intervening CTCF motifs not in the preferable 
orientation. This could also be seen in the increased distance separating pairs of motifs 
that do occur in the convergent orientation in both sets of CTCF sites investigated.  
The fact that motif orientations between pairs of neighbouring CTCF sites did not 
differ based on their evolutionary/tissue-specificity, or the type of cis/trans variant 
present is a testament to the plasticity of CTCF sites undergoing dynamic evolutionary 
rewiring to maintain existing structures and functions, as well as readily adopting them 
when new sites arise. This provides a rich source for lineage- and cell-type specific 
genomic innovation.    
 
 
 
 
 
 
 
 
Chapter 5 
 
Conclusions and future 
directions  
 
In this thesis, I have explored the regulatory evolution of a master genome regulator, 
the CTCF protein, in two mouse subspecies separated by a short evolutionary 
divergence time, which participate in transcriptional regulation of gene expression. The 
analyses described in this thesis were conducted using computational approaches on a 
genome-wide scale to study the binding pattern of CTCF and the biological 
implications of such occupancy in a tissue- and subpecies-specific manner. These 
projects aimed to understand how evolutionary divergent CTCF binding sites are 
shaped by evolutionary forces and what patterns their occupancy exhibits in both 
subpecies-specific and F1 hybrid biological contexts. Combining computational 
methods with advancement in next-generation sequencing (NGS) techniques, I was 
additionally able to leverage the availability of high-quality genome sequences, and the 
publicly available data, either from large-scale consortia efforts, or from data 
repositories of published work by our group and others.  
 
 The project covered in Chapter 2 investigated the mechanisms and possible 
functional consequences underlying the birth of evolutionary-young CTCF binding 
sites in short evolutionary time between two mouse subspecies in the murine lineage. 
A main finding from this investigation is that the evolution of novel CTCF binding 
sites is indeed driven, at least in half the cases, by transposable elements action, 
particularly from the B2-B4 family of SINE elements. In addition to confirming earlier 
reports[269, 384], this study elucidated that the process continued after the divergence 
of the two species, leading to the proliferation of thousands of new CTCF binding 
sites. Another key result concerned a subset of those young subpecies-specific sites 
which displayed consistent binding across multiple tissues in M. musculus domesticus 
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(BL6), suggesting that they may possess enhanced transcriptional regulatory 
functionality. In general, all subspecies-specific CTCF sites bore all genomic features 
and occupancy patterns of conserved CTCF sites, suggesting that they may all be 
functional. Furthermore, the study uncovered a novel BL6-specific immune locus 
consisting of a 15-gene cluster on chromosome 4, formed by a recurrent regulatory 
architecture consisting of a CTCF binding site and an interferon gene. These results 
provide evidence on how quickly evolutionary-young CTCF sites start to demonstrate 
several functional signatures shortly after their integration into the genome.   
 
 Chapter 3 focused on the effects of genetic sequence changes on CTCF binding 
site occupancy variation and the underlying mechanisms causing this variation. Using 
the F1 hybrid of the same two mouse subspecies in the first project to investigate 
CTCF binding divergence in response to cis- and trans-acting variation. The findings 
of this study demonstrate pervasive trans variation on CTCF occupancy influencing 
its allelic-specific binding in hybrid contexts in addition to established cis effects. The 
inheritance of these cis and trans effects, though additive, is visibly influenced by 
dominant effects. Lineage-specific binding events are more scarce owing the 
overwhelming conservation of CTCF binding between the two species demonstrated 
in the first study. Although CTCF is well-known to be heavily involved in long-range 
promoter-enhancer interaction via looping (see Chapter 1), CTCF binding sites under 
cis-acting variation do not display any measurable signal coordination over short or 
long genomic distance with other CTCF sites in an allele-specific manner. Taken 
together, the results of this project indicate the pervasive influence of trans-acting 
variation which contribute to the complex pattern of regulatory effects imposed on 
and by the universally expressed CTCF. 
 
To establish the extent and differences in regulatory potential of CTCF 
occupancy in short evolutionary time, Chapter 4 investigated several functional facets 
of CTCF binding sites either on the basis of their evolutionary/tissue-specificity 
(Chapter 2) and the binding variation they exhibit in the form of cis/trans variants 
(Chapter 3). Namely, we compared and contrasted the pattern observed between both 
sets of CTCF sites in terms of their repeat elements content and age, their binding in 
active regulatory elements, TAD-boundary association and their interaction with 
cohesin-complex proteins. Our results support our earlier findings of a recent, post-
divergence SINE-driven expansion of CTCF binding sites in subspecies-specific manner 
that is absent even from sites shared between the two strains, yet characterised by 
SNV insertion. We also further illustrate the dynamic evolution of CTCF association 
with TAD-boundaries, where conservation of binding coincides with substantial 
contribution of both sites under cis/trans regulatory variation and subspecies-specific 
CTCF sites. This was coupled with strong interactions with cohesin-complex proteins 
in both cis/trans-influenced sites and evolutionary young, tissue-shared sites. Taken 
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together, the functional regulatory aspects of evolutionary dynamic CTCF sites of all 
types considered in this thesis indicated that whilst the maintenance of pre-existing 
higher-order chromatin structures is evident, the evolution of CTCF occupancy, 
whether by SNVs or TE-derived insertions, provides a template for lineage- and tissue-
specific genomic innovation. 
 
 These results, put together, add to the increasing literature on the regulation 
of gene expression. Cis-regulatory elements such as promoters and enhancers are 
involved in a multitude of long-range contacts via a looping mechanism facilitated by 
CTCF and its associated cohesin complex in order to load the transcriptional 
machinery and allow the physical interaction between distal and proximal regions of 
the circuitry[660]. While CTCF is crucial to this process of chromatin interaction and 
3D architectural organisation during regulation of bilaterian animals gene expression, 
in non-bilaterian animal, this mechanism of long-range interactions between 
constituents of the regulatory machinery is lacking CTCF[273]. It has been proposed 
that in large genomes such as those of mammals, cis-regulatory elements can be 
distantly located to the target genes they regulate. Thus, they contain CTCF"
dependent boundaries to allow different combination of loci to display different 
chromatin/compartment states, and enable long"range interactions while effects from 
flanking TADs are insulated[323, 367, 661]. This could explain the observed pattern of 
proliferation of CTCF sites during evolutionary divergence. These evolutionary young 
sites, with their readily acquisition of typical functional signatures of CTCF, introduce 
a degree of redundancy in the system that may protect it from the potential effects of 
genetic and environmental abnormalities[662]. 
 
 Furthermore, although chromatin looping forming TADs usually appear 
conserved between tissues, cell-types and even in syntenic regions of related species, it 
has been recently found that some CTCF-mediated chromatin loops are not 
constitutive, but rather tissue"specific[663]. The subset of CTCF-mediated loops may 
have risen due to tissue-specific CTCF binding, mediated by other tissue-specific 
epigenetic modifications or transcription factors[664]. Alternatively, tissue-wide, 
constitutive CTCF binding sites may be involved in tissue"specific interactions 
mediated by the presence of additional looping co-factors to bring about cell-type-
specific CTCF-mediated interactions[665]. The subset of species-specific CTCF binding 
sites identified in the first study (Chapter 2) may provide an evolutionary mechanism 
for such tissue-specific interactions to originate. Since conserved CTCF sites and TAD 
domains do not appear to diverge significantly, especially between closely related 
species, such novel species-specific and tissue-variable sites offer a platform for cell-
type-specific interactions to occur. 
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 The analyses conducted in the second project was facilitated by the large 
number of SNVs (~19 M) previously identified[257], which is comparable to the number 
of SNVs between human populations[666], between the two mouse subspecies, allowing 
sufficient resolution to detect measurable difference in CTCF binding intensities. 
Dissecting the effects of cis- and trans-acting variant on CTCF binding intensity 
provides an opportunity to understand the consequences of sequence changes to the 
binding sites on CTCF function. This is particularly medically relevant. Although 
somatic mutations in the CTCF coding gene have been detected in cancer[667], a great 
number of recurrent mutations were identified in CTCF binding sites in a number of 
human cancers[668]. Some SNPs in the CTCF binding site have also been shown to 
increase disease susceptibility by impacting methylation levels at differentially 
methylated CTCF-binding sites[669]. Mutations and SNPs can additionally alter gene 
expression and tumour progression by disrupting the CTCF-mediated folding of 
chromatin[647]. A study combining Hi-C and ChIP-seq has shown that, whilst super 
enhancers (SEs) hub and non-hub enhancers share common histone marks, hub 
enhancers appear to associate with CTCF and cohesin binding sites and disease specific 
SNPs[665]. Although CTCF insulates super enhancers from non-target genes by 
forming boundaries between loci, this insulation action is fluid, and dependent on the 
strength of CTCF occupancy or “insulation score” at the SE boundary. Such 
occupancy-dependent insulation score could be investigated by measuring the relative 
contribution of cis- and trans-acting variation on candidate regions.  
  
 The analyses carried out in this thesis also offer some directions for future work. 
At the moment, publicly available Hi-C protocols in matched samples do not offer a 
resolution high enough to capture long-range chromatin interactions involving a pair 
of CTCF sites to the level of their binding motif. This is critical, particularly in the 
case of many of the species-specific CTCF binding sites identified in Chapter 2, as they 
often occurred in clusters with nearby conserved CTCF sites in regions a few kb long. 
Such regions could not be resolved using available data. This hampered the discovery 
of such an association of many of these sites with novel chromatin looping. 
Nevertheless, advances in chromatin capture technologies, super"resolution imaging, 
and sophisticated in silico modelling are likely to soon bridge this gap in knowledge 
and permit us to revisit this aspect in the future in order to verify whether such sites 
are indeed an evolutionary venue for regulatory innovation. For example, a recent 
publication reported the development of a machine learning algorithm, CTCF-MP, 
that combines functional genomic signals from CTCF ChIP-seq and DNase-seq to 
make accurate predictions on whether a pair of convergent CTCF binding motifs would 
form a loop[670]. The algorithm is based on word2vec, a popular word embedding 
model in natural language processing, and only utilizes sequence-based features to 
inform the model if a convergent CTCF motif pair have the capacity to for loop 
formation in a single cell type and also across different tissues.   
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 In addition, the application of ChIP-seq to study protein-DNA interactions 
requires tissue sample with a large number of cells and relies on several parameters 
such as the choice of single- vs. paired-end tags and antibody quality.  Advances in 
synthetic biology may allow the development of tailor-made antibodies with better 
affinity to the protein of choice, reducing the level of biological noise associated with 
ChIP-seq. A 2015 ChIP-seq protocol was developed to allow profiling of protein-DNA 
interactions with low input of cells[671].  
 
A powerful novel venue to develop a better understanding of the heterogeneity 
inherent to the system and cell-to-cell variability is to able to perform single-cell ChIP-
seq. A major breakthrough came by in 2017 when Stevens et al.[672] were able to 
study the 3D structures of complete genomes, the pattern of genome folding, TADs 
and loops at < 100 kb resolution in single cell level, leveraging data from the 3C 
method. They also reported evidence that TADs and CTCF cohesin loops form in 
partial cells and exhibit dynamic structural changes and variations in 12-62% of the 
cells. Another advancement came from Ren et al.[627] who combined gene editing 
technology with single-cell flow cytometry and single-molecule RNA-FISH assays to 
demonstrate that CTCF helps to stabilize enhancer-promoter interactions, resulting in 
maintenance of minimal variations of gene expression. 
 
Finally, despite the versatile regulatory functions of CTCF as a transcriptional 
activator/repressor, an insulator/boundary element binding factor, or a regulator of 
genomic imprinting and higher-order chromatin folding, the molecular mechanisms of 
CTCF in cell differentiation and disease development is still a work in progress. 
However, the progress made in our knowledge and understanding of the 3D 
conformation of the genome has been growing, and the plethora of loop types, shapes, 
and functions within the chromatin has become more complex. The identification and 
validation of CTCF-mediated mechanisms that affect biological function and 
transcriptional regulation in species-, tissue- and cell-specific fashion is a major step in 
the direction of untangling this complexity. 
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Appendix 1 
 
Repeat masking results of TF binding sites  
 
Table 1: CTCF 
 
Evolutionary 
type 
Repeat 
Element Class Family No. Elements Bases masked 
% of 
Sequence 
m
us
cu
lu
s -
co
m
m
on
 
In
te
rs
pe
rs
ed
 re
pe
at
s 
SINEs: Alu/B1 1101 87722 1.00% 
  B2-B4 6765 980357 11.12% 
  IDs 88 5469 0.06% 
  MIRs 142 12010 0.14% 
LINEs: LINE1 858 95385 1.08% 
  LINE2 71 6336 0.07% 
  L3/CR1 8 580 0.01% 
LTR ERVL 232 29157 0.33% 
  ERVL-MaLRs 581 77235 0.88% 
  ERV_classI 117 17128 0.19% 
  ERV_classII 256 33712 0.38% 
DNA hAT-Charlie 253 25839 0.29% 
  TcMar-Tigger 35 4684 0.05% 
Unclassified: 116 22599 0.26% 
Small RNAs: 73 6746 0.08% 
Satellites: 21 2174 0.02% 
Simple repeats: 4216 167652 1.90% 
Low complexity: 508 23979 0.27% 
Total 32155 1605391 18.21% 
BL
6-
sp
ec
ifi
c 
In
te
rs
pe
rs
ed
 re
pe
at
s  
SINEs: Alu/B1 129 10240 0.76% 
  B2-B4 3599 455525 33.66% 
  IDs 12 692 0.05% 
  MIRs 6 651 0.05% 
LINEs: LINE1 252 29837 2.20% 
  LINE2 7 543 0.04% 
  L3/CR1 0 0 0.00% 
LTR ERVL 25 2284 0.17% 
  ERVL-MaLRs 147 16705 1.23% 
  ERV_classI 117 17898 1.32% 
  ERV_classII 251 35358 2.61% 
DNA hAT-Charlie 28 2616 0.19% 
  TcMar-Tigger 3 300 0.02% 
Unclassified: 21 2964 0.22% 
Small RNAs: 16 2373 0.18% 
Satellites: 200 46504 3.44% 
Simple repeats: 554 24255 1.79% 
Low complexity: 35 1737 0.13% 
Total 7021 651800 48.16% 
C
AS
T-
sp
ec
ifi
c 
In
te
rs
pe
rs
ed
 
re
pe
at
s  
SINEs: Alu/B1 67 5145 0.67% 
  B2-B4 1842 232983 30.19% 
  IDs 4 238 0.03% 
  MIRs 5 443 0.06% 
LINEs: LINE1 209 23946 3.10% 
  LINE2 3 188 0.02% 
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  L3/CR1 2 131 0.02% 
LTR ERVL 29 3392 0.44% 
  ERVL-MaLRs 124 13294 1.72% 
  ERV_classI 31 4602 0.60% 
  ERV_classII 140 19390 2.51% 
DNA hAT-Charlie 21 1681 0.22% 
  TcMar-Tigger 1 125 0.02% 
Unclassified: 22 2884 0.37% 
Small RNAs: 2 216 0.03% 
Satellites: 23 4481 0.58% 
Simple repeats: 262 9667 1.25% 
Low complexity: 19 799 0.10% 
Total 4730 324033 41.98% 
 
Table 2: CEBPA 
 
Evolutionary type Repeat Element Class Family No. Elements Bases masked % of Sequence 
m
us
cu
lu
s-
co
m
m
on
 
In
te
rs
pe
rs
ed
 re
pe
at
s 
SINEs: Alu/B1 1505 134460 1.27% 
  B2-B4 2040 234401 2.21% 
  IDs 238 16216 0.15% 
  MIRs 811 86345 0.81% 
LINEs: LINE1 1341 220361 2.08% 
  LINE2 305 30240 0.29% 
  L3/CR1 47 5254 0.05% 
LTR ERVL 450 71587 0.68% 
  ERVL-MaLRs 1401 220386 2.08% 
  ERV_classI 304 52640 0.50% 
  ERV_classII 1007 192893 1.82% 
DNA hAT-Charlie 531 73582 0.69% 
  TcMar-Tigger 84 12851 0.12% 
Unclassified: 90 16667 0.16% 
Small RNAs: 135 11464 0.11% 
Satellites: 12 966 0.01% 
Simple repeats: 2393 82960 0.78% 
Low complexity: 227 9274 0.09% 
Total 39196 1499055 14.14% 
BL
6-
sp
ec
ifi
c 
In
te
rs
pe
rs
ed
 re
pe
at
s 
SINEs: Alu/B1 195 16629 1.16% 
  B2-B4 388 43896 3.07% 
  IDs 34 2307 0.16% 
  MIRs 64 6077 0.43% 
LINEs: LINE1 242 37972 2.66% 
  LINE2 24 2390 0.17% 
  L3/CR1 9 943 0.07% 
LTR ERVL 75 12583 0.88% 
  ERVL-MaLRs 273 40280 2.82% 
  ERV_classI 112 19000 1.33% 
  ERV_classII 500 85564 5.99% 
DNA hAT-Charlie 56 7208 0.50% 
  TcMar-Tigger 4 563 0.04% 
Unclassified: 24 4618 0.32% 
Small RNAs: 44 4545 0.32% 
Satellites: 205 85374 5.97% 
Simple repeats: 295 11121 0.78% 
Low complexity: 18 709 0.05% 
Total 6733 383229 26.81% 
C
AS
T-
sp
ec
ifi
c  
In
te
rs
pe
rs
ed
 
re
pe
at
s 
SINEs: Alu/B1 1570 133639 1.33% 
  B2-B4 2383 263074 2.61% 
  IDs 237 16362 0.16% 
  MIRs 525 51411 0.51% 
LINEs: LINE1 2944 420441 4.17% 
  LINE2 257 26643 0.26% 
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  L3/CR1 31 3500 0.03% 
LTR ERVL 496 70792 0.70% 
  ERVL-MaLRs 1685 248848 2.47% 
  ERV_classI 557 93316 0.93% 
  ERV_classII 2083 386285 3.83% 
DNA hAT-Charlie 540 69936 0.69% 
  TcMar-Tigger 86 11871 0.12% 
Unclassified: 113 18509 0.18% 
Small RNAs: 116 10594 0.11% 
Satellites: 1373 519949 5.16% 
Simple repeats: 2292 80701 0.80% 
Low complexity: 277 12353 0.12% 
Total 43546 2458654 24.40% 
 
Table 3: FOXA1 
 
Evolutionary type Repeat Element Class Family No. Elements Bases masked % of Sequence 
m
us
cu
lu
s-
co
m
m
on
 
In
te
rs
pe
rs
ed
 re
pe
at
s 
SINEs: Alu/B1 4099 386810 1.86% 
  B2-B4 4942 601384 2.90% 
  IDs 510 34911 0.17% 
  MIRs 1216 128461 0.62% 
LINEs: LINE1 2076 361939 1.74% 
  LINE2 696 75589 0.36% 
  L3/CR1 83 9548 0.05% 
LTR ERVL 743 129282 0.62% 
  ERVL-MaLRs 2293 389976 1.88% 
  ERV_classI 537 111838 0.54% 
  ERV_classII 1626 340159 1.64% 
DNA hAT-Charlie 790 113895 0.55% 
  TcMar-Tigger 166 25737 0.12% 
Unclassified: 156 36521 0.18% 
Small RNAs: 240 21490 0.10% 
Satellites: 71 6703 0.03% 
Simple repeats: 7023 271884 1.31% 
Low complexity: 705 31382 0.15% 
Total 57301 3123172 15.04% 
BL
6-
sp
ec
ifi
c 
In
te
rs
pe
rs
ed
 re
pe
at
s 
SINEs: Alu/B1 788 71476 1.83% 
  B2-B4 1177 136828 3.50% 
  IDs 72 4917 0.13% 
  MIRs 140 12938 0.33% 
LINEs: LINE1 516 84574 2.16% 
  LINE2 93 8858 0.23% 
  L3/CR1 8 666 0.02% 
LTR ERVL 160 25675 0.66% 
  ERVL-MaLRs 625 95394 2.44% 
  ERV_classI 290 71421 1.83% 
  ERV_classII 689 129920 3.32% 
DNA hAT-Charlie 113 15477 0.40% 
  TcMar-Tigger 14 1579 0.04% 
Unclassified: 59 13064 0.33% 
Small RNAs: 84 8949 0.23% 
Satellites: 92 24602 0.63% 
Simple repeats: 1340 56197 1.44% 
Low complexity: 122 6664 0.17% 
Total 16097 774402 19.82% 
C
AS
T-
sp
ec
ifi
c  
In
te
rs
pe
rs
ed
 
re
pe
at
s 
SINEs: Alu/B1 1812 166847 1.91% 
  B2-B4 2539 296600 3.40% 
  IDs 204 13954 0.16% 
  MIRs 421 43706 0.50% 
LINEs: LINE1 2169 346026 3.96% 
  LINE2 260 26039 0.30% 
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  L3/CR1 36 3995 0.05% 
LTR ERVL 459 70981 0.81% 
  ERVL-MaLRs 1543 247238 2.83% 
  ERV_classI 621 118649 1.36% 
  ERV_classII 1605 314595 3.60% 
DNA hAT-Charlie 387 52931 0.61% 
  TcMar-Tigger 71 10439 0.12% 
Unclassified: 114 22021 0.25% 
Small RNAs: 112 10653 0.12% 
Satellites: 500 97836 1.12% 
Simple repeats: 3158 124788 1.43% 
Low complexity: 327 15687 0.18% 
Total 32625 2000771 22.91% 
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The effect of biological replicates availability on cis/trans 
variation in TFs  
 
 
 
 
Figure S2.1: Improvement in category-assignment quality with increasing replicate 
number  
 
Boxplots of the differential BIC values for all TF binding sites under cis/trans 
regulatory variation in ascending number of libraries in FOXA1 (a) and HNF4A (b).  
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Figure S2.2: Increasing cis effect size on binding ratios between F1 and F0 
 
Hexagonal heatmaps for the F0 versus. F1 binding intensity ratios (BL6 vs. 
CAST) for every cis/trans site in 2 to 6 biological replicates in FOXA1 (a) and 
HNF4A (b).  
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Figure S2.3: Evolutionary direction of lineage- specific sites is enhanced with 
increasing replicate number  
 
Bar chart of the number of TF binding sites classed as lineage-specific for both 
cis and cistrans variants in 2 to 6 biological replicates in FOXA1 (a) and HNF4A 
(b), with scatter plots of average log2 F0 total read counts against average log2 
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F1 read count (BL6 plus CAST allele) multiplied by 2, using averages in 2 to 6 
biological replicates.  
 
 
Figure S2.4: Availability of more libraries markedly improves the determination 
of inheritance patterns of in cis/trans TF sites 
 
Bar plot of the number of binding sites based on their assigned mode of 
inheritance in ascending number of biological replicates in FOXA1 (a) and 
HNF4A (b). The circles illustrate the make-up of each mode of inheritance by 
the type of cis/trans variation acting on the binding site for each number of 
replicates, with the number of sites per category denoted inside the circles. 
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TE-masking and genomic features of cis/trans TF binding  
 
 
 
 
Figure S3.1: TE-derived binding in cis/trans-influenced binding of liver-specific 
TFs 
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Top horizontal bar chart shows the fractions of major TE classes in cis/trans TFs 
binding sites that are masked by repeat elements in CEBPA (a), FOXA1 (b) and 
HNF4A (c). The top bar refers to the percentage each TE class occupies in all repeat 
masked sequences in the BL6 mouse genome as a background.  
 
 
 
 
Figure S3.2: Enrichment of cis/trans CTCF sites at proximal active regulatory 
elements suggest potential regulatory activity   
 
The bar charts shows the fraction at which different TFs are found in the respective 
genomic element in CEBPA (a), FOXA1 (b) and HNF4A (c), with a breakdown by 
the type of cis/trans variant present at the binding site. 
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Scripts & Pipelines  
 
 
Alignment and Peak-calling Pipeline: 
 
 
#Align fastq files to BL6/CAST indexed assembly. 
 
bwa index -a bwtsw /genome/mm10.fa 
bwa mem /genome/mm10.fa CTCF_ChIPseq_library.p1.fq 
CTCF_ChIPseq_library.p2.fq > CTCF_ChIPseq_library.sam 
 
# Fetch uniquely mapped reads, outputting filtered SAM alignment files 
 
fgrep -w "XT:A:U" CTCF_ChIPseq_library.sam > 
CTCF_ChIPseq_library_filtered.sam 
 
#Convert SAM file to BAM, followed by sorting the BAM file 
 
samtools view -bSo CTCF_ChIPseq_library.bam 
CTCF_ChIPseq_library_filtered.sam 
samtools sort CTCF_ChIPseq_library.bam CTCF_ChIPseq_library.sorted 
 
#Index sorted BAM file 
 
samtools index CTCF_ChIPseq_library.sorted.bam 
 
#NOTE: repeat all steps above for control/input libraries 
 
#Peak-calling using MACS2 with default parameters 
 
macs2 callpeak -t CTCF_ChIPseq_library.sorted.bam -c 
CTCF_ChIPseq_input.sorted.bam -f 'BAM' -g 'mm' -n CTCF_ChIPseq_library 
-B --call-summits -p 0.001 
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Quality Control, Alignment and Peak-calling Pipeline (cis/trans): 
 
#Trim Library using min Phred score of 33, performing a sliding window 
trimming of window size 20, average quality of 30 and removing reads 
that fall below 40 minimal length 
 
java -jar trimmomatic-0.30.jar SE -phred33 CTCF_ChIPseq_library.fq 
CTCF_ChIPseq_library.fq_trim SLIDINGWINDOW:20:30 MINLEN:40 
 
#Align trimmed fastq files to joint assembly. First find SA coords of 
trim_fa (6 threads, 2 maximum mismatches) and output to .sai. Next, 
align to assembly using .sai and trim_fa, output to trim.m2.samtemp. 
 
bwa aln -t 6 -n 2 /genome/mm10 CTCF_ChIPseq_library.fq_trim > 
CTCF_ChIPseq_library.fq_trim.sai 
bwa samse CTCF_ChIPseq_library.fq_trim.sai 
CTCF_ChIPseq_library.fq_trim  > 
CTCF_ChIPseq_library.fq_trim.m2.samtemp 
 
# Fetch uniquely mapped reads, outputting SAM alignment files 
 
fgrep -w "XT:A:U" CTCF_ChIPseq_library.fq_trim.m2.samtemp > 
CTCF_ChIPseq_library.fq_trim.m2.sam 
 
#Convert SAM file to BAM, followed by sorting the BAM file 
 
samtools view -S -b CTCF_ChIPseq_library.fq_trim.m2.sam > 
CTCF_ChIPseq_library.fq_trim.m2.bam 
samtools sort CTCF_ChIPseq_library.fq_trim.m2.bam 
CTCF_ChIPseq_library.fq_trim.m2 
 
#mpileup used to count the number of reads that overlapped each base 
of the ref genome. Maximum depth of 100,000, No probabilistic 
realignment for the computation of base alignment quality (BAQ) or 
Minimum base quality. 
 
samtools mpileup -I  -d 100000 -BQ0 -f /genome/mm10.fa 
CTCF_ChIPseq_library.fq_trim.m2.bam > 
CTCF_ChIPseq_library.fq_trim.m2.mpileup 
 
#Index sorted BAM file 
 
samtools index CTCF_ChIPseq_library.fq_trim.m2.bam 
 
#Peak-calling using MACS2 with default parameters 
macs2 callpeak -t CTCF_ChIPseq_library.fq_trim.m2.bam -c 
do3072_input_liver_none_mm9BL6xCAST82602.0_CRI01.fq.gz_trim.m2.bam -f 
'BAM' -g 'mm' -n CTCF_ChIPseq_library.fq_trim.m2.sam_macs 
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#This R code runs statistical model fitting for category-assignment of 
cis/trans regulatory variants in TF binding sites. The code below uses 
an example of CTCF in 2 biological replicates. The R code sources the 
two helper functions f1_functions.R and cistrans.R. 
 
 
f1_functions.R 
 
library(DESeq) 
 
#This function normalizes F0 libraries based on library size using 
DESeq, producing a fitted dispersion parameter (r) for each SNV/site 
 
f0norm = function(pdata, pcondition){ 
pcds = newCountDataSet(pdata, pcondition) 
pcds = estimateSizeFactors(pcds) 
pcds = estimateDispersions(pcds, fitType='local') 
r = 1/fitInfo(pcds)$fittedDispEsts 
normcounts = cbind(as.matrix(counts(pcds, normalized=TRUE)), r) 
return(normcounts) 
} 
 
#This function normalizes F1 libraries based on library size using 
DESeq. 
 
f1norm = function(castf, b6f){ 
summed = castf + b6f 
b6f = subset(b6f, row.names(b6f) %in% row.names(summed)) 
castf = subset(castf, row.names(castf) %in% row.names(summed)) 
fract = b6f / (castf + b6f) 
condition = factor(rep('a', ncol(summed))) 
cds = newCountDataSet(summed, condition) 
cds = estimateSizeFactors(cds) 
normcounts = as.matrix(counts(cds, normalized=TRUE)) 
normb6 = normcounts * fract 
normcast = normcounts * (1 - fract) 
normb6[is.na(normb6)] = 0 
normcast[is.na(normcast)] = 0 
return(list(normb6, normcast)) 
} 
 
 
#This function estimates the Bayesian Information Criteria (BIC) 
 
BIC = function(loglik , npar , nobs){ 
bic = -2*loglik + npar*log(nobs) 
} 
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cistrans.R 
 
#Cis/trans function to model counts distribution between F0 and F1. F1 
are modelled on a beta-binomial distribution, and F0 counts are 
modelled on negative binomial distributions. 
 
f0f1_func = function(x, y, n, z, p1, p2, a, b, r) { 
sum(lchoose(n,z)+lbeta(z+a,n-z+b)-lbeta(a,b)) + 
sum(lgamma(r + x) - lfactorial(x) - lgamma(r) + x*log(p1) + 
r*log(1-p1)) + 
sum(lgamma(r + y) - lfactorial(y) - lgamma(r) + y*log(p2) + 
r*log(1-p2)) 
} 
 
#Parameter estimation of conserved scenario with 2 free parameters. 
 
cons_func = function(params, x, y, n, z, r) { 
p1 = params[1] 
p2 = p1 
a = params[2] 
b = a 
f0f1_func(x, y, n, z, p1, p2, a, b, r) 
} 
 
#Parameter estimation of cis scenario with 3 free parameters. 
 
cis_func = function(params, x, y, n, z, r) { 
p1 = params[1] 
p2 = params[2] 
a = params[3] 
b = (a * ((p1/(1-p1)) + (p2/(1-p2))) / (p1/(1-p1))) -a 
f0f1_func(x, y, n, z, p1, p2, a, b, r) 
} 
 
#Parameter estimation of trans scenario with 3 free parameters. 
 
trans_func = function(params, x, y, n, z, r) { 
p1 = params[1] 
p2 = params[2] 
a = params[3] 
b = a 
f0f1_func(x, y, n, z, p1, p2, a, b, r) 
} 
 
#Parameter estimation of cistrans scenario with 4 free parameters. 
 
cistrans_func = function(params, x, y, n, z, r) { 
p1 = params[1] 
p2 = params[2] 
a = params[3] 
b = params[4] 
f0f1_func(x, y, n, z, p1, p2, a, b, r) 
} 
 
#Statistical modelling of each scenario based on F0 & F1 normalised 
counts, dispersion and free parameters. 
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cistrans_ml = function(x, y, n, z, p1, p2, a, b, r) { 
res = c() 
for(i in 1:nrow(x)) { 
res = c(res, f0f1_func(x[i,], y[i,], n[i,], z[i,], p1[i], 
p2[i], a[i], b[i], r[i])) 
} 
return(res) 
} 
 
 
 
cistrans_cat_assignment.R 
 
library(DESeq) 
 
source("f1_functions.R") 
source("cistrans.R") 
 
# Load reads pileups for SNVs/sites for all F0 & F1 libraries 
filtered = read.delim("CTCF_reads_df") 
 
# Normalise reads from F0 libraries 
df=filtered[,c(2:5)] 
row.names(df)=filtered[,1] 
condition = factor(c('p1','p1' ,'p2','p2')) 
df = f0norm(df, condition) 
 
# Normalise reads from F1 libraries 
df1_cast=filtered[,c(6:9)] 
row.names(df1_cast)=filtered$chr 
df1_b6=filtered[,c(10:13)] 
row.names(df1_b6)=filtered$chr 
x = f1norm(df1_cast, df1_b6) 
norm_b6 = as.data.frame(x[1]) 
norm_cast = as.data.frame(x[2]) 
colnames(norm_cast) = colnames(df1_cast) 
f1 = cbind(norm_b6 , norm_cast) 
 
# Combine normalised counts for F0 & F1 libraries 
df = merge(df, f1, by='row.names') 
row.names(df) = df$Row.names 
df$Row.names = NULL 
 
# Set normalised counts for cis/trans category-assignment 
#x=F0 BL6, y=F0 CAST, n= F1 B6L+ F1 CAST, z=F1 BL6  
 
x=as.matrix(df[,c(1:2)]) 
y=as.matrix(df[,c(3:4)]) 
n=as.matrix(df[,c(6:9)]) + as.matrix(df[,c(10:13)]) 
z=as.matrix(df[,c(6:9)]) 
 
x=round(x) 
y=round(y) 
z=round(z) 
n=round(n) 
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r = df$r 
 
#For each SNV/site, x, y are the parental data, and n, z are the 
hybrid offspring data 
 
#Parameter estimation for the (conserved) scenario. initcons = initial 
values for parameter optimisation.  
 
 
res = c() 
initcons = c(0.5, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcons, cons_func, gr=NULL, x[i,], y[i,],n[i,], 
z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8, 1e-8), upper=c(0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "alpha") 
p1 = res[,"p1"] 
alpha = res[,"alpha"] 
 
cons = cistrans_ml(x, y, n, z, p1, p1, alpha, alpha, r) 
df = cbind(df, cons) 
 
#Parameter estimation for the (cis) scenario. initcons = initial 
values for parameter optimisation. 
 
res = c() 
initcis = c(0.5, 0.5, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcis, cis_func, gr=NULL, x[i,], y[i,], n[i,], 
z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "p2", "alpha") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
beta = (alpha*p2*(1-p1))/(p1*(1-p2)) 
 
cis = cistrans_ml(x, y, n, z, p1, p2, alpha, beta, r) 
df = cbind(df, cis) 
 
#Parameter estimation for the (trans) scenario. initcons = initial 
values for parameter optimisation. 
 
res = c() 
inittrans =c(0.5, 0.5, 1) 
for(i in 1:nrow(x)) { 
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ores = optim(inittrans, trans_func, gr=NULL, x[i,], y[i,], n[i,], 
z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "p2", "alpha") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
 
trans = cistrans_ml(x, y, n, z, p1, p2, alpha, alpha, r) 
df = cbind(df, trans) 
 
#Parameter estimation for the (cistrans) scenario. initcons = initial 
values for parameter optimisation. 
 
res = c() 
initcistrans =c(0.5, 0.5, 1, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcistrans, cistrans_func, gr=NULL, x[i,], y[i,], 
n[i,], z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6,1e6), control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "p2", "alpha", "beta") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
beta = res[,"beta"] 
 
cistrans = cistrans_ml(x, y, n, z, p1, p2, alpha, beta, r) 
df = cbind(df, cistrans) 
 
#Estimation of Bayesian Information Criteria (BIC). npar = Number of 
parameters. nobs = Number of samples/libraries. 
 
BIC = function(loglik , npar , nobs){ 
bic = -2*loglik + npar*log(nobs) 
} 
 
#BIC estimation for each scenario. BIC tests all possible models: 
#cons has 2 free parameters 
#cis and trans both have 3 free parameters 
#cistrans has 4 free parameters 
 
df$cons_bic = BIC(df$cons, 2 , 2) 
df$cis_bic = BIC(df$cis, 3 , 2) 
df$trans_bic = BIC(df$trans, 3 , 2) 
df$cistrans_bic = BIC(df$cistrans, 4 ,2) 
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#Assigning BIC values to all four models tested above 
 
inds = apply(df[,c("cons_bic" , "cis_bic" , "trans_bic" , 
"cistrans_bic")] , 1 , function(x) which(x==min(x), arr.ind=TRUE)) 
cat = c("cons" , "cis" , "trans" , "cistrans")[inds] 
df = cbind(df, cat) 
df$minBIC = apply(df[,c("cons_bic" , "cis_bic" , "trans_bic" , 
"cistrans_bic")] , 1 , min) 
minn = function(n) function(x) order(x, decreasing = FALSE)[n] 
df$secondlowestBIC = apply(df[,c("cons_bic" , "cis_bic" , "trans_bic" 
, "cistrans_bic")] , 1 , function(x) x[minn(2)(x)]) 
 
df$dif_bic =df$secondlowestBIC - df$minBIC 
 
write.table(df, "rdata/CTCF_df_x2_cistrans", sep="\t", row.names=TRUE, 
quote=FALSE, col.names=TRUE) 
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#This R code randomly subsamples n (here n=2) number of replicates out 
of 6, then runs statistical model fitting for category-assignment of 
cis/trans regulatory variants in TF binding sites. The code below uses 
an example of 2 biological replicates from a TF of interest. The shell 
script generate parallel jobs for the random subsampling. The R code 
sources the two helper functions f1_functions.R and cistrans.R 
detailed above. 
 
 
generate_jobs.sh 
 
#!/bin/bash 
if [[ "$#" -ne 3 ]]; then 
echo "Error: Usage ./generate_jobs.sh <jobs> <runs> <input file>" 
exit 1 
fi 
 
JOBS="$1" 
RUNS="$2" 
INPUT_FILE="$3" 
 
for ((i=1; i<=$JOBS; i++)) 
do 
echo "Running job: $i ($RUNS runs using $INPUT_FILE for input)" 
bsub rscript Random_Subsampling.r $i $RUNS $INPUT_FILE 
done 
 
 
Random_Subsamplingx2.r 
 
setwd("/Subsampling/x2/") 
 
library(DESeq) 
 
source("f1_functions.R") 
source("cistrans.R") 
 
# Get a list of args from the command line. 
args = commandArgs(trailingOnly=TRUE) 
 
# To run the script, three arguments are required:  
# 
# job: the number of the job being run 
# runs: the number of runs to go through 
# input file: the name of the input file 
# 
# Example: rscript Random_Subsampling.r 5 200 CEBPA_reads_df 
# 
if (length(args) != 3) { 
stop("Usage: rscript Random_Subsampling.r <job> <runs> <input 
file>") 
} 
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# Load the variables from the arguments. 
job_number = args[1] 
run_count = args[2] 
input_file_name = args[3] 
 
# Generate the output file name from the arguments. 
# The output file name has the format:  
# <input file name>_<job>_<runs> 
# 
# Example: CEBPA_reads_df_5_200 
# 
output_file_name = paste(input_file_name, job_number, run_count, 
sep="_") 
  
subsampling_stats = data.frame(cis= integer(0), cistrans = integer(0), 
cons= integer(0), trans= integer(0)) 
 
# Load reads pileups for SNVs/sites for all F0 & F1 libraries 
filtered = read.delim(input_file_name) 
 
 
for(i in 1:run_count) { 
print(i) 
 
start_time = Sys.time() 
 
#Randomly subsample n from 6 replicate (in this example n=2) 
xb6 = sample(2:7, 2) 
xcast = sample(8:13, 2) 
 
#Randomly subsample from 6 F1 replicate, selecting both alleles from 
the same hybrid offspring. 
xf1_cast_i = sample(14:19,2) 
xf1_cast_r = sample(20:25,2) 
xf1_b6_i = xf1_cast_i + 12 
xf1_b6_r = xf1_cast_r + 12 
 
tryCatch( 
{ 
# Normalise reads from F0 libraries 
df=filtered[,c(xb6,xcast)] 
row.names(df)=filtered[,1] 
condition = factor(c('p1','p1','p2','p2')) 
df = f0norm(df, condition) 
 
# Normalise reads from F1 libraries 
df1_cast=filtered[,c(xf1_cast_i, xf1_cast_r)] 
row.names(df1_cast)=filtered$chr 
df1_b6=filtered[,c(xf1_b6_i, xf1_b6_r)] 
row.names(df1_b6)=filtered$chr 
x = f1norm(df1_cast, df1_b6) 
norm_b6 = as.data.frame(x[1]) 
norm_cast = as.data.frame(x[2]) 
colnames(norm_cast) = colnames(df1_cast) 
f1 = cbind(norm_b6 , norm_cast) 
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# Combine normalised counts for F0 & F1 libraries 
df = merge(df, f1, by='row.names') 
row.names(df) = df$Row.names 
df$Row.names = NULL 
 
# Set normalised counts for cis/trans category-assignment 
#x=F0 BL6, y=F0 CAST, n= F1 B6L+ F1 CAST, z=F1 BL6  
 
x=as.matrix(df[,c(1:2)]) 
y=as.matrix(df[,c(3:4)]) 
n=as.matrix(df[,c(6:9)]) + as.matrix(df[,c(10:13)])  
z=as.matrix(df[,c(6:9)]) 
 
x=round(x) 
y=round(y) 
z=round(z) 
n=round(n) 
r = df$r 
 
#For each SNV/site, x, y are the parental data, and n, z are the 
hybrid offspring data 
 
#Parameter estimation for the (conserved) scenario. initcons = 
initial values for parameter optimisation.  
 
res = c() 
initcons = c(0.5, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcons, cons_func, gr=NULL, x[i,], y[i,],n[i,], 
z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8, 1e-8), 
upper=c(0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "alpha") 
p1 = res[,"p1"] 
alpha = res[,"alpha"] 
 
cons = cistrans_ml(x, y, n, z, p1, p1, alpha, alpha, r) 
df = cbind(df, cons) 
 
#Parameter estimation for the (cis) scenario. initcons = initial 
values for parameter optimisation.  
 
res = c() 
initcis = c(0.5, 0.5, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcis, cis_func, gr=NULL, x[i,], y[i,], n[i,], 
z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
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colnames(res) = c("p1", "p2", "alpha") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
beta = (alpha*p2*(1-p1))/(p1*(1-p2)) 
 
cis = cistrans_ml(x, y, n, z, p1, p2, alpha, beta, r) 
df = cbind(df, cis) 
 
#Parameter estimation for the (conserved) scenario. initcons = 
initial values for parameter optimisation.  
 
res = c() 
inittrans =c(0.5, 0.5, 1) 
for(i in 1:nrow(x)) { 
ores = optim(inittrans, trans_func, gr=NULL, x[i,], y[i,], 
n[i,], z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "p2", "alpha") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
 
trans = cistrans_ml(x, y, n, z, p1, p2, alpha, alpha, r) 
df = cbind(df, trans) 
 
#Parameter estimation for the (conserved) scenario. initcons = 
initial values for parameter optimisation.  
 
res = c() 
initcistrans =c(0.5, 0.5, 1, 1) 
for(i in 1:nrow(x)) { 
ores = optim(initcistrans, cistrans_func, gr=NULL, x[i,], 
y[i,], n[i,], z[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8,1e-8,1e-8), 
upper=c(0.9999,0.9999,1e6,1e6), control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("p1", "p2", "alpha", "beta") 
p1 = res[,"p1"] 
p2 = res[,"p2"] 
alpha = res[,"alpha"] 
beta = res[,"beta"] 
 
cistrans = cistrans_ml(x, y, n, z, p1, p2, alpha, beta, r) 
df = cbind(df, cistrans) 
 
#Estimation of Bayesian Information Criteria (BIC). npar = Number of 
parameters. nobs = Number of samples/libraries. 
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BIC = function(loglik , npar , nobs){ 
 
bic = -2*loglik + npar*log(nobs) 
} 
 
#BIC estimation for each scenario. BIC tests all possible models: 
#cons has 2 free parameters 
#cis and trans both have 3 free parameters 
#cistrans has 4 free parameters 
 
df$cons_bic = BIC(df$cons, 2 , 2) 
df$cis_bic = BIC(df$cis, 3 , 2) 
df$trans_bic = BIC(df$trans, 3 , 2) 
df$cistrans_bic = BIC(df$cistrans, 4 , 2) 
 
#Assigning BIC values to all four models tested above 
inds = apply(df[,c("cons_bic" , "cis_bic" , "trans_bic" , 
"cistrans_bic")] , 1 , function(x) which(x==min(x), arr.ind=TRUE)) 
cat = c("cons" , "cis" , "trans" , "cistrans")[inds] 
df = cbind(df, cat) 
df$minBIC = apply(df[,c("cons_bic" , "cis_bic" , "trans_bic" , 
"cistrans_bic")] , 1 , min) 
minn = function(n) function(x) order(x, decreasing = FALSE)[n] 
df$secondlowestBIC = apply(df[,c("cons_bic" , "cis_bic" , 
"trans_bic" , "cistrans_bic")] , 1 , function(x) x[minn(2)(x)]) 
 
df$dif_bic =df$secondlowestBIC - df$minBIC 
 
summary_stat = as.data.frame(as.list(summary(df$cat))) 
 
subsampling_stats = rbind(subsampling_stats,summary_stat) 
}, 
error = function(error_condition) { 
print(error_condition) 
print("------") 
print(xb6) 
print(xcast) 
print(xf1_cast_i) 
print(xf1_cast_r) 
print(xf1_b6_i) 
print(xf1_b6_r) 
print("------") 
}, 
finally={ 
end_time = Sys.time() 
print(end_time - start_time) 
} 
) 
 
} 
 
write.table(subsampling_stats, output_file_name, row.names=TRUE, 
sep="\t", quote=FALSE, col.names=TRUE) 
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#This R code runs a statistical model fitting for determining TF binding 
sites modes of inheritance. The code below uses an example of CTCF in 2 
biological replicates. 
 
 
inheritance_functions.R 
 
#Mode of inheritance assignment function modelling counts distribution 
between F0 and F1. All counts are modelled on negative binomial 
distributions. 
inheritance_func = function(xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, 
r) { 
sum(lgamma(r + xmax) - lfactorial(xmax) - lgamma(r) 
+xmax*log(inh_p1) + r*log(1-inh_p1)) + 
sum(lgamma(r + xmin) - lfactorial(xmin) - lgamma(r) 
+xmin*log(inh_p2) + r*log(1-inh_p2)) + 
sum(lgamma(r + yinh) - lfactorial(yinh) - lgamma(r) 
+yinh*log(inh_p3) + r*log(1-inh_p3)) 
} 
 
#Parameter estimation of additive mode with 3 free parameters. 
additive_func = function(params, xmax, xmin, yinh, r) { 
inh_p1 = params[1] 
inh_p2 = params[2] 
inh_p3 = params[3] 
inheritance_func(xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
} 
 
#Parameter estimation of dominant mode with 2 free parameters (3rd 
parameter = parameter 2). 
dom1_func = function(params, xmax, xmin, yinh, r) { 
inh_p1 = params[1] 
inh_p2 = params[2] 
inh_p3 = inh_p2 
inheritance_func(xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
} 
 
#Parameter estimation of dominant mode with 2 free parameters (3rd 
parameter = parameter 1). 
dom2_func = function(params, xmax, xmin, yinh, r) { 
inh_p1 = params[1] 
inh_p2 = params[2] 
inh_p3 = inh_p1 
inheritance_func (xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
} 
 
#Parameter estimation of the excluded set with 1 free parameters (3rd 
parameter = parameter 1 & 2 simultaneously). 
exclude_func = function(params, xmax, xmin, yinh, r) { 
inh_p1 = params[1] 
inh_p2 = inh_p1 
inh_p3 = inh_p2 
inheritance_func (xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
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} 
 
#Statistical modelling of each mode based on F0 & F1 counts, 
dispersion and free parameters. 
inheritance_ml = function(xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
{ 
res = c() 
for(i in 1:nrow(xmax)) { 
res = c(res, inheritance_func(xmax[i,], xmin[i,], yinh[i,], 
inh_p1[i], inh_p2[i], inh_p3[i], r[i])) 
} 
return(res) 
} 
 
 
 
inheritance_stat_modelling.R 
 
source("inheritance_functions.R") 
 
# Load category-assigned, normalised counts for SNVs/sites in all F0 & 
F1 libraries 
CTCF_analysis_x2_df = read.table("rdata/CTCF_df_x2_cistrans.txt", h=T) 
 
#Filter by differential BIC value >=1, sub-setting cis and trans 
categories for further analysis 
CTCF_x2_inh_df = subset(CTCF_analysis_x2_df, dif_bic >= 1) 
CTCF_x2_inh_df = subset(CTCF_x2_inh_df, cat == "cis" | cat == "trans") 
 
#Calculating the means of F0 between parental strains 
CTCF_x2_inh_df$f0_b6_av = apply(CTCF_x2_inh_df[,3:4], 1, mean) 
CTCF_x2_inh_df$f0_cast_av = apply(CTCF_x2_inh_df[,5:6], 1, mean) 
CTCF_x2_inh_df$diff_f0 = abs(CTCF_x2_inh_df$f0_b6_av-
CTCF_x2_inh_df$f0_cast_av) 
 
#Calculating the median binding intensity in both strains of F0 
CTCF_x2_inh_df$f0_b6_med = apply(CTCF_x2_inh_df[,3:4], 1, median) 
CTCF_x2_inh_df$f0_cast_med = apply(CTCF_x2_inh_df[,5:6], 1, median) 
 
#Calculating the median binding intensity in both alleles of F1, and 
summing them. 
CTCF_x2_inh_df$f1_total_av = (apply(CTCF_x2_inh_df[,8:11], 1, 
median))+(apply(CTCF_x2_inh_df[,12:15], 1, median)) 
 
#Determining the F0 parent with the higher/lower median binding 
intensity 
CTCF_x2_inh_df$xmax = 
apply(CTCF_x2_inh_df[,c("f0_b6_med","f0_cast_med")], 1, max) 
CTCF_x2_inh_df$xmin = 
apply(CTCF_x2_inh_df[,c("f0_b6_med","f0_cast_med")], 1, min) 
 
#For the F0 paerent with the higher median binding intensity, retrieve 
the F0 normalised counts for that parent to use in model fitting. 
 
x_max = data.frame() 
for(i in 1:nrow(CTCF_x2_inh_df)) { 
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if(CTCF_x2_inh_df[i,31] > CTCF_x2_inh_df[i,32]){ 
xmax = CTCF_x2_inh_df[i,3:4] 
names(xmax) = c("x1","x2) 
} else{ 
xmax = CTCF_x2_inh_df[i,5:6] 
names(xmax) = c("x1","x2") 
} 
x_max = rbind(x_max, xmax) 
} 
 
#For the F0 parent with the higher median binding intensity, retrieve 
the F0 normalised counts for that parent to use in model fitting. 
 
x_min = data.frame() 
for(i in 1:nrow(CTCF_x2_inh_df)) { 
if(CTCF_x2_inh_df[i,31] < CTCF_x2_inh_df[i,32]){ 
xmin = CTCF_x2_inh_df[i,3:4] 
names(xmin) = c("x1","x2") 
} else{ 
xmin = CTCF_x2_inh_df[i,5:6] 
names(xmin) = c("x1","x2") 
} 
x_min = rbind(x_min, xmin) 
} 
 
#Set variables for assigning modes of inheritance. 
#xmax=F0 with highest signal, xmin=F0 with lowest signal, yinh= total 
allelic signal in F1 
 
xmax=as.matrix(x_max) 
xmin=as.matrix(x_min) 
yinh=(as.matrix(CTCF_x2_inh_df[,c(8:11)]) + 
as.matrix(CTCF_x2_inh_df[,c(12:15)]))/2 
 
xmax=round(xmax) 
xmin=round(xmin) 
yinh=round(yinh) 
 
r = CTCF_x2_inh_df$r 
 
#For each SNV/site, xmax and xmin are the parental data, and yinh are 
the hybrid offspring data 
 
#Parameter estimation for the additive mode. initcons = initial values 
for parameter optimisation.  
 
res = c() 
init_add = c(0.5, 0.5, 0.5) 
for(i in 1:nrow(xmax)) { 
ores = optim(init_add, additive_func, gr=NULL, xmax[i,], 
xmin[i,],yinh[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8, 1e-8, 1e-8), 
upper=c(0.9999,0.9999,0.9999),  
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
Appendix 4 
 
 
 
 
203 
 
colnames(res) = c("inh_p1", "inh_p2", "inh_p3") 
inh_p1 = res[,"inh_p1"] 
inh_p2 = res[,"inh_p2"] 
inh_p3 = res[,"inh_p3"] 
 
additive = inheritance_ml(xmax, xmin, yinh, inh_p1, inh_p2, inh_p3, r) 
CTCF_x2_inh_df = cbind(CTCF_x2_inh_df, additive) 
 
# Parameter estimation of dominant mode with 2 free parameters (3rd 
parameter = parameter 2).  
 
res = c() 
init_dom1 = c(0.5, 0.5) 
for(i in 1:nrow(xmax)) { 
ores = optim(init_dom1, dom1_func, gr=NULL, xmax[i,], xmin[i,], 
yinh[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8), upper=c(0.9999,0.9999),  
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("inh_p1", "inh_p2") 
inh_p1 = res[,"inh_p1"] 
inh_p2 = res[,"inh_p2"] 
 
dom1 = inheritance_ml(xmax, xmin, yinh, inh_p1, inh_p2, inh_p2, r) 
CTCF_x2_inh_df = cbind(CTCF_x2_inh_df, dom1) 
 
 
# Parameter estimation of dominant mode with 2 free parameters (3rd 
parameter = parameter 1).  
 
res = c() 
init_hidom =c(0.5, 0.5) 
for(i in 1:nrow(xmax)) { 
ores = optim(init_hidom, dom2_func, gr=NULL, xmax[i,], xmin[i,], 
yinh[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8), upper=c(0.9999,0.9999), 
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("inh_p1", "inh_p2") 
inh_p1 = res[,"inh_p1"] 
inh_p2 = res[,"inh_p2"] 
 
dom2 = inheritance_ml(xmax, xmin, yinh, inh_p1, inh_p2, inh_p1, r) 
CTCF_x2_inh_df = cbind(CTCF_x2_inh_df, dom2) 
 
#Parameter estimation of the excluded set with 1 free parameters (3rd 
parameter = parameter 1 & 2 simultaneously). 
 
res = c() 
init_exc =c(0.5) 
for(i in 1:nrow(xmax)) { 
Appendix 4 
 
 
 
 
204 
ores = optim(init_exc, exclude_func, gr=NULL, xmax[i,], xmin[i,], 
yinh[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8), upper=c(0.9999), control = 
list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("inh_p1") 
inh_p1 = res[,"inh_p1"] 
 
exclude = inheritance_ml(xmax, xmin, yinh, inh_p1, inh_p1, inh_p1, r) 
CTCF_x2_inh_df = cbind(CTCF_x2_inh_df, exclude) 
 
#Estimation of Bayesian Information Criteria (BIC). npar = Number of 
parameters. nobs = Number of samples/libraries. 
 
BIC = function(loglik , npar , nobs){ 
 
bic = -2*loglik + npar*log(nobs) 
} 
 
#BIC estimation for each inheritance mode. BIC tests all possible 
models: 
#additive has 3 free parameters 
#both dominant modes have 2 free parameters 
#excluded sites have 1 free parameters 
 
CTCF_x2_inh_df$addit_bic = BIC(CTCF_x2_inh_df$additive, 3 ,2) 
CTCF_x2_inh_df$dom1_bic = BIC(CTCF_x2_inh_df$dom1, 2 ,2) 
CTCF_x2_inh_df$hidom_bic = BIC(CTCF_x2_inh_df$dom2, 2 ,2) 
CTCF_x2_inh_df$exclu_bic = BIC(CTCF_x2_inh_df$exclude, 1 ,2) 
 
#Assigning BIC values to all modes tested above 
inds = apply(CTCF_x2_inh_df[,c("addit_bic" , "dom1_bic" , "hidom_bic" 
, "exclu_bic")] , 1 , function(x) which(x==min(x), arr.ind=TRUE)) 
inh_cat = c("additive" , "dom1" , "dom2" , "exclude")[inds] 
CTCF_x2_inh_df = cbind(CTCF_x2_inh_df, inh_cat) 
CTCF_x2_inh_df$inh_minBIC = apply(CTCF_x2_inh_df[,c("addit_bic" , 
"dom1_bic" , "hidom_bic" , "exclu_bic")] , 1 , min) 
 
minn = function(n) function(x) order(x, decreasing = FALSE)[n] 
CTCF_x2_inh_df$inh_secondlowestBIC = 
apply(CTCF_x2_inh_df[,c("addit_bic" , "dom1_bic" , "hidom_bic" , 
"exclu_bic")] , 1 , function(x) x[minn(2)(x)]) 
CTCF_x2_inh_df$inh_dif_bic =CTCF_x2_inh_df$inh_secondlowestBIC - 
CTCF_x2_inh_df$inh_minBIC 
 
summary(CTCF_x2_inh_df$inh_cat[CTCF_x2_inh_df$cat == "cis"]) 
summary(CTCF_x2_inh_df$inh_cat[CTCF_x2_inh_df$cat == "trans"]) 
 
write.table(CTCF_x2_inh_df, "rdata/CTCF_x2_inh_df", sep="\t", row.names 
= TRUE, quote=FALSE, col.names=TRUE) 
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#This R code runs a statistical model fitting for lineage-specific TF 
binding sites. The code below uses an example of CTCF in 2 biological 
replicates. 
 
Lineage_spec_functions.R 
 
#Function modelling counts distribution in lineage-specific binding 
between F0 and F1. All counts are modelled on negative binomial 
distributions. 
 
lineage_func = function(xi, yi, lin_p1, lin_p2, r) { 
sum(lgamma(r + xi) - lfactorial(xi) - lgamma(r) +xi*log(lin_p1) + 
r*log(1-lin_p1)) + 
sum(lgamma(r + yi) - lfactorial(yi) - lgamma(r) +yi*log(lin_p2) + 
r*log(1-lin_p2)) 
} 
 
#Parameter estimation of lineage-specific cis scenario with 1 free 
parameter. 
 
lin_cis_func = function(params, xi, yi, r) { 
lin_p1 = params[1] 
lin_p2 = lin_p1 
lineage_func(xi, yi, lin_p1, lin_p2, r) 
} 
 
#Parameter estimation of lineage-specific cistrans scenario with 2 
free parameters. 
 
lin_cistrans_func = function(params, xi, yi, r) { 
lin_p1 = params[1] 
lin_p2 = params[2] 
lineage_func(xi, yi, lin_p1, lin_p2, r) 
} 
 
#Statistical modelling of each scenario based on F0 & F1 counts, 
dispersion and free parameters. 
 
lineage_ml = function(xi, yi, lin_p1, lin_p2, r) { 
res = c() 
for(i in 1:nrow(xi)) { 
res = c(res, lineage_func(xi[i,], yi[i,], lin_p1[i],  
lin_p2[i], r[i])) 
} 
return(res) 
} 
 
 
 
 
Lineage_spec_stat_modelling.R 
 
source("../lineage_functions.R") 
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# Load category-assigned, normalised counts for SNVs/sites in all F0 & 
F1 libraries 
CTCF_analysis_x2_df = read.table("rdata/CTCF_df_x2_cistrans.txt", h=T) 
 
#Calculating the ratios of F0 and F1 
CTCF_analysis_x2_df$f0_ratio = apply(CTCF_analysis_x2_df[,3:4], 1, 
sum)/ apply(CTCF_analysis_x2_df[,3:6], 1, sum) 
CTCF_analysis_x2_df$f1_ratio = apply(CTCF_analysis_x2_df[,8:11], 1, 
sum)/ apply(CTCF_analysis_x2_df[,8:15], 1, sum) 
 
#Calculating the means of F0 between parental strains 
CTCF_analysis_x2_df $f0_b6_av = apply(CTCF_analysis_x2_df[,3:4], 1, 
mean) 
CTCF_analysis_x2_df $f0_cast_av = apply(CTCF_analysis_x2_df[,5:6], 1, 
mean) 
 
#Calculating the mean binding intensity in both alleles of F1, and 
summing them. 
CTCF_analysis_x2_df$f1_total_av = (apply(CTCF_analysis_x2_df[,8:11], 
1, median))+(apply(CTCF_analysis_x2_df[,12:15], 1, mean)) 
 
#Determine lineage-specificity based on F0 and F1 ratios between 
parents and offspring for further analysis 
 
CTCF_x2_linspec_df = filter(CTCF_analysis_x2_df, f0_ratio > 0.95 & 
f1_ratio > 0.95 | f0_ratio < 0.05 & f1_ratio < 0.05) 
 
#Determining the F0 parent of lineage-specific binding. 
 
CTCF_x2_linspec_df$xi = 
apply(CTCF_x2_linspec_df[,c("f0_b6_av","f0_cast_av")], 1, max) 
 
 
#For the F0 parent of lineage-specific binding, retrieve the F0 
normalised counts for that parent to use in model fitting. 
 
x_i = data.frame() 
for(i in 1:nrow(CTCF_x2_linspec_df)) { 
if(CTCF_x2_linspec_df[i,30] > CTCF_x2_linspec_df[i,31]){ 
xi = CTCF_x2_linspec_df[i,3:4] 
names(xi) = c("x1","x2) 
} else{ 
xi = CTCF_x2_linspec_df[i,5:6] 
names(xi) = c("x1","x2") 
} 
x_i = rbind(x_i, xi) 
} 
 
#Set variables for investigating lineage-specificity of binding. 
#xi=F0 with lineage-spcific binding, yi= total allelic signal in F1 
 
xi=as.matrix(x_i) 
yi=(as.matrix(CTCF_x2_linspec_df[,c(8:11)]) + 
as.matrix(CTCF_x2_linspec_df[,c(12:15)])) 
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xi=round(xi) 
yi=round(2*yi) 
r = CTCF_x2_linspec_df$r 
 
#For each SNV/site, xi are the parental data, and yi are the hybrid 
offspring data 
 
#Parameter estimation for the cis scenario. initcons = initial values 
for parameter optimisation.  
 
res = c() 
init_lin_cis =c(0.5) 
for(i in 1:nrow(xi)) { 
ores = optim(init_lin_cis, lin_cis_func, gr=NULL, xi[i,], yi[i,],  
r[i], 
method = "L-BFGS-B", lower = c(1e-8), upper=c(0.9999), control =  
list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("lin_p1") 
lin_p1 = res[,"lin_p1"] 
 
lin_cis = lineage_ml(xi, yi, lin_p1, lin_p1, r) 
CTCF_x2_linspec_df = cbind(CTCF_x2_linspec_df, lin_cis) 
 
#Parameter estimation for the cistrans scenario.  
 
res = c() 
init_lin_cistrans = c(0.5, 0.5) 
for(i in 1:nrow(xi)) { 
ores = optim(init_lin_cistrans, lin_cistrans_func, gr=NULL,  
xi[i,], yi[i,], r[i], 
method = "L-BFGS-B", lower = c(1e-8,1e-8), upper=c(0.9999,0.9999),  
control = list(fnscale=-1)) 
res = rbind(res, ores$par) 
} 
 
colnames(res) = c("lin_p1", "lin_p2") 
lin_p1 = res[,"lin_p1"] 
lin_p2 = res[,"lin_p2"] 
 
lin_cistrans = lineage_ml(xi, yi, lin_p1, lin_p2, r) 
CTCF_x2_linspec_df = cbind(CTCF_x2_linspec_df, lin_cistrans) 
 
#Estimation of Bayesian Information Criteria (BIC). npar = Number of 
parameters. nobs = Number of samples/libraries. 
 
BIC = function(loglik , npar , nobs){ 
 
bic = -2*loglik + npar*log(nobs) 
} 
 
#BIC estimation for each scenario. BIC tests two possible models: 
#cis have 1 free parameter 
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#cistrans have 2 free parameters 
 
CTCF_x2_linspec_df$lin_cis_bic = BIC(CTCF_x2_linspec_df$lin_cis, 1 ,2) 
CTCF_x2_linspec_df$lin_cistrans_bic = 
BIC(CTCF_x2_linspec_df$lin_cistrans, 2 ,2) 
 
 
#Assigning BIC values to all scenarios tested above 
 
inds = apply(CTCF_x2_linspec_df[,c("lin_cis_bic" , 
"lin_cistrans_bic")] , 1 , function(x) which(x==min(x), arr.ind=TRUE)) 
lin_cat = c("lin_cis" , "lin_cistrans")[inds] 
CTCF_x2_linspec_df = cbind(CTCF_x2_linspec_df, lin_cat) 
CTCF_x2_linspec_df$lin_minBIC = 
apply(CTCF_x2_linspec_df[,c("lin_cis_bic" , "lin_cistrans_bic")] , 1 , 
min) 
 
minn = function(n) function(x) order(x, decreasing = FALSE)[n] 
CTCF_x2_linspec_df$lin_secondlowestBIC = 
apply(CTCF_x2_linspec_df[,c("lin_cis_bic" , "lin_cistrans_bic")] , 1 , 
function(x) x[minn(2)(x)]) 
 
CTCF_x2_linspec_df$lin_dif_bic =CTCF_x2_linspec_df$lin_secondlowestBIC 
- CTCF_x2_linspec_df$lin_minBIC 
 
write.table(CTCF_x2_linspec_df, "rdata/ CTCF_x2_linspec_df", sep="\t", 
row.names = TRUE, quote=FALSE, col.names=TRUE) 
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#This Python code with its helper function (helpers.py) takes as in 
input a csv filer with four columns. The first two columns describe the 
chromosome number and position of each cis SNV. The third and fourth 
columns describe the chromosome number and position of all SNVs. The 
function anchors each cis SNV and searches for other SNVs in downstream 
incremental genomic intervals (bins) of 1 kb (for 400 bins/kb), and 
returns the position of that SNV.  
 
 
helpers.py (Downstream) 
 
import csv 
import numpy 
import pandas 
 
# Search for matches, returning a series of Nulls and values matching 
the condition. 
def get_matches_in_column_in_range(df, col, lower_limit, upper_limit): 
potential_matches_vector = df[col].where((df[col] > lower_limit) & 
(df[col] < upper_limit)) 
 
# Trim the series of null values. 
potential_matches_vector = 
potential_matches_vector[~potential_matches_vector.isnull()] 
 
return potential_matches_vector 
 
# Get a series containing all matches 
def get_first_match_in_column_in_range(df, col, lower_limit, 
upper_limit): 
potential_matches_vector = get_matches_in_column_in_range(df, col, 
lower_limit, upper_limit) 
 
# Return the first match, or Nil otherwise 
match = numpy.nan if len(potential_matches_vector) < 1 else 
potential_matches_vector.iloc[0] 
index = numpy.nan if len(potential_matches_vector) < 1 else 
potential_matches_vector.index[0] 
return index, match 
 
 
 
inter_peak_coordination.py (Downstream) 
 
import csv 
import numpy as np 
import pandas as pd 
import helpers 
 
# CSV file constants 
INPUT_FILE_NAME = 'Input.csv' 
OUTPUT_FILE_NAME = 'Ouptut.csv' 
POSITION_1 = 'pos' 
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CHROMOSOME_1 = 'chr' 
POSITION_2 = 'pos_2' 
CHROMOSOME_2 = 'chr_2' 
 
# Bin constants 
BINS = 400 
BIN_LIST = range(1, BINS+1) 
INITIAL_LOWER_LIMIT = 1000 
BIN_STEP_SIZE = 1000 
 
# Read the inital data frame from the csv file, and 
# append a column for each bin to the data frame 
print('Started reading the dataframe...') 
data_frame = pd.read_csv(INPUT_FILE_NAME) 
for abin in BIN_LIST: 
data_frame[str(abin)] = np.nan 
print('Finished reading the dataframe') 
 
 
# Iterate through the data points 
print('Started processing the dataframe') 
data_point_count = len(data_frame) 
 
for index, data_point in data_frame.iterrows(): 
# Reset the limit values at each iteration, and 
# get the current position 
current_limit = INITIAL_LOWER_LIMIT 
pos = data_point[POSITION_1] 
 
# Iterate through the bins 
for abin in BIN_LIST: 
lower_limit = current_limit 
upper_limit = lower_limit + BIN_STEP_SIZE 
 
# Get the first match in the second position column, and 
# append the match to the dataframe 
match_index, match = 
helpers.get_first_match_in_column_in_range(data_frame, POSITION_2, pos 
+ lower_limit, pos + upper_limit) 
 
if match_index is not np.nan: 
matching_data_point_chromosome =  
data_frame.iloc[match_index][CHROMOSOME_2] 
if data_point[CHROMOSOME_1] !=  
matching_data_point_chromosome: 
data_frame.at[index, str(abin)] = 0 
else: 
data_frame.at[index, str(abin)] = match 
else: 
data_frame.at[index, str(abin)] = 0 
 
 
# Update the value of the limit 
current_limit = upper_limit 
print('Finished processing the dataframe') 
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# Write the resulting dataframe to the output file 
data_frame.to_csv(OUTPUT_FILE_NAME) 
 
 
 
#Similar to the Python code above, this function anchors each cis SNV 
and searches for other SNVs in upstream incremental genomic intervals 
(bins) of 1 kb (for 400 bins/kb), and returns the position of that SNV. 
 
 
helpers.py (Upstream) 
 
import csv 
import numpy 
import pandas 
 
# Search for matches, returning a series of Nulls and values matching 
the condition. 
def get_matches_in_column_in_range(df, col, lower_limit, upper_limit): 
potential_matches_vector = df[col].where((df[col] < lower_limit) & 
(df[col] > upper_limit)) 
 
# Trim the series of null values. 
potential_matches_vector = 
potential_matches_vector[~potential_matches_vector.isnull()] 
 
return potential_matches_vector 
 
# Get a series containing all matches 
def get_first_match_in_column_in_range(df, col, lower_limit, 
upper_limit): 
potential_matches_vector = get_matches_in_column_in_range(df, col, 
lower_limit, upper_limit) 
 
# Return the first match, or Nil otherwise 
match = numpy.nan if len(potential_matches_vector) < 1 else 
potential_matches_vector.iloc[0] 
index = numpy.nan if len(potential_matches_vector) < 1 else 
potential_matches_vector.index[0] 
return index, match 
 
 
inter_peak_coordination.py (Downstream) 
 
import csv 
import numpy as np 
import pandas as pd 
import helpers 
 
# CSV file constants 
INPUT_FILE_NAME = 'Input.csv' 
OUTPUT_FILE_NAME = 'Ouptut.csv' 
POSITION_1 = 'pos' 
CHROMOSOME_1 = 'chr' 
POSITION_2 = 'pos_2' 
CHROMOSOME_2 = 'chr_2' 
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# Bin constants 
BINS = 400 
BIN_LIST = range(1, BINS+1) 
INITIAL_LOWER_LIMIT = -1000 
BIN_STEP_SIZE = 1000 
 
# Read the inital data frame from the csv file, and 
# append a column for each bin to the data frame 
print('Started reading the dataframe...') 
data_frame = pd.read_csv(INPUT_FILE_NAME) 
for abin in BIN_LIST: 
data_frame[str(abin)] = np.nan 
print('Finished reading the dataframe') 
 
 
# Iterate through the data points 
print('Started processing the dataframe') 
data_point_count = len(data_frame) 
 
for index, data_point in data_frame.iterrows(): 
# Reset the limit values at each iteration, and 
# get the current position 
current_limit = INITIAL_LOWER_LIMIT 
pos = data_point[POSITION_1] 
 
# Iterate through the bins 
for abin in BIN_LIST: 
lower_limit = current_limit 
upper_limit = lower_limit - BIN_STEP_SIZE 
 
# Get the first match in the second position column, and 
# append the match to the dataframe 
match_index, match = 
helpers.get_first_match_in_column_in_range(data_frame, POSITION_2, pos 
+ lower_limit, pos + upper_limit) 
 
if match_index is not np.nan: 
matching_data_point_chromosome =  
data_frame.iloc[match_index][CHROMOSOME_2] 
if data_point[CHROMOSOME_1] !=  
matching_data_point_chromosome: 
data_frame.at[index, str(abin)] = 0 
else: 
data_frame.at[index, str(abin)] = match 
else: 
data_frame.at[index, str(abin)] = 0 
 
 
# Update the value of the limit 
current_limit = upper_limit 
print('Finished processing the dataframe') 
 
# Write the resulting dataframe to the output file 
data_frame.to_csv(OUTPUT_FILE_NAME) 
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#The outputs of the two python codes above are combined so that all SNVs 
in up/downstream bins are now in one bin for the same incremental 
interval. The positions of the SNVs are then replaced by their F1 allelic 
ratios (BL6/(BL6+CAST)). Spearman’s correlation coefficient of allelic 
ratios (BL6/(BL6+CAST)) is then computed between cis-acting variants and 
the SNVs in each successive bin. The following R code takes a dataframe 
of each cis and its F1 ratio and columns describing the F1 ratios for 
all SNVs in each bin. Spearman’s ρ for each mutually exclusive bin with 
the corresponding anchor cis CTCF site is then calculated and used as 
the outcome variable in a linear regression model.# 
 
inter_peak_Spearman_correlation.R 
 
corr_res_400_alt = c() 
for (i in 4:ncol(corr_df_400bin)){ 
corr = cbind(corr_df_400bin$f1_ratio,corr_df_400bin[,i]) 
corr = as.data.frame(corr) 
corr = filter(corr, corr[,1] > 0, corr[,2] > 0,) 
sp_corr = cor.test(corr$V1, corr$V2,method = "spearman", 
exact=FALSE) 
corr_res_400_alt = rbind(corr_res_400_alt, sp_corr$estimate) 
} 
 
corr_x_400_alt = 1:400 
corr_res_400_alt = cbind(corr_x_400_alt,corr_res_400_alt[,1]) 
colnames(corr_res_400_alt) = c("Bin_kb", "rho") 
corr_res_400_alt = as.data.frame(corr_res_400_alt) 
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